SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    0 According to a recent article in the New England Journal of Medicine , total pharmaceutical industry spending on direct-to-consumer ( DTC ) advertising of prescription drugs rose from $985 million in 1996 to $4.2 billion in 2005--an increase of 330%. n1 As a result , advertisements for prescription drugs are pervasive and consumers regularly view them in magazines and online , watch them on television , and listen to them on the radio .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    0 According_II21 to_II22 a_AT1 recent_JJ article_NN1 in_II the_AT New_NP1 England_NP1 Journal_NN1 of_IO Medicine_NN1 ,_Y total_JJ pharmaceutical_JJ industry_NN1 spending_VVG_NN1 on_II direct-to-consumer_NN1_JJ (_Y DTC_NP1 )_Y advertising_NN1 of_IO prescription_NN1 drugs_NN2 rose_VVD from_II $985_NNU million_M in_II 1996_MC to_II $4.2_NNU billion_M in_II 2005--an_AT1 increase_NN1 of_IO 330%._FO n1_FO As_II a_AT1 result_NN1 ,_Y advertisements_NN2 for_IF prescription_NN1 drugs_NN2 are_VBR pervasive_JJ and_CC consumers_NN2 regularly_RR view_VV0@ them_PPHO2 in_II magazines_NN2 and_CC online_RR_JJ ,_Y watch_VV0 them_PPHO2 on_II television_NN1 ,_Y and_CC listen_VV0 to_II them_PPHO2 on_II the_AT radio_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    1 <p> This figure , however , must be put in perspective .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    1 <p>_Y This_DD1 figure_NN1 ,_Y however_RR ,_Y must_VM be_VBI put_VVN in_II perspective_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    2 Research also shows that during the same period , spending on pharmaceutical marketing increased not only for DTC advertising , but also across the board , from about $11.4 billion to $29.9 billion. n2 In fact , although DTC advertising has increased steadily both in absolute terms and as a percentage of pharmaceutical sales , promotion of drug treatments directly to physicians and other health care professionals still far outweighs DTC advertising. n3 In 2005 , $7.2 billion was spent on promotion to physicians alone. n4 Relatively speaking , DTC advertising is concentrated on a small number of brands. n5 Its reach the subject of significant debate among courts and commentators. ( n6 ) <p> In light of these changes in the marketing environment , this Article examines whether traditional legal principles governing the duty to warn of the risks of pharmaceutical products remain sound public policy .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    2 Research_VV0@_NN1 also_RR shows_VVZ that_CST during_II the_AT same_DA period_NN1 ,_Y spending_VVG on_II_RP@ pharmaceutical_JJ marketing_NN1 increased_VVD_VVN not_XX only_RR for_IF DTC_NP1 advertising_NN1 ,_Y but_CCB also_RR across_II the_AT board_NN1 ,_Y from_II about_RG $11.4_NNU billion_M to_II $29.9_NNU billion._M n2_FO In_II fact_NN1 ,_Y although_CS DTC_NP1 advertising_NN1 has_VHZ increased_VVN steadily_RR both_RR in_II absolute_JJ terms_NN2 and_CC as_II_CSA a_AT1 percentage_NN1 of_IO pharmaceutical_JJ sales_NN ,_Y promotion_NN1 of_IO drug_NN1 treatments_NN2 directly_RR to_II physicians_NN2 and_CC other_JJ health_NN1 care_NN1 professionals_NN2 still_RR far_RR outweighs_VVZ DTC_NP1 advertising._NNU n3_FO In_II 2005_MC ,_Y $7.2_NNU billion_M was_VBDZ spent_VVN on_II promotion_NN1 to_II physicians_NN2 alone._NNU n4_FO Relatively_RR speaking_VVG_JJ@ ,_Y DTC_NP1 advertising_NN1 is_VBZ concentrated_VVN on_II a_AT1 small_JJ number_NN1 of_IO brands._NNU n5_FO Its_Z' reach_NN1 the_AT subject_NN1 of_IO significant_JJ debate_NN1 among_II courts_NN2 and_CC commentators._NNU (_Y n6_FO )_Y <p>_Y In_II31 light_II32 of_II33 these_DD2 changes_NN2 in_II the_AT marketing_NN1 environment_NN1 ,_Y this_DD1 Article_NN1 examines_VVZ whether_CSW traditional_JJ legal_JJ principles_NN2 governing_VVG the_AT duty_NN1 to_TO warn_VVI of_IO the_AT risks_NN2 of_IO pharmaceutical_JJ products_NN2 remain_VV0 sound_JJ@_NN1 public_JJ_NN1 policy_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    3 First , the Article considers the early history of the sale and marketing of pharmaceutical products , discussing the initial tragic absence of regulation , followed by the establishment of the FDA and the pre-market approval process .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    3 First_MD ,_Y the_AT Article_NN1 considers_VVZ the_AT early_JJ history_NN1 of_IO the_AT sale_NN1 and_CC marketing_NN1 of_IO pharmaceutical_JJ products_NN2 ,_Y discussing_VVG the_AT initial_JJ_NN1 tragic_JJ absence_NN1 of_IO regulation_NN1 ,_Y followed_VVN by_II the_AT establishment_NN1 of_IO the_AT FDA_NN1_NP1 and_CC the_AT pre-market_JJ_NN1 approval_NN1 process_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    4 It then examines the modern age of pharmaceutical advertising , including the FDA 's relatively recent guidance on DTC broadcast advertising and the extent of its regulation .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    4 It_PPH1 then_RT examines_VVZ the_AT modern_JJ age_NN1 of_IO pharmaceutical_JJ advertising_NN1 ,_Y including_II_VVG@ the_AT FDA_NN1_NP1 's_GE relatively_RR recent_JJ guidance_NN1 on_II DTC_NP1 broadcast_NN1_VV0_JJ@ advertising_NN1 and_CC the_AT extent_NN1 of_IO its_Z' regulation_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    5 Finally , the Article examines rules of law that establish the legal landscape for warnings and advertising in the pharmaceutical context .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    5 Finally_RR ,_Y the_AT Article_NN1 examines_VVZ rules_NN2 of_IO law_NN1 that_CST establish_VV0 the_AT legal_JJ landscape_NN1 for_IF warnings_NN2 and_CC advertising_NN1_VVG@ in_II the_AT pharmaceutical_JJ context_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    6 This includes the learned intermediary doctrine , the effect of regulatory compliance on product liability and consumer protection claims , and the application of conflict preemption principles to tort law claims involving FDA-approved products .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    6 This_DD1 includes_VVZ the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 ,_Y the_AT effect_NN1 of_IO regulatory_JJ compliance_NN1 on_II product_NN1 liability_NN1 and_CC consumer_NN1 protection_NN1 claims_NN2_VVZ ,_Y and_CC the_AT application_NN1 of_IO conflict_NN1 preemption_NN1 principles_NN2 to_TO tort_VVI law_NN1 claims_NN2_VVZ involving_VVG FDA-approved_JJ_NN1 products_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    7 <p> The Article finds that the two foundational tenets underlying these doctrines have not changed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    7 <p>_Y The_AT Article_NN1 finds_VVZ that_CST the_AT two_MC foundational_JJ tenets_NN2 underlying_VVG these_DD2 doctrines_NN2 have_VH0 not_XX changed_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    8 First , on a societal level , both in approving pharmaceutical products as safe and effective for certain classes of patients and in mandating disclosure of risks so that physicians can accurately counsel their patients .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    8 First_MD ,_Y on_II a_AT1 societal_JJ level_NN1_JJ ,_Y both_RR_DB2 in_II approving_VVG pharmaceutical_JJ products_NN2 as_CSA_RG@_II@ safe_JJ and_CC effective_JJ for_IF certain_JJ classes_NN2 of_IO patients_NN2 and_CC in_II mandating_VVG_JJ@ disclosure_NN1 of_IO risks_NN2 so_CS21 that_CS22 physicians_NN2 can_VM accurately_RR counsel_VVI their_APPGE patients_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0    9 Second , physicians remain individually responsible for diagnosing each patient regardless of advertising and for helping each patient make an educated treatment decision in light of the risks and benefits of a drug .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0    9 Second_MD ,_Y physicians_NN2 remain_VV0 individually_RR responsible_JJ for_IF diagnosing_VVG each_DD1 patient_NN1_JJ regardless_RR of_IO advertising_NN1 and_CC for_IF helping_VVG each_DD1 patient_NN1 make_VVI an_AT1 educated_JJ treatment_NN1 decision_NN1 in_II31 light_II32 of_II33 the_AT risks_NN2 and_CC benefits_NN2 of_IO a_AT1 drug_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   10 Because of their authority to write prescriptions , physicians have ultimate responsibility for deciding whether a given drug is appropriate and beneficial for the patient .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   10 Because_II21 of_II22 their_APPGE authority_NN1 to_TO write_VVI prescriptions_NN2 ,_Y physicians_NN2 have_VH0 ultimate_JJ responsibility_NN1 for_IF deciding_VVG whether_CSW a_AT1 given_JJ@ drug_NN1 is_VBZ appropriate_JJ and_CC beneficial_JJ for_IF the_AT patient_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   11 Prescription drug manufacturers , therefore , have obligations to report all material information to the FDA , both before and after approval , so that the FDA can make a fully informed decision about what products should be available to the market and can convey adequate information to physicians for patient counseling purposes .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   11 Prescription_NN1 drug_NN1 manufacturers_NN2 ,_Y therefore_RR ,_Y have_VH0 obligations_NN2 to_TO report_VVI all_DB material_JJ@_NN1 information_NN1 to_II the_AT FDA_NN1_NP1 ,_Y both_RR before_CS_II_RT@ and_CC after_II_CS approval_NN1 ,_Y so_CS21 that_CS22 the_AT FDA_NN1_NP1 can_VM make_VVI a_AT1 fully_RR informed_VVN_JJ@_VVD decision_NN1 about_II what_DDQ products_NN2 should_VM be_VBI available_JJ to_II the_AT market_NN1 and_CC can_VM convey_VVI adequate_JJ information_NN1 to_II physicians_NN2 for_IF patient_JJ_NN1 counseling_NN1 purposes_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   12 <p> The Article concludes that , irrespective of the rise of DTC advertising , traditional principles of law fully retain their viability in the post-DTC world both as a matter of jurisprudence and sound public policy .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   12 <p>_Y The_AT Article_NN1 concludes_VVZ that_CST_DD1 ,_Y irrespective_II21 of_II22 the_AT rise_NN1 of_IO DTC_NP1 advertising_NN1 ,_Y traditional_JJ principles_NN2 of_IO law_NN1 fully_RR retain_VV0 their_APPGE viability_NN1 in_II the_AT post-DTC_JJ world_NN1 both_RR as_II a_AT1 matter_NN1 of_IO jurisprudence_NN1 and_CC sound_JJ@_NN1_VV0@ public_JJ_NN1 policy_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   13 <p> I. MARKETING AND REGULATION OF PHARMACEUTICALS FROM PAST TO examining modern regulation of pharmaceutical products and their advertising , placing the current system in historical context is useful .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   13 <p>_Y I._NP1 MARKETING_NN1 AND_CC REGULATION_NN1 OF_IO PHARMACEUTICALS_NN2 FROM_II PAST_NN1 TO_II examining_VVG modern_JJ regulation_NN1 of_IO pharmaceutical_JJ products_NN2 and_CC their_APPGE advertising_NN1 ,_Y placing_VVG the_AT current_JJ system_NN1 in_II historical_JJ context_NN1 is_VBZ useful_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   14 Companies that sell medications have advertised their products directly to consumers since the beginning of medicine .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   14 Companies_NN2 that_CST sell_VV0 medications_NN2 have_VH0 advertised_VVN their_APPGE products_NN2 directly_RR to_II consumers_NN2 since_CS_II@ the_AT beginning_NN1 of_IO medicine_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   15 The increasing regulatory scrutiny regarding approval , marketing , and sale of prescription drugs , however , is a relatively recent development .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   15 The_AT increasing_JJ regulatory_JJ scrutiny_NN1 regarding_II_VVG approval_NN1 ,_Y marketing_NN1_VVG@ ,_Y and_CC sale_NN1 of_IO prescription_NN1 drugs_NN2 ,_Y however_RR ,_Y is_VBZ a_AT1 relatively_RR recent_JJ development_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   16 The new oversight is meant to ensure that drugs are safe and effective and that drug advertising does not mislead the public .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   16 The_AT new_JJ oversight_NN1 is_VBZ meant_VVN to_TO ensure_VVI that_CST drugs_NN2 are_VBR safe_JJ and_CC effective_JJ and_CC that_DD1 drug_NN1 advertising_NN1 does_VDZ not_XX mislead_VVI the_AT public_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   17 <p> During much of the eighteenth and nineteenth centuries , companies regularly advertised patent medicines , which were available without a prescription , directly to consumers in American newspapers .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   17 <p>_Y During_II much_DA1 of_IO the_AT eighteenth_MD and_CC nineteenth_MD centuries_NNT2 ,_Y companies_NN2 regularly_RR advertised_VVN_VVD_JJ@ patent_NN1_JJ@ medicines_NN2 ,_Y which_DDQ were_VBDR available_JJ without_IW a_AT1 prescription_NN1 ,_Y directly_RR to_II consumers_NN2 in_II American_JJ newspapers_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   18 Indeed , during the 1800s , patent medicine advertisers spent more on newspaper advertisements than any other group. n7 At the time , no regulatory structure existed to provide for pre-market review of these medicines to ensure their safety or efficacy or to substantiate the claims their producers made in these advertisements .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   18 Indeed_RR ,_Y during_II the_AT 1800s_MC2 ,_Y patent_NN1_JJ@ medicine_NN1 advertisers_NN2 spent_VVN_VVD more_RRR_DAR on_II newspaper_NN1 advertisements_NN2 than_CSN any_DD other_JJ group._NNU n7_FO At_II the_AT time_NNT1 ,_Y no_AT regulatory_JJ structure_NN1 existed_VVD to_TO provide_VVI for_IF pre-market_JJ_NN1 review_NN1 of_IO these_DD2 medicines_NN2 to_TO ensure_VVI their_APPGE safety_NN1 or_CC efficacy_NN1 or_CC to_TO substantiate_VVI the_AT claims_NN2 their_APPGE producers_NN2 made_VVN_VVD in_II these_DD2 advertisements_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   19 The grifting snake oil salesman , a character that still pervades the mythology of the American West , dates to this unregulated period .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   19 The_AT grifting_JJ@_NN1@ snake_NN1 oil_NN1 salesman_NN1 ,_Y a_AT1 character_NN1 that_CST still_RR pervades_VVZ the_AT mythology_NN1 of_IO the_AT American_JJ West_ND1 ,_Y dates_VVZ_NN2 to_II this_DD1 unregulated_JJ period_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   20 <p> Jungle , with its detailed account of the unsanitary conditions of the Chicago stockyards. n8 Prompted by the resulting public outcry from the book and public reaction to similar disclosures in the nation 's newspapers about poisonous preservatives and dyes in foods and cure-all patent medicines , Congress passed the original Pure Food and Drugs Act. ( n9 ) <p> But if the 1906 Act was meant to curb the deceptive practices of snake oil salesmen , it was poorly equipped for the task .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   20 <p>_Y Jungle_NN1 ,_Y with_IW its_Z' detailed_JJ account_NN1 of_IO the_AT unsanitary_JJ_NN1 conditions_NN2 of_IO the_AT Chicago_NP1 stockyards._NNU n8_FO Prompted_VVN by_II the_AT resulting_JJ public_JJ_NN1 outcry_NN1 from_II the_AT book_NN1 and_CC public_JJ_NN1 reaction_NN1 to_II similar_JJ disclosures_NN2 in_II the_AT nation_NN1 's_GE newspapers_NN2 about_II poisonous_JJ preservatives_NN2 and_CC dyes_NN2 in_II foods_NN2 and_CC cure-all_DB_RR@ patent_JJ@_NN1 medicines_NN2 ,_Y Congress_NN1 passed_VVD_VVN the_AT original_JJ Pure_JJ Food_NN1 and_CC Drugs_NN2 Act._NP1 (_Y n9_FO )_Y <p>_Y But_CCB if_CS the_AT 1906_MC Act_NN1 was_VBDZ meant_VVN to_TO curb_VVI the_AT deceptive_JJ practices_NN2 of_IO snake_NN1 oil_NN1 salesmen_NN2 ,_Y it_PPH1 was_VBDZ poorly_RR equipped_VVN for_IF the_AT task_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   21 First , the 1906 Act did not prevent manufacturers from placing worthless medicines on the market because proof of safety or efficacy was not required .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   21 First_MD ,_Y the_AT 1906_MC Act_NN1 did_VDD not_XX prevent_VVI manufacturers_NN2 from_II placing_VVG worthless_JJ medicines_NN2 on_II the_AT market_NN1 because_CS proof_NN1 of_IO safety_NN1 or_CC efficacy_NN1 was_VBDZ not_XX required_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   22 Second , the Act was directed only at product labels , not extra-label advertising. n10 It defined a drug as " misbranded " only if the stated claims on the label regarding its curative or therapeutic qualities were proven false or fraudulent. ( n11 ) <p> These inadequacies became tragically apparent some three decades later .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   22 Second_MD ,_Y the_AT Act_NN1 was_VBDZ directed_VVN only_RR at_II product_NN1 labels_NN2 ,_Y not_XX extra-label_VV0 advertising._NNU n10_FO It_PPH1_NN1@ defined_VVD a_AT1 drug_NN1 as_CSA "_Y misbranded_VVN@_JJ@_VVD "_Y only_RR_JJ if_CS the_AT stated_JJ@ claims_NN2 on_II the_AT label_NN1 regarding_II_VVG its_Z' curative_NN1_JJ or_CC therapeutic_JJ qualities_NN2 were_VBDR proven_VVN_JJ false_JJ or_CC fraudulent._NNU (_Y n11_FO )_Y <p>_Y These_DD2 inadequacies_NN2 became_VVD tragically_RR apparent_JJ some_DD three_MC decades_NNT2 later_RRR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   23 In June 1937 , a salesman for the S.E. Massengill Co. reported that his customers sought a liquid version of the drug sulfanilamide , been proven to have dramatic curative effects in tablet or powder form. n12 Responding to the market need , a chemist and pharmacist for the company experimented with sulfanilamide 's solubility and found that it would dissolve in diethylene glycol. n13 Although the company tested the product for flavor , appearance , and fragrance , it did not test the product 's toxicity. n14 In sufficient doses , diethylene glycol is toxic to humans and animals , causing renal failure , encephalopathy , and death. n15 A scientific literature review or a few simple animal tests would have revealed its lethal properties. n16 S.E. Massengill , however , shipped the product without taking these precautions .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   23 In_II June_NPM1 1937_MC ,_Y a_AT1 salesman_NN1 for_IF the_AT S.E._ND1 Massengill_NP1 Co._NP1 reported_VVD that_CST his_APPGE customers_NN2 sought_VVD_VVN a_AT1 liquid_JJ_NN1 version_NN1 of_IO the_AT drug_NN1 sulfanilamide_NN1_VV0 ,_Y been_VBN proven_VVN to_TO have_VHI dramatic_JJ curative_JJ_NN1 effects_NN2 in_II tablet_NN1 or_CC powder_VV0@_NN1 form._NNU n12_FO Responding_VVG to_II the_AT market_NN1 need_NN1_VV0 ,_Y a_AT1 chemist_NN1 and_CC pharmacist_NN1 for_IF the_AT company_NN1 experimented_VVN_VVD with_IW sulfanilamide_NN1 's_GE solubility_NN1 and_CC found_VVN that_CST it_PPH1 would_VM dissolve_VVI in_II diethylene_NN1 glycol._NNU n13_FO Although_CS the_AT company_NN1 tested_VVD_VVN the_AT product_NN1 for_IF flavor_NN1 ,_Y appearance_NN1 ,_Y and_CC fragrance_NN1 ,_Y it_PPH1 did_VDD not_XX test_VVI the_AT product_NN1 's_GE toxicity._NNU n14_FO In_II sufficient_JJ doses_NN2 ,_Y diethylene_NN1 glycol_NN1 is_VBZ toxic_JJ to_II humans_NN2 and_CC animals_NN2 ,_Y causing_VVG renal_JJ failure_NN1 ,_Y encephalopathy_NN1 ,_Y and_CC death._NNU n15_FO A_ZZ1 scientific_JJ literature_NN1 review_NN1 or_CC a_AT1 few_DA2 simple_JJ animal_NN1 tests_NN2 would_VM have_VHI revealed_VVN its_Z' lethal_JJ properties._NNU n16_FO S.E._ND1 Massengill_NP1 ,_Y however_RR ,_Y shipped_VVD_VVN the_AT product_NN1 without_IW taking_VVG these_DD2 precautions_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   24 Between September and October 1937 , more than one hundred people across the country obtained the product from their doctors or bought it from a pharmacy and died after consuming it. ( n17 ) <p> After news of the strange deaths began surfacing , the FDA investigated and intervened , seizing shipments from pharmacies and doctor 's offices across the country .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   24 Between_II September_NPM1 and_CC October_NPM1 1937_MC ,_Y more_DAR than_CSN one_MC1 hundred_M people_NN across_II the_AT country_NN1 obtained_VVD_VVN the_AT product_NN1 from_II their_APPGE doctors_NN2 or_CC bought_VVD it_PPH1 from_II a_AT1 pharmacy_NN1 and_CC died_VVD after_II consuming_VVG it._NNU (_Y n17_FO )_Y <p>_Y After_CS_II news_NN1 of_IO the_AT strange_JJ deaths_NN2 began_VVD surfacing_VVG ,_Y the_AT FDA_NN1_NP1 investigated_VVN_VVD and_CC intervened_VVN ,_Y seizing_VVG_JJ shipments_NN2 from_II pharmacies_NN2 and_CC doctor_NN1 's_GE offices_NN2 across_II the_AT country_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   25 But the FDA 's sole authority for these seizures was not--as one might toxicity review .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   25 But_CCB the_AT FDA_NP1_NN1 's_GE sole_JJ authority_NN1 for_IF these_DD2 seizures_NN2 was_VBDZ not--as_CSA_RG@ one_PN1_MC1 might_VM_NN1% toxicity_NN1 review_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   26 Ironically , the FDA only had authority to intervene through the 1906 Act 's prohibition against label misbranding. n18 The term " elixir " on the product 's label implied that the product was an alcohol solution when , in fact , it contained no alcohol. n19 Had the product instead been labeled a " solution , " the FDA would have had no authority under the 1906 Act to intervene. ( n20 ) <p> In response to the crisis , Congress repealed the 1906 Act and replaced it with the Federal Food , Drug , and Cosmetic Act of 1938 ( FDCA ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   26 Ironically_RR ,_Y the_AT FDA_NN1_NP1 only_RR had_VHN@_VHD authority_NN1 to_TO intervene_VVI through_II the_AT 1906_MC Act_NN1 's_GE prohibition_NN1 against_II label_NN1 misbranding._NNU n18_FO The_AT term_NN1 "_Y elixir_NN1 "_Y on_II the_AT product_NN1 's_GE label_NN1 implied_VVD_VVN that_CST the_AT product_NN1 was_VBDZ an_AT1 alcohol_NN1 solution_NN1 when_RRQ_CS ,_Y in_II fact_NN1 ,_Y it_PPH1 contained_VVD no_AT alcohol._NNU n19_FO Had_VHD the_AT product_NN1 instead_RR been_VBN labeled_VVN@ a_AT1 "_Y solution_NN1 ,_Y "_Y the_AT FDA_NN1_NP1 would_VM have_VHI had_VHN@ no_AT authority_NN1 under_II the_AT 1906_MC Act_NN1_VV0@ to_II intervene._NNU (_Y n20_FO )_Y <p>_Y In_II31 response_II32 to_II33 the_AT crisis_NN1 ,_Y Congress_NN1 repealed_VVD_VVN the_AT 1906_MC Act_NN1 and_CC replaced_VVD_VVN it_PPH1 with_IW the_AT Federal_JJ Food_NN1 ,_Y Drug_NN1 ,_Y and_CC Cosmetic_JJ Act_NN1 of_IO 1938_MC (_Y FDCA_NP1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   27 n21 The increased protections of the new act included an FDA pre-market notification ( but not approval ) requirement for all " new drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   27 n21_FO The_AT increased_JJ protections_NN2 of_IO the_AT new_JJ act_NN1 included_VVD_VVN an_AT1 FDA_NN1 pre-market_NN1_JJ notification_NN1 (_Y but_CCB not_XX approval_NN1 )_Y requirement_NN1 for_IF all_DB "_Y new_JJ drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   28 " n22 In order to market a new drug , a manufacturer would submit a New Drug Application ( NDA ) to the FDA .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   28 "_Y n22_FO In_BCL21 order_BCL22 to_TO market_VVI a_AT1 new_JJ drug_NN1 ,_Y a_AT1 manufacturer_NN1 would_VM submit_VVI a_AT1 New_JJ Drug_NN1 Application_NN1 (_Y NDA_NP1 )_Y to_II the_AT FDA_NN1_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   29 If the FDA did not affirmatively deny the application within sixty days , then the manufacturer could market the drug immediately. n23 Unsurprisingly , given the Elixir Sulfanilamide incident , this pre-market notification safety , not its efficacy. n24 Thus , the FDA retained jurisdiction over the product label and it obtained authority under the 1938 Act to conduct a pre-market safety review .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   29 If_CS the_AT FDA_NP1_NN1 did_VDD not_XX affirmatively_RR deny_VVI the_AT application_NN1 within_II sixty_MC days_NNT2 ,_Y then_RT the_AT manufacturer_NN1 could_VM market_VVI the_AT drug_NN1 immediately._NNU n23_FO Unsurprisingly_RR ,_Y given_VVN the_AT Elixir_NP1_NN1 Sulfanilamide_NP1_NN1 incident_NN1 ,_Y this_DD1 pre-market_JJ_NN1 notification_NN1 safety_NN1 ,_Y not_XX its_Z' efficacy._NNU n24_FO Thus_RR ,_Y the_AT FDA_NP1_NN1 retained_VVD_VVN_JJ@ jurisdiction_NN1 over_II the_AT product_NN1 label_NN1 and_CC it_PPH1 obtained_VVD authority_NN1 under_II the_AT 1938_MC Act_NN1_VV0@ to_TO conduct_VVI a_AT1 pre-market_JJ_NN1 safety_NN1 review_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   30 <p> In the same year Congress expressly vested jurisdiction over all drug advertisements with the Federal Trade Commission ( FTC ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   30 <p>_Y In_II the_AT same_DA year_NNT1 Congress_NN1 expressly_RR vested_JJ_VVN jurisdiction_NN1 over_II_RP all_DB drug_NN1 advertisements_NN2 with_IW the_AT Federal_JJ Trade_NN1 Commission_NN1 (_Y FTC_NP1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   31 n25 Congress had created the FTC in 1914 with the passage of the Federal Trade Commission Act. n26 Under that Act , Congress authorized the FTC to regulate advertising generally , though the Supreme Court 's interpretation of the statute limited the FTC 's purview to deceptive advertising that harmed a competitor company. ( n27 ) <p> Earlier proposals to amend the 1906 Act had sought to regulate DTC advertising of drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   31 n25_FO Congress_NN1 had_VHD created_VVN the_AT FTC_NP1 in_II 1914_MC with_IW the_AT passage_NN1 of_IO the_AT Federal_JJ Trade_NN1 Commission_NN1 Act._NP1 n26_FO Under_II that_DD1 Act_NN1 ,_Y Congress_NN1 authorized_VVN_VVD@ the_AT FTC_NP1 to_TO regulate_VVI advertising_NN1_VVG@ generally_RR ,_Y though_CS the_AT Supreme_JJ Court_NN1 's_GE interpretation_NN1 of_IO the_AT statute_NN1 limited_VVN_VVD@ the_AT FTC_NP1 's_GE purview_NN1 to_II deceptive_JJ advertising_NN1 that_CST harmed_VVD a_AT1 competitor_NN1 company._NNU (_Y n27_FO )_Y <p>_Y Earlier_JJR proposals_NN2 to_TO amend_VVI the_AT 1906_MC Act_NN1 had_VHD sought_VVN to_TO regulate_VVI DTC_NP1 advertising_NN1 of_IO drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   32 The legislative history of those attempts reveals the nature and extent of DTC advertising at the time .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   32 The_AT legislative_JJ history_NN1 of_IO those_DD2 attempts_NN2 reveals_VVZ the_AT nature_NN1 and_CC extent_NN1 of_IO DTC_NP1 advertising_NN1 at_II the_AT time_NNT1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   33 Legislation introduced in 1933 named some thirty-six particular disease states or conditions for which any advertising would be necessarily deemed false , including measles , mumps , scarlet fever , sexual impotence , tuberculosis , and venereal diseases. n28 The bill included an exception , however , medical and pharmacological professions only or if the advertisement appears in scientific periodicals .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   33 Legislation_NN1 introduced_VVN_VVD in_II 1933_MC named_VVD_VVN some_DD thirty-six_MC particular_JJ disease_NN1 states_NN2_VVZ or_CC conditions_NN2 for_IF which_DDQ any_DD advertising_NN1 would_VM be_VBI necessarily_RR deemed_VVN false_JJ_RR@ ,_Y including_II_VVG@ measles_NN ,_Y mumps_NN2_VVZ ,_Y scarlet_JJ fever_NN1 ,_Y sexual_JJ impotence_NN1 ,_Y tuberculosis_NN1 ,_Y and_CC venereal_JJ diseases._NNU n28_FO The_AT bill_NN1 included_VVD_VVN an_AT1 exception_NN1 ,_Y however_RR ,_Y medical_JJ and_CC pharmacological_JJ professions_NN2 only_RR_JJ or_CC if_CS_CSW@ the_AT advertisement_NN1 appears_VVZ in_II scientific_JJ periodicals_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   34 " n29 The list of diseases and the need for a direct-to-physician exception suggest that DTC advertising was pervasive in the early 1930s and provide clues as to the conditions these products were marketed to address .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   34 "_Y n29_FO The_AT list_NN1 of_IO diseases_NN2 and_CC the_AT need_NN1 for_IF a_AT1 direct-to-physician_JJ_NN1 exception_NN1 suggest_VV0 that_CST DTC_NP1 advertising_NN1 was_VBDZ pervasive_JJ in_II the_AT early_JJ 1930s_MC2 and_CC provide_VV0 clues_NN2 as_II21 to_II22 the_AT conditions_NN2 these_DD2 products_NN2 were_VBDR marketed_VVN to_TO address_VVI ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   35 <p> B. Establishment of the Modern Regulatory Regime for Approval and Marketing of Prescription Drugs Before 1951 , there was no recognized category under federal law for prescription drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   35 <p>_Y B._NP1 Establishment_NN1 of_IO the_AT Modern_JJ Regulatory_JJ Regime_NN1 for_IF Approval_NN1 and_CC Marketing_NN1 of_IO Prescription_NN1 Drugs_NN2 Before_II 1951_MC ,_Y there_EX was_VBDZ no_AT recognized_JJ@ category_NN1 under_II_RG@ federal_JJ law_NN1 for_IF prescription_NN1 drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   36 That year , Congress enacted the Durham-Humphrey Amendments to the FDCA , which required licensed pharmacists to dispense drugs that can not be safely used without medical supervision. n30 It is uncertain whether the prescription requirement put an immediate halt to DTC advertising .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   36 That_DD1 year_NNT1 ,_Y Congress_NN1 enacted_VVD_VVN the_AT Durham-Humphrey_NP1 Amendments_NN2 to_II the_AT FDCA_NN1_NP1 ,_Y which_DDQ required_VVD@_JJ licensed_JJ pharmacists_NN2 to_TO dispense_VVI drugs_NN2 that_CST_DD1 can_VM not_XX be_VBI safely_RR used_VVN_VVD without_IW medical_JJ supervision._NNU n30_FO It_PPH1 is_VBZ uncertain_JJ whether_CSW the_AT prescription_NN1 requirement_NN1 put_VVD_VVN_VV0 an_AT1 immediate_JJ halt_NN1 to_II DTC_NP1 advertising_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   37 If we assume that the history of the 1933 legislation is indicative of the nature and extent of DTC advertising at the time of that bill 's consideration , then we can extrapolate on the legislative history of the next major alteration to the FDCA , the 1962 Kefauver-Harris Drug Amendments .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   37 If_CS we_PPIS2 assume_VV0 that_CST the_AT history_NN1 of_IO the_AT 1933_MC legislation_NN1 is_VBZ indicative_JJ of_IO the_AT nature_NN1 and_CC extent_NN1 of_IO DTC_NP1 advertising_NN1 at_II the_AT time_NNT1 of_IO that_DD1 bill_NN1 's_GE consideration_NN1 ,_Y then_RT we_PPIS2 can_VM extrapolate_VVI on_II the_AT legislative_JJ history_NN1 of_IO the_AT next_MD major_JJ alteration_NN1 to_II the_AT FDCA_NN1_NP1 ,_Y the_AT 1962_MC Kefauver-Harris_NP1 Drug_NN1 Amendments_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   38 That legislative history suggests that implementation of a prescription-drug regulatory scheme in 1951 curbed marketing focus to physicians and heath care professionals .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   38 That_DD1 legislative_JJ history_NN1 suggests_VVZ that_DD1_CST implementation_NN1 of_IO a_AT1 prescription-drug_JJ regulatory_JJ scheme_NN1 in_II 1951_MC curbed_VVD marketing_NN1 focus_NN1_VV0 to_II physicians_NN2 and_CC heath_NN1 care_NN1 professionals_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   39 <p> In 1962 , the Kefauver-Harris Drug Amendments authorized the FDA to regulate the marketing of prescription drugs. n31 By this time , Congress was drawing a distinction between the advertising of over-the-counter ( OTC ) medicines , which are directed at consumers , and the marketing of prescription drugs , the bulk of which , in Congress 's estimation , was already directed at the medical community. n32 A memorandum of understanding between the two agencies governs this allocation of responsibilities in which the FTC continues to regulate OTC advertising , whereas the FDA regulates the marketing of prescription drugs. ( n33 ) <p> The 1962 Amendments and their implementing regulations set two major requirements for all prescription drug advertising. n34 First , advertisements must contain a " summary " that provides a description of the drug 's side effects , contraindications , warnings , and precautions , as well as its directions for use. n35 Second , the advertisement , when viewed in its entirety , must present a " fair balance " between the information relating to the drug profile. ( n36 ) <p> The 1962 Amendments also strengthened the FDA 's pre-market review process , implementing the procedure that remains largely in effect today .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   39 <p>_Y In_II 1962_MC ,_Y the_AT Kefauver-Harris_NP1 Drug_NN1 Amendments_NN2 authorized_VVN_VVD@ the_AT FDA_NN1_NP1 to_TO regulate_VVI the_AT marketing_NN1 of_IO prescription_NN1 drugs._NNU n31_FO By_II this_DD1 time_NNT1 ,_Y Congress_NN1 was_VBDZ drawing_VVG a_AT1 distinction_NN1 between_II the_AT advertising_NN1 of_IO over-the-counter_NN1_JJ (_Y OTC_NP1 )_Y medicines_NN2 ,_Y which_DDQ are_VBR directed_VVN at_II consumers_NN2 ,_Y and_CC the_AT marketing_NN1 of_IO prescription_NN1 drugs_NN2 ,_Y the_AT bulk_NN1 of_IO which_DDQ ,_Y in_II Congress_NN1 's_GE estimation_NN1 ,_Y was_VBDZ already_RR directed_VVN_VVD at_II the_AT medical_JJ community._NNU n32_FO A_ZZ1 memorandum_NN1 of_IO understanding_VVG_NN1 between_II the_AT two_MC agencies_NN2 governs_VVZ this_DD1 allocation_NN1 of_IO responsibilities_NN2 in_II which_DDQ the_AT FTC_NP1 continues_VVZ to_TO regulate_VVI OTC_NN1_NP1 advertising_NN1 ,_Y whereas_CS the_AT FDA_NN1_NP1 regulates_VVZ the_AT marketing_NN1 of_IO prescription_NN1 drugs._NNU (_Y n33_FO )_Y <p>_Y The_AT 1962_MC Amendments_NN2 and_CC their_APPGE implementing_VVG_NN1% regulations_NN2 set_VVD_VV0_VVN two_MC major_JJ requirements_NN2 for_IF all_DB prescription_NN1 drug_NN1 advertising._NNU n34_FO First_MD ,_Y advertisements_NN2 must_VM contain_VVI a_AT1 "_Y summary_NN1 "_Y that_CST_DD1 provides_VVZ a_AT1 description_NN1 of_IO the_AT drug_NN1 's_GE side_NN1 effects_NN2 ,_Y contraindications_NN2 ,_Y warnings_NN2 ,_Y and_CC precautions_NN2 ,_Y as_II31 well_II32 as_II33 its_Z' directions_NN2 for_IF use._NNU n35_FO Second_MD ,_Y the_AT advertisement_NN1 ,_Y when_CS_RRQ viewed_VVN in_II its_Z' entirety_NN1 ,_Y must_VM present_VVI a_AT1 "_Y fair_JJ balance_NN1 "_Y between_II the_AT information_NN1 relating_VVG to_II the_AT drug_NN1 profile._NNU (_Y n36_FO )_Y <p>_Y The_AT 1962_MC Amendments_NN2 also_RR strengthened_VVD_VVN the_AT FDA_NP1_NN1 's_GE pre-market_JJ_NN1 review_NN1 process_NN1_VV0 ,_Y implementing_VVG the_AT procedure_NN1 that_CST_DD1 remains_VVZ largely_RR in_II effect_NN1 today_RT ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   40 Once again , the prompt for regulation arose out of a public health crisis .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   40 Once_RR21 again_RR22 ,_Y the_AT prompt_NN1_JJ for_IF regulation_NN1 arose_VVD out_II21 of_II22 a_AT1 public_JJ_NN1 health_NN1 crisis_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   41 Thalidomide , a drug approved for marketing in various European countries , was discovered to be a teratogen , an agent that can cause malformations of an embryo or fetus. n37 A manufacturer had submitted an NDA to market the drug for use in the United States , which was pending at the time of this discovery .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   41 Thalidomide_VV0_NN1_NP1@ ,_Y a_AT1 drug_NN1 approved_VVN_VVD for_IF marketing_NN1_VVG@ in_II various_JJ European_JJ countries_NN2 ,_Y was_VBDZ discovered_VVN@ to_TO be_VBI a_AT1 teratogen_NN1 ,_Y an_AT1 agent_NN1 that_CST_DD1 can_VM cause_VVI malformations_NN2 of_IO an_AT1 embryo_NN1 or_CC fetus._NNU n37_FO A_ZZ1 manufacturer_NN1 had_VHD submitted_VVN an_AT1 NDA_NN1 to_TO market_VVI the_AT drug_NN1 for_IF use_NN1 in_II the_AT United_NP1 States_NP1 ,_Y which_DDQ was_VBDZ pending_JJ at_II the_AT time_NNT1 of_IO this_DD1 discovery_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   42 Congress responded by amending the FDCA to require affirmative approval by the FDA for NDAs , replacing the notification and automatic-approval system put in place by the 1938 Act. n38 In addition , Congress required manufacturers submitting NDAs to prove not only that a drug was safe , n39 but also that the product was effective. n40 For its part , the FDA now had to reach an affirmative conclusion that the drug was both safe and effective before the drug could be marketed. n41 The standards for approval have remained to guide both the industry and the FDA in their daily decisions to the present. ( n42 ) <p> Procedurally , the FDA 's Center for Drug Evaluation and Research ( CDER ) reviews and approves NDAs , n43 and then evalutes the drug 's proposed labeling. n44 The FDA must find that the results and data submitted in the NDA justify each statement proposed for drug labeling. n45 Federal regulations require dividing the label 's content into sections , including a list of the drug 's approved indications and usage , n46 contraindications , n47 warnings , n48 precautions , n49 and adverse reactions. n50 The FDA must approve the label 's content before it accepts the NDA and the company begins marketing the drug .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   42 Congress_NN1 responded_VVN by_II amending_VVG the_AT FDCA_NN1_NP1 to_TO require_VVI affirmative_JJ_NN1 approval_NN1 by_II the_AT FDA_NN1 for_IF NDAs_NN2 ,_Y replacing_VVG the_AT notification_NN1 and_CC automatic-approval_JJ_NN1 system_NN1 put_VVN_VVD in_II place_NN1 by_II the_AT 1938_MC Act._NP1 n38_FO In_RR21 addition_RR22 ,_Y Congress_NN1 required_JJ_VVN manufacturers_NN2 submitting_VVG NDAs_NN2 to_TO prove_VVI not_XX only_RR that_CST a_AT1 drug_NN1 was_VBDZ safe_JJ ,_Y n39_FO but_CCB also_RR that_CST the_AT product_NN1 was_VBDZ effective._NNU n40_FO For_IF its_Z' part_NN1 ,_Y the_AT FDA_NN1_NP1 now_RT had_VHD to_TO reach_VVI an_AT1 affirmative_JJ_NN1 conclusion_NN1 that_CST the_AT drug_NN1 was_VBDZ both_RR safe_JJ and_CC effective_JJ before_II_CS the_AT drug_NN1 could_VM be_VBI marketed._NNU n41_FO The_AT standards_NN2 for_IF approval_NN1 have_VH0 remained_VVN to_TO guide_VVI both_DB2_RR the_AT industry_NN1 and_CC the_AT FDA_NN1_NP1 in_II their_APPGE daily_JJ decisions_NN2 to_II the_AT present._NNU (_Y n42_FO )_Y <p>_Y Procedurally_RR_NP1@ ,_Y the_AT FDA_NP1_NN1 's_GE Center_NN1 for_IF Drug_NN1 Evaluation_NN1 and_CC Research_NN1 (_Y CDER_NP1 )_Y reviews_NN2_VVZ and_CC approves_VVZ NDAs_NP2_NN2 ,_Y n43_FO and_CC then_RT evalutes_VVZ the_AT drug_NN1 's_VBZ_GE_VHZ@ proposed_VVN_JJ labeling._NNU n44_FO The_AT FDA_NN1_NP1 must_VM find_VVI that_CST the_AT results_NN2 and_CC data_NN submitted_VVN_VVD in_II the_AT NDA_NN1_NP1 justify_VV0 each_DD1 statement_NN1 proposed_VVN_VVD for_IF drug_NN1 labeling._NNU n45_FO Federal_JJ regulations_NN2 require_VV0 dividing_VVG the_AT label_NN1 's_GE content_NN1_JJ into_II sections_NN2 ,_Y including_II_VVG@ a_AT1 list_NN1 of_IO the_AT drug_NN1 's_GE approved_JJ_VVN indications_NN2 and_CC usage_NN1 ,_Y n46_FO contraindications_NN2 ,_Y n47_FO warnings_NN2 ,_Y n48_FO precautions_NN2 ,_Y n49_FO and_CC adverse_JJ reactions._NNU n50_FO The_AT FDA_NN1_NP1 must_VM approve_VVI the_AT label_NN1 's_GE content_NN1_JJ before_CS it_PPH1 accepts_VVZ the_AT NDA_NN1_NP1 and_CC the_AT company_NN1 begins_VVZ marketing_VVG the_AT drug_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   43 <p> C. DTC Advertising and Its Regulation Today The Division of Drug Marketing , Advertising , and Communications ( DDMAC ) , a separate component of CDER , reviews pharmaceutical marketing practices .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   43 <p>_Y C._NP1 DTC_NP1 Advertising_NN1 and_CC Its_Z' Regulation_NN1 Today_RT The_AT Division_NN1 of_IO Drug_NN1 Marketing_NN1 ,_Y Advertising_NN1_VVG@ ,_Y and_CC Communications_NN2 (_Y DDMAC_NP1 )_Y ,_Y a_AT1 separate_JJ component_NN1 of_IO CDER_NP1_NN1 ,_Y reviews_VVZ pharmaceutical_JJ marketing_NN1 practices_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   44 There are no formal regulations that distinguish DTC advertising from direct-to-physician advertising. n51 Rather , the FDA recognizes three distinct types of advertising , based on the advertisements ' content .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   44 There_EX are_VBR no_AT formal_JJ regulations_NN2 that_CST distinguish_VV0 DTC_NP1 advertising_NN1 from_II direct-to-physician_JJ_NN1 advertising._NNU n51_FO Rather_RR@_RG ,_Y the_AT FDA_NN1_NP1 recognizes_VVZ three_MC distinct_JJ types_NN2 of_IO advertising_NN1 ,_Y based_VVN on_II the_AT advertisements_NN2 '_GE content_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   45 call attention to a product or brand name , but contain no reference to the purpose of the drug , its benefits , or risks. n52 Reminder advertisements are exempt from the brief-summary requirement. n53 Second , " help-seeking " advertisements describe a disease or condition and direct the consumer to see his doctor , but do not mention the drug 's name. n54 Finally , product-claim advertisements reveal both the product 's name and its contraindications. n55 These product-claim advertisements must satisfy the " brief summary " and " fair balance " requirements. ( n56 ) <p> In the twenty years following enactment of the 1962 Amendments , pharmaceutical manufacturers directed advertisements and promotional practices almost exclusively toward physicians. n57 It was not until the early 1980s that manufacturers began to place advertisements for prescription medicines in mainstream print media n58 Soon after these advertisements began to run , the FDA asked for a voluntary moratorium of the practice. ( n59 ) <p> In 1985 , the FDA decided to permit DTC advertising so long as the manufacturer complied with the " brief summary " and " fair balance " media , the product 's approved physician labeling was reprinted in the advertisement to satisfy the " brief summary " requirement .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   45 call_VV0_NN1 attention_NN1 to_II a_AT1 product_NN1 or_CC brand_NN1_VV0@ name_NN1 ,_Y but_CCB contain_VV0 no_AT reference_NN1 to_II the_AT purpose_NN1 of_IO the_AT drug_NN1 ,_Y its_Z' benefits_NN2 ,_Y or_CC risks._NNU n52_FO Reminder_NN1 advertisements_NN2 are_VBR exempt_JJ from_II the_AT brief-summary_NN1 requirement._NNU n53_FO Second_MD ,_Y "_Y help-seeking_JJ_NN1 "_Y advertisements_NN2 describe_VV0 a_AT1 disease_NN1 or_CC condition_NN1 and_CC direct_VV0@_RR@ the_AT consumer_NN1 to_TO see_VVI his_APPGE doctor_NN1 ,_Y but_CCB do_VD0 not_XX mention_VVI the_AT drug_NN1 's_GE name._NNU n54_FO Finally_RR ,_Y product-claim_JJ_NN1 advertisements_NN2 reveal_VV0 both_RR the_AT product_NN1 's_GE name_NN1 and_CC its_Z' contraindications._NNU n55_FO These_DD2 product-claim_JJ advertisements_NN2 must_VM satisfy_VVI the_AT "_Y brief_JJ summary_NN1 "_Y and_CC "_Y fair_JJ balance_NN1 "_Y requirements._NNU (_Y n56_FO )_Y <p>_Y In_II the_AT twenty_MC years_NNT2 following_RA@_VVG_II@ enactment_NN1 of_IO the_AT 1962_MC Amendments_NN2 ,_Y pharmaceutical_JJ manufacturers_NN2 directed_VVD_VVN advertisements_NN2 and_CC promotional_JJ practices_NN2 almost_RR exclusively_RR toward_II physicians._NNU n57_FO It_PPH1 was_VBDZ not_XX until_CS_II@ the_AT early_JJ 1980s_MC2 that_CST manufacturers_NN2 began_VVD to_TO place_VVI advertisements_NN2 for_IF prescription_NN1 medicines_NN2 in_II mainstream_JJ print_NN1 media_NN n58_FO Soon_RR after_CS_II these_DD2 advertisements_NN2 began_VVD to_TO run_VVI ,_Y the_AT FDA_NP1_NN1 asked_VVD for_IF a_AT1 voluntary_JJ moratorium_NN1 of_IO the_AT practice._NNU (_Y n59_FO )_Y <p>_Y In_II 1985_MC ,_Y the_AT FDA_NP1_NN1 decided_VVD_VVN to_TO permit_VVI DTC_NP1 advertising_NN1_VVG@ so_RG long_RR_JJ as_CSA the_AT manufacturer_NN1 complied_VVN_VVD with_IW the_AT "_Y brief_JJ summary_NN1 "_Y and_CC "_Y fair_JJ balance_NN1 "_Y media_NN ,_Y the_AT product_NN1 's_GE approved_JJ_VVN physician_NN1 labeling_NN1@_VVG was_VBDZ reprinted_VVN in_II the_AT advertisement_NN1 to_TO satisfy_VVI the_AT "_Y brief_JJ summary_NN1 "_Y requirement_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   46 This practice , however , presented challenges for broadcast advertising .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   46 This_DD1 practice_NN1 ,_Y however_RR ,_Y presented_VVD_JJ@_VVN challenges_NN2 for_IF broadcast_NN1_JJ@ advertising_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   47 A thirty-second TV spot was both too expensive and too short for a manufacturer to read the brief summary or scroll through the product 's package insert. ( n61 ) <p> In response to industry inquiry , the FDA held public hearings on DTC broadcast advertising in 1995 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   47 A_AT1_ZZ1 thirty-second_MD_NNU TV_NN1 spot_NN1 was_VBDZ both_RR too_RG expensive_JJ and_CC too_RG short_JJ_RR@ for_IF a_AT1 manufacturer_NN1 to_TO read_VVI the_AT brief_JJ summary_NN1 or_CC scroll_VV0_NN1 through_II the_AT product_NN1 's_GE package_NN1 insert._NNU (_Y n61_FO )_Y <p>_Y In_II31 response_II32 to_II33 industry_NN1 inquiry_NN1 ,_Y the_AT FDA_NP1_NN1 held_VVD_VVN public_JJ hearings_NN2 on_II DTC_NP1 broadcast_NN1_VV0_JJ@ advertising_NN1_VVG@ in_II 1995_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   48 The agency issued a Draft Guidance document in 1997 , which became its final position in 1999. n62 The Guidance document removed barriers to broadcast advertising largely by transforming the " brief summary " requirement for print advertising into what is now known as the " major statement " requirement for broadcast advertising. n63 Under that requirement , the advertisement need not repeat all potential side effects , contraindications , warnings , and precautions associated with the product , but it must , in consumer-friendly language , disclose the drug 's major risks in either the audio or visual component. n64 Further , to make " adequate provision " clear that the advertisement must publicize a toll-free telephone number through which the patient can obtain a copy of the product 's label refer the patient to a print advertisement or other non-web-based resource for additional information , include a web address providing access to the product 's labeling , and refer the patient to his doctor or pharmacist. n65 Although the Guidance document does not have binding legal effect , the FDA essentially placed manufacturers on notice that it would not take regulatory action when a broadcast advertisement complies with the Guidance document 's terms. ( n66 ) <p> Additionally , as with all advertisements , the broadcast messaging must not be false or misleading in any respect .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   48 The_AT agency_NN1 issued_VVD_VVN a_AT1 Draft_NN1 Guidance_NN1 document_NN1 in_II 1997_MC ,_Y which_DDQ became_VVD its_Z' final_JJ_NN1 position_NN1 in_II 1999._MC n62_FO The_AT Guidance_NN1 document_NN1 removed_VVD_VVN barriers_NN2 to_TO broadcast_VVI advertising_NN1_VVG@ largely_RR by_II transforming_VVG the_AT "_Y brief_JJ summary_NN1 "_Y requirement_NN1 for_IF print_NN1 advertising_NN1_VVG@ into_II what_DDQ is_VBZ now_RT known_VVN as_II the_AT "_Y major_JJ statement_NN1 "_Y requirement_NN1 for_IF broadcast_NN1_JJ@_VVN advertising._NNU n63_FO Under_II that_DD1 requirement_NN1 ,_Y the_AT advertisement_NN1 need_VM@ not_XX repeat_VVI all_DB potential_JJ side_NN1 effects_NN2 ,_Y contraindications_NN2 ,_Y warnings_NN2 ,_Y and_CC precautions_NN2 associated_VVN with_IW the_AT product_NN1 ,_Y but_CCB it_PPH1 must_VM ,_Y in_II consumer-friendly_JJ language_NN1 ,_Y disclose_VV0 the_AT drug_NN1 's_GE major_JJ risks_NN2 in_II_RP@ either_RR the_AT audio_NN1_JJ or_CC visual_JJ component._NNU n64_FO Further_RRR@ ,_Y to_TO make_VVI "_Y adequate_JJ provision_NN1 "_Y clear_JJ that_CST the_AT advertisement_NN1 must_VM publicize_VVI a_AT1 toll-free_JJ telephone_NN1 number_NN1 through_II which_DDQ the_AT patient_NN1 can_VM obtain_VVI a_AT1 copy_NN1 of_IO the_AT product_NN1 's_GE label_NN1 refer_VV0 the_AT patient_NN1_JJ to_II a_AT1 print_NN1 advertisement_NN1 or_CC other_JJ non-web-based_JJ_NN1 resource_NN1_VV0 for_IF additional_JJ information_NN1 ,_Y include_VV0 a_AT1 web_NN1 address_NN1 providing_VVG access_NN1 to_II the_AT product_NN1 's_GE labeling_VVG_NN1@_JJ@ ,_Y and_CC refer_VV0 the_AT patient_NN1_JJ to_II his_APPGE doctor_NN1 or_CC pharmacist._NNU n65_FO Although_CS the_AT Guidance_NN1 document_NN1 does_VDZ not_XX have_VHI binding_JJ legal_JJ effect_NN1 ,_Y the_AT FDA_NN1_NP1 essentially_RR placed_VVN manufacturers_NN2 on_II notice_NN1 that_CST it_PPH1 would_VM not_XX take_VVI regulatory_JJ action_NN1 when_CS_RRQ a_AT1 broadcast_NN1_JJ@ advertisement_NN1 complies_VVZ with_IW the_AT Guidance_NN1 document_NN1 's_GE terms._NNU (_Y n66_FO )_Y <p>_Y Additionally_RR ,_Y as_CSA with_IW all_DB advertisements_NN2 ,_Y the_AT broadcast_NN1_JJ@ messaging_NN1 must_VM not_XX be_VBI false_JJ or_CC misleading_JJ in_II any_DD respect_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   49 Beyond assessing the pure content , DDMAC may also consider the form of the audio and video production and presentation ( for example , the graphics and superimposition of text , the pacing and clarity of voiceovers , the visual editing , and sound effects or music ) to ensure that the advertisement is " fairly balanced " and that risk information is adequately communicated. ( n67 ) <p> Should DDMAC the law or FDA guidelines , it sends one of two types of letters to the offender. n68 Minor violations are noted in a Notice of Violation ( NOV ) letter. n69 A recipient of an NOV letter typically discontinues the offending marketing practice and responds to DDMAC in writing within ten days , informing it of the discontinuation. n70 For more serious violations , DDMAC sends a warning letter. n71 These letters put the recipient on notice of the FDA 's intent to initiate further regulatory action against the recipient if it refuses to rectify the offending practice promptly .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   49 Beyond_II assessing_VVG the_AT pure_JJ content_NN1_JJ ,_Y DDMAC_NP1_NN1 may_VM also_RR consider_VVI the_AT form_NN1 of_IO the_AT audio_NN1_JJ and_CC video_NN1_VV0@ production_NN1 and_CC presentation_NN1 (_Y for_REX21 example_REX22 ,_Y the_AT graphics_NN and_CC superimposition_NN1 of_IO text_NN1 ,_Y the_AT pacing_VVG and_CC clarity_NN1 of_IO voiceovers_VVZ ,_Y the_AT visual_JJ editing_NN1 ,_Y and_CC sound_NN1 effects_NN2 or_CC music_NN1 )_Y to_TO ensure_VVI that_CST the_AT advertisement_NN1 is_VBZ "_Y fairly_RR balanced_VVN_JJ "_Y and_CC that_DD1_CST risk_NN1_VV0 information_NN1 is_VBZ adequately_RR communicated._NNU (_Y n67_FO )_Y <p>_Y Should_VM DDMAC_NP1_NN1 the_AT law_NN1 or_CC FDA_NN1_NP1 guidelines_NN2 ,_Y it_PPH1 sends_VVZ one_MC1 of_IO two_MC types_NN2 of_IO letters_NN2 to_II the_AT offender._NNU n68_FO Minor_JJ violations_NN2 are_VBR noted_VVN in_II a_AT1 Notice_NN1 of_IO Violation_NN1 (_Y NOV_NPM1 )_Y letter._NNU n69_FO A_ZZ1 recipient_NN1 of_IO an_AT1 NOV_NPM1 letter_NN1 typically_RR discontinues_VVZ the_AT offending_JJ_NN1 marketing_NN1 practice_NN1 and_CC responds_VVZ to_II DDMAC_NP1_NN1_JJ in_II writing_VVG_NN1 within_II ten_M days_NNT2 ,_Y informing_VVG it_PPH1 of_IO the_AT discontinuation._NNU n70_FO For_IF more_RGR_DAR serious_JJ violations_NN2 ,_Y DDMAC_NP1_NN1 sends_VVZ a_AT1 warning_NN1 letter._NNU n71_FO These_DD2 letters_NN2 put_VV0_VVD the_AT recipient_NN1 on_II notice_NN1 of_IO the_AT FDA_NP1_NN1 's_GE intent_NN1_JJ to_TO initiate_VVI further_RRR_JJR@ regulatory_JJ action_NN1 against_II the_AT recipient_NN1 if_CS it_PPH1 refuses_VVZ to_TO rectify_VVI the_AT offending_JJ_NN1 practice_NN1 promptly_RR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   50 Manufacturers have consistently taken the appropriate corrective action indicated in such letters , without the need for further action from the FDA. n72 In addition , the Food and Drug Administration Amendments Act of 2007 ( FDAAA ) gave the FDA the authority to impose civil penalties directly for false or misleading advertisements. ( n73 ) <p> Federal law does not currently mandate pre-market review of DTC advertising .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   50 Manufacturers_NN2 have_VH0 consistently_RR taken_VVN the_AT appropriate_JJ corrective_JJ_NN1 action_NN1 indicated_VVN_VVD in_II such_DA letters_NN2 ,_Y without_IW the_AT need_NN1 for_IF further_JJR@ action_NN1 from_II the_AT FDA._NP1 n72_FO In_RR21 addition_RR22 ,_Y the_AT Food_NN1 and_CC Drug_NN1 Administration_NN1 Amendments_NN2 Act_NN1 of_IO 2007_MC (_Y FDAAA_NP1 )_Y gave_VVD the_AT FDA_NN1_NP1 the_AT authority_NN1 to_TO impose_VVI civil_JJ penalties_NN2 directly_RR for_IF false_JJ or_CC misleading_JJ advertisements._NNU (_Y n73_FO )_Y <p>_Y Federal_JJ law_NN1 does_VDZ not_XX currently_RR mandate_NN1 pre-market_NN1_JJ review_NN1 of_IO DTC_NP1 advertising_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   51 Rather , unless the FDA provides otherwise , n74 manufacturers are required to submit their marketing materials to the agency at n75 Many manufacturers , however , routinely submit proposed advertisements before dissemination on a voluntary basis .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   51 Rather_RR@_RG ,_Y unless_CS the_AT FDA_NN1_NP1 provides_VVZ otherwise_RR ,_Y n74_FO manufacturers_NN2 are_VBR required_VVN to_TO submit_VVI their_APPGE marketing_NN1 materials_NN2 to_II the_AT agency_NN1 at_II n75_FO Many_DA2 manufacturers_NN2 ,_Y however_RR ,_Y routinely_RR submit_VV0 proposed_JJ advertisements_NN2 before_II_CS dissemination_NN1 on_II a_AT1 voluntary_JJ basis_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   52 This provides the FDA with an opportunity to review advertisements before they are released publicly and to suggest improvements. n76 For example , between 2000 and 2006 , the FDA received an average of approximately 150 television advertisements each year for advisory review. n77 In fact , the Pharmaceutical Research and Manufacturers of America ( PhRMA ) , the leading industry group of drug manufacturers , encourages its members to submit all television advertising to the FDA for review before airing. n78 Manufacturers have widely adopted the PhRMA code and continue the longstanding practice of submitting DTC advertisements to the FDA before dissemination. ( n79 ) <p> Some critics , including the General Accounting Office ( GAO ) , have highlighted shortcomings in the regulatory process overseeing pharmaceutical marketing and have suggested that DDMAC needs additional resources .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   52 This_DD1 provides_VVZ the_AT FDA_NN1 with_IW an_AT1 opportunity_NN1 to_TO review_VVI advertisements_NN2 before_CS they_PPHS2 are_VBR released_VVN publicly_RR and_CC to_TO suggest_VVI improvements._NNU n76_FO For_REX21 example_REX22 ,_Y between_II 2000_MC and_CC 2006_MC ,_Y the_AT FDA_NP1_NN1 received_VVD_VVN an_AT1 average_NN1 of_IO approximately_RR 150_MC television_NN1 advertisements_NN2 each_DD1 year_NNT1 for_IF advisory_JJ review._NNU n77_FO In_II fact_NN1 ,_Y the_AT Pharmaceutical_JJ Research_NN1 and_CC Manufacturers_NN2 of_IO America_NP1 (_Y PhRMA_NP1 )_Y ,_Y the_AT leading_JJ industry_NN1 group_NN1 of_IO drug_NN1 manufacturers_NN2 ,_Y encourages_VVZ its_Z' members_NN2 to_TO submit_VVI all_DB television_NN1 advertising_NN1_VVG@ to_II the_AT FDA_NN1 for_IF review_NN1 before_II airing._NNU n78_FO Manufacturers_NN2 have_VH0 widely_RR adopted_VVN the_AT PhRMA_NP1_NN1@ code_NN1 and_CC continue_VV0 the_AT longstanding_JJ practice_NN1 of_IO submitting_VVG DTC_NP1 advertisements_NN2 to_II the_AT FDA_NN1_NP1 before_II dissemination._NNU (_Y n79_FO )_Y <p>_Y Some_DD critics_NN2 ,_Y including_II_VVG@ the_AT General_JJ_NN1 Accounting_NN1_VVG_JJ@ Office_NN1 (_Y GAO_NP1 )_Y ,_Y have_VH0 highlighted_VVN shortcomings_NN2 in_II the_AT regulatory_JJ process_NN1 overseeing_VVG pharmaceutical_JJ marketing_NN1 and_CC have_VH0 suggested_VVN that_CST_DD1 DDMAC_NP1_NN1_JJ needs_VVZ_NN2 additional_JJ resources_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   53 In 2002 , a GAO study examined two deficiencies in the regulation of DTC advertising : the FDA 's inability to be certain that manufacturers submit their advertisements to the agency and the lengthy period before information. n80 When the GAO revisited the issue four years later , it found that this lag time had worsened considerably , leading to a situation where , more often than not , the publication or broadcast of the misleading advertisement had already concluded before the FDA issued its violation letter. n81 It also noted that the FDA had the capacity to review only a small portion of the increasingly large amount of the DTC materials submitted .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   53 In_II 2002_MC ,_Y a_AT1 GAO_NP1 study_NN1 examined_VVD_VVN two_MC deficiencies_NN2 in_II the_AT regulation_NN1 of_IO DTC_NP1 advertising_NN1 :_Y the_AT FDA_NP1_NN1 's_GE inability_NN1 to_TO be_VBI certain_JJ that_CST manufacturers_NN2 submit_VV0 their_APPGE advertisements_NN2 to_II the_AT agency_NN1 and_CC the_AT lengthy_JJ period_NN1 before_II_CS information._NNU n80_FO When_RRQ_CS the_AT GAO_NP1 revisited_VVD the_AT issue_NN1 four_MC years_NNT2 later_RRR ,_Y it_PPH1 found_VVD that_CST this_DD1 lag_NN1 time_NNT1 had_VHD worsened_VVN considerably_RR ,_Y leading_VVG to_II a_AT1 situation_NN1 where_RRQ ,_Y more_RGR often_RR than_CSN not_XX ,_Y the_AT publication_NN1 or_CC broadcast_NN1 of_IO the_AT misleading_JJ advertisement_NN1 had_VHD already_RR concluded_VVN before_II_CS the_AT FDA_NP1_NN1 issued_VVD its_Z' violation_NN1 letter._NNU n81_FO It_PPH1_NN1@ also_RR noted_VVN_VVD that_CST the_AT FDA_NN1_NP1 had_VHD the_AT capacity_NN1 to_TO review_VVI only_RR a_AT1 small_JJ portion_NN1 of_IO the_AT increasingly_RR large_JJ amount_NN1 of_IO the_AT DTC_NP1 materials_NN2 submitted_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   54 Therefore , the FDA closely examined only advertisements for those drugs with the greatest potential to impact the public health. n82 As the FDA recently noted , " the lack of timely , predictable FDA review times for DTC television advertisements has hindered companies ' ability to accurately set timeframes for their marketing campaigns and has discouraged companies from taking advantage of the DTC advisory review process .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   54 Therefore_RR ,_Y the_AT FDA_NN1_NP1 closely_RR examined_VVN_VVD only_JJ advertisements_NN2 for_IF those_DD2 drugs_NN2 with_IW the_AT greatest_JJT potential_NN1_JJ to_II impact_NN1 the_AT public_JJ_NN1 health._NNU n82_FO As_II_CSA the_AT FDA_NN1_NP1 recently_RR noted_VVN_VVD ,_Y "_Y the_AT lack_NN1 of_IO timely_JJ ,_Y predictable_JJ FDA_NN1 review_NN1 times_NNT2_VVZ% for_IF DTC_NP1 television_NN1 advertisements_NN2 has_VHZ hindered_VVN companies_NN2 '_GE ability_NN1 to_TO accurately_RR set_VVI timeframes_NN2 for_IF their_APPGE marketing_NN1 campaigns_NN2 and_CC has_VHZ discouraged_VVN companies_NN2 from_II taking_VVG advantage_NN1 of_IO the_AT DTC_NP1 advisory_JJ review_NN1 process_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   55 " ( n83 ) <p> Congress attempted to address the inability of the FDA to keep pace with the increasing number of DTC advertisements submitted for its review when it enacted FDAAA , which included a new user 's fee program to provide the agency program. n84 The program would have required any company that intended to submit DTC television advertisements for voluntary FDA review to pay an annual fee to help maintain the program. n85 The Act provided , however , that this new program would not go into effect unless the FDA received $11,250,000 in fees within 120 days of enactment ( that is , by January 25 , 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   55 "_Y (_Y n83_FO )_Y <p>_Y Congress_NN1 attempted_VVD_VVN to_TO address_VVI the_AT inability_NN1 of_IO the_AT FDA_NN1_NP1 to_TO keep_VVI pace_NN1 with_IW the_AT increasing_JJ number_NN1 of_IO DTC_NP1 advertisements_NN2 submitted_VVN_VVD for_IF its_Z' review_NN1 when_CS_RRQ it_PPH1 enacted_VVD FDAAA_NP1_NN1 ,_Y which_DDQ included_VVD a_AT1 new_JJ user_NN1 's_GE fee_NN1 program_NN1 to_TO provide_VVI the_AT agency_NN1 program._NNU n84_FO The_AT program_NN1 would_VM have_VHI required_VVN any_DD company_NN1 that_CST intended_VVD to_TO submit_VVI DTC_NP1 television_NN1 advertisements_NN2 for_IF voluntary_JJ FDA_NN1_NP1 review_NN1_VV0 to_TO pay_VVI an_AT1 annual_JJ fee_NN1 to_TO help_VVI maintain_VVI the_AT program._NNU n85_FO The_AT Act_NN1 provided_VVD_VVN_CS ,_Y however_RR ,_Y that_CST this_DD1 new_JJ program_NN1 would_VM not_XX go_VVI into_II effect_NN1 unless_CS the_AT FDA_NP1_NN1 received_VVD $11,250,000_NNU in_II fees_NN2 within_II 120_MC days_NNT2 of_IO enactment_NN1 (_Y that_REX21 is_REX22 ,_Y by_II January_NPM1 25_MC ,_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   56 n86 In January 2008 , the FDA announced that because a subsequent appropriation bill did not include a corresponding authorization for the FDA to collect and spend user fees for the purposes of the program , and because the FDA had not collected the mandated minimum level of funds , it would not implement the new program. n87 Therefore , the FDA continues to review advertisements voluntarily submitted for review " in as timely a manner as resources permit .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   56 n86_FO In_II January_NPM1 2008_MC ,_Y the_AT FDA_NP1_NN1 announced_VVD_VVN that_CST because_CS a_AT1 subsequent_JJ appropriation_NN1 bill_NN1 did_VDD not_XX include_VVI a_AT1 corresponding_JJ authorization_NN1 for_IF the_AT FDA_NN1_NP1 to_TO collect_VVI and_CC spend_VVI user_NN1 fees_NN2 for_IF the_AT purposes_NN2 of_IO the_AT program_NN1 ,_Y and_CC because_CS the_AT FDA_NN1_NP1 had_VHD not_XX collected_VVN the_AT mandated_JJ@ minimum_JJ_NN1 level_NN1 of_IO funds_NN2 ,_Y it_PPH1 would_VM not_XX implement_VVI the_AT new_JJ program._NNU n87_FO Therefore_RR ,_Y the_AT FDA_NN1_NP1 continues_VVZ to_TO review_VVI advertisements_NN2 voluntarily_RR submitted_VVN_VVD for_IF review_NN1 "_Y in_II_RP@ as_RG@_CSA timely_JJ a_AT1 manner_NN1 as_CSA_II@ resources_NN2 permit_VV0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   57 " ( n88 ) <p> D. The Relevance of History to DTC Advertising Today The previously discussed history and development of pharmaceutical regulation reveals some interesting insights .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   57 "_Y (_Y n88_FO )_Y <p>_Y D._NP1 The_AT Relevance_NN1 of_IO History_NN1 to_II DTC_NP1 Advertising_NN1 Today_RT The_AT previously_RR discussed_VVN_VVD history_NN1 and_CC development_NN1 of_IO pharmaceutical_JJ regulation_NN1 reveals_VVZ some_DD interesting_JJ insights_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   58 First , DTC advertising is not a new phenomenon ; in fact , it in early pharmaceutical regulation , the 1906 Pure Food and Drugs Act and the Federal Food , Drug , and Cosmetic Act of 1938 , were born out of responses to public health crises resulting from inadequate testing , not deficiencies specific to DTC advertising. n90 Third , regulation discouraging DTC advertising ( by deeming it false ) was initially proposed and rejected by Congress in an age when the advertisements were likely to have been in printed materials. n91 This history implies that Congress did not find DTC advertising a significant threat to consumer safety , given the need for a prescribing physician. ( n92 ) <p> Modern regulation of pharmaceuticals follows such sentiment .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   58 First_MD ,_Y DTC_NP1 advertising_NN1 is_VBZ not_XX a_AT1 new_JJ phenomenon_NN1 ;_Y in_II fact_NN1 ,_Y it_PPH1 in_II early_JJ_RR pharmaceutical_JJ regulation_NN1 ,_Y the_AT 1906_MC Pure_JJ Food_NN1 and_CC Drugs_NN2 Act_NN1_VV0@ and_CC the_AT Federal_JJ Food_NN1 ,_Y Drug_NN1 ,_Y and_CC Cosmetic_JJ Act_NN1 of_IO 1938_MC ,_Y were_VBDR born_VVN out_II21 of_II22 responses_NN2 to_II public_JJ_NN1 health_NN1 crises_NN2 resulting_VVG from_II inadequate_JJ testing_NN1 ,_Y not_XX deficiencies_NN2 specific_JJ to_II DTC_NP1 advertising._NNU n90_FO Third_MD ,_Y regulation_NN1 discouraging_VVG_JJ DTC_NP1 advertising_NN1 (_Y by_II deeming_VVG it_PPH1 false_RR@_JJ )_Y was_VBDZ initially_RR proposed_VVN_JJ_VVD and_CC rejected_VVN by_II Congress_NN1 in_II an_AT1 age_NN1 when_CS_RRQ the_AT advertisements_NN2 were_VBDR likely_JJ_RR@ to_TO have_VHI been_VBN in_II printed_JJ materials._NNU n91_FO This_DD1 history_NN1 implies_VVZ that_DD1_CST Congress_NN1 did_VDD not_XX find_VVI DTC_NP1 advertising_VVG@_NN1 a_AT1 significant_JJ threat_NN1 to_II consumer_NN1 safety_NN1 ,_Y given_VVN the_AT need_NN1 for_IF a_AT1 prescribing_NN1@_VVG physician._NNU (_Y n92_FO )_Y <p>_Y Modern_JJ regulation_NN1 of_IO pharmaceuticals_NN2 follows_VVZ such_DA sentiment_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   59 In developing comprehensive regulation regarding the safety , efficacy , and marketing of a drug , the FDA has refrained from regulation specific to DTC advertising and has instead approached this form of marketing under the same analysis as direct-to-physician advertising. n93 As DTC advertising resurfaced from dormancy and became more mainstream in the early 1980s , the FDA instituted a voluntary moratorium to examine again whether DTC advertising posed a legitimate concern to consumers FDA has clearly recognized , through its Guidance document and other agency statements , that DTC marketing does not pose a heightened risk to consumers , and may actually prove beneficial. ( n95 ) <p> There is , however , a recognized need to provide the FDA with additional staffing so that it may more promptly review advertisements and suggest improvements .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   59 In_II developing_VVG_JJ comprehensive_JJ regulation_NN1 regarding_II_VVG the_AT safety_NN1 ,_Y efficacy_NN1 ,_Y and_CC marketing_NN1 of_IO a_AT1 drug_NN1 ,_Y the_AT FDA_NN1_NP1 has_VHZ refrained_VVN from_II regulation_NN1 specific_JJ_NN1% to_II DTC_NP1 advertising_NN1 and_CC has_VHZ instead_RR approached_VVN this_DD1 form_NN1 of_IO marketing_NN1_VVG@ under_II the_AT same_DA analysis_NN1 as_CSA direct-to-physician_JJ_NN1 advertising._NNU n93_FO As_CSA DTC_NP1 advertising_NN1 resurfaced_VVD_VVN@ from_II dormancy_NN1 and_CC became_VVD more_RGR_DAR mainstream_JJ in_II the_AT early_JJ 1980s_MC2 ,_Y the_AT FDA_NP1_NN1 instituted_VVD_VVN a_AT1 voluntary_JJ moratorium_NN1 to_TO examine_VVI again_RT whether_CSW DTC_NP1 advertising_NN1 posed_VVD_VVN a_AT1 legitimate_JJ concern_NN1 to_II consumers_NN2 FDA_NN1_NP1 has_VHZ clearly_RR recognized_VVN ,_Y through_II its_Z' Guidance_NN1 document_NN1 and_CC other_JJ agency_NN1 statements_NN2 ,_Y that_CST DTC_NP1 marketing_NN1 does_VDZ not_XX pose_VVI a_AT1 heightened_JJ risk_NN1 to_II consumers_NN2 ,_Y and_CC may_VM actually_RR prove_VVI beneficial._NNU (_Y n95_FO )_Y <p>_Y There_EX is_VBZ ,_Y however_RR ,_Y a_AT1 recognized_JJ@ need_NN1 to_TO provide_VVI the_AT FDA_NN1 with_IW additional_JJ staffing_NN1 so_CS21 that_CS22 it_PPH1 may_VM more_RGR_RRR promptly_RR review_VVI advertisements_NN2 and_CC suggest_VVI improvements_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   60 Such action can only come from Congress .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   60 Such_DA action_NN1 can_VM only_RR come_VVI from_II Congress_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   61 Despite that particular criticism regarding the regulatory review of DTC advertisements , repeated examination of DTC advertising over the past century has not found that it interferes with the doctor-patient relationship or diminishes the role of the FDA in closely regulating the safety and efficacy of the drug .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   61 Despite_II that_DD1 particular_JJ criticism_NN1 regarding_II_VVG the_AT regulatory_JJ review_NN1 of_IO DTC_NP1 advertisements_NN2 ,_Y repeated_VVD_JJ@_VVN examination_NN1 of_IO DTC_NP1 advertising_NN1_VVG@ over_II_RP the_AT past_JJ_NN1 century_NNT1 has_VHZ not_XX found_VVN that_CST it_PPH1 interferes_VVZ with_IW the_AT doctor-patient_JJ_NN1 relationship_NN1 or_CC diminishes_VVZ the_AT role_NN1 of_IO the_AT FDA_NN1_NP1 in_II_RP@ closely_RR regulating_VVG the_AT safety_NN1 and_CC efficacy_NN1 of_IO the_AT drug_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   62 Because DTC marketing of prescription drugs has not fundamentally altered the playing field , traditional rules of law should remain fully viable .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   62 Because_CS DTC_NP1 marketing_NN1 of_IO prescription_NN1 drugs_NN2 has_VHZ not_XX fundamentally_RR altered_VVN the_AT playing_JJ%_VVG_NN1% field_NN1 ,_Y traditional_JJ rules_NN2 of_IO law_NN1 should_VM remain_VVI fully_RR viable_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   63 <p> II .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   63 <p>_Y II_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   64 THE POTENTIAL BENEFITS AND PITFALLS OF DTC ADVERTISING Reaction to the resurgence of DTC advertising within the modern regulated pharmaceutical environment is mixed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   64 THE_AT POTENTIAL_JJ_NN1 BENEFITS_NN2 AND_CC PITFALLS_NN2 OF_IO DTC_NP1 ADVERTISING_NN1 Reaction_NN1 to_II the_AT resurgence_NN1 of_IO DTC_NP1 advertising_NN1 within_II the_AT modern_JJ regulated_JJ@_VVD_VVN pharmaceutical_JJ environment_NN1 is_VBZ mixed_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   65 Critics argue that DTC advertising overemphasizes benefits and downplays risks , which might cause patients to believe that a particular medicine works critics express concern that the presence of DTC campaigns negatively affect the doctor-patient relationship , prompting patients to pressure their physicians to prescribe unneeded medications or to demand a brand name pharmaceutical over cheaper or safer generic alternatives. n97 Beyond issues with the message itself , critics cite the rapid increase in industry spending on DTC advertising--a 330% rise from $985 million in 1996 to $4.2 billion in 2005--as contributing to a contemporaneous rise in drug spending. n98 Critics also perceive an inverse relationship between this increased spending and decreasing regulatory action documenting noncompliance , such as NOV or warning letters , as evidence of an overworked and inefficient FDA. ( n99 ) <p> Proponents counter that DTC advertising fosters healthy physician-patient relationships by providing information to patients that prompts discussion with their physicians .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   65 Critics_NN2 argue_VV0 that_CST DTC_NP1 advertising_NN1 overemphasizes_VVZ benefits_NN2 and_CC downplays_VVZ_NN2 risks_NN2 ,_Y which_DDQ might_VM cause_VVI patients_NN2 to_TO believe_VVI that_CST a_AT1 particular_JJ medicine_NN1 works_VVZ critics_NN2 express_VV0 concern_NN1_VV0@ that_CST the_AT presence_NN1 of_IO DTC_NP1 campaigns_NN2 negatively_RR affect_VV0 the_AT doctor-patient_JJ_NN1 relationship_NN1 ,_Y prompting_VVG patients_NN2 to_II pressure_NN1 their_APPGE physicians_NN2 to_TO prescribe_VVI unneeded_JJ medications_NN2 or_CC to_TO demand_VVI a_AT1 brand_NN1 name_NN1_VV0@ pharmaceutical_JJ over_II cheaper_JJR or_CC safer_RRR_JJR generic_JJ alternatives._NNU n97_FO Beyond_II issues_NN2 with_IW the_AT message_NN1 itself_PPX1 ,_Y critics_NN2 cite_VV0 the_AT rapid_JJ increase_NN1 in_II industry_NN1 spending_VVG_NN1 on_II DTC_NP1 advertising--a_NN1_VVG@ 330%_NNU rise_NN1_VV0 from_II $985_NNU million_M in_II 1996_MC to_II $4.2_NNU billion_M in_II 2005--as_CSA_RG@_II@ contributing_VVG_JJ@ to_II a_AT1 contemporaneous_JJ rise_NN1 in_II drug_NN1 spending._NNU n98_FO Critics_NN2 also_RR perceive_VV0 an_AT1 inverse_JJ_NN1 relationship_NN1 between_II this_DD1 increased_JJ spending_NN1 and_CC decreasing_JJ_VVG regulatory_JJ action_NN1 documenting_VVG_NN1@_JJ@ noncompliance_NN1 ,_Y such_II21 as_II22 NOV_NPM1 or_CC warning_NN1_VVG@ letters_NN2 ,_Y as_CSA evidence_NN1 of_IO an_AT1 overworked_JJ and_CC inefficient_JJ FDA._NP1 (_Y n99_FO )_Y <p>_Y Proponents_NN2 counter_VV0 that_CST DTC_NP1 advertising_NN1 fosters_VVZ healthy_JJ physician-patient_JJ_NN1 relationships_NN2 by_II providing_VVG information_NN1 to_II patients_NN2 that_CST_DD1 prompts_VVZ discussion_NN1 with_IW their_APPGE physicians_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   66 When first surveyed in the 1980s about whether they would value DTC advertising , patients responded that they believed DTC advertising would be useful , but they would still prefer that physicians control prescribing decisions. n100 Twenty years later , in response to one study on consumer perceptions , the majority of patients reported that DTC in their own health care and encouraged them to seek medical care from their physicians. n101 Nevertheless , DTC advertising ranked dead last in a recent poll of which sources consumers report relying upon to provide accurate information about prescription medications .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   66 When_CS first_MD surveyed_VVN_VVD in_II the_AT 1980s_MC2 about_II whether_CSW they_PPHS2 would_VM value_NN1 DTC_NP1 advertising_NN1 ,_Y patients_NN2 responded_VVD_VVN that_CST they_PPHS2 believed_VVD DTC_NP1 advertising_NN1 would_VM be_VBI useful_JJ ,_Y but_CCB they_PPHS2 would_VM still_RR prefer_VVI that_CST physicians_NN2 control_VV0 prescribing_VVG decisions._NNU n100_FO Twenty_MC years_NNT2 later_RRR ,_Y in_II31 response_II32 to_II33 one_MC1 study_NN1 on_II consumer_NN1 perceptions_NN2 ,_Y the_AT majority_NN1 of_IO patients_NN2 reported_VVD_VVN that_CST DTC_NP1 in_II their_APPGE own_DA health_NN1 care_NN1 and_CC encouraged_VVD them_PPHO2 to_TO seek_VVI medical_JJ care_NN1 from_II their_APPGE physicians._NNU n101_FO Nevertheless_RR ,_Y DTC_NP1 advertising_NN1 ranked_VVN_VVD@ dead_JJ_RG@ last_MD_NN1% in_II a_AT1 recent_JJ poll_NN1 of_IO which_DDQ sources_NN2 consumers_NN2 report_VV0@_NN1 relying_VVG upon_II to_TO provide_VVI accurate_JJ information_NN1 about_II prescription_NN1 medications_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   67 Internet websites , family and friends , the FDA , the package label and pharmacists all ranked progressively higher on the list .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   67 Internet_NN1_NP1@ websites_NN2 ,_Y family_NN1 and_CC friends_NN2 ,_Y the_AT FDA_NN1_NP1 ,_Y the_AT package_NN1 label_NN1 and_CC pharmacists_NN2 all_RR@_DB ranked_VVN progressively_RR higher_JJR_RRR@ on_II the_AT list_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   68 In fact , " Your doctor " topped the list overwhelmingly. ( n102 ) <p> Doctors , for their part , greeted DTC advertising with skepticism , but by the early 1990s , the American Academy of Family Physicians expressed an opinion that DTC advertising encourages patients to seek needed medical care. n103 Later , the American Medical Association reversed its blanket policy against DTC advertising in favor of a case-by-case approach. n104 By 2002 , one report showed that the " overwhelming " majority of physicians polled believed that DTC advertising has had a beneficial effect on the doctor-patient relationship. ( n105 ) <p> In 2003 , the FDA published results from what is perhaps the most comprehensive survey to date of physician attitudes toward and 250 specialists in the fields of dermatology , allergy , endocrinology , and psychiatry. n107 Most doctors polled believed that DTC advertising led patients to ask more thoughtful questions , made patients more aware of possible treatments , made patients more concerned about their health care , prompted better discussions between patients and physicians about health , and thus helped educate patients about their health problems. n108 The survey also found that doctors believe patients understand that they need to consult a healthcare professional about appropriate treatment. ( n109 ) <p> This Article does not attempt to resolve this debate or answer whether DTC advertising is good or bad for the industry , patients , or physicians .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   68 In_II fact_NN1 ,_Y "_Y Your_APPGE doctor_NN1 "_Y topped_VVD_VVN the_AT list_NN1 overwhelmingly._NNU (_Y n102_FO )_Y <p>_Y Doctors_NN2 ,_Y for_IF their_APPGE part_NN1 ,_Y greeted_VVD DTC_NP1 advertising_NN1 with_IW skepticism_NN1 ,_Y but_CCB by_II the_AT early_JJ 1990s_MC2 ,_Y the_AT American_JJ Academy_NN1 of_IO Family_NN1 Physicians_NN2 expressed_VVD_VVN an_AT1 opinion_NN1 that_CST DTC_NP1 advertising_NN1 encourages_VVZ patients_NN2 to_TO seek_VVI needed_JJ@_VVN medical_JJ care._NNU n103_FO Later_RRR ,_Y the_AT American_JJ Medical_JJ Association_NN1 reversed_VVD_VVN its_Z' blanket_NN1 policy_NN1 against_II DTC_NP1 advertising_NN1 in_II31 favor_II32 of_II33 a_AT1 case-by-case_JJ_NN1 approach._NNU n104_FO By_II 2002_MC ,_Y one_MC1 report_NN1 showed_VVD that_CST the_AT "_Y overwhelming_JJ "_Y majority_NN1 of_IO physicians_NN2 polled_VVD_VVN believed_VVN_VVD that_CST DTC_NP1 advertising_NN1 has_VHZ had_VHN a_AT1 beneficial_JJ effect_NN1 on_II the_AT doctor-patient_JJ_NN1 relationship._NNU (_Y n105_FO )_Y <p>_Y In_II 2003_MC ,_Y the_AT FDA_NP1_NN1 published_VVD_VVN results_NN2 from_II what_DDQ is_VBZ perhaps_RR the_AT most_RGT comprehensive_JJ survey_NN1 to_II date_NN1 of_IO physician_NN1 attitudes_NN2 toward_II and_CC 250_MC specialists_NN2 in_II the_AT fields_NN2 of_IO dermatology_NN1 ,_Y allergy_NN1 ,_Y endocrinology_NN1 ,_Y and_CC psychiatry._NNU n107_FO Most_DAT doctors_NN2 polled_VVD_VVN believed_VVN_VVD that_CST DTC_NP1 advertising_NN1 led_VVD_VVN patients_NN2 to_TO ask_VVI more_RGR_DAR thoughtful_JJ questions_NN2 ,_Y made_VVD_VVN patients_NN2 more_RGR aware_JJ of_IO possible_JJ treatments_NN2 ,_Y made_VVD_VVN patients_NN2 more_RGR concerned_JJ about_II their_APPGE health_NN1 care_NN1 ,_Y prompted_VVD_VVN better_JJR discussions_NN2 between_II patients_NN2 and_CC physicians_NN2 about_II health_NN1 ,_Y and_CC thus_RR helped_VVN_VVD educate_VVI patients_NN2 about_II their_APPGE health_NN1 problems._NNU n108_FO The_AT survey_NN1 also_RR found_VVN_VVD that_CST doctors_NN2 believe_VV0 patients_NN2 understand_VV0 that_CST they_PPHS2 need_VV0 to_TO consult_VVI a_AT1 healthcare_NN1 professional_NN1@_JJ about_II appropriate_JJ treatment._NNU (_Y n109_FO )_Y <p>_Y This_DD1 Article_NN1 does_VDZ not_XX attempt_VVI to_TO resolve_VVI this_DD1 debate_NN1 or_CC answer_VV0 whether_CSW DTC_NP1 advertising_NN1 is_VBZ good_JJ or_CC bad_JJ for_IF the_AT industry_NN1 ,_Y patients_NN2 ,_Y or_CC physicians_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   69 But however valid the arguments are on both sides , neither the available data nor current medical practice supports the notion that DTC advertising alters a physician 's control of , or ethical and legal responsibility for , the ultimate decision to prescribe medicines to a patient .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   69 But_CCB however_RGQV valid_JJ the_AT arguments_NN2 are_VBR on_II both_DB2 sides_NN2 ,_Y neither_RR the_AT available_JJ data_NN nor_CC current_JJ medical_JJ practice_NN1 supports_VVZ the_AT notion_NN1 that_CST DTC_NP1 advertising_NN1 alters_VVZ a_AT1 physician_NN1 's_GE control_NN1 of_IO ,_Y or_CC ethical_JJ and_CC legal_JJ responsibility_NN1 for_IF ,_Y the_AT ultimate_JJ decision_NN1 to_TO prescribe_VVI medicines_NN2 to_II a_AT1 patient_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   70 For example , the FDA responded to concerns of undue influence in prescribing decisions by asking doctors in its 2003 survey whether a patient the doctor when interacting with that patient .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   70 For_REX21 example_REX22 ,_Y the_AT FDA_NN1_NP1 responded_VVN_VVD to_II concerns_NN2 of_IO undue_JJ influence_NN1 in_II prescribing_VVG decisions_NN2 by_II asking_VVG doctors_NN2 in_II its_Z' 2003_MC survey_VV0@_NN1 whether_CSW a_AT1 patient_NN1 the_AT doctor_NN1 when_CS interacting_VVG_JJ with_IW that_DD1 patient_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   71 Overwhelmingly , those polled responded that it did not. n110 Of the 18% who did believe that problems arose , most reported that the problem either stemmed from additional time spent with the patient correcting misperceptions about the product or confirming that the patient did not have the condition the drug was designed to treat. n111 When asked whether the patient tried " to influence the course of treatment in a way that would have been harmful to him or her , " 91% of doctors polled said no. n112 Furthermore , although some doctors reported moderate to heavy pressure to prescribe medications to their patients , the majority of doctors polled reported that they felt " not at all pressured " to do so. n113 In any event , even those reporting some level of pressure to prescribe still ultimately had to make the decision whether to prescribe individually .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   71 Overwhelmingly_RR ,_Y those_DD2 polled_VVN_VVD responded_VVD_VVN that_CST it_PPH1 did_VDD not._NNU n110_FO Of_IO the_AT 18%_NNU who_PNQS did_VDD believe_VVI that_CST problems_NN2 arose_VVD ,_Y most_RRT@_DAT_RGT reported_VVN_VVD_JJ@ that_CST the_AT problem_NN1 either_RR stemmed_VVD_VVN@_JJ from_II additional_JJ time_NNT1 spent_VVN with_IW the_AT patient_NN1_JJ correcting_VVG_JJ@ misperceptions_NN2 about_II the_AT product_NN1 or_CC confirming_VVG that_CST the_AT patient_NN1 did_VDD not_XX have_VHI the_AT condition_NN1 the_AT drug_NN1 was_VBDZ designed_VVN to_II treat._NNU n111_FO When_RRQ_CS asked_VVD_VVN@ whether_CSW the_AT patient_NN1 tried_VVD "_Y to_TO influence_VVI the_AT course_NN1 of_IO treatment_NN1 in_II a_AT1 way_NN1 that_CST_DD1 would_VM have_VHI been_VBN harmful_JJ to_II him_PPHO1 or_CC her_PPHO1 ,_Y "_Y 91%_NNU of_IO doctors_NN2 polled_VVN_VVD said_VVD no._UH n112_FO Furthermore_RR ,_Y although_CS some_DD doctors_NN2 reported_VVD_VVN moderate_JJ to_II heavy_JJ pressure_NN1 to_TO prescribe_VVI medications_NN2 to_II their_APPGE patients_NN2 ,_Y the_AT majority_NN1 of_IO doctors_NN2 polled_VVD_VVN reported_VVN_VVD_JJ@ that_CST they_PPHS2 felt_VVD "_Y not_XX at_RR21 all_RR22 pressured_VVD_VVN@ "_Y to_TO do_VDI so._NNU n113_FO In_II any_DD event_NN1 ,_Y even_RR those_DD2 reporting_VVG some_DD level_NN1 of_IO pressure_NN1 to_TO prescribe_VVI still_RR ultimately_RR had_VHN@_VHD to_TO make_VVI the_AT decision_NN1 whether_CSW to_TO prescribe_VVI individually_RR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   72 Thus , the results of the survey demonstrate that prescribing decisions still rest firmly with the physician and that the patient relies necessarily upon his physician 's medical judgment .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   72 Thus_RR ,_Y the_AT results_NN2 of_IO the_AT survey_NN1 demonstrate_VV0 that_CST_DD1 prescribing_VVG_NN1@ decisions_NN2 still_RR rest_VV0 firmly_RR with_IW the_AT physician_NN1 and_CC that_CST the_AT patient_NN1 relies_VVZ necessarily_RR upon_II his_APPGE physician_NN1 's_GE medical_JJ judgment_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   73 <p> III POLICY TODAY Three traditional rules--the learned intermediary doctrine , regulatory compliance exemptions to consumer protection statutes , and federal preemption--are particularly relevant in evaluating liability related to drug warnings .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   73 <p>_Y III_MC POLICY_NN1 TODAY_RT Three_MC traditional_JJ rules--the_NN2 learned_VVD_VVN intermediary_NN1 doctrine_NN1 ,_Y regulatory_JJ compliance_NN1 exemptions_NN2 to_II consumer_NN1 protection_NN1 statutes_NN2 ,_Y and_CC federal_JJ preemption--are_VBR particularly_RR relevant_JJ in_II evaluating_VVG liability_NN1 related_VVN_VVD to_II drug_NN1 warnings_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   74 The learned intermediary doctrine is a judicial doctrine , regulatory compliance is a statutory policy rooted in common law , and federal preemption is a constitutional principle deriving from the Supremacy Clause of the Constitution .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   74 The_AT learned_JJ@ intermediary_NN1 doctrine_NN1 is_VBZ a_AT1 judicial_JJ doctrine_NN1 ,_Y regulatory_JJ compliance_NN1 is_VBZ a_AT1 statutory_JJ policy_NN1 rooted_VVN in_II_RR21 common_JJ_RR22 law_NN1 ,_Y and_CC federal_JJ preemption_NN1 is_VBZ a_AT1 constitutional_JJ principle_NN1 deriving_VVG from_II the_AT Supremacy_NN1 Clause_NN1 of_IO the_AT Constitution_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   75 Although each originates from a different source , they share a common underlying policy .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   75 Although_CS each_DD1 originates_VVZ from_II a_AT1 different_JJ source_NN1 ,_Y they_PPHS2 share_VV0 a_AT1 common_JJ underlying_JJ policy_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   76 That policy recognizes that close regulation by the FDA and oversight by individual doctors appropriately preclude holding pharmaceutical manufacturers liable for alleged flaws in communicating information to individual patients .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   76 That_DD1 policy_NN1 recognizes_VVZ that_CST_DD1 close_JJ_VV0 regulation_NN1 by_II the_AT FDA_NN1_NP1 and_CC oversight_VV0_NN1 by_II individual_JJ_NN1 doctors_NN2 appropriately_RR preclude_VV0 holding_VVG pharmaceutical_JJ manufacturers_NN2 liable_JJ for_IF alleged_JJ flaws_NN2 in_II communicating_JJ_VVG_NN1 information_NN1 to_II individual_JJ_NN1 patients_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   77 <p> A. Ask Your Doctor : The Learned Intermediary Doctrine 1 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   77 <p>_Y A._ZZ Ask_VV0 Your_APPGE Doctor_NN1 :_Y The_AT Learned_JJ@ Intermediary_NN1 Doctrine_NN1 1_MC1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   78 Learned Intermediary Fundamentals The learned intermediary doctrine provides that manufacturers or suppliers of prescription drugs fulfill their duty to warn consumers of the dangerous propensities of their products by conveying accurate warning information to prescribing physicians. n114 It is the physician 's duty to evaluate the benefits and risks of the medication as they apply to the individual patient. n115 The rule establishes a manufacturer 's legal duty n116 ) <p> Several commonsense rationales support the learned intermediary doctrine .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   78 Learned_JJ@_VVN Intermediary_NN1 Fundamentals_NP1 The_AT learned_JJ@ intermediary_NN1 doctrine_NN1 provides_VVZ that_CST manufacturers_NN2 or_CC suppliers_NN2 of_IO prescription_NN1 drugs_NN2 fulfill_VV0 their_APPGE duty_NN1 to_TO warn_VVI consumers_NN2 of_IO the_AT dangerous_JJ propensities_NN2 of_IO their_APPGE products_NN2 by_II conveying_VVG accurate_JJ warning_NN1 information_NN1 to_II prescribing_VVG physicians._NNU n114_FO It_PPH1 is_VBZ the_AT physician_NN1 's_GE duty_NN1 to_TO evaluate_VVI the_AT benefits_NN2 and_CC risks_NN2 of_IO the_AT medication_NN1 as_CSA they_PPHS2 apply_VV0 to_II the_AT individual_JJ_NN1 patient._NNU n115_FO The_AT rule_NN1 establishes_VVZ a_AT1 manufacturer_NN1 's_GE legal_JJ duty_NN1 n116_FO )_Y <p>_Y Several_DA2 commonsense_JJ rationales_NN2 support_VV0 the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   79 First , training and experience place physicians in a better position than the manufacturer to convey complex medical information and terminology to patients. n117 Second , the physician has a relationship with the individual patient , making it possible to evaluate the patient 's treatment needs and provide an assessment of the potential benefits and likely risks specific to the patient 's medical and family history. n118 Third , it is more effective and efficient for manufacturers to provide a common set of warnings to an intermediary with more definable knowledge and skill characteristics than to a broad spectrum of consumers .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   79 First_MD ,_Y training_NN1_VVG@ and_CC experience_NN1_VV0 place_NN1_VV0 physicians_NN2 in_II a_AT1 better_JJR position_NN1 than_CSN the_AT manufacturer_NN1 to_TO convey_VVI complex_JJ medical_JJ information_NN1 and_CC terminology_NN1 to_II patients._NNU n117_FO Second_MD ,_Y the_AT physician_NN1 has_VHZ a_AT1 relationship_NN1 with_IW the_AT individual_JJ_NN1 patient_NN1_JJ ,_Y making_VVG it_PPH1 possible_JJ to_TO evaluate_VVI the_AT patient_NN1 's_GE treatment_NN1 needs_NN2_VVZ and_CC provide_VV0 an_AT1 assessment_NN1 of_IO the_AT potential_JJ_NN1 benefits_NN2 and_CC likely_JJ risks_NN2 specific_JJ to_II the_AT patient_NN1 's_GE_VBZ medical_JJ and_CC family_NN1 history._NNU n118_FO Third_MD ,_Y it_PPH1 is_VBZ more_RGR effective_JJ and_CC efficient_JJ for_IF manufacturers_NN2 to_TO provide_VVI a_AT1 common_JJ set_NN1 of_IO warnings_NN2 to_II an_AT1 intermediary_NN1 with_IW more_RGR_DAR definable_JJ knowledge_NN1 and_CC skill_NN1 characteristics_NN2 than_CSN to_II a_AT1 broad_JJ spectrum_NN1 of_IO consumers_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   80 In fact , it is difficult , if not impossible , to convey comprehensive drug warnings to consumers because of the highly technical nature of the information and the various needs of individual patients. n119 The learned intermediary doctrine was established , therefore , in recognition of these significant challenges and the physician 's superior position and ability to communicate warnings. ( n120 ) <p> Almost all jurisdictions follow the learned intermediary doctrine with regard to claims by the Eighth Circuit , which recognized that pharmaceutical companies have a duty to warn physicians directly about potential risks of their products , whereas physicians must serve as " learned intermediaries " who interpret this information and advise patients appropriately. n122 It was embraced quickly by other jurisdictions. n123 The doctrine has also come to include prescription medical devices under the same rationale. n124 Although the doctrine finds support in the Restatement ( Second ) of Torts 388 , n125 Restatement ( Third ) of Torts : Products Liability 6 sets forth its underpinnings more completely. n126 The Restatement ( Third ) specifically addresses liability for sellers of prescription drugs and medical devices , deals with the application of the learned intermediary rule , and sets forth narrow exceptions to the doctrine 's application. n127 It presents the rule as adopted by the majority of jurisdictions , either through judicial pronouncement or statutory enactment. ( n128 ) <p> 2 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   80 In_II fact_NN1 ,_Y it_PPH1 is_VBZ difficult_JJ ,_Y if_CS not_XX impossible_JJ ,_Y to_TO convey_VVI comprehensive_JJ drug_NN1 warnings_NN2 to_II consumers_NN2 because_II21 of_II22 the_AT highly_RR technical_JJ nature_NN1 of_IO the_AT information_NN1 and_CC the_AT various_JJ needs_NN2 of_IO individual_JJ_NN1 patients._NNU n119_FO The_AT learned_JJ@ intermediary_NN1 doctrine_NN1 was_VBDZ established_VVN ,_Y therefore_RR ,_Y in_II recognition_NN1 of_IO these_DD2 significant_JJ challenges_NN2 and_CC the_AT physician_NN1 's_GE superior_JJ position_NN1 and_CC ability_NN1 to_TO communicate_VVI warnings._NNU (_Y n120_FO )_Y <p>_Y Almost_RR all_DB jurisdictions_NN2 follow_VV0 the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 with_II31 regard_II32 to_II33 claims_NN2 by_II the_AT Eighth_MD Circuit_NN1 ,_Y which_DDQ recognized_VVD that_CST_DD1 pharmaceutical_JJ companies_NN2 have_VH0 a_AT1 duty_NN1 to_TO warn_VVI physicians_NN2 directly_RR about_II_RG% potential_JJ_NN1 risks_NN2 of_IO their_APPGE products_NN2 ,_Y whereas_CS physicians_NN2 must_VM serve_VVI as_RG@_CSA "_Y learned_JJ@_VVN intermediaries_NN2 "_Y who_PNQS interpret_VV0 this_DD1 information_NN1 and_CC advise_VV0 patients_NN2 appropriately._NNU n122_FO It_PPH1 was_VBDZ embraced_VVN quickly_RR by_II other_JJ jurisdictions._NNU n123_FO The_AT doctrine_NN1 has_VHZ also_RR come_VVN to_TO include_VVI prescription_NN1 medical_JJ devices_NN2 under_II the_AT same_DA rationale._NNU n124_FO Although_CS the_AT doctrine_NN1 finds_VVZ support_NN1_VV0 in_II the_AT Restatement_NN1 (_Y Second_MD_NNT1 )_Y of_IO Torts_NP1_NN2 388_MC ,_Y n125_FO Restatement_NN1 (_Y Third_MD_NP1% )_Y of_IO Torts_NP1_NN2 :_Y Products_NN2 Liability_NN1 6_MC sets_VVZ_NN2 forth_RR its_Z' underpinnings_NN2 more_RRR_RGR completely._NNU n126_FO The_AT Restatement_NN1 (_Y Third_MD_NP1% )_Y specifically_RR addresses_VVZ liability_NN1 for_IF sellers_NN2 of_IO prescription_NN1 drugs_NN2 and_CC medical_JJ devices_NN2 ,_Y deals_VVZ_NN2 with_IW the_AT application_NN1 of_IO the_AT learned_JJ@ intermediary_NN1 rule_NN1 ,_Y and_CC sets_VVZ_NN2 forth_RR narrow_JJ exceptions_NN2 to_II the_AT doctrine_NN1 's_GE application._NNU n127_FO It_PPH1 presents_VVZ the_AT rule_NN1 as_CSA adopted_VVN by_II the_AT majority_NN1 of_IO jurisdictions_NN2 ,_Y either_RR through_II judicial_JJ pronouncement_NN1 or_CC statutory_JJ enactment._NNU (_Y n128_FO )_Y <p>_Y 2_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   81 Traditional Limited Exceptions to the Rule The Restatement ( Third ) , recognizes a limited set of circumstances in which applying the learned intermediary doctrine may be inappropriate. n129 This the personal intervention or evaluation of a health-care provider .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   81 Traditional_JJ Limited_JJ Exceptions_NN2 to_II the_AT Rule_NN1 The_AT Restatement_NN1 (_Y Third_MD_NP1% )_Y ,_Y recognizes_VVZ a_AT1 limited_JJ set_NN1 of_IO circumstances_NN2 in_II which_DDQ applying_VVG the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 may_VM be_VBI inappropriate._NNU n129_FO This_DD1 the_AT personal_JJ intervention_NN1 or_CC evaluation_NN1 of_IO a_AT1 health-care_NN1 provider_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   82 " n130 In such situations , manufacturers are directly responsible for providing patients with warnings and instructions .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   82 "_Y n130_FO In_II such_DA situations_NN2 ,_Y manufacturers_NN2 are_VBR directly_RR responsible_JJ for_IF providing_VVG patients_NN2 with_IW warnings_NN2 and_CC instructions_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   83 <p> Vaccines and other immunizations administered en masse or to the general public present the most common example of this exception to the learned intermediary rule. n131 Health care providers typically dispense these treatments in an expedited manner without establishing a doctor-patient relationship or evaluating risks given the patient 's medical history .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   83 <p>_Y Vaccines_NN2 and_CC other_JJ immunizations_NN2 administered_VVN_VVD@ en_RR21 masse_RR22 or_CC to_II the_AT general_JJ_NN1 public_JJ_NN1 present_NN1_VV0@ the_AT most_RGT common_JJ example_NN1 of_IO this_DD1 exception_NN1 to_II the_AT learned_JJ@ intermediary_NN1 rule._NNU n131_FO Health_NN1 care_NN1 providers_NN2 typically_RR dispense_VV0 these_DD2 treatments_NN2 in_II an_AT1 expedited_JJ@ manner_NN1 without_IW establishing_VVG a_AT1 doctor-patient_JJ_NN1 relationship_NN1 or_CC evaluating_VVG risks_NN2 given_VVN the_AT patient_NN1 's_GE medical_JJ history_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   84 In some instances , the role of the physician may be reduced to that of a delivery mechanism , leaving the position of learned intermediary vacant .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   84 In_II some_DD instances_NN2 ,_Y the_AT role_NN1 of_IO the_AT physician_NN1 may_VM be_VBI reduced_VVN to_II that_DD1 of_IO a_AT1 delivery_NN1 mechanism_NN1 ,_Y leaving_VVG the_AT position_NN1 of_IO learned_JJ@ intermediary_NN1 vacant_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   85 Thus , in such rare instances , the manufacturer may reemerge as the entity best suited to warn consumers directly of the risks associated with its vaccine. ( n132 ) <p> Courts deciding whether to apply the exception to the learned intermediary doctrine for mass immunizations have tread carefully , resisting hard-line rules or blanket policy exemptions. n133 For example , a federal court applying Georgia law held that manufacturers of a measles , mumps , and rubella vaccine were not required to administered as part of a massive , nationwide immunization program. n134 In that case , the court found that a vaccination program aimed only at select students throughout a county was enough to retain application of the learned intermediary defense. n135 Similarly , a federal court in Oklahoma avoided adopting an over-expansive exception to the rule after a child developed permanent neurological damage after receiving a diphtheria vaccine. n136 Because the child 's personal physician administered the vaccine at her office , it was impermissible to apply the exception. n137 Moreover , as these cases illustrate , courts have shown great reluctance to define exceptions to the learned intermediary doctrine broadly , and apply this exception only where immunizations are conducted in an " assembly-line " or " clinic-like " fashion where no individualized medical judgment is rendered. n138 An additional consideration arises because , as a matter of public policy , placing special liability on manufacturers who develop vaccines might have adverse consequences for public health. ( n139 ) <p> A minority of courts have adopted an even narrower exception to the learned intermediary doctrine with regard to oral contraceptives. pills because they believe that a unique set of circumstances separates oral contraceptives from other prescription drugs. n141 For instance , the Massachusetts Supreme Judicial Court reasoned that : <p> Whereas a patient 's involvement in decision-making concerning use of a prescription drug necessary to treat a malady is typically minimal or nonexistent , the healthy , young consumer of oral contraceptives is usually actively involved in the decision to use " the pill , " as opposed to other available birth control products , and the prescribing physician is relegated to a relatively passive role. ( n142 ) <p> The court went on to conclude that oral contraceptives " stand apart " from ordinary prescription drugs , permitting liability when a manufacturer fails to convey an adequate warning directly to consumers. ( n143 ) <p> There is considerable judicial disagreement over the merits of allowing an exception for oral contraceptives. n144 This debate has also spread to contraceptive intrauterine devices ( IUDs ) , which a few jurisdictions have exempted from the doctrine by applying a similar rationale as that used to exclude drug contraceptives. n145 Courts opposed to this nature of treatment for contraceptives , yet strongly relied on the principle that " in the final analysis it is the physician who ultimately prescribes the drug or device .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   85 Thus_RR ,_Y in_II such_DA rare_JJ instances_NN2 ,_Y the_AT manufacturer_NN1 may_VM reemerge_VVI as_II the_AT entity_NN1 best_RRT suited_VVN to_TO warn_VVI consumers_NN2 directly_RR of_IO the_AT risks_NN2 associated_VVN with_IW its_Z' vaccine._NNU (_Y n132_FO )_Y <p>_Y Courts_NN2 deciding_VVG whether_CSW to_TO apply_VVI the_AT exception_NN1 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 for_IF mass_JJ_NN1 immunizations_NN2 have_VH0 tread_NN1%_VV0 carefully_RR ,_Y resisting_VVG hard-line_JJ rules_NN2 or_CC blanket_NN1_VV0@ policy_NN1 exemptions._NNU n133_FO For_REX21 example_REX22 ,_Y a_AT1 federal_JJ court_NN1 applying_VVG Georgia_NP1 law_NN1 held_VVD_VVN that_CST manufacturers_NN2 of_IO a_AT1 measles_NN ,_Y mumps_NN2_VVZ ,_Y and_CC rubella_NN1 vaccine_NN1 were_VBDR not_XX required_VVN to_TO administered_VVN as_II part_NN1 of_IO a_AT1 massive_JJ ,_Y nationwide_JJ immunization_NN1 program._NNU n134_FO In_II that_DD1 case_NN1 ,_Y the_AT court_NN1 found_VVD_VVN that_CST a_AT1 vaccination_NN1 program_NN1 aimed_VVD_VVN only_RR at_II select_JJ students_NN2 throughout_II a_AT1 county_NN1 was_VBDZ enough_DD to_TO retain_VVI application_NN1 of_IO the_AT learned_JJ@ intermediary_NN1 defense._NNU n135_FO Similarly_RR ,_Y a_AT1 federal_JJ court_NN1 in_II Oklahoma_NP1 avoided_VVD adopting_VVG an_AT1 over-expansive_JJ exception_NN1 to_II the_AT rule_NN1 after_II_CS a_AT1 child_NN1 developed_VVD_VVN_JJ permanent_JJ neurological_JJ damage_NN1 after_II receiving_VVG a_AT1 diphtheria_NN1 vaccine._NNU n136_FO Because_CS the_AT child_NN1 's_GE personal_JJ physician_NN1 administered_VVN_VVD@ the_AT vaccine_NN1 at_II her_APPGE office_NN1 ,_Y it_PPH1 was_VBDZ impermissible_JJ to_TO apply_VVI the_AT exception._NNU n137_FO Moreover_RR ,_Y as_CSA these_DD2 cases_NN2 illustrate_VV0 ,_Y courts_NN2 have_VH0 shown_VVN great_JJ reluctance_NN1 to_TO define_VVI exceptions_NN2 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 broadly_RR ,_Y and_CC apply_VV0 this_DD1 exception_NN1 only_RR where_CS_RRQ immunizations_NN2 are_VBR conducted_VVN in_II an_AT1 "_Y assembly-line_NN1 "_Y or_CC "_Y clinic-like_JJ "_Y fashion_NN1 where_CS_RRQ no_AT individualized_JJ@ medical_JJ judgment_NN1 is_VBZ rendered._NNU n138_FO An_AT1 additional_JJ consideration_NN1 arises_VVZ because_CS ,_Y as_II a_AT1 matter_NN1 of_IO public_JJ_NN1 policy_NN1 ,_Y placing_VVG special_JJ liability_NN1 on_II manufacturers_NN2 who_PNQS develop_VV0 vaccines_NN2 might_VM have_VHI adverse_JJ consequences_NN2 for_IF public_JJ_NN1_RR@ health._NNU (_Y n139_FO )_Y <p>_Y A_AT1 minority_NN1 of_IO courts_NN2 have_VH0 adopted_VVN an_AT1 even_RR narrower_JJR exception_NN1 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 with_II31 regard_II32 to_II33 oral_JJ_NN1 contraceptives._NNU pills_NN2 because_CS they_PPHS2 believe_VV0 that_CST a_AT1 unique_JJ set_NN1 of_IO circumstances_NN2 separates_VVZ oral_JJ contraceptives_NN2 from_II other_JJ prescription_NN1 drugs._NNU n141_FO For_REX21 instance_REX22 ,_Y the_AT Massachusetts_NP1 Supreme_JJ Judicial_JJ Court_NN1 reasoned_VVD that_CST :_Y <p>_Y Whereas_CS a_AT1 patient_NN1 's_GE involvement_NN1 in_II decision-making_NN1_JJ concerning_II_VVG use_NN1 of_IO a_AT1 prescription_NN1 drug_NN1 necessary_JJ to_TO treat_VVI a_AT1 malady_NN1 is_VBZ typically_RR minimal_JJ or_CC nonexistent_JJ ,_Y the_AT healthy_JJ ,_Y young_JJ consumer_NN1 of_IO oral_JJ_NN1 contraceptives_NN2 is_VBZ usually_RR actively_RR involved_JJ in_II the_AT decision_NN1 to_TO use_VVI "_Y the_AT pill_NN1 ,_Y "_Y as_II31 opposed_II32 to_II33 other_JJ available_JJ birth_NN1 control_NN1 products_NN2 ,_Y and_CC the_AT prescribing_NN1@ physician_NN1 is_VBZ relegated_VVN to_II a_AT1 relatively_RR passive_JJ role._NNU (_Y n142_FO )_Y <p>_Y The_AT court_NN1 went_VVD on_RP to_TO conclude_VVI that_DD1_CST oral_JJ_NN1 contraceptives_NN2 "_Y stand_VV0 apart_RL "_Y from_II ordinary_JJ prescription_NN1 drugs_NN2 ,_Y permitting_VVG liability_NN1 when_CS_RRQ a_AT1 manufacturer_NN1 fails_VVZ to_TO convey_VVI an_AT1 adequate_JJ warning_NN1 directly_RR to_II consumers._NNU (_Y n143_FO )_Y <p>_Y There_EX is_VBZ considerable_JJ judicial_JJ disagreement_NN1 over_II the_AT merits_NN2 of_IO allowing_VVG an_AT1 exception_NN1 for_IF oral_JJ_NN1 contraceptives._NNU n144_FO This_DD1 debate_NN1 has_VHZ also_RR spread_VVN to_II contraceptive_JJ_NN1 intrauterine_JJ_NN1 devices_NN2 (_Y IUDs_NN2 )_Y ,_Y which_DDQ a_AT1 few_DA2 jurisdictions_NN2 have_VH0 exempted_VVN from_II the_AT doctrine_NN1 by_II applying_VVG a_AT1 similar_JJ rationale_NN1 as_CSA that_CST_DD1 used_VMK_VVN to_TO exclude_VVI drug_NN1 contraceptives._NNU n145_FO Courts_NN2 opposed_VVN_VVD to_II this_DD1 nature_NN1 of_IO treatment_NN1 for_IF contraceptives_NN2 ,_Y yet_RR strongly_RR relied_VVN_VVD on_II the_AT principle_NN1 that_CST "_Y in_II the_AT final_JJ_NN1 analysis_NN1 it_PPH1 is_VBZ the_AT physician_NN1 who_PNQS ultimately_RR prescribes_VVZ the_AT drug_NN1 or_CC device_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   86 " n146 For this reason , courts have rejected further exceptions to the learned intermediary rule for other prescription treatments with characteristics arguably similar to prescription contraceptives , n147 while declining to apply the learned intermediary rule to nonprescription contraceptives. ( n148 ) <p> 3 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   86 "_Y n146_FO For_IF this_DD1 reason_NN1 ,_Y courts_NN2 have_VH0 rejected_VVN further_RRR_JJR@ exceptions_NN2 to_II the_AT learned_JJ@ intermediary_NN1 rule_NN1 for_IF other_JJ prescription_NN1 treatments_NN2 with_IW characteristics_NN2 arguably_RR similar_JJ to_II prescription_NN1 contraceptives_NN2 ,_Y n147_FO while_CS declining_VVG_JJ to_TO apply_VVI the_AT learned_JJ@ intermediary_NN1 rule_NN1 to_II nonprescription_NN1 contraceptives._NNU (_Y n148_FO )_Y <p>_Y 3_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   87 A Few Recent Decisions Chip Away at the Learned Intermediary Rule Jurisprudence keeping exceptions to the learned intermediary doctrine very limited has remained remarkably consistent since the rule 's inception .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   87 A_AT1 Few_DA2 Recent_JJ Decisions_NN2 Chip_NN1 Away_RL at_II the_AT Learned_JJ@ Intermediary_NN1 Rule_NN1 Jurisprudence_NP1_NN1@ keeping_VVG_NN1@ exceptions_NN2 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 very_RG limited_JJ has_VHZ remained_VVN remarkably_RR consistent_JJ since_CS_II@ the_AT rule_NN1 's_GE inception_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   88 The debate over the scope of the traditional exceptions is more a product of reasonable disagreement over the physician 's role in issuing one unique type of prescription than any challenge to the basic functioning of the doctrine. n149 In fact , the debate regarding courts ' aversion to expanding exceptions for mass immunizations not conducted in " clinic like " conditions and contraceptives illustrates just how solidified the doctrine has become .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   88 The_AT debate_NN1 over_II the_AT scope_NN1 of_IO the_AT traditional_JJ exceptions_NN2 is_VBZ more_RRR a_AT1 product_NN1 of_IO reasonable_JJ disagreement_NN1 over_II the_AT physician_NN1 's_GE role_NN1 in_II issuing_VVG_JJ one_MC1 unique_JJ type_NN1 of_IO prescription_NN1 than_CSN any_DD challenge_NN1_VV0 to_II the_AT basic_JJ functioning_NN1@ of_IO the_AT doctrine._NNU n149_FO In_II fact_NN1 ,_Y the_AT debate_NN1 regarding_II_VVG courts_NN2 '_GE aversion_NN1 to_II expanding_JJ_VVG exceptions_NN2 for_IF mass_JJ_NN1 immunizations_NN2 not_XX conducted_VVN in_II "_Y clinic_NN1 like_II "_Y conditions_NN2 and_CC contraceptives_NN2 illustrates_VVZ just_RR how_RRQ solidified_VVD the_AT doctrine_NN1 has_VHZ become_VVN@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   89 In the past decade , however , Oklahoma has recognized a New Jersey and West Virginia have made a sudden , radical departure from this long-established judicial rule .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   89 In_II the_AT past_JJ_NN1 decade_NNT1 ,_Y however_RR ,_Y Oklahoma_NP1 has_VHZ recognized_VVN a_AT1 New_NP1 Jersey_NP1 and_CC West_NP1 Virginia_NP1 have_VH0 made_VVN a_AT1 sudden_JJ ,_Y radical_JJ_NN1 departure_NN1 from_II this_DD1 long-established_JJ judicial_JJ rule_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   90 <p> In 1997 , Oklahoma recognized a very limited exception to the learned intermediary doctrine in a failure-to-warn claim involving a prescription nicotine patch .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   90 <p>_Y In_II 1997_MC ,_Y Oklahoma_NP1 recognized_VVD a_AT1 very_RG limited_JJ exception_NN1 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 in_II a_AT1 failure-to-warn_VV0 claim_NN1_VV0 involving_VVG a_AT1 prescription_NN1 nicotine_NN1 patch_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   91 In Edwards v. Basel Pharmaceuticals , the Oklahoma Supreme Court held that an exception to the rule applied where the FDA mandated that manufacturers , through labeling their products , directly communicate warnings to patients. n150 In such situations , the court ruled , " an exception to the ' learned intermediary doctrine ' has occurred and the manufacturer is not automatically shielded from any liability by properly warning the prescribing physician .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   91 In_II Edwards_NP1 v._II Basel_NP1 Pharmaceuticals_NN2 ,_Y the_AT Oklahoma_NP1 Supreme_JJ Court_NN1 held_VVD_VVN that_CST an_AT1 exception_NN1 to_II the_AT rule_NN1 applied_VVN_VVD where_CS_RRQ the_AT FDA_NN1 mandated_VVN that_CST manufacturers_NN2 ,_Y through_II labeling_VVG their_APPGE products_NN2 ,_Y directly_RR communicate_VV0 warnings_NN2 to_II patients._NNU n150_FO In_II such_DA situations_NN2 ,_Y the_AT court_NN1 ruled_VVD_VVN ,_Y "_Y an_AT1 exception_NN1 to_II the_AT '_GE learned_JJ@ intermediary_NN1 doctrine_NN1 '_GE has_VHZ occurred_VVN and_CC the_AT manufacturer_NN1 is_VBZ not_XX automatically_RR shielded_VVN_VVD from_II any_DD liability_NN1 by_II properly_RR warning_VVG@ the_AT prescribing_NN1@ physician_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   92 " n151 Rather , the court declared that when the FDA requires manufacturers to provide DTC information , the warning must adequately explain to the user the possible danger associated with the product. n152 The Oklahoma Supreme Court 's decision does not abrogate the learned intermediary doctrine on the basis of DTC advertising , but only in those rare instances in which the FDA mandates communication of warnings directly from manufacturer to patient .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   92 "_Y n151_FO Rather_RR@_RG ,_Y the_AT court_NN1 declared_VVD_VVN that_CST when_CS the_AT FDA_NN1_NP1 requires_VVZ manufacturers_NN2 to_TO provide_VVI DTC_NP1 information_NN1 ,_Y the_AT warning_NN1 must_VM adequately_RR explain_VVI to_II the_AT user_NN1 the_AT possible_JJ danger_NN1 associated_VVN with_IW the_AT product._NNU n152_FO The_AT Oklahoma_NP1 Supreme_JJ Court_NN1 's_GE decision_NN1 does_VDZ not_XX abrogate_VVI the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 on_II the_AT basis_NN1 of_IO DTC_NP1 advertising_NN1 ,_Y but_CCB only_RR in_II those_DD2 rare_JJ instances_NN2 in_II which_DDQ the_AT FDA_NN1_NP1 mandates_NN2 communication_NN1 of_IO warnings_NN2 directly_RR from_II manufacturer_NN1 to_II patient_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   93 <p> Jersey Supreme Court 's decision in Perez v. Wyeth Labs. , Inc. n153 Perez involved a prescription contraceptive called Norplant , a " hybrid " medical device consisting of a drug capsule that is surgically implanted in the patient. n154 The plaintiffs alleged inadequate DTC warnings concerning the possibility of pain and other side effects. n155 In reversing an intermediate appellate court ruling , the New Jersey Supreme Court went beyond adopting the minority approach of exempting contraceptives , and created a broader exception to the learned intermediary doctrine for prescription drugs or devices marketed through DTC advertising. n156 This about-face was largely premised on the court 's belief that " our medical-legal jurisprudence is based on images of health care that no longer exist .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   93 <p>_Y Jersey_NP1 Supreme_JJ Court_NN1 's_GE decision_NN1 in_II Perez_NP1 v._II Wyeth_NP1 Labs._ZZ ,_Y Inc._JJ n153_FO Perez_NP1 involved_VVD a_AT1 prescription_NN1 contraceptive_NN1 called_VVN Norplant_NP1 ,_Y a_AT1 "_Y hybrid_JJ "_Y medical_JJ device_NN1 consisting_VVG of_IO a_AT1 drug_NN1 capsule_NN1 that_CST_DD1 is_VBZ surgically_RR implanted_VVN in_II the_AT patient._NNU n154_FO The_AT plaintiffs_NN2 alleged_VVD_VVN_JJ inadequate_JJ DTC_NP1 warnings_NN2 concerning_II_VVG the_AT possibility_NN1 of_IO pain_NN1 and_CC other_JJ side_NN1 effects._NNU n155_FO In_II reversing_VVG an_AT1 intermediate_JJ appellate_JJ court_NN1 ruling_NN1 ,_Y the_AT New_NP1 Jersey_NP1 Supreme_JJ Court_NN1 went_VVD beyond_II adopting_VVG the_AT minority_NN1 approach_NN1 of_IO exempting_VVG contraceptives_NN2 ,_Y and_CC created_VVD_VVN a_AT1 broader_JJR exception_NN1 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 for_IF prescription_NN1 drugs_NN2 or_CC devices_NN2 marketed_VVN_VVD through_II DTC_NP1 advertising._NNU n156_FO This_DD1 about-face_NN1 was_VBDZ largely_RR premised_VVN_VVD on_II the_AT court_NN1 's_GE belief_NN1 that_CST "_Y our_APPGE medical-legal_JJ jurisprudence_NN1 is_VBZ based_VVN on_II images_NN2 of_IO health_NN1 care_NN1_VV0 that_CST no_RR21 longer_RR22 exist_VV0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   94 " n157 DTC marketing , the court explained , fundamentally changed the medical landscape through radio , television , internet , and print advertisements such that it was no longer justified for consumers to rely exclusively on their physicians for risk information concerning a prescription drug or device. n158 As a result , the court held that the doctrine no longer provided full protection for benefits and risks of a drug .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   94 "_Y n157_FO DTC_NP1 marketing_NN1 ,_Y the_AT court_NN1 explained_VVD_VVN ,_Y fundamentally_RR changed_VVD_VVN the_AT medical_JJ landscape_NN1 through_II radio_NN1 ,_Y television_NN1 ,_Y internet_NN1 ,_Y and_CC print_VV0_NN1 advertisements_NN2 such_CS21 that_CS22 it_PPH1 was_VBDZ no_RR21 longer_RR22 justified_VVN for_IF consumers_NN2 to_TO rely_VVI exclusively_RR on_II their_APPGE physicians_NN2 for_IF risk_NN1 information_NN1 concerning_II_VVG a_AT1 prescription_NN1 drug_NN1 or_CC device._NNU n158_FO As_II a_AT1 result_NN1 ,_Y the_AT court_NN1 held_VVD_VVN that_CST the_AT doctrine_NN1 no_RR21 longer_RR22 provided_VVN_VVD_CS full_JJ protection_NN1 for_IF benefits_NN2 and_CC risks_NN2 of_IO a_AT1 drug_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   95 <p> For almost a decade , Oklahoma and New Jersey stood alone in permitting a DTC-marketing exception to the learned intermediary doctrine. n159 Courts applying the doctrine during this period repeatedly rejected attempts to create such an exception. n160 Then , in 2007 , another crack appeared in the dam .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   95 <p>_Y For_IF almost_RR a_AT1 decade_NNT1 ,_Y Oklahoma_NP1 and_CC New_NP1 Jersey_NP1 stood_VVD alone_RR_JJ in_II permitting_VVG a_AT1 DTC-marketing_JJ_NN1 exception_NN1 to_II the_AT learned_JJ@ intermediary_NN1 doctrine._NNU n159_FO Courts_NN2 applying_VVG the_AT doctrine_NN1 during_II this_DD1 period_NN1 repeatedly_RR rejected_VVN_VVD_JJ@ attempts_NN2 to_TO create_VVI such_DA an_AT1 exception._NNU n160_FO Then_RT ,_Y in_II 2007_MC ,_Y another_DD1 crack_NN1 appeared_VVD_VVN@ in_II the_AT dam_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   96 In State ex rel .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   96 In_II State_NN1_NP1@ ex_II rel_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   97 Johnson Johnson Corp .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   97 Johnson_NP1 Johnson_NP1 Corp_NPX ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   98 v. Karl , the West Virginia Supreme Court of Appeals arrived at the same result as the New Jersey Supreme Court with regard to DTC marketing , but followed a different approach , wholly rejecting the learned intermediary doctrine. ( n161 ) <p> Before 2007 , the West Virginia high court had not considered application of the doctrine .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   98 v._II Karl_NP1 ,_Y the_AT West_NP1 Virginia_NP1 Supreme_JJ Court_NN1 of_IO Appeals_NN2 arrived_VVN_VVD at_II the_AT same_DA result_NN1 as_CSA the_AT New_NP1 Jersey_NP1 Supreme_JJ Court_NN1 with_II31 regard_II32 to_II33 DTC_NP1 marketing_NN1 ,_Y but_CCB followed_VVD a_AT1 different_JJ approach_NN1 ,_Y wholly_RR rejecting_VVG the_AT learned_JJ@ intermediary_NN1 doctrine._NNU (_Y n161_FO )_Y <p>_Y Before_II_CS 2007_MC ,_Y the_AT West_NP1 Virginia_NP1 high_JJ court_NN1 had_VHD not_XX considered_VVN application_NN1 of_IO the_AT doctrine_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0   99 Deciding the case as one of first impression , the court found the " justifications for the learned intermediary doctrine to be largely outdated and unpersuasive. " n162 Specifically , the court named DTC marketing as the impetus for its holding , stating that the " Norman Rockwell image of the family doctor no longer exists " n163 and that the doctor-patient relationship has premises are absent .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0   99 Deciding_VVG the_AT case_NN1 as_CSA_II@ one_MC1 of_IO first_MD impression_NN1 ,_Y the_AT court_NN1 found_VVD_VVN the_AT "_Y justifications_NN2 for_IF the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 to_TO be_VBI largely_RR outdated_JJ_VVN@ and_CC unpersuasive._NNU "_Y n162_FO Specifically_RR ,_Y the_AT court_NN1 named_VVD DTC_NP1 marketing_NN1 as_II_CSA the_AT impetus_NN1 for_IF its_Z' holding_NN1@_JJ@ ,_Y stating_VVG that_CST the_AT "_Y Norman_NP1_JJ Rockwell_NP1_NN1@ image_NN1 of_IO the_AT family_NN1 doctor_NN1 no_RR21 longer_RR22 exists_VVZ "_Y n163_FO and_CC that_CST the_AT doctor-patient_JJ_NN1 relationship_NN1 has_VHZ premises_NN2 are_VBR absent_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  100 " n164 Although the court acknowledged that four state supreme courts had adopted the now " widely accepted " doctrine during the very same decade in which DTC advertising proliferated , it determined that these decisions did not adequately consider changes occurring in the pharmaceutical industry. ( n165 ) <p> In addition , the West Virginia court found traditional exceptions to the learned intermediary doctrine to be unwieldy , stating , " Given the plethora of exceptions to the learned intermediary doctrine , we ascertain no benefit in adopting a doctrine that would require the simultaneous adoption of numerous exceptions in order to be justly utilized .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  100 "_Y n164_FO Although_CS the_AT court_NN1 acknowledged_VVD_VVN that_CST_DD1 four_MC state_VV0_NN1 supreme_JJ courts_NN2 had_VHD adopted_VVN the_AT now_RT "_Y widely_RR accepted_JJ_VVN "_Y doctrine_NN1 during_II the_AT very_RG same_DA decade_NNT1 in_II which_DDQ DTC_NP1 advertising_NN1 proliferated_VVD ,_Y it_PPH1 determined_VVD@_VVN_JJ that_CST these_DD2 decisions_NN2 did_VDD not_XX adequately_RR consider_VVI changes_NN2 occurring_VVG in_II the_AT pharmaceutical_JJ industry._NNU (_Y n165_FO )_Y <p>_Y In_RR21 addition_RR22 ,_Y the_AT West_NP1 Virginia_NP1 court_NN1 found_VVD_VVN traditional_JJ exceptions_NN2 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 to_TO be_VBI unwieldy_JJ ,_Y stating_VVG ,_Y "_Y Given_VVN the_AT plethora_NN1 of_IO exceptions_NN2 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 ,_Y we_PPIS2 ascertain_VV0 no_AT benefit_NN1 in_II adopting_VVG a_AT1 doctrine_NN1 that_CST_DD1 would_VM require_VVI the_AT simultaneous_JJ adoption_NN1 of_IO numerous_JJ exceptions_NN2 in_BCL21 order_BCL22 to_TO be_VBI justly_RR utilized_VVN_VVD ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  101 " n166 Based on these rationales , the court concluded that , under West Virginia law , the learned intermediary doctrine did not apply to warnings relating to pharmaceutical products .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  101 "_Y n166_FO Based_VVN on_II these_DD2 rationales_NN2 ,_Y the_AT court_NN1 concluded_VVD_VVN that_CST_DD1 ,_Y under_II West_NP1 Virginia_NP1 law_NN1 ,_Y the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 did_VDD not_XX apply_VVI to_II warnings_NN2 relating_VVG to_II pharmaceutical_JJ products_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  102 West Virginia law provides , therefore , that manufacturers are directly liable for conveying warnings and may not rely on physicians to transmit correct drug information to patients .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  102 West_NP1 Virginia_NP1 law_NN1 provides_VVZ ,_Y therefore_RR ,_Y that_CST manufacturers_NN2 are_VBR directly_RR liable_JJ for_IF conveying_VVG warnings_NN2 and_CC may_VM not_XX rely_VVI on_II_RP@ physicians_NN2 to_TO transmit_VVI correct_JJ drug_NN1 information_NN1 to_II patients_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  103 <p> The court clearly was incorrect , however , when it spoke of a " plethora " of exceptions to immunizations , prescription contraceptives--followed by only a minority of courts--and the uncommon situation where the FDA explicitly requires a DTC warning .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  103 <p>_Y The_AT court_NN1 clearly_RR was_VBDZ incorrect_JJ ,_Y however_RR ,_Y when_CS_RRQ it_PPH1 spoke_VVD of_IO a_AT1 "_Y plethora_NN1 "_Y of_IO exceptions_NN2 to_II immunizations_NN2 ,_Y prescription_NN1 contraceptives--followed_NN2 by_II only_RR a_AT1 minority_NN1 of_IO courts--and_NN2 the_AT uncommon_JJ situation_NN1 where_RRQ the_AT FDA_NN1_NP1 explicitly_RR requires_VVZ a_AT1 DTC_NP1 warning_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  104 The absolute rule drastically expands the analysis of Perez by making West Virginia the only state expressly to reject the learned intermediary doctrine .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  104 The_AT absolute_JJ rule_NN1 drastically_RR expands_VVZ the_AT analysis_NN1 of_IO Perez_NP1 by_II making_VVG West_NP1 Virginia_NP1 the_AT only_JJ state_NN1 expressly_RR to_TO reject_VVI the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  105 <p> 4 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  105 <p>_Y 4_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  106 Exceptions for DTC Marketing Represent Unsound Policy Perez and Karl each dramatically depart from the traditional rule of law relating to prescription drug warnings .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  106 Exceptions_NN2 for_IF DTC_NP1 Marketing_NN1 Represent_VV0 Unsound_JJ Policy_NN1 Perez_NP1 and_CC Karl_NP1 each_DD1 dramatically_RR depart_VV0 from_II the_AT traditional_JJ rule_NN1 of_IO law_NN1 relating_VVG to_II prescription_NN1 drug_NN1 warnings_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  107 These departures are unsupported by precedent , practice , or sound public policy .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  107 These_DD2 departures_NN2 are_VBR unsupported_JJ by_II precedent_NN1 ,_Y practice_NN1 ,_Y or_CC sound_JJ@_NN1_VV0@ public_JJ_NN1 policy_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  108 Established exceptions to the learned intermediary doctrine remain few and narrowly designed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  108 Established_JJ@_VVN exceptions_NN2 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 remain_VV0 few_DA2 and_CC narrowly_RR designed_VVN_VVD ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  109 Perez , however , creates a gaping exception for DTC marketing .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  109 Perez_NP1 ,_Y however_RR ,_Y creates_VVZ a_AT1 gaping_JJ exception_NN1 for_IF DTC_NP1 marketing_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  110 The primary justification for this exception is that increasingly common DTC advertisements fundamentally change the physician-patient relationship. n167 Yet the ethical and legal obligations of the medical community with regard to communicating drug warnings are unchanged and show no indication of abrogation .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  110 The_AT primary_JJ_NN1 justification_NN1 for_IF this_DD1 exception_NN1 is_VBZ that_CST_DD1_RG% increasingly_RR common_JJ DTC_NP1 advertisements_NN2 fundamentally_RR change_VV0 the_AT physician-patient_JJ_NN1 relationship._NNU n167_FO Yet_RR the_AT ethical_JJ and_CC legal_JJ obligations_NN2 of_IO the_AT medical_JJ community_NN1 with_II31 regard_II32 to_II33 communicating_JJ_VVG_NN1 drug_NN1 warnings_NN2 are_VBR unchanged_JJ and_CC show_VV0 no_AT indication_NN1 of_IO abrogation_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  111 As the dissent in Karl further explained : " By attaching undue importance to the effects of direct marketing , the majority downplays the continuing and vital role that a physician plays in the decision patient based upon that particular individual 's specific medical needs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  111 As_II_CSA the_AT dissent_NN1 in_II Karl_NP1 further_RRR explained_VVD_VVN :_Y "_Y By_II attaching_VVG undue_JJ importance_NN1 to_II the_AT effects_NN2 of_IO direct_JJ marketing_NN1 ,_Y the_AT majority_NN1 downplays_VVZ the_AT continuing_JJ and_CC vital_JJ role_NN1 that_CST a_AT1 physician_NN1 plays_VVZ_NN2 in_II the_AT decision_NN1 patient_NN1 based_VVN upon_II that_DD1 particular_JJ individual_NN1 's_GE_VBZ specific_JJ medical_JJ needs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  112 " ( n168 ) <p> Comparatively , a DTC marketing exception does not comport with the traditional learned intermediary doctrine exceptions .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  112 "_Y (_Y n168_FO )_Y <p>_Y Comparatively_RR ,_Y a_AT1 DTC_NP1 marketing_NN1 exception_NN1 does_VDZ not_XX comport_VVI with_IW the_AT traditional_JJ learned_JJ@ intermediary_NN1 doctrine_NN1 exceptions_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  113 A DTC marketing exception is open-ended , theoretically encompassing all drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  113 A_ZZ1_AT1 DTC_NP1 marketing_NN1 exception_NN1 is_VBZ open-ended_JJ ,_Y theoretically_RR encompassing_VVG all_DB drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  114 The three established exceptions represent a small fraction of prescription drugs where it is apparent the physician does not provide an individualized medical assessment .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  114 The_AT three_MC established_JJ@_VVD exceptions_NN2 represent_VV0 a_AT1 small_JJ fraction_NN1 of_IO prescription_NN1 drugs_NN2 where_CS_RRQ it_PPH1 is_VBZ apparent_JJ the_AT physician_NN1 does_VDZ not_XX provide_VVI an_AT1 individualized_JJ@ medical_JJ assessment_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  115 This is simply not the case with all DTC-marketed prescription drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  115 This_DD1 is_VBZ simply_RR not_XX the_AT case_NN1 with_IW all_DB DTC-marketed_JJ prescription_NN1 drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  116 Physicians have a legal and ethical duty to provide an individualized medical assessment before prescribing a drug regardless of how often it is advertised on television , radio , or any other media. n169 Suggesting that the playing field has changed to the extent physicians can no longer be fully relied upon to discuss with their patients the benefits and risks of a drug presents an untenable and illogical assertion when juxtaposed with the fact that no court has made any attempt to modify this basic duty of physicians .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  116 Physicians_NN2 have_VH0 a_AT1 legal_JJ and_CC ethical_JJ duty_NN1 to_TO provide_VVI an_AT1 individualized_JJ@ medical_JJ assessment_NN1 before_II prescribing_VVG a_AT1 drug_NN1 regardless_RR of_IO how_RGQ often_RR it_PPH1 is_VBZ advertised_VVN on_II television_NN1 ,_Y radio_NN1 ,_Y or_CC any_DD other_JJ media._NNU n169_FO Suggesting_VVG that_CST the_AT playing_JJ%_VVG_NN1% field_NN1 has_VHZ changed_VVN to_II the_AT extent_NN1 physicians_NN2 can_VM no_RR21 longer_RR22 be_VBI fully_RR relied_VVN_VVD upon_II to_TO discuss_VVI with_IW their_APPGE patients_NN2 the_AT benefits_NN2 and_CC risks_NN2 of_IO a_AT1 drug_NN1 presents_VVZ an_AT1 untenable_JJ and_CC illogical_JJ assertion_NN1 when_CS_RRQ juxtaposed_VVN_JJ with_IW the_AT fact_NN1 that_CST no_AT court_NN1 has_VHZ made_VVN any_DD attempt_NN1_VV0 to_TO modify_VVI this_DD1 basic_JJ duty_NN1 of_IO physicians_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  117 <p> The relatively recent development of the Restatement ( Third ) of Torts : Products Liability , 6 , the learned intermediary doctrine 's application to DTC-marketed prescription drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  117 <p>_Y The_AT relatively_RR recent_JJ development_NN1 of_IO the_AT Restatement_NN1 (_Y Third_MD_NP1% )_Y of_IO Torts_NP1_NN2 :_Y Products_NN2 Liability_NN1 ,_Y 6_MC ,_Y the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 's_GE application_NN1 to_II DTC-marketed_JJ_NN1 prescription_NN1 drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  118 An early draft of the Restatement ( Third ) section relating to pharmaceutical manufacturer liability included an exception to the doctrine where " the manufacturer advertised or otherwise promoted the drug or medical device directly to users and consumers .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  118 An_AT1 early_JJ draft_NN1 of_IO the_AT Restatement_NN1 (_Y Third_MD_NP1% )_Y section_NN1 relating_VVG to_II pharmaceutical_JJ manufacturer_NN1 liability_NN1 included_VVD_VVN an_AT1 exception_NN1 to_II the_AT doctrine_NN1 where_CS_RRQ "_Y the_AT manufacturer_NN1 advertised_VVN_VVD or_CC otherwise_RR promoted_VVN_VVD@ the_AT drug_NN1 or_CC medical_JJ device_NN1 directly_RR to_II users_NN2 and_CC consumers_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  119 " n170 This black letter exception in Council Draft I was promptly deleted a few months later by the Reporters in Council Draft 1A. n171 The Reporters explained that the change was a result of Council discussions that " demonstrated concern about creating a wholly new common law duty to warn when there was no case law to support it .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  119 "_Y n170_FO This_DD1 black_JJ letter_NN1 exception_NN1 in_II Council_NN1 Draft_VV0_NN1 I_PPIS1 was_VBDZ promptly_RR deleted_VVN_VVD a_AT1 few_DA2 months_NNT2 later_RRR by_II the_AT Reporters_NN2 in_II Council_NN1 Draft_NN1_VV0 1A._FO n171_FO The_AT Reporters_NN2 explained_VVD_VVN that_CST the_AT change_NN1 was_VBDZ a_AT1 result_NN1 of_IO Council_NN1 discussions_NN2 that_CST "_Y demonstrated_VVD_JJ@ concern_NN1 about_II creating_VVG a_AT1 wholly_RR new_JJ common_JJ law_NN1 duty_NN1 to_TO warn_VVI when_RRQ_CS there_EX was_VBDZ no_AT case_NN1 law_NN1 to_TO support_VVI it_PPH1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  120 " ( n172 ) <p> Comment e accompanying the amended draft explained that the DTC marketing exception merged into the draft 's learned intermediary exception for FDA-required warnings. n173 Practically speaking , however , the deletion marked a clear retreat from acknowledging the third exception to the rule .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  120 "_Y (_Y n172_FO )_Y <p>_Y Comment_VV0 e_ZZ1 accompanying_VVG the_AT amended_JJ draft_NN1 explained_VVD_VVN that_CST the_AT DTC_NP1 marketing_NN1 exception_NN1 merged_VVN_VVD into_II the_AT draft_NN1 's_VBZ_GE_VHZ@ learned_VVN_JJ@ intermediary_NN1 exception_NN1 for_IF FDA-required_JJ_NN1 warnings._NNU n173_FO Practically_RR speaking_VVG_JJ@ ,_Y however_RR ,_Y the_AT deletion_NN1 marked_VVN_VVD@ a_AT1 clear_JJ retreat_NN1 from_II acknowledging_VVG the_AT third_MD exception_NN1 to_II the_AT rule_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  121 By the time the Council issued Tentative Draft No. 1 later that year--four years before the final Restatement draft was published--both the DTC-marketing exception and the doctrine 's inapplicability where Only the exception for mass immunizations withstood the scrutiny of the Council .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  121 By_II the_AT time_NNT1 the_AT Council_NN1 issued_VVD_VVN Tentative_JJ Draft_NN1 No._XX 1_MC1 later_JJR that_CST_DD1 year--four_MC years_NNT2 before_II_CS the_AT final_JJ_NN1 Restatement_NN1 draft_NN1 was_VBDZ published--both_RR the_AT DTC-marketing_JJ_NN1 exception_NN1 and_CC the_AT doctrine_NN1 's_GE inapplicability_NN1 where_CS_RRQ Only_RR the_AT exception_NN1 for_IF mass_JJ_NN1 immunizations_NN2 withstood_VVD_VVN the_AT scrutiny_NN1 of_IO the_AT Council_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  122 There was also no revival by the Reporters of the Restatement , the Advisory Committee , or the articulate plaintiffs ' and defense counsel membership at the ALI of the express DTC marketing exception in any of the subsequent Restatement drafts. n175 Instead , the final version of comment e inserts a catch-all that " leaves to developing case law " the determination of whether any other exceptions to the learned intermediary doctrine exist. ( n176 ) <p> In the decade following the issuance of the Restatement ( Third ) , it is notable that no state court except the New Jersey Supreme Court in Perez created an express DTC marketing exception to its learned intermediary rule .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  122 There_EX was_VBDZ also_RR no_AT revival_NN1 by_II the_AT Reporters_NN2 of_IO the_AT Restatement_NN1 ,_Y the_AT Advisory_JJ Committee_NN1 ,_Y or_CC the_AT articulate_JJ plaintiffs_NN2 '_GE and_CC defense_NN1 counsel_NN1_VV0 membership_NN1 at_II the_AT ALI_NP1 of_IO the_AT express_JJ@ DTC_NP1 marketing_NN1 exception_NN1 in_II any_DD of_IO the_AT subsequent_JJ Restatement_NN1 drafts._NNU n175_FO Instead_RR ,_Y the_AT final_JJ_NN1 version_NN1 of_IO comment_NN1 e_ZZ1 inserts_VVZ a_AT1 catch-all_JJ that_CST "_Y leaves_VVZ_NN2 to_II developing_JJ_VVG case_NN1 law_NN1 "_Y the_AT determination_NN1 of_IO whether_CSW any_DD other_JJ exceptions_NN2 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 exist._NNU (_Y n176_FO )_Y <p>_Y In_II the_AT decade_NNT1 following_VVG_II@_RA@ the_AT issuance_NN1 of_IO the_AT Restatement_NN1 (_Y Third_MD_NP1% )_Y ,_Y it_PPH1 is_VBZ notable_JJ that_CST no_AT state_NN1 court_NN1 except_II_CS the_AT New_NP1 Jersey_NP1 Supreme_JJ Court_NN1 in_II Perez_NP1 created_VVD an_AT1 express_JJ@ DTC_NP1 marketing_NN1 exception_NN1 to_II its_Z' learned_JJ@ intermediary_NN1 rule_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  123 On the contrary , over the same period , four state supreme courts joined the growing list of high courts to adopt expressly the Restatement version of the rule. n177 Further , sound public policy supporting the doctrine has led to its significant expansion in other ways .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  123 On_II the_AT contrary_NN1_JJ ,_Y over_II the_AT same_DA period_NN1 ,_Y four_MC state_VV0_NN1 supreme_JJ courts_NN2 joined_VVD_VVN the_AT growing_JJ list_NN1 of_IO high_JJ courts_NN2 to_TO adopt_VVI expressly_RR the_AT Restatement_NN1 version_NN1 of_IO the_AT rule._NNU n177_FO Further_RRR@ ,_Y sound_VV0@_JJ@_NN1 public_JJ_NN1 policy_NN1 supporting_VVG the_AT doctrine_NN1 has_VHZ led_VVN to_II its_Z' significant_JJ expansion_NN1 in_II other_JJ ways_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  124 For example , some courts have extended the doctrine beyond the doctor-patient it to veterinarians. n179 The doctrine has also expanded outside the medical community and into the workplace where courts routinely analyze the rule in conjunction with the bulk-supplier and sophisticated-user defenses .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  124 For_REX21 example_REX22 ,_Y some_DD courts_NN2 have_VH0 extended_VVN the_AT doctrine_NN1 beyond_II the_AT doctor-patient_JJ_NN1 it_PPH1 to_II veterinarians._NNU n179_FO The_AT doctrine_NN1 has_VHZ also_RR expanded_VVN outside_II the_AT medical_JJ community_NN1 and_CC into_II the_AT workplace_NN1 where_RRQ_CS courts_NN2 routinely_RR analyze_VV0 the_AT rule_NN1 in_II31 conjunction_II32 with_II33 the_AT bulk-supplier_NN1_JJ and_CC sophisticated-user_JJ_NN1 defenses_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  125 These defenses incorporate similar rationales to relieve industrial manufacturers and intermediaries of a duty to warn directly end-user workers and to impart that duty on the most knowledgeable party .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  125 These_DD2 defenses_NN2 incorporate_VV0 similar_JJ rationales_NN2 to_TO relieve_VVI industrial_JJ manufacturers_NN2 and_CC intermediaries_NN2 of_IO a_AT1 duty_NN1 to_TO warn_VVI directly_RR end-user_JJ@_NN1 workers_NN2 and_CC to_TO impart_VVI that_DD1_CST duty_NN1 on_II the_AT most_RGT knowledgeable_JJ party_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  126 That party is usually the purchaser or employer who knows the use for the materials and the associated risks and can best communicate the warning and provide protective equipment. ( n180 ) <p> Such extensions of the principles underlying the learned intermediary doctrine , in addition to courts ' general repudiation of additional exceptions when left to " developing case law , " clearly support the continued viability of the rule .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  126 That_DD1 party_NN1 is_VBZ usually_RR the_AT purchaser_NN1 or_CC employer_NN1 who_PNQS knows_VVZ the_AT use_NN1 for_IF the_AT materials_NN2 and_CC the_AT associated_JJ risks_NN2 and_CC can_VM best_RRT communicate_VVI the_AT warning_NN1 and_CC provide_VVI protective_JJ equipment._NNU (_Y n180_FO )_Y <p>_Y Such_DA extensions_NN2 of_IO the_AT principles_NN2 underlying_VVG the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 ,_Y in_II31 addition_II32 to_II33 courts_NN2 '_GE general_JJ_NN1 repudiation_NN1 of_IO additional_JJ exceptions_NN2 when_CS_RRQ left_VVN to_II "_Y developing_JJ_VVG case_NN1 law_NN1 ,_Y "_Y clearly_RR support_VV0 the_AT continued_JJ viability_NN1 of_IO the_AT rule_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  127 Courts and commentators have long recognized that physicians are in the best position to determine the appropriateness , effectiveness , and risks of a drug based on a patient 's medical and family history. n181 Physicians ' legal and ethical duty to warn patients adequately about any treatment , including prescription drugs , extends from this relationship find otherwise would presume that the physician 's legal and ethical duties to warn either no longer exist or are so altered that a physician need not exercise any individualized medical judgment when determining a treatment course. n182 This proposition would turn the law , and medical practice , on its head .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  127 Courts_NN2 and_CC commentators_NN2 have_VH0 long_RR recognized_VVN that_CST physicians_NN2 are_VBR in_II the_AT best_JJT position_NN1_VV0@ to_TO determine_VVI the_AT appropriateness_NN1 ,_Y effectiveness_NN1 ,_Y and_CC risks_NN2 of_IO a_AT1 drug_NN1 based_VVN on_II a_AT1 patient_NN1 's_GE_VBZ medical_JJ and_CC family_NN1 history._NNU n181_FO Physicians_NN2 '_GE legal_JJ and_CC ethical_JJ duty_NN1 to_TO warn_VVI patients_NN2 adequately_RR about_II any_DD treatment_NN1 ,_Y including_II_VVG@ prescription_NN1 drugs_NN2 ,_Y extends_VVZ from_II this_DD1 relationship_NN1 find_VVI otherwise_RR would_VM presume_VVI that_CST the_AT physician_NN1 's_GE_VBZ legal_JJ and_CC ethical_JJ duties_NN2 to_TO warn_VVI either_RR_DD1 no_RR21 longer_RR22 exist_VV0 or_CC are_VBR so_RR_RG altered_VVN_VVD_JJ that_CST a_AT1 physician_NN1 need_VM@ not_XX exercise_VVI any_DD individualized_JJ@_VVD medical_JJ judgment_NN1 when_CS determining_VVG a_AT1 treatment_NN1 course._NNU n182_FO This_DD1 proposition_NN1 would_VM turn_VVI the_AT law_NN1 ,_Y and_CC medical_JJ practice_NN1 ,_Y on_II its_Z' head_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  128 It would require redefining the physician 's duty to warn and effectively lessen the duty requirements and ethical obligations of doctors in the name of strengthening patient care .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  128 It_PPH1 would_VM require_VVI redefining_VVG the_AT physician_NN1 's_GE duty_NN1 to_TO warn_VVI and_CC effectively_RR lessen_VVI the_AT duty_NN1 requirements_NN2 and_CC ethical_JJ obligations_NN2 of_IO doctors_NN2 in_II the_AT name_NN1 of_IO strengthening_VVG_NN1 patient_NN1 care_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  129 Not surprisingly , no case law appears to advocate lessening the duty of physicians to warn ; if anything , the physician 's duty to warn has become more comprehensive. ( n183 ) <p> In addition to placing the responsibility of translating drug warnings on the more able physician , the learned intermediary doctrine achieves other important practical policy objectives .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  129 Not_XX surprisingly_RR ,_Y no_AT case_NN1 law_NN1 appears_VVZ to_TO advocate_VVI lessening_VVG the_AT duty_NN1 of_IO physicians_NN2 to_TO warn_VVI ;_Y if_CS anything_PN1 ,_Y the_AT physician_NN1 's_GE duty_NN1 to_TO warn_VVI has_VHZ become_VVN@ more_RRR_RGR_DAR comprehensive._NNU (_Y n183_FO )_Y <p>_Y In_II31 addition_II32 to_II33 placing_VVG the_AT responsibility_NN1 of_IO translating_VVG drug_NN1 warnings_NN2 on_II the_AT more_RGR able_JJ physician_NN1 ,_Y the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 achieves_VVZ other_JJ important_JJ practical_JJ policy_NN1 objectives_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  130 The broad range and complexities of potential prescription drug users make it ill-advised , and perhaps impossible , to tailor comprehensive warnings to consumers .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  130 The_AT broad_JJ range_NN1 and_CC complexities_NN2 of_IO potential_JJ_NN1 prescription_NN1 drug_NN1 users_NN2 make_VV0 it_PPH1 ill-advised_JJ ,_Y and_CC perhaps_RR impossible_JJ ,_Y to_TO tailor_VVI comprehensive_JJ warnings_NN2 to_II consumers_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  131 Differences in patients ' medical histories , ages , education levels , and drug interactions with current treatments are only a few of to overcome if directly liable for warnings both to doctors and to consumers .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  131 Differences_NN2 in_II patients_NN2 '_GE medical_JJ histories_NN2 ,_Y ages_NN2 ,_Y education_NN1 levels_NN2 ,_Y and_CC drug_NN1 interactions_NN2 with_IW current_JJ treatments_NN2 are_VBR only_RR a_AT1 few_DA2 of_IO to_TO overcome_VVI if_CS_CSW@ directly_RR liable_JJ for_IF warnings_NN2 both_RR to_II doctors_NN2 and_CC to_II consumers_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  132 Liability for two types of warnings could serve to eliminate DTC marketing because no prescription drug company could warn effectively .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  132 Liability_NN1 for_IF two_MC types_NN2 of_IO warnings_NN2 could_VM serve_VVI to_TO eliminate_VVI DTC_NP1 marketing_NN1 because_CS no_AT prescription_NN1 drug_NN1 company_NN1 could_VM warn_VVI effectively_RR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  133 The result would impede the attempts of many consumers to take a more active role in their personal health .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  133 The_AT result_NN1 would_VM impede_VVI the_AT attempts_NN2 of_IO many_DA2 consumers_NN2 to_TO take_VVI a_AT1 more_RGR active_JJ role_NN1 in_II their_APPGE personal_JJ health_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  134 The extended liability would also likely increase drug prices , hampering the accessibility of the drugs. n184 Worse , if a majority of courts held drug manufacturers liable for DTC advertisements , it could create a self-fulfilling prophecy whereby consumers , aware of this obligation , begin to rely solely on the less comprehensive DTC warnings and physicians take fewer steps to evaluate treatments individually because there is shared liability with manufacturers .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  134 The_AT extended_JJ@ liability_NN1 would_VM also_RR likely_RR@ increase_VVI drug_NN1 prices_NN2 ,_Y hampering_VVG the_AT accessibility_NN1 of_IO the_AT drugs._NNU n184_FO Worse_RRR@ ,_Y if_CS a_AT1 majority_NN1 of_IO courts_NN2 held_VVD_VVN drug_NN1 manufacturers_NN2 liable_JJ for_IF DTC_NP1 advertisements_NN2 ,_Y it_PPH1 could_VM create_VVI a_AT1 self-fulfilling_JJ_NN1 prophecy_NN1 whereby_RRQ consumers_NN2 ,_Y aware_JJ of_IO this_DD1 obligation_NN1 ,_Y begin_VV0 to_TO rely_VVI solely_RR on_II the_AT less_RGR comprehensive_JJ DTC_NP1 warnings_NN2 and_CC physicians_NN2 take_VV0 fewer_DAR steps_NN2 to_TO evaluate_VVI treatments_NN2 individually_RR because_CS there_EX is_VBZ shared_JJ_VVN liability_NN1 with_IW manufacturers_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  135 <p> As the saying goes , " A little knowledge can be a dangerous thing .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  135 <p>_Y As_II_CSA the_AT saying_NN1@ goes_VVZ ,_Y "_Y A_AT1 little_JJ knowledge_NN1 can_VM be_VBI a_AT1 dangerous_JJ thing_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  136 " With prescription drugs , it can turn into a deadly thing .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  136 "_Y With_IW prescription_NN1 drugs_NN2 ,_Y it_PPH1 can_VM turn_VVI into_II a_AT1 deadly_JJ thing_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  137 For that reason , liability for prescription drug warnings to consumers is entrusted to physicians and not to less comprehensive DTC advertisements .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  137 For_IF that_DD1 reason_NN1 ,_Y liability_NN1 for_IF prescription_NN1 drug_NN1 warnings_NN2 to_II consumers_NN2 is_VBZ entrusted_VVN to_II physicians_NN2 and_CC not_XX to_II less_RGR_DAR comprehensive_JJ DTC_NP1 advertisements_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  138 Rather , DTC advertisements caution to " see your doctor " can take on a more active role while the doctor calculates the array of treatment risks .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  138 Rather_RR@_RG ,_Y DTC_NP1 advertisements_NN2 caution_VV0@_NN1 to_TO "_Y see_VVI your_APPGE doctor_NN1 "_Y can_VM take_VVI on_RP a_AT1 more_RGR active_JJ role_NN1 while_CS the_AT doctor_NN1 calculates_VVZ the_AT array_NN1 of_IO treatment_NN1 risks_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  139 Because the learned intermediary doctrine establishes liability rules to facilitate this practice and improve health care , it is as viable in today 's world of DTC marketing as it ever was .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  139 Because_CS the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 establishes_VVZ liability_NN1 rules_NN2_VVZ@ to_TO facilitate_VVI this_DD1 practice_NN1 and_CC improve_VVI health_NN1 care_NN1 ,_Y it_PPH1 is_VBZ as_RG@ viable_JJ in_II today_RT 's_GE world_NN1 of_IO DTC_NP1 marketing_NN1 as_CSA it_PPH1 ever_RR was_VBDZ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  140 <p> B. Effect of Compliance with FDA Requirements on Liability Whereas the learned intermediary doctrine places the duty to warn patients of the risks of drugs on physicians , other common law and statutory enactments consider the deference warnings should receive when they are reviewed and approved by government regulators .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  140 <p>_Y B._NP1 Effect_NN1 of_IO Compliance_NN1 with_IW FDA_NN1_NP1 Requirements_NN2 on_II Liability_NN1 Whereas_CS the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 places_VVZ@_NN2 the_AT duty_NN1 to_TO warn_VVI patients_NN2 of_IO the_AT risks_NN2 of_IO drugs_NN2 on_II physicians_NN2 ,_Y other_JJ common_JJ law_NN1 and_CC statutory_JJ enactments_NN2 consider_VV0 the_AT deference_NN1 warnings_NN2 should_VM receive_VVI when_RRQ_CS they_PPHS2 are_VBR reviewed_VVN and_CC approved_VVN by_II government_NN1 regulators_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  141 <p> 1 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  141 <p>_Y 1_MC1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  142 Common Law Principles In the absence of a statute instructing courts how to weigh compliance with a government safety standard or government approval of a product or service , states vary on how they consider such evidence .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  142 Common_JJ Law_NN1 Principles_NN2 In_II the_AT absence_NN1 of_IO a_AT1 statute_NN1 instructing_VVG_NN1@ courts_NN2 how_RRQ to_TO weigh_VVI compliance_NN1 with_IW a_AT1 government_NN1 safety_NN1 standard_NN1_JJ or_CC government_NN1 approval_NN1 of_IO a_AT1 product_NN1 or_CC service_NN1 ,_Y states_NN2 vary_VV0 on_II_RP@ how_RRQ they_PPHS2 consider_VV0 such_DA evidence_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  143 Most courts find that compliance with government standards is one of many factors to be considered by the jury in determining whether or not a product is unreasonably dangerous. n185 These courts reason that government regulations provide only " minimum standards , " and , therefore , are not to warn. n186 Although most jurisdictions consider a violation of a safety regulation as evidence that a product is defective as a matter of law , they do not accord evidence of compliance with government regulations similarly deferential treatment. ( n187 ) <p> In 1991 , the American Law Institute ( ALI ) published a Reporter 's study recommending that compliance with regulatory requirements imposed by a government agency preclude tort liability in certain situations .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  143 Most_DAT courts_NN2 find_VV0 that_DD1_CST compliance_NN1 with_IW government_NN1 standards_NN2 is_VBZ one_MC1 of_IO many_DA2 factors_NN2 to_TO be_VBI considered_VVN by_II the_AT jury_NN1 in_II determining_VVG whether_CSW31 or_CSW32 not_CSW33 a_AT1 product_NN1 is_VBZ unreasonably_RR dangerous._NNU n185_FO These_DD2 courts_NN2 reason_VV0@ that_DD1_CST government_NN1 regulations_NN2 provide_VV0 only_RR_JJ "_Y minimum_JJ_NN1 standards_NN2 ,_Y "_Y and_CC ,_Y therefore_RR ,_Y are_VBR not_XX to_II warn._NNU n186_FO Although_CS most_DAT jurisdictions_NN2 consider_VV0 a_AT1 violation_NN1 of_IO a_AT1 safety_NN1 regulation_NN1 as_CSA_II@ evidence_NN1 that_CST a_AT1 product_NN1 is_VBZ defective_JJ as_II a_AT1 matter_NN1 of_IO law_NN1 ,_Y they_PPHS2 do_VD0 not_XX accord_VVI evidence_NN1 of_IO compliance_NN1 with_IW government_NN1 regulations_NN2 similarly_RR deferential_JJ treatment._NNU (_Y n187_FO )_Y <p>_Y In_II 1991_MC ,_Y the_AT American_JJ Law_NN1 Institute_NN1 (_Y ALI_NP1 )_Y published_VVD a_AT1 Reporter_NN1 's_GE study_NN1 recommending_VVG that_DD1_CST compliance_NN1 with_IW regulatory_JJ requirements_NN2 imposed_VVN by_II a_AT1 government_NN1 agency_NN1 preclude_VV0 tort_NN1_VV0 liability_NN1 in_II certain_JJ situations_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  144 Under the Reporter 's study recommendations , tort liability would be precluded when : ( 1 ) a legislature has placed the risk at issue under the authority of a specialized administrative agency ; ( 2 ) that agency has established and periodically revises regulatory safety controls ; ( 3 ) the manufacturer or other entity complied with the relevant regulatory standards ; and ( 4 ) the manufacturer or other entity disclosed to the agency any material information in its possession , or of which it has reason to be aware , concerning the products ' risks and means of controlling them. ( n188 ) <p> The Restatement ( Third ) incorporates a similar considered defective as a matter of law in the following circumstances : <p> When the safety statute or regulation was promulgated recently , thus supplying currency to the standard therein established ; when the specific standard addresses the very issue of product design or warning presented in the case before the court ; and when the court is confident that the deliberative process by which the safety standard was established was full , fair , and thorough and reflected substantial expertise. ( n189 ) <p> The Restatement ( Third ) also acknowledges that this liability protection would not apply " when the deliberative process that led to the safety standard ... was tainted by the supplying of false information to , or the withholding of necessary and valid information from , the agency that promulgated the standard or certified or approved the product .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  144 Under_II the_AT Reporter_NN1 's_GE study_NN1 recommendations_NN2 ,_Y tort_VV0_NN1 liability_NN1 would_VM be_VBI precluded_VVN when_CS_RRQ :_Y (_Y 1_MC1 )_Y a_AT1 legislature_NN1 has_VHZ placed_VVN the_AT risk_NN1 at_II issue_NN1 under_II the_AT authority_NN1 of_IO a_AT1 specialized_JJ administrative_JJ agency_NN1 ;_Y (_Y 2_MC )_Y that_DD1_CST agency_NN1 has_VHZ established_VVN and_CC periodically_RR revises_VVZ regulatory_JJ safety_NN1 controls_NN2_VVZ ;_Y (_Y 3_MC )_Y the_AT manufacturer_NN1 or_CC other_JJ entity_NN1 complied_VVN_VVD with_IW the_AT relevant_JJ regulatory_JJ standards_NN2 ;_Y and_CC (_Y 4_MC )_Y the_AT manufacturer_NN1 or_CC other_JJ entity_NN1 disclosed_VVN to_II the_AT agency_NN1 any_DD material_NN1_JJ@ information_NN1 in_II its_Z' possession_NN1 ,_Y or_CC of_IO which_DDQ it_PPH1 has_VHZ reason_NN1 to_TO be_VBI aware_JJ ,_Y concerning_VVG_II the_AT products_NN2 '_GE risks_NN2 and_CC means_NN of_IO controlling_VVG them._ZZ (_Y n188_FO )_Y <p>_Y The_AT Restatement_NN1 (_Y Third_MD_NP1% )_Y incorporates_VVZ a_AT1 similar_JJ considered_VVN defective_JJ as_II a_AT1 matter_NN1 of_IO law_NN1 in_II the_AT following_JJ circumstances_NN2 :_Y <p>_Y When_CS the_AT safety_NN1 statute_NN1 or_CC regulation_NN1 was_VBDZ promulgated_VVN recently_RR ,_Y thus_RR supplying_VVG currency_NN1 to_II the_AT standard_NN1_JJ therein_RR established_VVN_VVD ;_Y when_CS_RRQ the_AT specific_JJ standard_NN1 addresses_VVZ the_AT very_JJ issue_NN1 of_IO product_NN1 design_NN1 or_CC warning_NN1 presented_VVN_VVD in_II the_AT case_NN1 before_II_CS the_AT court_NN1 ;_Y and_CC when_CS_RRQ the_AT court_NN1 is_VBZ confident_JJ that_CST the_AT deliberative_JJ process_NN1 by_II which_DDQ the_AT safety_NN1 standard_NN1 was_VBDZ established_VVN was_VBDZ full_JJ ,_Y fair_JJ_RR@ ,_Y and_CC thorough_JJ and_CC reflected_VVD_VVN_JJ@ substantial_JJ expertise._NNU (_Y n189_FO )_Y <p>_Y The_AT Restatement_NN1 (_Y Third_MD_NP1% )_Y also_RR acknowledges_VVZ that_CST this_DD1 liability_NN1 protection_NN1 would_VM not_XX apply_VVI "_Y when_RRQ_CS the_AT deliberative_JJ process_NN1 that_CST led_VVD to_II the_AT safety_NN1 standard_NN1 ..._... was_VBDZ tainted_VVN by_II the_AT supplying_NN1 of_IO false_JJ information_NN1 to_II_TO ,_Y or_CC the_AT withholding_NN1 of_IO necessary_JJ and_CC valid_JJ information_NN1 from_II ,_Y the_AT agency_NN1 that_CST promulgated_VVD@ the_AT standard_NN1_JJ or_CC certified_JJ_VVN or_CC approved_VVD_VVN the_AT product_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  145 " ( n190 ) <p> The Restatement ( Third ) recognizes that courts frequently cite compliance with safety regulations as a factor used to justify a directed verdict for a defendant. n191 In some cases , courts have accorded weight to government safety standards and approvals , n192 Courts occasionally find that meeting a safety standard set by government regulations precludes tort liability. n193 For example , the Maryland Court of Appeals has recognized that " where no special circumstances require extra caution , a court may find that conformity to the statutory standard amounts to due care as a matter of law .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  145 "_Y (_Y n190_FO )_Y <p>_Y The_AT Restatement_NN1 (_Y Third_MD_NP1% )_Y recognizes_VVZ that_CST_DD1 courts_VVZ@_NN2 frequently_RR cite_VV0 compliance_NN1 with_IW safety_NN1 regulations_NN2 as_II_CSA a_AT1 factor_NN1 used_VMK to_TO justify_VVI a_AT1 directed_JJ@ verdict_NN1 for_IF a_AT1 defendant._NNU n191_FO In_II some_DD cases_NN2 ,_Y courts_NN2 have_VH0 accorded_VVN weight_NN1 to_II government_NN1 safety_NN1 standards_NN2 and_CC approvals_NN2 ,_Y n192_FO Courts_NN2_VVZ% occasionally_RR find_VV0 that_CST_DD1 meeting_VVG a_AT1 safety_NN1 standard_NN1_JJ set_VVN by_II government_NN1 regulations_NN2 precludes_VVZ tort_NN1_VV0 liability._NNU n193_FO For_REX21 example_REX22 ,_Y the_AT Maryland_NP1 Court_NN1 of_IO Appeals_NN2 has_VHZ recognized_VVN that_CST "_Y where_CS no_AT special_JJ circumstances_NN2 require_VV0 extra_JJ caution_NN1 ,_Y a_AT1 court_NN1 may_VM find_VVI that_DD1_CST conformity_NN1 to_II the_AT statutory_JJ standard_JJ_NN1 amounts_NN2 to_II due_JJ care_NN1 as_II a_AT1 matter_NN1 of_IO law_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  146 " ( n194 ) <p> 2 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  146 "_Y (_Y n194_FO )_Y <p>_Y 2_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  147 Statutory Consideration of the Effect of Regulatory Compliance on Liability Aside from these common law principles , three types of state statutes impact liability related to the marketing of pharmaceutical products .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  147 Statutory_JJ Consideration_NN1 of_IO the_AT Effect_NN1 of_IO Regulatory_JJ Compliance_NN1 on_II Liability_NN1 Aside_II21 from_II22 these_DD2 common_JJ law_NN1 principles_NN2 ,_Y three_MC types_NN2 of_IO state_NN1 statutes_NN2 impact_NN1_VV0% liability_NN1 related_VVN_VVD to_II the_AT marketing_NN1 of_IO pharmaceutical_JJ products_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  148 The first comes into play in product liability cases and provides a presumption that a product approved by a government agency is not defective .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  148 The_AT first_MD comes_VVZ into_II play_NN1 in_II product_NN1 liability_NN1 cases_NN2 and_CC provides_VVZ a_AT1 presumption_NN1 that_CST a_AT1 product_NN1 approved_VVN by_II a_AT1 government_NN1 agency_NN1 is_VBZ not_XX defective_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  149 The second type of these laws , also applicable in product liability actions , precludes an award of punitive damages with respect to injuries from FDA-approved drugs , with limited exceptions .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  149 The_AT second_MD type_NN1 of_IO these_DD2 laws_NN2 ,_Y also_RR applicable_JJ in_II product_NN1 liability_NN1 actions_NN2 ,_Y precludes_VVZ an_AT1 award_NN1 of_IO punitive_JJ damages_NN2 with_II31 respect_II32 to_II33 injuries_NN2 from_II FDA-approved_JJ_NN1 drugs_NN2 ,_Y with_IW limited_JJ exceptions_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  150 The third includes provisions which place conduct that is closely regulated or approved by government agencies beyond the scope of more general state statutes prohibiting deceptive advertising .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  150 The_AT third_MD includes_VVZ provisions_NN2 which_DDQ place_VV0 conduct_VV0_NN1 that_DD1_CST is_VBZ closely_RR regulated_VVN_VVD or_CC approved_VVN by_II government_NN1 agencies_NN2 beyond_II the_AT scope_NN1 of_IO more_RGR_DAR general_JJ state_NN1 statutes_NN2 prohibiting_VVG deceptive_JJ advertising_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  151 <p> a .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  151 <p>_Y a_AT1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  152 Presumption of Nondefectiveness Seven states provide that rebuttable presumption that a product is not defective. n195 The relevant statutes respect the decision making of federal and state regulatory agencies charged with protecting public safety in tort lawsuits .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  152 Presumption_NN1 of_IO Nondefectiveness_NP1_NN1 Seven_MC states_NN2 provide_VV0 that_DD1_CST rebuttable_JJ presumption_NN1 that_CST a_AT1 product_NN1 is_VBZ not_XX defective._NNU n195_FO The_AT relevant_JJ statutes_NN2 respect_VV0@ the_AT decision_NN1 making_NN1@_VVG of_IO federal_JJ and_CC state_VV0 regulatory_JJ agencies_NN2 charged_VVN_VVD with_IW protecting_VVG_JJ@ public_JJ_NN1 safety_NN1 in_II tort_NN1 lawsuits_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  153 Such laws are broadly applicable to any product governed by government safety regulations and have been invoked in cases involving a wide range of products including ladders , n196 nail guns , n197 cleaning products , n198 clothing , n199 airplanes , n200 and automobiles. n201 The statutes generally provide a presumption that a product is not unreasonably dangerous if it meets safety requirements , thus reducing the potential for a finding of liability .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  153 Such_DA laws_NN2 are_VBR broadly_RR applicable_JJ to_II any_DD product_NN1 governed_VVN by_II government_NN1 safety_NN1 regulations_NN2 and_CC have_VH0 been_VBN invoked_VVN in_II cases_NN2 involving_VVG a_AT1 wide_JJ range_NN1 of_IO products_NN2 including_II ladders_NN2 ,_Y n196_FO nail_NN1_VV0@ guns_NN2 ,_Y n197_FO cleaning_NN1_VVG products_NN2 ,_Y n198_FO clothing_NN1 ,_Y n199_FO airplanes_NN2 ,_Y n200_FO and_CC automobiles._NNU n201_FO The_AT statutes_NN2 generally_RR provide_VV0 a_AT1 presumption_NN1 that_CST a_AT1 product_NN1 is_VBZ not_XX unreasonably_RR dangerous_JJ if_CS_CSW@ it_PPH1 meets_VVZ safety_NN1 requirements_NN2 ,_Y thus_RR reducing_VVG the_AT potential_NN1_JJ for_IF a_AT1 finding_NN1 of_IO liability_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  154 For example , since 1977 Colorado law has provided : <p> In any product liability action , it shall be rebuttably presumed that the product which caused the injury , death , or property damage was not defective and that the manufacturer or seller thereof was not negligent if the product ... complied with , at the time of sale by the manufacturer , any applicable code , standard , or regulation adopted or promulgated by the United States or by this state. ( n202 Texas , and Utah have chosen similar routes. n203 These laws assure that courts allow juries to hear and appropriately consider a product 's compliance with government standards when they consider whether the product is defective .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  154 For_REX21 example_REX22 ,_Y since_II 1977_MC Colorado_NP1 law_NN1 has_VHZ provided_VVN :_Y <p>_Y In_II any_DD product_NN1 liability_NN1 action_NN1 ,_Y it_PPH1 shall_VM be_VBI rebuttably_RR presumed_VVN_VVD that_CST the_AT product_NN1 which_DDQ caused_VVD the_AT injury_NN1 ,_Y death_NN1 ,_Y or_CC property_NN1 damage_NN1 was_VBDZ not_XX defective_JJ and_CC that_CST the_AT manufacturer_NN1 or_CC seller_NN1 thereof_RR was_VBDZ not_XX negligent_JJ if_CS_CSW@ the_AT product_NN1 ..._... complied_VVN_VVD with_IW ,_Y at_II the_AT time_NNT1 of_IO sale_NN1 by_II the_AT manufacturer_NN1 ,_Y any_DD applicable_JJ code_NN1 ,_Y standard_NN1_JJ ,_Y or_CC regulation_NN1 adopted_VVN_VVD or_CC promulgated_VVN by_II the_AT United_NP1 States_NP1 or_CC by_II this_DD1 state._NNU (_Y n202_FO Texas_NP1 ,_Y and_CC Utah_NP1 have_VH0 chosen_VVN similar_JJ routes._NNU n203_FO These_DD2 laws_NN2 assure_VV0 that_CST courts_NN2 allow_VV0 juries_NN2 to_TO hear_VVI and_CC appropriately_RR consider_VVI a_AT1 product_NN1 's_GE compliance_NN1 with_IW government_NN1 standards_NN2 when_CS_RRQ they_PPHS2 consider_VV0 whether_CSW the_AT product_NN1 is_VBZ defective_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  155 <p> Such laws appear to include claims challenging the sufficiency of a pharmaceutical product 's labeling and warnings , including failure-to-warn claims associated with DTC marketing .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  155 <p>_Y Such_DA laws_NN2 appear_VV0 to_TO include_VVI claims_NN2 challenging_VVG the_AT sufficiency_NN1 of_IO a_AT1 pharmaceutical_JJ product_NN1 's_VBZ_GE labeling_VVG_NN1@_JJ@ and_CC warnings_NN2 ,_Y including_VVG@_II failure-to-warn_VV0 claims_NN2 associated_VVN with_IW DTC_NP1 marketing_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  156 Curiously , there is very little case law applying the statutory presumptions of nondefectiveness to FDA-approved warnings. ( n204 ) <p> b .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  156 Curiously_RR ,_Y there_EX is_VBZ very_RG little_DA1 case_NN1 law_NN1 applying_VVG the_AT statutory_JJ presumptions_NN2 of_IO nondefectiveness_NN1 to_II FDA-approved_JJ_NN1 warnings._NNU (_Y n204_FO )_Y <p>_Y b_ZZ1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  157 Preclusion of Punitive Damages for FDA-Approved Pharmaceuticals Special considerations come into play when lawsuits charge that a prescription drug manufacturer acted with such malice in offering a product to patients that it should be subject to punitive damages even though the FDA approval process includes a rigorous review that can span thousands of hours over more than a decade. ( n205 ) <p> For this reason , five states have enacted statutes that preclude punitive damage liability when the manufacturer received FDA approval for the product at issue .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  157 Preclusion_NN1 of_IO Punitive_JJ Damages_NN2 for_IF FDA-Approved_JJ_NN1 Pharmaceuticals_NN2 Special_JJ considerations_NN2 come_VV0_VVN@ into_II play_NN1 when_RRQ_CS lawsuits_NN2 charge_VV0@ that_CST a_AT1 prescription_NN1 drug_NN1 manufacturer_NN1 acted_VVN_VVD with_IW such_DA malice_NN1 in_II offering_VVG a_AT1 product_NN1 to_II patients_NN2 that_CST it_PPH1 should_VM be_VBI subject_II21 to_II22 punitive_JJ damages_NN2 even_CS21 though_CS22 the_AT FDA_NN1_NP1 approval_NN1 process_NN1 includes_VVZ a_AT1 rigorous_JJ review_NN1 that_CST_DD1 can_VM span_VVI thousands_M of_IO hours_NNT2 over_II_RP more_DAR_RRR than_CSN a_AT1 decade._NNU (_Y n205_FO )_Y <p>_Y For_IF this_DD1 reason_NN1 ,_Y five_MC states_NN2 have_VH0 enacted_VVN statutes_NN2 that_CST preclude_VV0 punitive_JJ damage_NN1 liability_NN1 when_CS_RRQ the_AT manufacturer_NN1 received_VVD_VVN FDA_NP1_NN1 approval_NN1 for_IF the_AT product_NN1 at_II issue_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  158 New Jersey , Oregon , and Ohio were the first states to adopt such laws. punitive damages in cases involving FDA-approved or licensed products. n207 Additionally , Michigan , a state that does not recognize punitive damages , limits manufacturer liability for compensatory damages in product liability actions involving FDA-approved drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  158 New_NP1 Jersey_NP1 ,_Y Oregon_NP1 ,_Y and_CC Ohio_NP1 were_VBDR the_AT first_MD states_VVZ_NN2 to_TO adopt_VVI such_DA laws._NNU punitive_JJ damages_NN2 in_II cases_NN2 involving_VVG FDA-approved_JJ_NN1 or_CC licensed_JJ_VVD@_VVN products._NNU n207_FO Additionally_RR ,_Y Michigan_NP1 ,_Y a_AT1 state_NN1 that_CST_DD1 does_VDZ not_XX recognize_VVI punitive_JJ damages_NN2 ,_Y limits_VVZ_NN2 manufacturer_NN1 liability_NN1 for_IF compensatory_JJ damages_NN2 in_II product_NN1 liability_NN1 actions_NN2 involving_VVG FDA-approved_JJ_NN1 drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  159 Michigan law defers to the federal agency 's comprehensive regulatory process by providing a rebuttable presumption that a drug , including its labeling and packaging , is not defective or unreasonably dangerous if the drug is approved for safety and efficacy by the FDA. ( n208 ) <p> There are variations as to the scope of these laws , such as whether the limitation on liability applies solely to prescription drugs or to other FDA-approved products as well .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  159 Michigan_NP1 law_NN1 defers_VVZ to_II the_AT federal_JJ agency_NN1 's_GE_VBZ comprehensive_JJ regulatory_JJ process_NN1 by_II providing_VVG a_AT1 rebuttable_JJ presumption_NN1 that_CST a_AT1 drug_NN1 ,_Y including_II_VVG@ its_Z' labeling_NN1@_JJ@ and_CC packaging_NN1 ,_Y is_VBZ not_XX defective_JJ or_CC unreasonably_RR dangerous_JJ if_CS_CSW@ the_AT drug_NN1 is_VBZ approved_VVN for_IF safety_NN1 and_CC efficacy_NN1 by_II the_AT FDA._NP1 (_Y n208_FO )_Y <p>_Y There_EX are_VBR variations_NN2 as_II21 to_II22 the_AT scope_NN1 of_IO these_DD2 laws_NN2 ,_Y such_II21 as_II22 whether_CSW the_AT limitation_NN1 on_II liability_NN1 applies_VVZ solely_RR to_II prescription_NN1 drugs_NN2 or_CC to_II other_JJ FDA-approved_JJ_NN1 products_NN2 as_RR21_RG well_RR22_RR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  160 Generally , each law includes exceptions permitting full liability in three circumstances : ( 1 ) if the drug was sold after an FDA product recall or withdrawal of approval ; ( 2 ) if the defendant knowingly withheld material information from or misrepresented material information to the FDA ; or ( 3 ) if the defendant bribed a public official .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  160 Generally_RR ,_Y each_DD1 law_NN1 includes_VVZ exceptions_NN2 permitting_VVG full_JJ liability_NN1 in_II three_MC circumstances_NN2 :_Y (_Y 1_MC1 )_Y if_CS the_AT drug_NN1 was_VBDZ sold_VVN after_II an_AT1 FDA_NN1 product_NN1 recall_NN1@_VV0 or_CC withdrawal_NN1 of_IO approval_NN1 ;_Y (_Y 2_MC )_Y if_CS the_AT defendant_NN1 knowingly_RR withheld_VVN_VVD material_NN1_JJ@ information_NN1 from_II or_CC misrepresented_JJ@_VVD material_NN1_JJ@ information_NN1 to_II the_AT FDA_NN1_NP1 ;_Y or_CC (_Y 3_MC )_Y if_CS the_AT defendant_NN1 bribed_VVD_VVN a_AT1 public_JJ_NN1 official_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  161 Ohio law further permits punitive damages upon a finding that the manufacturer acted might be harmed by the product " and provides that the court is to decide the amount of punitive damages upon a jury verdict finding punitive damages appropriate. n209 The laws also differ on the burden of proof required to overcome the limitation on liability. ( n210 ) <p> It is inaccurate , however , to call this an " FDA-approval " defense .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  161 Ohio_NP1 law_NN1 further_RRR permits_VVZ punitive_JJ damages_NN2 upon_II a_AT1 finding_NN1 that_CST the_AT manufacturer_NN1 acted_VVN_VVD might_VM be_VBI harmed_VVN by_II the_AT product_NN1 "_Y and_CC provides_VVZ that_CST the_AT court_NN1 is_VBZ to_TO decide_VVI the_AT amount_NN1 of_IO punitive_JJ damages_NN2 upon_II a_AT1 jury_NN1 verdict_NN1 finding_VVG punitive_JJ damages_NN2 appropriate._NNU n209_FO The_AT laws_NN2 also_RR differ_VV0 on_II_RP@ the_AT burden_NN1 of_IO proof_NN1 required_VVN to_TO overcome_VVI the_AT limitation_NN1 on_II liability._NNU (_Y n210_FO )_Y <p>_Y It_PPH1 is_VBZ inaccurate_JJ ,_Y however_RR ,_Y to_TO call_VVI this_DD1 an_AT1 "_Y FDA-approval_JJ_NN1 "_Y defense_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  162 The defense neither completely eliminates liability ( except in Michigan , with limited exceptions ) , nor results in the elimination of punitive damages simply based on FDA approval .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  162 The_AT defense_NN1 neither_RR_DD1 completely_RR eliminates_VVZ liability_NN1 (_Y except_CS_VV0% in_II Michigan_NP1 ,_Y with_IW limited_JJ exceptions_NN2 )_Y ,_Y nor_CC results_NN2_VVZ@ in_II the_AT elimination_NN1 of_IO punitive_JJ damages_NN2 simply_RR based_VVN on_II FDA_NP1_NN1 approval_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  163 FDA approval of a prescription drug is insufficient to merit such treatment unless the manufacturer follows FDA rules and submits the extensive test results required by FDA regulations .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  163 FDA_NP1_NN1 approval_NN1 of_IO a_AT1 prescription_NN1 drug_NN1 is_VBZ insufficient_JJ to_TO merit_VVI such_DA treatment_NN1 unless_CS the_AT manufacturer_NN1 follows_VVZ FDA_NN1_NP1 rules_NN2 and_CC submits_VVZ the_AT extensive_JJ test_NN1 results_NN2 required_VVN by_II FDA_NP1_NN1 regulations_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  164 In addition , FDA regulations require submission of certain information after approval of the drug , such as adverse reaction reports and new developments in scientific knowledge on the drug , which allows the agency to determine whether it should withdraw its approval and require the manufacturer to withdraw the product. ( n211 ) <p> Protection from punitive damages would only apply when the manufacturer has met all companies to disclose fully all pre- and post-marketing data and to meet or exceed the agency 's requirements in order to qualify for protection from extensive punitive damages should it later be found that the manufacturer failed to warn of known risk .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  164 In_RR21 addition_RR22 ,_Y FDA_NP1_NN1 regulations_NN2 require_VV0 submission_NN1 of_IO certain_JJ information_NN1 after_II_CS approval_NN1 of_IO the_AT drug_NN1 ,_Y such_II21 as_II22 adverse_JJ reaction_NN1 reports_NN2_VVZ and_CC new_JJ developments_NN2 in_II scientific_JJ knowledge_NN1 on_II the_AT drug_NN1 ,_Y which_DDQ allows_VVZ the_AT agency_NN1 to_TO determine_VVI whether_CSW it_PPH1 should_VM withdraw_VVI its_Z' approval_NN1 and_CC require_VVI the_AT manufacturer_NN1 to_TO withdraw_VVI the_AT product._NNU (_Y n211_FO )_Y <p>_Y Protection_NN1 from_II punitive_JJ damages_NN2 would_VM only_RR apply_VVI when_RRQ_CS the_AT manufacturer_NN1 has_VHZ met_VVN all_DB companies_NN2 to_TO disclose_VVI fully_RR all_DB pre-_JJ and_CC post-marketing_JJ data_NN and_CC to_TO meet_VVI or_CC exceed_VVI the_AT agency_NN1 's_GE requirements_NN2 in_BCL21 order_BCL22 to_TO qualify_VVI for_IF protection_NN1 from_II extensive_JJ punitive_JJ damages_NN2 should_VM it_PPH1 later_RRR be_VBI found_VVN that_CST the_AT manufacturer_NN1 failed_VVD_VVN to_TO warn_VVI of_IO known_JJ@ risk_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  165 <p> c .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  165 <p>_Y c_ZZ1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  166 Placing Regulated Conduct Beyond the Scope of Consumer Protection Laws Product liability claims against pharmaceutical manufacturers are generally brought on behalf of plaintiffs who have experienced physical injuries .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  166 Placing_VVG_NN1 Regulated_JJ@_VVD_VVN Conduct_NN1 Beyond_II the_AT Scope_NN1 of_IO Consumer_NN1 Protection_NN1 Laws_NN2 Product_NN1 liability_NN1 claims_VVZ_NN2 against_II pharmaceutical_JJ manufacturers_NN2 are_VBR generally_RR brought_VVN_VVD on_II31 behalf_II32 of_II33 plaintiffs_NN2 who_PNQS have_VH0 experienced_VVN physical_JJ injuries_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  167 Increasingly , lawyers are alleging claims under state consumer protection laws. n212 Although these types of claims appear to be increasing across the board , pharmaceutical manufacturers are a principal target. ( n213 ) <p> Typically , lawyers bring Consumer Protection Act ( CPA ) claims involving prescription drugs as class actions on behalf of a group of individuals who purchased the drug but did not suffer any ill effects .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  167 Increasingly_RR ,_Y lawyers_NN2 are_VBR alleging_VVG claims_NN2 under_II state_NN1 consumer_NN1 protection_NN1 laws._NNU n212_FO Although_CS these_DD2 types_NN2 of_IO claims_NN2 appear_VV0 to_TO be_VBI increasing_VVG_JJ across_II the_AT board_NN1 ,_Y pharmaceutical_JJ manufacturers_NN2 are_VBR a_AT1 principal_JJ_NN1 target._NNU (_Y n213_FO )_Y <p>_Y Typically_RR ,_Y lawyers_NN2 bring_VV0 Consumer_NN1 Protection_NN1 Act_NN1 (_Y CPA_NP1 )_Y claims_VVZ_NN2 involving_VVG prescription_NN1 drugs_NN2 as_CSA_II@ class_NN1_JJ% actions_NN2_VVZ@ on_II31 behalf_II32 of_II33 a_AT1 group_NN1 of_IO individuals_NN2 who_PNQS purchased_VVD the_AT drug_NN1 but_CCB did_VDD not_XX suffer_VVI any_DD ill_Z' effects_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  168 These lawsuits usually allege that the company promoted a drug as safe and effective , when in fact either the product was not as effective as consumers believed or the advertising failed to disclose a known risk associated with the drug .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  168 These_DD2 lawsuits_NN2 usually_RR allege_VV0 that_CST the_AT company_NN1 promoted_VVN_VVD@ a_AT1 drug_NN1 as_CSA_RG@_II@ safe_JJ and_CC effective_JJ ,_Y when_CS_RRQ in_II fact_NN1 either_RR the_AT product_NN1 was_VBDZ not_XX as_RG effective_JJ as_CSA consumers_NN2 believed_VVN_VVD or_CC the_AT advertising_NN1 failed_VVD_VVN to_TO disclose_VVI a_AT1 known_JJ@ risk_NN1 associated_VVN with_IW the_AT drug_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  169 Claims may allege in artificial inflation of the product 's price beyond its actual value .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  169 Claims_NN2 may_VM allege_VVI in_II artificial_JJ inflation_NN1 of_IO the_AT product_NN1 's_GE price_NN1 beyond_II its_Z' actual_JJ value_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  170 Damages sought are usually either a complete refund of the purchase price ( on behalf of thousands of consumers ) or the difference between the sale price and the hypothetical actual value .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  170 Damages_NN2 sought_VVN are_VBR usually_RR either_RR a_AT1 complete_JJ refund_NN1 of_IO the_AT purchase_NN1 price_NN1 (_Y on_II31 behalf_II32 of_II33 thousands_M of_IO consumers_NN2 )_Y or_CC the_AT difference_NN1 between_II the_AT sale_NN1 price_NN1 and_CC the_AT hypothetical_JJ actual_JJ value_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  171 In recent years , such claims have been made involving Claritin , n214 OxyContin , n215 Prempro , n216 Rezulin , n217 and Vioxx , n218 among other products .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  171 In_II recent_JJ years_NNT2 ,_Y such_DA claims_NN2 have_VH0 been_VBN made_VVN involving_VVG Claritin_NP1 ,_Y n214_FO OxyContin_NP1 ,_Y n215_FO Prempro_NP1_NN1 ,_Y n216_FO Rezulin_NP1 ,_Y n217_FO and_CC Vioxx_NP1_NN1_VV0 ,_Y n218_FO among_II other_JJ products_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  172 <p> State consumer protection laws were once primarily used by government regulators to attack truly deceptive practices and by consumers to bring small claims to get reimbursement for being duped at the cash register , but now they are routinely tacked on to substantial lawsuits. n219 These laws are particularly attractive for private claims because they often provide for minimum awards set by statute in absence of proof of injury , treble damages , and attorneys ' fees. ( n220 ) <p> Some have argued that the scope of CPAs was never meant to include FDA-approved drugs. n221 That is why approximately two-thirds of CPAs exclude from their scope conduct regulated by state or federal is that CPAs were meant to fill a " legal gap " by protecting consumers where product safety was not already closely monitored and regulated by the government. n223 These provisions are only infrequently applied in cases involving pharmaceutical marketing .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  172 <p>_Y State_VV0_NN1 consumer_NN1 protection_NN1 laws_NN2 were_VBDR once_RR primarily_RR used_VVN by_II government_NN1 regulators_NN2 to_TO attack_VVI truly_RR deceptive_JJ practices_NN2 and_CC by_II consumers_NN2 to_TO bring_VVI small_JJ claims_NN2 to_TO get_VVI reimbursement_NN1 for_IF being_VBG duped_VVN at_II the_AT cash_NN1 register_NN1_VV0 ,_Y but_CCB now_RT they_PPHS2 are_VBR routinely_RR tacked_VVN_VVD on_II21_RP to_II22_II substantial_JJ lawsuits._NNU n219_FO These_DD2 laws_NN2 are_VBR particularly_RR attractive_JJ for_IF private_JJ claims_NN2 because_CS they_PPHS2 often_RR provide_VV0 for_IF minimum_JJ_NN1 awards_NN2 set_VVN by_II statute_NN1 in_II absence_NN1 of_IO proof_NN1 of_IO injury_NN1 ,_Y treble_JJ_VV0_NN1 damages_NN2 ,_Y and_CC attorneys_NN2 '_GE fees._NNU (_Y n220_FO )_Y <p>_Y Some_DD have_VH0 argued_VVN that_CST the_AT scope_NN1 of_IO CPAs_NP2 was_VBDZ never_RR meant_VVN_VVD to_TO include_VVI FDA-approved_JJ_NN1 drugs._NNU n221_FO That_DD1 is_VBZ why_RRQ approximately_RR two-thirds_MF of_IO CPAs_NP2_NN2 exclude_VV0 from_II their_APPGE scope_NN1 conduct_NN1 regulated_VVN by_II state_NN1 or_CC federal_JJ is_VBZ that_CST CPAs_NN2 were_VBDR meant_VVN to_TO fill_VVI a_AT1 "_Y legal_JJ gap_NN1 "_Y by_II protecting_VVG_JJ@ consumers_NN2 where_RRQ_CS product_NN1 safety_NN1 was_VBDZ not_XX already_RR closely_RR monitored_VVN_VVD and_CC regulated_VVN by_II the_AT government._NNU n223_FO These_DD2 provisions_NN2 are_VBR only_RR infrequently_RR applied_VVN_VVD in_II cases_NN2 involving_VVG pharmaceutical_JJ marketing_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  173 Instead , courts appear more frequently to apply principles of conflict preemption in claims challenging drug warnings. ( n224 ) <p> C. Conflicts with Federal Authority : Preemption The constitutional principle of preemption provides a final safeguard in the development and communication of drug warnings .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  173 Instead_RR ,_Y courts_NN2 appear_VV0 more_RGR_RRR frequently_RR to_TO apply_VVI principles_NN2 of_IO conflict_NN1 preemption_NN1 in_II claims_NN2 challenging_VVG_JJ drug_NN1 warnings._NNU (_Y n224_FO )_Y <p>_Y C._NP1 Conflicts_NN2 with_IW Federal_JJ Authority_NN1 :_Y Preemption_NN1_NP1@ The_AT constitutional_JJ principle_NN1 of_IO preemption_NN1 provides_VVZ a_AT1 final_JJ safeguard_NN1 in_II the_AT development_NN1 and_CC communication_NN1 of_IO drug_NN1 warnings_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  174 Under the Supremacy Clause of the United States Constitution , state law must yield to federal law when the two conflict. n225 Acts of Congress or agencies empowered to act on Congress 's behalf override any state law that is inconsistent with the exercise of federal power. n226 In the prescription drug context , the FDA acting pursuant to the FDCA is such an agency , able to exercise federal power. n227 In some instances , preemption establishes an affirmative defense for drug manufacturers , in effect barring state tort actions that rely on court decisions contrary to FDA decisions .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  174 Under_II the_AT Supremacy_NN1 Clause_NN1 of_IO the_AT United_NP1 States_NP1 Constitution_NN1 ,_Y state_VV0_NN1 law_NN1 must_VM yield_VVI to_II federal_JJ law_NN1 when_CS_RRQ the_AT two_MC conflict._NNU n225_FO Acts_NN2_VVZ of_IO Congress_NN1 or_CC agencies_NN2 empowered_VVD_VVN to_TO act_VVI on_II Congress_NN1 's_GE behalf_NN1 override_VV0_NN1 any_DD state_NN1_VV0 law_NN1 that_CST_DD1 is_VBZ inconsistent_JJ with_IW the_AT exercise_NN1 of_IO federal_JJ power._NNU n226_FO In_II the_AT prescription_NN1 drug_NN1 context_NN1 ,_Y the_AT FDA_NN1_NP1 acting_VVG pursuant_II21 to_II22 the_AT FDCA_NN1_NP1 is_VBZ such_DA an_AT1 agency_NN1 ,_Y able_JK to_TO exercise_VVI federal_JJ power._NNU n227_FO In_II some_DD instances_NN2 ,_Y preemption_NN1 establishes_VVZ an_AT1 affirmative_JJ_NN1 defense_NN1 for_IF drug_NN1 manufacturers_NN2 ,_Y in_II effect_NN1 barring_II_VVG state_NN1 tort_NN1 actions_VVZ@_NN2 that_CST rely_VV0 on_II_RP@ court_NN1 decisions_NN2 contrary_II21 to_II22 FDA_NP1_NN1 decisions_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  175 <p> 1 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  175 <p>_Y 1_MC1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  176 The most straightforward , known as " express preemption , " occurs where a federal law preempts state statutes and common law within the text of the statute .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  176 The_AT most_RGT straightforward_JJ ,_Y known_VVN as_II "_Y express_JJ@ preemption_NN1 ,_Y "_Y occurs_VVZ where_RRQ_CS a_AT1 federal_JJ law_NN1 preempts_NN2_VVZ state_VV0_NN1 statutes_NN2 and_CC common_JJ law_NN1 within_II the_AT text_NN1 of_IO the_AT statute_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  177 For example , the Medical Device Amendments to the FDCA contain an express preemption provision barring certain state actions where the device complies with FDA regulations. n228 This practice has the benefit of reducing uncertainty over Congressional intent ; it may still , however , leave questions over the scope of the preemption. ( n229 ) <p> In other cases , preemption can be implied through the purpose or structure of the federal law. n230 Such " implied preemption " occurs in three situations : ( 1 ) " field preemption , " in which Congress intends to occupy an entire regulatory field , leaving no room for state lawmaking ; n231 ( 2 ) " conflict preemption , " in which " compliance with both federal and state regulations is a physical impossibility " ; n232 and ( 3 ) " obstacle preemption , " in which state law " stands as an obstacle to the accomplishment and execution of the practice , only the latter two forms apply to prescription drugs as no court has yet found implied field preemption for the FDA 's regulation of drugs and medical devices. n234 These two forms are generally joined together by courts and commentators under the term " conflict preemption " despite distinct inquiries of analysis. n235 Because express preemption is relatively clear cut in most instances and field preemption is not yet recognized for the FDA 's regulatory coverage , implied conflict preemption principles represent the common method for recognizing preemption in pharmaceutical regulations .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  177 For_REX21 example_REX22 ,_Y the_AT Medical_JJ Device_NN1 Amendments_NN2 to_II the_AT FDCA_NN1_NP1 contain_VV0 an_AT1 express_JJ@ preemption_NN1 provision_NN1 barring_II_VVG certain_JJ state_NN1 actions_NN2_VVZ@ where_RRQ_CS the_AT device_NN1 complies_VVZ with_IW FDA_NN1_NP1 regulations._NNU n228_FO This_DD1 practice_NN1 has_VHZ the_AT benefit_NN1 of_IO reducing_VVG_JJ@ uncertainty_NN1 over_II Congressional_JJ intent_NN1_JJ ;_Y it_PPH1 may_VM still_RR ,_Y however_RR ,_Y leave_VV0_NN1 questions_NN2 over_II the_AT scope_NN1 of_IO the_AT preemption._NNU (_Y n229_FO )_Y <p>_Y In_II other_JJ cases_NN2 ,_Y preemption_NN1 can_VM be_VBI implied_VVN through_II the_AT purpose_NN1 or_CC structure_NN1 of_IO the_AT federal_JJ law._NNU n230_FO Such_DA "_Y implied_JJ@ preemption_NN1 "_Y occurs_VVZ in_II three_MC situations_NN2 :_Y (_Y 1_MC1 )_Y "_Y field_NN1_VV0@ preemption_NN1 ,_Y "_Y in_II which_DDQ Congress_NN1 intends_VVZ to_TO occupy_VVI an_AT1 entire_JJ regulatory_JJ field_NN1 ,_Y leaving_VVG no_AT room_NN1 for_IF state_NN1 lawmaking_VVG_NN1@ ;_Y n231_FO (_Y 2_MC )_Y "_Y conflict_NN1_VV0@ preemption_NN1 ,_Y "_Y in_II which_DDQ "_Y compliance_NN1 with_IW both_DB2_RR federal_JJ and_CC state_VV0_NN1 regulations_NN2 is_VBZ a_AT1 physical_JJ impossibility_NN1 "_Y ;_Y n232_FO and_CC (_Y 3_MC )_Y "_Y obstacle_NN1 preemption_NN1 ,_Y "_Y in_II which_DDQ state_VV0_NN1 law_NN1 "_Y stands_VVZ_NN2 as_II_CSA an_AT1 obstacle_NN1 to_II the_AT accomplishment_NN1 and_CC execution_NN1 of_IO the_AT practice_NN1 ,_Y only_RR the_AT latter_DA two_MC forms_NN2 apply_VV0 to_II prescription_NN1 drugs_NN2 as_II_CSA no_AT court_NN1 has_VHZ yet_RR found_VVN implied_JJ@ field_NN1 preemption_NN1 for_IF the_AT FDA_NP1_NN1 's_GE regulation_NN1 of_IO drugs_NN2 and_CC medical_JJ devices._NNU n234_FO These_DD2 two_MC forms_NN2 are_VBR generally_RR joined_VVN_VVD together_RL by_II courts_NN2 and_CC commentators_NN2 under_II the_AT term_NN1 "_Y conflict_NN1 preemption_NN1 "_Y despite_II distinct_JJ inquiries_NN2 of_IO analysis._NNU n235_FO Because_CS express_JJ@ preemption_NN1 is_VBZ relatively_RR clear_RR cut_VVN in_II most_DAT instances_NN2 and_CC field_NN1 preemption_NN1 is_VBZ not_XX yet_RR recognized_VVN_VVD for_IF the_AT FDA_NP1_NN1 's_GE regulatory_JJ coverage_NN1 ,_Y implied_VVD_JJ@_VVN conflict_NN1 preemption_NN1 principles_NN2 represent_VV0 the_AT common_JJ method_NN1 for_IF recognizing_VVG preemption_NN1 in_II pharmaceutical_JJ regulations_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  178 <p> 2 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  178 <p>_Y 2_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  179 The FDA 's Changing Priorities in a DTC Environment In recent years , the FDA has increasingly recognized implied conflict preemption of state tort claims as a result of its regulations and decision making. n236 Since 2000 , the agency has filed a number of amicus curiae briefs arguing that its regulatory interpretations support a finding of preemption. n237 As amicus , the FDA takes the clear position that , under the agency 's comprehensive regulatory scheme , a drug manufacturer can not unilaterally strengthen a drug warning without FDA approval. n238 This view , " its " thorough understanding of its own regulation , " and its " uniquely qualified " position to " comprehend the likely impact of state requirements .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  179 The_AT FDA_NP1_NN1 's_GE Changing_JJ Priorities_NN2 in_II a_AT1 DTC_NP1 Environment_NN1 In_II recent_JJ years_NNT2 ,_Y the_AT FDA_NN1_NP1 has_VHZ increasingly_RR recognized_VVN implied_JJ@ conflict_NN1 preemption_NN1 of_IO state_NN1 tort_NN1 claims_VVZ_NN2 as_II a_AT1 result_NN1 of_IO its_Z' regulations_NN2 and_CC decision_NN1 making._NNU n236_FO Since_II 2000_MC ,_Y the_AT agency_NN1 has_VHZ filed_VVN a_AT1 number_NN1 of_IO amicus_NN1 curiae_NN2 briefs_NN2_VVZ@ arguing_VVG that_CST its_Z' regulatory_JJ interpretations_NN2 support_VV0 a_AT1 finding_NN1 of_IO preemption._NNU n237_FO As_CSA_II@ amicus_NN1 ,_Y the_AT FDA_NN1_NP1 takes_VVZ the_AT clear_JJ position_NN1 that_CST_DD1 ,_Y under_II the_AT agency_NN1 's_GE_VBZ comprehensive_JJ regulatory_JJ scheme_NN1 ,_Y a_AT1 drug_NN1 manufacturer_NN1 can_VM not_XX unilaterally_RR strengthen_VVI a_AT1 drug_NN1 warning_NN1_VVG@ without_IW FDA_NN1_NP1 approval._NNU n238_FO This_DD1 view_NN1 ,_Y "_Y its_Z' "_Y thorough_JJ understanding_NN1 of_IO its_Z' own_DA regulation_NN1 ,_Y "_Y and_CC its_Z' "_Y uniquely_RR qualified_JJ_VVN "_Y position_NN1 to_TO "_Y comprehend_VVI the_AT likely_JJ impact_NN1 of_IO state_NN1 requirements_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  180 " ( n239 ) <p> In 2006 , the FDA issued a Preamble to a rule updating and strengthening prescription drug labeling requirements , which expressed its view that several types of product liability claims were preempted by federal regulation. n240 The agency explained that these claims either stood as an obstacle to carrying out its mission or conflicted with the FDA 's decision-making authority .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  180 "_Y (_Y n239_FO )_Y <p>_Y In_II 2006_MC ,_Y the_AT FDA_NP1_NN1 issued_VVD_VVN a_AT1 Preamble_NN1 to_II a_AT1 rule_NN1 updating_VVG and_CC strengthening_VVG_NN1 prescription_NN1 drug_NN1 labeling_VVG_NN1@ requirements_NN2 ,_Y which_DDQ expressed_VVD its_Z' view_NN1 that_CST several_DA2 types_NN2 of_IO product_NN1 liability_NN1 claims_NN2 were_VBDR preempted_VVN by_II federal_JJ regulation._NNU n240_FO The_AT agency_NN1 explained_VVD_VVN that_CST these_DD2 claims_NN2 either_RR stood_VVD_VVN@ as_II an_AT1 obstacle_NN1 to_II carrying_VVG out_RP its_Z' mission_NN1 or_CC conflicted_VVD_VVN@ with_IW the_AT FDA_NP1_NN1 's_GE decision-making_JJ_NN1 authority_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  181 Specifically , the Preamble states that " FDA approval of labeling under the new guidelines ... preempts conflicting or contrary State law , regulations , or decisions of a court of law for purposes of product liability litigation .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  181 Specifically_RR ,_Y the_AT Preamble_NN1 states_VVZ_NN2 that_CST_DD1 "_Y FDA_NP1_NN1 approval_NN1 of_IO labeling_VVG under_II the_AT new_JJ guidelines_NN2 ..._... preempts_VVZ_NN2 conflicting_JJ or_CC contrary_JJ_NN1 State_NN1 law_NN1 ,_Y regulations_NN2 ,_Y or_CC decisions_NN2 of_IO a_AT1 court_NN1 of_IO law_NN1 for_IF purposes_NN2 of_IO product_NN1 liability_NN1 litigation_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  182 " n241 The Preamble emphasizes the agency 's " statutorily prescribed role as the expert Federal agency responsible for evaluating and regulating drugs , " n242 and cautions that state tort actions can " encourage , and in fact require , lay judges and juries to second guess the assessment of benefits versus risks of a specific to add warnings ... and to propose ' defensive labeling ' ... which , if implemented , could result in scientifically unsubstantiated warnings and underutilization of beneficial treatments .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  182 "_Y n241_FO The_AT Preamble_NN1 emphasizes_VVZ the_AT agency_NN1 's_VBZ "_Y statutorily_RR prescribed_JJ_VVN role_NN1 as_II_CSA the_AT expert_NN1_JJ@ Federal_JJ agency_NN1 responsible_JJ for_IF evaluating_VVG and_CC regulating_VVG drugs_NN2 ,_Y "_Y n242_FO and_CC cautions_VVZ_NN2 that_CST_DD1 state_VV0_NN1 tort_NN1_VV0 actions_NN2 can_VM "_Y encourage_VV0 ,_Y and_CC in_II fact_NN1 require_VV0 ,_Y lay_VVD_VV0_JJ@ judges_NN2 and_CC juries_NN2 to_II second_NNT1_MD guess_VV0 the_AT assessment_NN1 of_IO benefits_NN2 versus_II risks_NN2 of_IO a_AT1 specific_JJ to_TO add_VVI warnings_NN2 ..._... and_CC to_TO propose_VVI '_GE defensive_JJ labeling_NN1@ '_GE ..._... which_DDQ ,_Y if_CS implemented_VVN ,_Y could_VM result_VVI in_II scientifically_RR unsubstantiated_JJ warnings_NN2 and_CC underutilization_NN1 of_IO beneficial_JJ treatments_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  183 " n243 The Preamble cites six instances where preemption should be implied. n244 Hence , although still acknowledging that " FDA labeling requirements represent a minimum safety standard , " the FDA interpreted its comprehensive regulatory procedures as creating " both a " floor ' and a ' ceiling ' " for the imposition of liability. ( n245 ) <p> The Preamble sparked debate over the FDA 's role in regulating drugs n246 and the relative deference a court should afford an agency 's interpretation of the scope of preemption as expressed in a preamble. n247 Courts have varied in the deference given to the FDA 's view. n248 In past decisions , the Supreme Court has expressed the view that agency statements warrant some degree of deference .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  183 "_Y n243_FO The_AT Preamble_NN1 cites_VVZ six_MC instances_NN2 where_RRQ_CS preemption_NN1 should_VM be_VBI implied._NNU n244_FO Hence_RR ,_Y although_CS still_RR acknowledging_VVG that_DD1_CST "_Y FDA_NN1_NP1 labeling_VVG_JJ@_NN1@ requirements_NN2 represent_VV0 a_AT1 minimum_JJ_NN1 safety_NN1 standard_NN1 ,_Y "_Y the_AT FDA_NP1_NN1 interpreted_VVD its_Z' comprehensive_JJ regulatory_JJ procedures_NN2 as_CSA_II@ creating_VVG "_Y both_RR a_AT1 "_Y floor_NN1 '_GE and_CC a_AT1 '_GE ceiling_NN1 '_GE "_Y for_IF the_AT imposition_NN1 of_IO liability._NNU (_Y n245_FO )_Y <p>_Y The_AT Preamble_NN1 sparked_VVD_VVN debate_NN1 over_II the_AT FDA_NP1_NN1 's_GE role_NN1 in_II regulating_VVG drugs_NN2 n246_FO and_CC the_AT relative_JJ_NN1 deference_NN1 a_AT1 court_NN1 should_VM afford_VVI an_AT1 agency_NN1 's_GE interpretation_NN1 of_IO the_AT scope_NN1 of_IO preemption_NN1 as_CSA expressed_VVN in_II a_AT1 preamble._NNU n247_FO Courts_NN2 have_VH0 varied_VVN in_II the_AT deference_NN1 given_VVN to_II the_AT FDA_NP1_NN1 's_GE view._NNU n248_FO In_II past_JJ_NN1 decisions_NN2 ,_Y the_AT Supreme_JJ Court_NN1 has_VHZ expressed_VVN the_AT view_NN1 that_CST_DD1 agency_NN1 statements_NN2 warrant_VV0 some_DD degree_NN1 of_IO deference_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  184 For example , in Medtronic , Inc. v. Lohr , a medical device case , Justice Breyer 's concurrence noted , " in the absence of a clear congressional command as to preemption a degree of leeway to determine which rules , regulations , or other administrative actions will have pre-emptive effect .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  184 For_REX21 example_REX22 ,_Y in_II Medtronic_JJ ,_Y Inc._JJ v._II Lohr_NP1_NN1 ,_Y a_AT1 medical_JJ device_NN1 case_NN1 ,_Y Justice_NP1@_NN1 Breyer_NP1 's_GE concurrence_NN1 noted_VVD_VVN ,_Y "_Y in_II the_AT absence_NN1 of_IO a_AT1 clear_JJ congressional_JJ command_NN1 as_II21 to_II22 preemption_NN1 a_AT1 degree_NN1 of_IO leeway_NN1 to_TO determine_VVI which_DDQ rules_VVZ@_NN2 ,_Y regulations_NN2 ,_Y or_CC other_JJ administrative_JJ actions_NN2 will_VM have_VHI pre-emptive_JJ effect_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  185 " n249 Likewise , in Hillsborough County v. Automated Medical Laboratories , Inc. , the Court recognized that " because agencies normally address problems in a detailed manner and can speak through a variety of means , including regulations , preambles , interpretative statements , and responses to comments , we can expect that they will make their intentions clear if they intend for their regulations to be exclusive .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  185 "_Y n249_FO Likewise_RR ,_Y in_II Hillsborough_NP1 County_NN1 v._II Automated_JJ Medical_JJ Laboratories_NN2 ,_Y Inc._JJ ,_Y the_AT Court_NN1 recognized_VVD_VVN that_CST "_Y because_CS agencies_NN2 normally_RR address_VV0@_NN1 problems_NN2 in_II a_AT1 detailed_JJ manner_NN1 and_CC can_VM speak_VVI through_II_RP@ a_AT1 variety_NN1 of_IO means_NN ,_Y including_II_VVG@ regulations_NN2 ,_Y preambles_NN2 ,_Y interpretative_JJ statements_NN2 ,_Y and_CC responses_NN2 to_II comments_NN2 ,_Y we_PPIS2 can_VM expect_VVI that_CST they_PPHS2 will_VM make_VVI their_APPGE intentions_NN2 clear_VVI if_CSW@_CS they_PPHS2 intend_VV0 for_IF their_APPGE regulations_NN2 to_TO be_VBI exclusive_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  186 " ( n250 ) <p> Although the Court has not yet directly addressed the preemptive effect of the FDA 's regulation of prescription drugs or the level of deference to be accorded to the FDA 's view , the Court 's consideration of Levine v. Wyeth is likely to shine significant light on these issues as well as the modem role of the FDA. n251 In Levine , the plaintiff went to the hospital for treatment of a serious migraine headache and , after injection with the drug Phenergan , was left with injuries that led to the amputation of her intravenous ( IV ) injection , a risk the FDA had closely considered when deeming the anti-nausea medication safe for use. n253 The agency approved a warning cautioning against inadvertent injection and providing instructions to minimize the risk but chose not to prohibit IV push as a means of administration. n254 In fact , Wyeth asked the FDA in 2000 to alter the warning to place greater emphasis on the risk at issue , but the FDA indicated the warning should remain unaltered. n255 Wyeth acquiesced and the warning was unchanged leading up to the state lawsuit .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  186 "_Y (_Y n250_FO )_Y <p>_Y Although_CS the_AT Court_NN1 has_VHZ not_XX yet_RR directly_RR addressed_VVD_VVN the_AT preemptive_JJ effect_NN1 of_IO the_AT FDA_NP1_NN1 's_GE regulation_NN1 of_IO prescription_NN1 drugs_NN2 or_CC the_AT level_NN1 of_IO deference_NN1 to_TO be_VBI accorded_VVN to_II the_AT FDA_NP1_NN1 's_GE view_NN1 ,_Y the_AT Court_NN1 's_GE consideration_NN1 of_IO Levine_NP1_NN1@ v._II Wyeth_NP1 is_VBZ likely_JJ to_TO shine_VVI significant_JJ light_NN1 on_II these_DD2 issues_NN2 as_II31 well_II32 as_II33 the_AT modem_NN1 role_NN1 of_IO the_AT FDA._NP1 n251_FO In_II Levine_NP1 ,_Y the_AT plaintiff_NN1 went_VVD to_II the_AT hospital_NN1 for_IF treatment_NN1 of_IO a_AT1 serious_JJ migraine_NN1 headache_NN1 and_CC ,_Y after_CS_II injection_NN1 with_IW the_AT drug_NN1 Phenergan_NP1_NN1@ ,_Y was_VBDZ left_VVN with_IW injuries_NN2 that_CST led_VVD to_II the_AT amputation_NN1 of_IO her_APPGE_PPHO1 intravenous_JJ (_Y IV_MC )_Y injection_NN1 ,_Y a_AT1 risk_NN1 the_AT FDA_NN1_NP1 had_VHD closely_RR considered_VVN when_CS deeming_VVG the_AT anti-nausea_JJ_NN1 medication_NN1 safe_NN1@_JJ for_IF use._NNU n253_FO The_AT agency_NN1 approved_VVD_VVN a_AT1 warning_NN1 cautioning_VVG against_II inadvertent_JJ_NN1 injection_NN1 and_CC providing_VVG instructions_NN2 to_TO minimize_VVI the_AT risk_NN1 but_CCB chose_VVD not_XX to_TO prohibit_VVI IV_MC push_VV0_NN1@ as_II a_AT1 means_NN of_IO administration._NNU n254_FO In_II fact_NN1 ,_Y Wyeth_NP1 asked_VVD the_AT FDA_NN1_NP1 in_II 2000_MC to_TO alter_VVI the_AT warning_NN1 to_TO place_VVI greater_JJR emphasis_NN1 on_II the_AT risk_NN1 at_II issue_NN1 ,_Y but_CCB the_AT FDA_NP1_NN1 indicated_VVD the_AT warning_NN1 should_VM remain_VVI unaltered._NNU n255_FO Wyeth_NP1_VVZ acquiesced_VVD_VVN and_CC the_AT warning_NN1 was_VBDZ unchanged_JJ leading_JJ_VVG up_II21 to_II22 the_AT state_NN1 lawsuit_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  187 <p> The Vermont Supreme Court found that FDA compliance is only a minimum standard and referred to FDA approval as simply a " first step " in pharmaceutical labeling. n256 The court rejected both conflict and obstacle preemption , concluding that the manufacturer was " free " to supplement or strengthen warnings at any time. n257 The court also acknowledged the FDA Preamble , yet held that " irrespective of the level of deference it might apply , the statement would not affect the outcome of the appeal , " and further stated ( n258 ) <p> The Solicitor General , in a brief as amicus curiae filed at the invitation of the U.S. Supreme Court , disagreed with the Vermont ruling. n259 The Solicitor recognized that labeling is an inextricable component of the approval process , noting that the FDA may convey to physicians and their patients the conditions under which the potential benefits of the product exceed its risks , while not unnecessarily deterring beneficial uses. n260 " If manufacturers were free to make unilateral changes to labeling the day after FDA 's approval , based on information that was previously available to FDA , the approval process would be greatly undermined and the agency 's careful balancing of risks and benefits thwarted .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  187 <p>_Y The_AT Vermont_NP1 Supreme_JJ Court_NN1 found_VVD_VVN that_CST_DD1 FDA_NP1_NN1 compliance_NN1 is_VBZ only_RR a_AT1 minimum_JJ_NN1 standard_NN1_JJ and_CC referred_VVN_VVD to_II FDA_NP1_NN1 approval_NN1 as_CSA_RG@ simply_RR a_AT1 "_Y first_MD step_NN1_VV0 "_Y in_II pharmaceutical_JJ labeling._NNU n256_FO The_AT court_NN1 rejected_VVD_VVN both_RR conflict_VV0@_NN1 and_CC obstacle_NN1 preemption_NN1 ,_Y concluding_VVG that_CST the_AT manufacturer_NN1 was_VBDZ "_Y free_JJ "_Y to_TO supplement_VVI or_CC strengthen_VVI warnings_NN2 at_II any_DD time._NNU n257_FO The_AT court_NN1 also_RR acknowledged_VVD_VVN the_AT FDA_NN1_NP1 Preamble_NN1 ,_Y yet_RR held_VVN_VVD that_CST_DD1 "_Y irrespective_II21 of_II22 the_AT level_NN1 of_IO deference_NN1 it_PPH1 might_VM apply_VVI ,_Y the_AT statement_NN1 would_VM not_XX affect_VVI the_AT outcome_NN1 of_IO the_AT appeal_NN1 ,_Y "_Y and_CC further_RRR stated_VVN_VVD (_Y n258_FO )_Y <p>_Y The_AT Solicitor_NN1 General_NN1 ,_Y in_II a_AT1 brief_JJ as_CSA_II@ amicus_NN1 curiae_NN2 filed_VVN_VVD at_II the_AT invitation_NN1 of_IO the_AT U.S._NP1 Supreme_JJ Court_NN1 ,_Y disagreed_VVD with_IW the_AT Vermont_NP1 ruling._NNU n259_FO The_AT Solicitor_NN1 recognized_VVD_VVN that_DD1_CST labeling_NN1@_VVG is_VBZ an_AT1 inextricable_JJ component_NN1 of_IO the_AT approval_NN1 process_NN1_VV0 ,_Y noting_VVG that_CST the_AT FDA_NN1_NP1 may_VM convey_VVI to_II physicians_NN2 and_CC their_APPGE patients_NN2 the_AT conditions_NN2 under_II which_DDQ the_AT potential_JJ_NN1 benefits_NN2 of_IO the_AT product_NN1 exceed_VV0 its_Z' risks_NN2 ,_Y while_CS not_XX unnecessarily_RR deterring_VVG beneficial_JJ uses._NNU n260_FO "_Y If_CS manufacturers_NN2 were_VBDR free_JJ to_TO make_VVI unilateral_JJ changes_NN2 to_II labeling_VVG the_AT day_NNT1 after_II_CS FDA_NP1 's_GE approval_NN1 ,_Y based_VVN on_II information_NN1 that_CST_DD1 was_VBDZ previously_RR available_JJ to_II FDA_NP1_NN1 ,_Y the_AT approval_NN1 process_NN1 would_VM be_VBI greatly_RR undermined_VVN_VVD and_CC the_AT agency_NN1 's_GE careful_JJ balancing_NN1@ of_IO risks_NN2 and_CC benefits_NN2 thwarted_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  188 " n261 Having granted certiorari , the Court will decide whether FDA-approved warnings are merely a floor , as suggested by the Vermont Supreme Court , or both floor and ceiling , as argued by the Solicitor General. ( n262 ) <p> Other courts have found that state tort law claims challenging conduct in compliance with FDA requirements are preempted .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  188 "_Y n261_FO Having_VHG granted_VVN certiorari_NN2 ,_Y the_AT Court_NN1 will_VM decide_VVI whether_CSW FDA-approved_JJ warnings_NN2 are_VBR merely_RR a_AT1 floor_NN1 ,_Y as_CSA suggested_VVN by_II the_AT Vermont_NP1 Supreme_JJ Court_NN1 ,_Y or_CC both_RR floor_NN1 and_CC ceiling_NN1 ,_Y as_CSA argued_VVN by_II the_AT Solicitor_NN1 General._ZZ (_Y n262_FO )_Y <p>_Y Other_JJ courts_NN2 have_VH0 found_VVN that_CST_DD1 state_VV0_NN1 tort_NN1_VV0 law_NN1 claims_VVZ_NN2 challenging_JJ_VVG conduct_NN1 in_II compliance_NN1 with_IW FDA_NN1_NP1 requirements_NN2 are_VBR preempted_VVN@_JJ@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  189 For instance , a federal district court to an anti-depression and anti-anxiety drug 's ( Paxil ) risk of suicide , and found them to be preempted. n263 The case , which also involved the drug 's generic versions , examined the FDA 's position on preemption , holding that it is " abundantly clear " that such evidence of intent is entitled to " significant deference .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  189 For_REX21 instance_REX22 ,_Y a_AT1 federal_JJ district_NN1 court_NN1 to_II an_AT1 anti-depression_NN1_JJ and_CC anti-anxiety_JJ_NN1 drug_NN1 's_GE (_Y Paxil_NP1 )_Y risk_NN1 of_IO suicide_NN1 ,_Y and_CC found_VVD them_PPHO2 to_TO be_VBI preempted._NNU n263_FO The_AT case_NN1 ,_Y which_DDQ also_RR involved_VVD_VVN the_AT drug_NN1 's_GE generic_JJ versions_NN2 ,_Y examined_VVD_VVN the_AT FDA_NP1_NN1 's_GE position_NN1 on_II preemption_NN1 ,_Y holding_VVG that_CST it_PPH1 is_VBZ "_Y abundantly_RR clear_VV0@_JJ "_Y that_CST_DD1 such_DA evidence_NN1 of_IO intent_NN1 is_VBZ entitled_VVN to_II "_Y significant_JJ deference_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  190 " n264 Similarly , a federal district court in California reached a similar determination and preempted state claims for failure to warn of the drug Celebrex 's cardiovascular risks. ( n265 ) <p> Armed with evidence of the FDA 's understanding of the scope of preemption , a growing number of courts acknowledge implied conflict preemption in drug warnings .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  190 "_Y n264_FO Similarly_RR ,_Y a_AT1 federal_JJ district_NN1 court_NN1 in_II California_NP1 reached_VVD a_AT1 similar_JJ determination_NN1 and_CC preempted_JJ@_VVD state_NN1 claims_NN2_VVZ for_IF failure_NN1 to_TO warn_VVI of_IO the_AT drug_NN1 Celebrex_NP1_NN1 's_GE_VBZ cardiovascular_JJ risks._NNU (_Y n265_FO )_Y <p>_Y Armed_VVN_JJ with_IW evidence_NN1 of_IO the_AT FDA_NP1_NN1 's_GE understanding_NN1 of_IO the_AT scope_NN1 of_IO preemption_NN1 ,_Y a_AT1 growing_JJ number_NN1 of_IO courts_NN2 acknowledge_VV0 implied_JJ@ conflict_NN1 preemption_NN1 in_II drug_NN1 warnings_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  191 Although this development is gradual and uneven , it signals a renewed viability of implied preemption as a final , constitutional check on the sufficiency of drug warnings .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  191 Although_CS this_DD1 development_NN1 is_VBZ gradual_JJ and_CC uneven_JJ ,_Y it_PPH1 signals_VVZ@ a_AT1 renewed_JJ viability_NN1 of_IO implied_JJ@ preemption_NN1 as_II_CSA a_AT1 final_JJ_NN1 ,_Y constitutional_JJ check_NN1 on_II the_AT sufficiency_NN1 of_IO drug_NN1 warnings_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  192 <p> Federal law may not only preclude state product liability claims , but it may also preempt CPA claims .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  192 <p>_Y Federal_JJ law_NN1 may_VM not_XX only_RR preclude_VVI state_NN1 product_NN1 liability_NN1 claims_NN2_VVZ ,_Y but_CCB it_PPH1 may_VM also_RR preempt_VVI CPA_NN1_NP1 claims_NN2_VVZ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  193 For example , in Pennsylvania Employees Benefit Trust Fund v. Zeneca , Inc. , the plaintiffs claimed that the manufacturer of Nexium was superior to Prilosec. n266 Both drugs treat acid reflux disease and frequent heartburn .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  193 For_REX21 example_REX22 ,_Y in_II Pennsylvania_NP1 Employees_NN2 Benefit_VV0 Trust_NN1_VV0 Fund_NN1 v._II Zeneca_NP1 ,_Y Inc._JJ ,_Y the_AT plaintiffs_NN2 claimed_VVD_VVN that_CST the_AT manufacturer_NN1 of_IO Nexium_NP1_NN1 was_VBDZ superior_JJ to_II Prilosec._NP1 n266_FO Both_DB2 drugs_NN2 treat_VV0 acid_NN1 reflux_NN1 disease_NN1 and_CC frequent_JJ heartburn_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  194 Delaware 's consumer protection law exempts advertising or mechanizing practices that comply with the rules and regulations of the FTC , but does not contain a general regulatory compliance exemption for conduct in compliance with the rules of other government agencies. n267 The Third Circuit , although noting that the FTC and FDA initially had concurrent jurisdiction over prescription drug advertising , declined to extend the clear statutory language to conduct that now falls exclusively within the FDA 's jurisdiction. n268 The court found , however , that the purpose of the Food , Drug , and Cosmetic Act " would be frustrated if states were allowed to interpose consumer fraud laws that permitted plaintiffs to question the veracity of statements approved by the FDA. " n269 Thus , the court found claims under Delaware 's consumer protection law challenging labeling or advertising of FDA-approved prescription drugs implicitly preempted. ( n270 ) <p> 3 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  194 Delaware_NP1 's_GE consumer_NN1 protection_NN1 law_NN1 exempts_VVZ advertising_NN1 or_CC mechanizing_VVG_JJ@ practices_NN2 that_CST comply_VV0 with_IW the_AT rules_NN2 and_CC regulations_NN2 of_IO the_AT FTC_NP1 ,_Y but_CCB does_VDZ not_XX contain_VVI a_AT1 general_JJ regulatory_JJ compliance_NN1 exemption_NN1 for_IF conduct_NN1 in_II compliance_NN1 with_IW the_AT rules_NN2 of_IO other_JJ government_NN1 agencies._NNU n267_FO The_AT Third_MD Circuit_NN1 ,_Y although_CS noting_VVG that_CST the_AT FTC_NP1 and_CC FDA_NP1_NN1 initially_RR had_VHN@_VHD concurrent_JJ jurisdiction_NN1 over_II prescription_NN1 drug_NN1 advertising_NN1 ,_Y declined_VVD_VVN to_TO extend_VVI the_AT clear_JJ statutory_JJ language_NN1 to_TO conduct_VVI that_CST_DD1 now_RT falls_VVZ exclusively_RR within_II the_AT FDA_NP1_NN1 's_GE jurisdiction._NNU n268_FO The_AT court_NN1 found_VVD_VVN ,_Y however_RR ,_Y that_CST the_AT purpose_NN1 of_IO the_AT Food_NN1 ,_Y Drug_NN1 ,_Y and_CC Cosmetic_JJ Act_NN1 "_Y would_VM be_VBI frustrated_VVN if_CS_CSW@ states_NN2 were_VBDR allowed_VVN to_TO interpose_VVI consumer_NN1 fraud_NN1 laws_NN2 that_CST permitted_VVD_JJ@ plaintiffs_NN2 to_TO question_VVI the_AT veracity_NN1 of_IO statements_NN2 approved_VVN by_II the_AT FDA._NP1 "_Y n269_FO Thus_RR ,_Y the_AT court_NN1 found_VVD_VVN claims_NN2 under_II Delaware_NP1 's_GE consumer_NN1 protection_NN1 law_NN1 challenging_JJ_VVG labeling_NN1@_JJ@_VVG or_CC advertising_NN1 of_IO FDA-approved_JJ_NN1 prescription_NN1 drugs_NN2 implicitly_RR preempted._NNU (_Y n270_FO )_Y <p>_Y 3_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  195 Public Policy Supports Expanding Scope of Preemption The FDA 's interpretation of the scope of implied preemption appears cognizant of the scale and complexity of pharmaceutical production reaches new heights , the need for comprehensive federal regulation becomes increasingly imperative. n271 Greater recognition of federal preemption helps to achieve the objectives of such regulation by assuring definitive and uniform application .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  195 Public_JJ_NN1 Policy_NN1 Supports_VVZ_NN2 Expanding_JJ_VVG Scope_NN1 of_IO Preemption_NN1_NP1@ The_AT FDA_NP1_NN1 's_GE interpretation_NN1 of_IO the_AT scope_NN1 of_IO implied_JJ@ preemption_NN1 appears_VVZ cognizant_NN1_JJ of_IO the_AT scale_NN1 and_CC complexity_NN1 of_IO pharmaceutical_JJ production_NN1 reaches_VVZ new_JJ heights_NN2 ,_Y the_AT need_NN1 for_IF comprehensive_JJ federal_JJ regulation_NN1 becomes_VVZ increasingly_RR imperative._NNU n271_FO Greater_NP1 recognition_NN1 of_IO federal_JJ preemption_NN1 helps_VVZ to_TO achieve_VVI the_AT objectives_NN2 of_IO such_DA regulation_NN1 by_II assuring_VVG definitive_JJ and_CC uniform_JJ_NN1 application_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  196 Further , preemption serves public policy goals of predictability and fundamental fairness by informing pharmaceutical participants of their complete set of legal obligations rather than simply setting a floor and forcing manufacturers to abide by fifty different state law interpretations. ( n272 ) <p> From a practical standpoint , the FDA 's interpretation is a logical , perhaps inevitable , step toward meeting its congressional mandate as the federal agency responsible for regulating drugs. n273 The FDCA , originally enacted in 1938 , does not contain express preemption language with regard to drug regulation. n274 Hence , implied conflict preemption is necessary for the FDA to assert its regulatory authority , provide definitive standards , and safeguard drug manufacturers when they comply with existing regulations .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  196 Further_RRR_JJR ,_Y preemption_NN1 serves_VVZ public_JJ policy_NN1 goals_NN2 of_IO predictability_NN1 and_CC fundamental_JJ fairness_NN1 by_II informing_VVG pharmaceutical_JJ participants_NN2 of_IO their_APPGE complete_JJ set_NN1 of_IO legal_JJ obligations_NN2 rather_II21_CS21@ than_II22_CS22@ simply_RR setting_VVG a_AT1 floor_NN1 and_CC forcing_VVG manufacturers_NN2 to_TO abide_VVI by_II fifty_MC different_JJ state_NN1 law_NN1 interpretations._NNU (_Y n272_FO )_Y <p>_Y From_II a_AT1 practical_JJ standpoint_NN1 ,_Y the_AT FDA_NP1_NN1 's_GE interpretation_NN1 is_VBZ a_AT1 logical_JJ ,_Y perhaps_RR inevitable_JJ ,_Y step_VV0_NN1 toward_II meeting_VVG its_Z' congressional_JJ mandate_NN1 as_II_CSA the_AT federal_JJ agency_NN1 responsible_JJ for_IF regulating_VVG drugs._NNU n273_FO The_AT FDCA_NN1_NP1 ,_Y originally_RR enacted_VVN_VVD in_II 1938_MC ,_Y does_VDZ not_XX contain_VVI express_JJ@ preemption_NN1 language_NN1 with_II31 regard_II32 to_II33 drug_NN1 regulation._NNU n274_FO Hence_RR ,_Y implied_VVD_JJ@_VVN conflict_NN1 preemption_NN1 is_VBZ necessary_JJ for_IF the_AT FDA_NN1_NP1 to_TO assert_VVI its_Z' regulatory_JJ authority_NN1 ,_Y provide_VV0 definitive_JJ standards_NN2 ,_Y and_CC safeguard_VV0_NN1 drug_NN1 manufacturers_NN2 when_CS_RRQ they_PPHS2 comply_VV0 with_IW existing_JJ regulations_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  197 <p> In comparison , the MDA , enacted over a half century after the FDCA , does contain an express preemption provision for medical such as application of the learned intermediary rule , between prescription drugs and prescription medical devices , n276 there appears to be little justification for such a discrepancy if the FDA was not supposed to preempt implicitly state laws regarding drug warnings .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  197 <p>_Y In_II comparison_NN1 ,_Y the_AT MDA_NN1_NP1 ,_Y enacted_VVD_VVN over_RP_II a_AT1 half_DB century_NNT1 after_II_CS the_AT FDCA_NN1_NP1 ,_Y does_VDZ contain_VVI an_AT1 express_JJ@ preemption_NN1 provision_NN1 for_IF medical_JJ such_II21 as_II22 application_NN1 of_IO the_AT learned_JJ@ intermediary_NN1 rule_NN1 ,_Y between_II prescription_NN1 drugs_NN2 and_CC prescription_NN1 medical_JJ devices_NN2 ,_Y n276_FO there_EX appears_VVZ to_TO be_VBI little_JJ_DA1 justification_NN1 for_IF such_DA a_AT1 discrepancy_NN1 if_CS the_AT FDA_NN1_NP1 was_VBDZ not_XX supposed_JJ to_TO preempt_VVI implicitly_RR state_VV0 laws_NN2 regarding_II_VVG drug_NN1 warnings_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  198 Rather , the FDA 's stronger endorsement of implied preemption seems to align preemption principles between these Acts , promoting the policy goal of consistency among laws .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  198 Rather_RR@_RG ,_Y the_AT FDA_NN1_NP1 's_GE stronger_JJR endorsement_NN1 of_IO implied_JJ@ preemption_NN1 seems_VVZ to_TO align_VVI preemption_NN1 principles_NN2 between_II these_DD2 Acts_NN2 ,_Y promoting_VVG the_AT policy_NN1 goal_NN1 of_IO consistency_NN1 among_II laws_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  199 <p> Growth in DTC marketing plays an important part in the changing landscape of drug regulation and the modem role of the FDA .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  199 <p>_Y Growth_NN1 in_II DTC_NP1 marketing_NN1 plays_VVZ an_AT1 important_JJ part_NN1 in_II the_AT changing_JJ landscape_NN1 of_IO drug_NN1 regulation_NN1 and_CC the_AT modem_NN1 role_NN1 of_IO the_AT FDA_NN1_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  200 Although the dynamics of the physician-patient relationship remain unaffected by DTC marketing , the scale of the marketing efforts is national and warrants comprehensive federal regulation .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  200 Although_CS the_AT dynamics_NN of_IO the_AT physician-patient_JJ_NN1 relationship_NN1 remain_VV0 unaffected_JJ by_II DTC_NP1 marketing_NN1 ,_Y the_AT scale_NN1 of_IO the_AT marketing_NN1 efforts_NN2 is_VBZ national_JJ and_CC warrants_VVZ_NN2 comprehensive_JJ federal_JJ regulation_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  201 Many states have long recognized the policy benefits of a uniform federal system of regulation and apply state law regulatory compliance exceptions to further this result. n277 Where the scope of these regulatory exemptions is limited , constitutional principles of preemption should apply to preclude most state tort claims based on design , failure to warn , and consumer protection acts if the drug manufacturer strictly complies with federal encourages individuals to seek effective treatment for health conditions or pushes them to pressure their doctors for unnecessary designer medications is likely to rage on far into the future .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  201 Many_DA2 states_NN2 have_VH0 long_RR recognized_VVN the_AT policy_NN1 benefits_NN2 of_IO a_AT1 uniform_JJ federal_JJ system_NN1 of_IO regulation_NN1 and_CC apply_VV0 state_NN1_VV0 law_NN1 regulatory_JJ compliance_NN1 exceptions_NN2 to_II_TO further_RRR this_DD1 result._NNU n277_FO Where_RRQ_CS the_AT scope_NN1 of_IO these_DD2 regulatory_JJ exemptions_NN2 is_VBZ limited_VVN_JJ ,_Y constitutional_JJ principles_NN2 of_IO preemption_NN1 should_VM apply_VVI to_TO preclude_VVI most_DAT_RRT@ state_NN1_VV0 tort_NN1_VV0 claims_NN2 based_VVN on_II design_NN1 ,_Y failure_NN1 to_TO warn_VVI ,_Y and_CC consumer_NN1 protection_NN1 acts_VVZ_NN2 if_CS_CSW@ the_AT drug_NN1 manufacturer_NN1 strictly_RR complies_VVZ with_IW federal_JJ encourages_VVZ individuals_NN2 to_TO seek_VVI effective_JJ treatment_NN1 for_IF health_NN1 conditions_NN2 or_CC pushes_VVZ them_PPHO2 to_II pressure_NN1 their_APPGE doctors_NN2 for_IF unnecessary_JJ designer_NN1 medications_NN2 is_VBZ likely_JJ to_TO rage_VVI on_RP@_II far_RR_JJ into_II the_AT future_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  202 The answer to that question is beyond the scope of this Article .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  202 The_AT answer_NN1 to_II that_DD1 question_NN1 is_VBZ beyond_II the_AT scope_NN1 of_IO this_DD1 Article_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  203 What is clear , however , is that despite increasing DTC advertising , the basic relationship between pharmaceutical manufacturers and the medical community with regard to drug warnings remains virtually unchanged .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  203 What_DDQ is_VBZ clear_JJ ,_Y however_RR ,_Y is_VBZ that_CST_DD1 despite_II increasing_VVG_JJ DTC_NP1 advertising_NN1 ,_Y the_AT basic_JJ relationship_NN1 between_II pharmaceutical_JJ manufacturers_NN2 and_CC the_AT medical_JJ community_NN1 with_II31 regard_II32 to_II33 drug_NN1 warnings_NN2 remains_VVZ virtually_RR unchanged_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  204 After the FDA approves a prescription drug as safe and effective , patients must still consult with a physician before obtaining the medication .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  204 After_CS_II the_AT FDA_NN1_NP1 approves_VVZ a_AT1 prescription_NN1 drug_NN1 as_CSA_RG@_II@ safe_JJ and_CC effective_JJ ,_Y patients_NN2 must_VM still_RR consult_VVI with_IW a_AT1 physician_NN1 before_II obtaining_VVG the_AT medication_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  205 Physicians , based on the specific medical history and individual characteristics of each patient , must adequately inform their patients of potential side effects and evaluate other relevant risks before pursuing a treatment course .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  205 Physicians_NN2 ,_Y based_VVN on_II the_AT specific_JJ medical_JJ history_NN1 and_CC individual_JJ characteristics_NN2 of_IO each_DD1 patient_NN1_JJ ,_Y must_VM adequately_RR inform_VVI their_APPGE patients_NN2 of_IO potential_JJ_NN1 side_NN1 effects_NN2 and_CC evaluate_VV0 other_JJ relevant_JJ risks_NN2 before_II pursuing_VVG a_AT1 treatment_NN1 course_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  206 The role , and indeed the objective , of DTC advertising in this doctor-patient relationship is to prompt the patient to question his doctor about potential drug treatments .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  206 The_AT role_NN1 ,_Y and_CC indeed_RR the_AT objective_NN1_JJ ,_Y of_IO DTC_NP1 advertising_NN1 in_II this_DD1 doctor-patient_JJ_NN1 relationship_NN1 is_VBZ to_TO prompt_VVI the_AT patient_JJ_NN1 to_TO question_VVI his_APPGE doctor_NN1 about_II potential_JJ_NN1 drug_NN1 treatments_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  207 Even though all advertisements direct patients to , " ask their doctor about " the drug in question , it remains the physician 's ultimate responsibility to evaluate a beneficial , treatment .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  207 Even_CS21 though_CS22 all_DB advertisements_NN2 direct_JJ_VV0@ patients_NN2 to_II_TO ,_Y "_Y ask_VV0 their_APPGE doctor_NN1 about_II "_Y the_AT drug_NN1 in_II question_NN1 ,_Y it_PPH1 remains_VVZ the_AT physician_NN1 's_GE ultimate_JJ responsibility_NN1 to_TO evaluate_VVI a_AT1 beneficial_JJ ,_Y treatment_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  208 DTC advertising can never replace or undermine the personal relationship between a physician and a patient and the communication of the risks and benefits of a drug discussed in the doctor 's office .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  208 DTC_NP1 advertising_NN1 can_VM never_RR replace_VVI or_CC undermine_VVI the_AT personal_JJ relationship_NN1 between_II a_AT1 physician_NN1 and_CC a_AT1 patient_NN1_JJ and_CC the_AT communication_NN1 of_IO the_AT risks_NN2 and_CC benefits_NN2 of_IO a_AT1 drug_NN1 discussed_VVN_VVD in_II the_AT doctor_NN1 's_GE office_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  209 That many patients are able to become more informed about possible treatments through DTC advertising and take a more active role in improving their health should be viewed as a considerable benefit to the healthcare system--one that in no way undercuts the traditional rules of law related to drug warnings. ( n278 ) <p> All this is not to say , however , that the regulation of DTC advertising is without any gaps or weaknesses .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  209 That_CST_DD1_RG% many_DA2 patients_NN2 are_VBR able_JK to_TO become_VVI more_RRR_DAR informed_VVN_VVD about_II possible_JJ treatments_NN2 through_II DTC_NP1 advertising_NN1 and_CC take_VV0 a_AT1 more_RGR active_JJ role_NN1 in_II improving_VVG their_APPGE health_NN1 should_VM be_VBI viewed_VVN as_II a_AT1 considerable_JJ benefit_NN1 to_II the_AT healthcare_NN1 system--one_MC that_CST_DD1 in_II no_AT way_NN1 undercuts_VVZ the_AT traditional_JJ rules_NN2 of_IO law_NN1 related_VVN_VVD to_II drug_NN1 warnings._NNU (_Y n278_FO )_Y <p>_Y All_DB this_DD1 is_VBZ not_XX to_TO say_VVI ,_Y however_RR ,_Y that_CST the_AT regulation_NN1 of_IO DTC_NP1 advertising_NN1 is_VBZ without_IW any_DD gaps_NN2 or_CC weaknesses_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  210 Regulation could potentially be improved if the FDA considered making predissemination submission of DTC advertisements for the agency 's review mandatory , rather than voluntary , and requiring affirmative FDA approval before permitting advertisements to air .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  210 Regulation_NN1 could_VM potentially_RR be_VBI improved_VVN if_CS_CSW@ the_AT FDA_NP1_NN1 considered_VVD_VVN making_VVG predissemination_NN1 submission_NN1 of_IO DTC_NP1 advertisements_NN2 for_IF the_AT agency_NN1 's_GE review_NN1 mandatory_JJ ,_Y rather_II21_CS21@ than_II22_CS22@ voluntary_JJ ,_Y and_CC requiring_VVG affirmative_JJ_NN1 FDA_NN1 approval_NN1 before_II permitting_VVG advertisements_NN2 to_II air_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  211 The practicality , effectiveness , and fairness of such a requirement , however , would largely depend on whether Congress provided the FDA with sufficient resources to review promptly a surge in submissions , because , according to the .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  211 The_AT practicality_NN1 ,_Y effectiveness_NN1 ,_Y and_CC fairness_NN1 of_IO such_DA a_AT1 requirement_NN1 ,_Y however_RR ,_Y would_VM largely_RR depend_VVI on_II whether_CSW Congress_NN1 provided_CS_VVD the_AT FDA_NN1 with_IW sufficient_JJ resources_NN2 to_TO review_VVI promptly_RR a_AT1 surge_NN1 in_II submissions_NN2 ,_Y because_CS ,_Y according_II21 to_II22 the_AT ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  212 <p> Despite the potential benefit of the aforementioned changes , this Article has shown that the learned intermediary doctrine retains its viability in our current post-DTC world .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  212 <p>_Y Despite_II the_AT potential_JJ_NN1 benefit_NN1 of_IO the_AT aforementioned_JJ changes_NN2 ,_Y this_DD1 Article_NN1 has_VHZ shown_VVN that_CST the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 retains_VVZ its_Z' viability_NN1 in_II our_APPGE current_JJ post-DTC_JJ world_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  213 Most state courts continue to apply the doctrine fully , despite aberrations such as the recent West Virginia Supreme Court of Appeals decision or more limited exclusions for common oral contraceptives .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  213 Most_DAT state_VV0_NN1 courts_NN2 continue_VV0 to_TO apply_VVI the_AT doctrine_NN1 fully_RR ,_Y despite_II aberrations_NN2 such_II21 as_II22 the_AT recent_JJ West_NP1 Virginia_NP1 Supreme_JJ Court_NN1 of_IO Appeals_NN2 decision_NN1 or_CC more_RGR_DAR limited_JJ exclusions_NN2 for_IF common_JJ oral_JJ_NN1 contraceptives_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  214 Moreover , this Article has also shown that extensive federal regulation of pharmaceutical products , including DTC advertising , should preclude state product liability and consumer protection claims , whether on the basis of common-law compliance with standards defenses , statutory exemption , or federal preemption .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  214 Moreover_RR ,_Y this_DD1 Article_NN1 has_VHZ also_RR shown_VVN that_CST_DD1 extensive_JJ federal_JJ regulation_NN1 of_IO pharmaceutical_JJ products_NN2 ,_Y including_II DTC_NP1 advertising_NN1 ,_Y should_VM preclude_VVI state_NN1 product_NN1 liability_NN1 and_CC consumer_NN1 protection_NN1 claims_NN2_VVZ ,_Y whether_CSW on_II the_AT basis_NN1 of_IO common-law_NN1 compliance_NN1 with_IW standards_NN2 defenses_NN2 ,_Y statutory_JJ exemption_NN1 ,_Y or_CC federal_JJ preemption_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  215 These measures are all supported by sound public policy , particularly where there is tension between the FDA 's reasoned decision making and the theory of the lawsuit .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  215 These_DD2 measures_NN2 are_VBR all_DB_RR@ supported_VVN by_II sound_NN1_JJ@ public_NN1_JJ policy_NN1 ,_Y particularly_RR where_CS_RRQ there_EX is_VBZ tension_NN1 between_II the_AT FDA_NP1_NN1 's_GE reasoned_JJ decision_NN1 making_VVG_NN1@ and_CC the_AT theory_NN1 of_IO the_AT lawsuit_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  216 <p> L : Footnotes -- ( n1 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  216 <p>_Y L_ZZ1_NP1@ :_Y Footnotes_NN2 --_NN1_JJ (_Y n1_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  217 ) Julie M. Donohue et al. , A Decade of Direct-to-Consumer Advertising of Prescription Drugs , 357 NEW ENG .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  217 )_Y Julie_NP1 M._NN1 Donohue_NP1 et_RA21 al._RA22 ,_Y A_ZZ1_AT1@ Decade_NNT1 of_IO Direct-to-Consumer_NP1 Advertising_NN1 of_IO Prescription_NN1 Drugs_NN2 ,_Y 357_MC NEW_JJ ENG_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  218 J. MED. 673 , 673 , 676 ( 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  218 J._NP1 MED._NP1 673_MC ,_Y 673_MC ,_Y 676_MC (_Y 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  219 <p> -- ( n2 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  219 <p>_Y --_NN1_JJ (_Y n2_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  220 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  220 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  221 <p> -- ( n3 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  221 <p>_Y --_NN1_JJ (_Y n3_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  222 ) See total industry expenditures on pharmaceutical promotion were devoted to DTC advertising in 2005 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  222 )_Y See_VV0 total_JJ_NN1 industry_NN1 expenditures_NN2 on_II pharmaceutical_JJ promotion_NN1 were_VBDR devoted_JJ_VVN% to_II DTC_NP1 advertising_NN1 in_II 2005_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  223 <p> -- ( n4 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  223 <p>_Y --_NN1_JJ (_Y n4_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  224 ) U.S. GEN .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  224 )_Y U.S._NP1 GEN_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  225 ACCOUNTING OFFICE , GAO-07-54 , PRESCRIPTION DRUGS : IMPROVEMENTS NEEDED IN FDA 'S OVERSIGHT OF DIRECT-TO-CONSUMER ADVERTISING 13 ( 2006 ) hereinafter 2006 GAO REPORT .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  225 ACCOUNTING_VVG_NN1_JJ@ OFFICE_NN1 ,_Y GAO-07-54_NP1 ,_Y PRESCRIPTION_NN1 DRUGS_NN2 :_Y IMPROVEMENTS_NN2 NEEDED_VVN_VVD IN_II FDA_NP1 'S_GE OVERSIGHT_NN1 OF_IO DIRECT-TO-CONSUMER_JJ_NN1 ADVERTISING_NN1 13_MC (_Y 2006_MC )_Y hereinafter_RR 2006_MC GAO_NP1 REPORT_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  226 Manufacturer spending on DTC advertising also pales in comparison to industry spending on research and development , with $31.4 billion spent in 2005 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  226 Manufacturer_NN1 spending_VVG_NN1 on_II DTC_NP1 advertising_NN1_VVG@ also_RR pales_VVZ in_II comparison_NN1 to_II industry_NN1 spending_VVG_NN1 on_II research_NN1 and_CC development_NN1 ,_Y with_IW $31.4_NNU billion_M spent_VVN_VVD in_II 2005_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  227 Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  227 Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  228 <p> -- ( n5 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  228 <p>_Y --_NN1_JJ (_Y n5_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  229 ) Donohue , supra note 1 , at 676 ( finding that the twenty drugs with the highest DTC spending made up 54.4% of total industry spending on DTC advertising ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  229 )_Y Donohue_NP1 ,_Y supra_NN1 note_NN1_VV0 1_MC1 ,_Y at_II 676_MC (_Y finding_VVG_NN1 that_CST the_AT twenty_MC drugs_NN2 with_IW the_AT highest_JJT DTC_NP1 spending_NN1 made_VVD_VVN up_RP_II@ 54.4%_FO of_IO total_JJ_NN1 industry_NN1 spending_VVG_NN1 on_II DTC_NP1 advertising_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  230 <p> -- ( n6 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  230 <p>_Y --_NN1_JJ (_Y n6_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  231 ) See , e.g. , infra Part III.C ( discussing the preemption debate for DTC-advertised drugs ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  231 )_Y See_VV0 ,_Y e.g._REX ,_Y infra_RR Part_NN1 III.C_NP1 (_Y discussing_VVG the_AT preemption_NN1 debate_NN1 for_IF DTC-advertised_JJ_NN1 drugs_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  232 <p> -- ( n7 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  232 <p>_Y --_NN1_JJ (_Y n7_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  233 ) See Michael S. Wilkes et al. , Direct-To-Consumer Prescription Drug Advertising : Trends , Impact , and Implications , 19 HEALTH AFF. 110 , 112 ( 2000 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  233 )_Y See_VV0 Michael_NP1 S._NP1 Wilkes_NP1 et_RA21 al._RA22 ,_Y Direct-To-Consumer_NP1 Prescription_NN1 Drug_NN1 Advertising_NN1 :_Y Trends_NN2 ,_Y Impact_NN1 ,_Y and_CC Implications_NN2 ,_Y 19_MC HEALTH_NN1 AFF._NP1 110_MC ,_Y 112_MC (_Y 2000_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  234 <p> -- ( n8 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  234 <p>_Y --_NN1_JJ (_Y n8_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  235 ) See UPTON SINCLAIR , THE JUNGLE ( n1906 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  235 )_Y See_VV0 UPTON_NP1 SINCLAIR_NP1 ,_Y THE_AT JUNGLE_NN1 (_Y n1906_FO )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  236 <p> -- ( n9 Pub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  236 <p>_Y --_NN1_JJ (_Y n9_FO Pub_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  237 L. No. 59-384 , 34 Stat. 768 , repealed by the Federal Food , Drug , and Cosmetic Act of 1938 , Pub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  237 L._NP1 No._XX 59-384_MCMC ,_Y 34_MC Stat._NP1 768_MC ,_Y repealed_VVN by_II the_AT Federal_JJ Food_NN1 ,_Y Drug_NN1 ,_Y and_CC Cosmetic_JJ Act_NN1 of_IO 1938_MC ,_Y Pub_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  238 L. No. 75-717 , 52 Stat. 1040 ( codified as amended at 21 U.S.C. Subsection 301-399 ( 2000 ) ) ; see also U.S. Food Drug Admin. , Milestones in U.S. Food and Drug Law History , FDA BACKGROUNDER , May 3 , 1999 , http : **45;1347;TOOLONG ( citing , in addition to reaction to The Jungle , public unrest over " the use of poisonous preservatives and dyes in foods , and cure-all claims for worthless and dangerous patent medicines " as the " major problems leading to the enactment of " the 1906 Act and the Meat Inspection Act ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  238 L._NP1 No._XX 75-717_MCMC ,_Y 52_MC Stat._NP1 1040_MC (_Y codified_VVN@_JJ@_VVD as_CSA amended_VVN at_II 21_MC U.S.C._NP1 Subsection_NP1@_NN1 301-399_MCMC (_Y 2000_MC )_Y )_Y ;_Y see_VV0 also_RR U.S._NP1 Food_NN1 Drug_NN1 Admin._NP1 ,_Y Milestones_NP2_NN2@ in_II U.S._NP1 Food_NN1 and_CC Drug_NN1 Law_NN1 History_NN1 ,_Y FDA_NP1_NN1 BACKGROUNDER_NN1 ,_Y May_NPM1 3_MC ,_Y 1999_MC ,_Y http_NNU :_Y **45;1347;TOOLONG_FU (_Y citing_VVG ,_Y in_II31 addition_II32 to_II33 reaction_NN1 to_II The_AT Jungle_NN1 ,_Y public_JJ_NN1 unrest_NN1 over_II "_Y the_AT use_NN1 of_IO poisonous_JJ preservatives_NN2 and_CC dyes_NN2 in_II foods_NN2 ,_Y and_CC cure-all_DB claims_NN2 for_IF worthless_JJ and_CC dangerous_JJ patent_NN1_JJ@ medicines_NN2 "_Y as_II_CSA the_AT "_Y major_JJ problems_NN2 leading_VVG to_II the_AT enactment_NN1 of_IO "_Y the_AT 1906_MC Act_NN1 and_CC the_AT Meat_NN1 Inspection_NN1 Act_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  239 <p> -- ( n10 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  239 <p>_Y --_NN1_JJ (_Y n10_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  240 ) See Francis B. Palumbo C. Daniel Mullins , The Development of Direct-to-Consumer Prescription Drug Advertising Regulation , 57 FOOD DRUG L.J .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  240 )_Y See_VV0 Francis_NP1 B._NP1 Palumbo_NP1 C._NP1 Daniel_NP1 Mullins_NP1 ,_Y The_AT Development_NN1 of_IO Direct-to-Consumer_NP1 Prescription_NN1 Drug_NN1 Advertising_NN1 Regulation_NN1 ,_Y 57_MC FOOD_NN1 DRUG_NN1 L.J_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  241 423 , 424-25 n.12 ( 2002 ) ( noting the portion of the 1906 Act stating that a drug would be deemed misbranded if " ' its package or or device regarding the curative or therapeutic effect of such article ... which is false or fraudulent ' " ( quoting the Pure Food and Drugs Act 8 , 34 Stat. at 770 ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  241 423_MC ,_Y 424-25_MCMC n.12_FO (_Y 2002_MC )_Y (_Y noting_VVG the_AT portion_NN1 of_IO the_AT 1906_MC Act_NN1_VV0@ stating_VVG that_CST a_AT1 drug_NN1 would_VM be_VBI deemed_VVN misbranded_VVD_JJ@_VVN@ if_CS_CSW@ "_Y '_"@_GE its_Z' package_NN1 or_CC or_CC device_NN1 regarding_II_VVG the_AT curative_NN1_JJ or_CC therapeutic_JJ effect_NN1 of_IO such_DA article_NN1 ..._... which_DDQ is_VBZ false_JJ or_CC fraudulent_JJ '_GE "_Y (_Y quoting_VVG the_AT Pure_JJ Food_NN1 and_CC Drugs_NN2 Act_VV0@_NN1 8_MC ,_Y 34_MC Stat._NP1 at_II 770_MC )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  242 <p> -- ( n11 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  242 <p>_Y --_NN1_JJ (_Y n11_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  243 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  243 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  244 at 425 n.12 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  244 at_II 425_MC n.12_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  245 <p> -- ( n12 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  245 <p>_Y --_NN1_JJ (_Y n12_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  246 ) See Carol Ballentine , Taste of Raspberries , Taste of Death : The 1937 Elixir Sulfanilamide Incident , FDA CONSUMER , June 1981 , available at http : **36;1394;TOOLONG .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  246 )_Y See_VV0 Carol_NP1 Ballentine_NP1 ,_Y Taste_NN1 of_IO Raspberries_NN2 ,_Y Taste_NN1 of_IO Death_NN1 :_Y The_AT 1937_MC Elixir_NP1_NN1 Sulfanilamide_NP1_NN1 Incident_NN1 ,_Y FDA_NP1_NN1 CONSUMER_NN1 ,_Y June_NPM1 1981_MC ,_Y available_JJ at_II http_NNU :_Y **36;1394;TOOLONG_FU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  247 <p> -- ( n13 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  247 <p>_Y --_NN1_JJ (_Y n13_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  248 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  248 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  249 <p> -- ( n14 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  249 <p>_Y --_NN1_JJ (_Y n14_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  250 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  250 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  251 <p> -- ( n15 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  251 <p>_Y --_NN1_JJ (_Y n15_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  252 ) See , e.g. , Pankaj Hari et al. , Fatal Encephalopathy and Renal Failure Caused by Diethylene Glycol Poisoning , 56 J. TROPICAL PEDIATRICS 442 ( 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  252 )_Y See_VV0 ,_Y e.g._REX ,_Y Pankaj_NP1 Hari_NP1 et_RA21 al._RA22 ,_Y Fatal_JJ Encephalopathy_NN1 and_CC Renal_JJ_NP1 Failure_NN1 Caused_VVN by_II Diethylene_NP1 Glycol_NP1_NN1 Poisoning_NN1_VVG ,_Y 56_MC J._NP1 TROPICAL_JJ PEDIATRICS_NN1 442_MC (_Y 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  253 <p> -- ( n16 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  253 <p>_Y --_NN1_JJ (_Y n16_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  254 ) See Ballentine , supra note 12 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  254 )_Y See_VV0 Ballentine_NP1 ,_Y supra_NN1 note_NN1_VV0 12_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  255 <p> -- ( n17 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  255 <p>_Y --_NN1_JJ (_Y n17_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  256 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  256 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  257 <p> -- ( n18 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  257 <p>_Y --_NN1_JJ (_Y n18_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  258 ) See David F. Cavers , The Food , Drug , and Cosmetic Act of 1938 : Its Legislative History and Its Substantive Provisions , n1939 ) , reprinted in PETER BARTON HUTT ET AL. , FOOD AND DRUG LAW , CASES AND MATERIALS 577 , 577-78 ( 3d ed. 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  258 )_Y See_VV0 David_NP1 F._NP1 Cavers_NP1 ,_Y The_AT Food_NN1 ,_Y Drug_NN1 ,_Y and_CC Cosmetic_JJ Act_NN1 of_IO 1938_MC :_Y Its_Z' Legislative_JJ History_NN1 and_CC Its_Z' Substantive_JJ Provisions_NN2 ,_Y n1939_FO )_Y ,_Y reprinted_VVN in_II PETER_NP1 BARTON_NP1 HUTT_NP1 ET_RA21 AL._RA22 ,_Y FOOD_NN1 AND_CC DRUG_NN1 LAW_NN1 ,_Y CASES_NN2 AND_CC MATERIALS_NN2 577_MC ,_Y 577-78_MCMC (_Y 3d_NNU ed._NN1 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  259 <p> -- ( n19 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  259 <p>_Y --_NN1_JJ (_Y n19_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  260 ) See Ballentine , supra note 12 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  260 )_Y See_VV0 Ballentine_NP1 ,_Y supra_NN1 note_NN1_VV0 12_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  261 <p> -- ( n20 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  261 <p>_Y --_NN1_JJ (_Y n20_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  262 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  262 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  263 <p> -- ( n21 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  263 <p>_Y --_NN1_JJ (_Y n21_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  264 ) Federal Food , Drug , and Cosmetic Act of 1938 , Pub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  264 )_Y Federal_JJ Food_NN1 ,_Y Drug_NN1 ,_Y and_CC Cosmetic_JJ Act_NN1 of_IO 1938_MC ,_Y Pub_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  265 L. No. 75-717 , 52 Stat. 1040 ( codified as amended at 21 U.S.C. Subsection 301-399 ( 2000 ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  265 L._NP1 No._XX 75-717_MCMC ,_Y 52_MC Stat._NP1 1040_MC (_Y codified_VVN@_JJ@_VVD as_CSA amended_VVN at_II 21_MC U.S.C._NP1 Subsection_NP1@_NN1 301-399_MCMC (_Y 2000_MC )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  266 <p> -- ( n22 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  266 <p>_Y --_NN1_JJ (_Y n22_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  267 ) HUTT ET AL. , supra note 18 , at 577 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  267 )_Y HUTT_NP1_VV0 ET_RA21 AL._RA22 ,_Y supra_NN1 note_NN1_VV0 18_MC ,_Y at_II 577_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  268 <p> -- ( n23 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  268 <p>_Y --_NN1_JJ (_Y n23_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  269 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  269 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  270 <p> -- ( n24 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  270 <p>_Y --_NN1_JJ (_Y n24_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  271 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  271 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  272 at 578 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  272 at_II 578_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  273 <p> -- ( n25 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  273 <p>_Y --_NN1_JJ (_Y n25_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  274 ) See Palumbo Mullins , supra note 10 , at 426 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  274 )_Y See_VV0 Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 426_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  275 <p> -- ( n26 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  275 <p>_Y --_NN1_JJ (_Y n26_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  276 ) Federal Trade Commission Act , Pub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  276 )_Y Federal_JJ Trade_NN1 Commission_NN1 Act_NN1 ,_Y Pub_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  277 L. No. 63-203 , 38 Stat. 717 ( n1914 ) ( codified as amended at 15 U.S.C. Subsection 41-58 ( 2000 ) ) ( establishing the FTC ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  277 L._NP1 No._XX 63-203_MCMC ,_Y 38_MC Stat._NP1 717_MC (_Y n1914_FO )_Y (_Y codified_VVN@_JJ@_VVD as_CSA amended_VVN at_II 15_MC U.S.C._NP1 Subsection_NP1@_NN1 41-58_MCMC (_Y 2000_MC )_Y )_Y (_Y establishing_VVG the_AT FTC_NP1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  278 <p> -- ( 10 , at 425 n.14 ( citing FTC v. Raladam Co. , 283 U.S. 643 ( n1931 ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  278 <p>_Y --_NN1_JJ (_Y 10_MC ,_Y at_II 425_MC n.14_FO (_Y citing_VVG FTC_NP1 v._II Raladam_NP1 Co._NP1 ,_Y 283_MC U.S._NP1 643_MC (_Y n1931_FO )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  279 <p> -- ( n28 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  279 <p>_Y --_NN1_JJ (_Y n28_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  280 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  280 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  281 at 425 n.18 ( quoting S. 1944 , 73d Cong .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  281 at_II 425_MC n.18_FO (_Y quoting_VVG S._NP1_NN1@ 1944_MC ,_Y 73d_NNU Cong_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  282 9(c) ( n1933 ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  282 9(c)_FO (_Y n1933_FO )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  283 <p> -- ( n29 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  283 <p>_Y --_NN1_JJ (_Y n29_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  284 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  284 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  285 <p> -- ( n30 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  285 <p>_Y --_NN1_JJ (_Y n30_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  286 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  286 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  287 at 426 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  287 at_II 426_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  288 <p> -- ( n31. ) 1962 Kefauver-Harris Drug Amendments , Pub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  288 <p>_Y --_NN1_JJ (_Y n31._FO )_Y 1962_MC Kefauver-Harris_NP1 Drug_NN1 Amendments_NN2 ,_Y Pub_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  289 L. No. 87-781 , 76 Stat. 780 ( n1962 ) ( codified as amended at 21 U.S.C. 352(n) ( 2000 ) ) ; see also 15 U.S.C. Subsection 45 , 52 ( 2000 ) ; 21 U.S.C. 352(n) ( 2000 ) ( removing any " advertisement of a prescription drug , published after the effective date of regulations issued under this paragraph applicable to advertisements of prescription drugs , " from the purview of the provisions of 15 U.S.C. Subsection 52-57 ) ; 21 U.S.C. 393(b) ( n1 ) ( 2000 ) ( " The FDA shall ... promote the public health by ... taking appropriate action on the marketing of regulated -- ( n32 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  289 L._NP1 No._XX 87-781_MCMC ,_Y 76_MC Stat._NP1 780_MC (_Y n1962_FO )_Y (_Y codified_VVN@_JJ@_VVD as_CSA amended_VVN at_II 21_MC U.S.C._NP1 352(n)_FO (_Y 2000_MC )_Y )_Y ;_Y see_VV0 also_RR 15_MC U.S.C._NP1 Subsection_NN1_NP1@ 45_MC ,_Y 52_MC (_Y 2000_MC )_Y ;_Y 21_MC U.S.C._NP1 352(n)_FO (_Y 2000_MC )_Y (_Y removing_VVG any_DD "_Y advertisement_NN1 of_IO a_AT1 prescription_NN1 drug_NN1 ,_Y published_VVN_VVD after_II_CS the_AT effective_JJ date_NN1 of_IO regulations_NN2 issued_VVN_VVD under_II this_DD1 paragraph_NN1 applicable_JJ to_II advertisements_NN2 of_IO prescription_NN1 drugs_NN2 ,_Y "_Y from_II the_AT purview_NN1 of_IO the_AT provisions_NN2 of_IO 15_MC U.S.C._NP1 Subsection_NP1@_NN1 52-57_MCMC )_Y ;_Y 21_MC U.S.C._NP1 393(b)_FO (_Y n1_FO )_Y (_Y 2000_MC )_Y (_Y "_Y The_AT FDA_NN1_NP1 shall_VM ..._... promote_VV0 the_AT public_JJ_NN1 health_NN1 by_II ..._... taking_VVG appropriate_JJ action_NN1 on_II the_AT marketing_NN1 of_IO regulated_JJ@ --_NN1_JJ (_Y n32_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  290 ) See Palumbo Mullins , supra note 10 , at 427 n.29 ( " There is a marked difference in the advertising and promotion of proprietary and ethical drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  290 )_Y See_VV0 Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 427_MC n.29_FO (_Y "_Y There_EX_RL is_VBZ a_AT1 marked_JJ difference_NN1 in_II the_AT advertising_NN1 and_CC promotion_NN1 of_IO proprietary_JJ and_CC ethical_JJ drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  291 Proprietary drugs--those sold over the drugstore counter--are like most other products in that sales pressures are exerted upon the final consumer who is subjected to an intensive barrage of advertisements for brand name products in newspapers , magazines , radio , and television .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  291 Proprietary_JJ drugs--those_NN2 sold_VVN_VVD over_II_RP the_AT drugstore_NN1 counter--are_NN1_VV0 like_II most_DAT other_JJ products_NN2 in_II that_DD1 sales_NN pressures_NN2 are_VBR exerted_VVN upon_II the_AT final_JJ_NN1 consumer_NN1 who_PNQS is_VBZ subjected_VVN to_II an_AT1 intensive_JJ barrage_NN1 of_IO advertisements_NN2 for_IF brand_NN1 name_NN1 products_NN2 in_II newspapers_NN2 ,_Y magazines_NN2 ,_Y radio_NN1 ,_Y and_CC television_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  292 In the case of ethical drugs--those sold under prescription-the brunt of promotion effort is directed to the prescribing physician .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  292 In_II the_AT case_NN1 of_IO ethical_JJ drugs--those_NN2 sold_VVN_VVD under_II prescription-the_AT brunt_NN1 of_IO promotion_NN1 effort_NN1 is_VBZ directed_VVN to_II the_AT prescribing_NN1@ physician_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  293 Since his prescription dictates the particular drug to be used , usually the brand name , the physician is the focal center of advertising and promotional pressures .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  293 Since_CS his_APPGE prescription_NN1 dictates_VVZ the_AT particular_JJ drug_NN1 to_TO be_VBI used_VVN ,_Y usually_RR the_AT brand_NN1 name_NN1 ,_Y the_AT physician_NN1 is_VBZ the_AT focal_JJ center_NN1 of_IO advertising_NN1 and_CC promotional_JJ pressures_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  294 " ( citing S. Rep. No. 87-448 , at 115 et seq .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  294 "_Y (_Y citing_VVG S._NP1_NN1@ Rep._NN1@ No._XX 87-448_MCMC ,_Y at_II 115_MC et_FW seq_FW ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  295 ( n1961 ) ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  295 (_Y n1961_FO )_Y )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  296 <p> -- ( n33 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  296 <p>_Y --_NN1_JJ (_Y n33_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  297 ) See Memorandum of Understanding Between FTC and the FDA , 36 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  297 )_Y See_VV0 Memorandum_NN1 of_IO Understanding_VVG_NN1 Between_II FTC_NP1 and_CC the_AT FDA_NN1_NP1 ,_Y 36_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  298 Reg. 18,539 ( Sept. 15 , 1971 ) ( providing most recent agreement ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  298 Reg._NN1 18,539_MC (_Y Sept._NPM1 15_MC ,_Y 1971_MC )_Y (_Y providing_VVG_CS@ most_RGT_DAT recent_JJ agreement_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  299 <p> -- ( n34 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  299 <p>_Y --_NN1_JJ (_Y n34_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  300 ) The FDCA 's treatment of that the advertisement include the drug 's name and formula , and a brief summary describing the drug 's effectiveness and its safety risks .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  300 )_Y The_AT FDCA_NP1_NN1 's_GE treatment_NN1 of_IO that_CST the_AT advertisement_NN1 include_VV0 the_AT drug_NN1 's_GE name_NN1 and_CC formula_NN1 ,_Y and_CC a_AT1 brief_JJ summary_NN1 describing_VVG the_AT drug_NN1 's_GE effectiveness_NN1 and_CC its_Z' safety_NN1 risks_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  301 See Palumbo Mullins , supra note 10 , at 428 ( citing 21 U.S.C. 352(n) ( 2002 ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  301 See_VV0 Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 428_MC (_Y citing_VVG 21_MC U.S.C._NP1 352(n)_FO (_Y 2002_MC )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  302 Shortly after the 1962 Drug Amendments ' passage , the FDA implemented its original drug-advertising regulations .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  302 Shortly_RR after_II_CS the_AT 1962_MC Drug_NN1 Amendments_NN2 '_GE passage_NN1 ,_Y the_AT FDA_NN1_NP1 implemented_VVN_VVD@ its_Z' original_JJ drug-advertising_JJ_NN1 regulations_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  303 See HUTT ET AL. , supra note 18 , at 535 ( citing 28 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  303 See_VV0 HUTT_NP1 ET_RA21 AL._RA22 ,_Y supra_NN1 note_NN1_VV0 18_MC ,_Y at_II 535_MC (_Y citing_VVG 28_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  304 Reg. 1448 ( Feb. 14 , 1963 ) , 28 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  304 Reg._NN1 1448_MC (_Y Feb._NPM1 14_MC ,_Y 1963_MC )_Y ,_Y 28_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  305 Reg. 6375 ( June 20 , 1963 ) , 28 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  305 Reg._NN1 6375_MC (_Y June_NPM1 20_MC ,_Y 1963_MC )_Y ,_Y 28_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  306 Reg. 9837 ( Sept. 10 , 1963 ) , 28 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  306 Reg._NN1 9837_MC (_Y Sept._NPM1 10_MC ,_Y 1963_MC )_Y ,_Y 28_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  307 Reg. 10993 ( Oct. 15 , 1963 ) , 29 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  307 Reg._NN1 10993_MC (_Y Oct._NPM1 15_MC ,_Y 1963_MC )_Y ,_Y 29_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  308 Reg. 257 ( Jan. 10 , 1964 ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  308 Reg._NN1 257_MC (_Y Jan._NPM1 10_MC ,_Y 1964_MC )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  309 The FDA further revised those regulations later that same decade .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  309 The_AT FDA_NN1_NP1 further_RRR revised_VVD_VVN those_DD2 regulations_NN2 later_RRR that_DD1 same_DA decade_NNT1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  310 See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  310 See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  311 <p> -- ( n35. ) 21 C.F.R. 202.1(e) ( n1979 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  311 <p>_Y --_NN1_JJ (_Y n35._FO )_Y 21_MC C.F.R._NP1 202.1(e)_FO (_Y n1979_FO )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  312 <p> -- ( n36. ) 21 C.F.R. 202.1(e) ( 5 ) ( ii ) ( n1979 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  312 <p>_Y --_NN1_JJ (_Y n36._FO )_Y 21_MC C.F.R._NP1 202.1(e)_FO (_Y 5_MC )_Y (_Y ii_MC )_Y (_Y n1979_FO )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  313 <p> -- ( n37 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  313 <p>_Y --_NN1_JJ (_Y n37_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  314 ) See HUTT ET AL. ( n38 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  314 )_Y See_VV0 HUTT_NP1 ET_RA21 AL._RA22 (_Y n38_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  315 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  315 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  316 at 579 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  316 at_II 579_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  317 <p> -- ( n39 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  317 <p>_Y --_NN1_JJ (_Y n39_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  318 ) Section 505(d) of the FDCA requires " the FDA to withhold approval unless the sponsor 's NDA shows the drug to be safe ' by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions of use prescribed , recommended , or suggested ' in the proposed labeling .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  318 )_Y Section_NN1 505(d)_FO of_IO the_AT FDCA_NN1_NP1 requires_VVZ "_Y the_AT FDA_NN1_NP1 to_TO withhold_VVI approval_NN1 unless_CS the_AT sponsor_NN1 's_GE NDA_NN1_NP1 shows_VVZ the_AT drug_NN1 to_TO be_VBI safe_JJ_NN1@ '_GE by_II all_DB methods_NN2 reasonably_RR applicable_JJ to_TO show_VVI whether_CSW31 or_CSW32 not_CSW33 such_DA drug_NN1 is_VBZ safe_JJ for_IF use_NN1 under_II the_AT conditions_NN2 of_IO use_NN1 prescribed_VVN_JJ_VVD@ ,_Y recommended_VVD_VVN ,_Y or_CC suggested_JJ@ '_GE in_II the_AT proposed_JJ labeling_NN1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  319 " Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  319 "_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  320 at 685 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  320 at_II 685_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  321 <p> -- ( n40 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  321 <p>_Y --_NN1_JJ (_Y n40_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  322 ) Section 505(d) of the FDCA requires the FDA to withhold approval unless the sponsor 's NDA provides " ' substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed , recommended , or suggested in the proposed labeling .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  322 )_Y Section_NN1 505(d)_FO of_IO the_AT FDCA_NN1_NP1 requires_VVZ the_AT FDA_NN1_NP1 to_TO withhold_VVI approval_NN1 unless_CS the_AT sponsor_NN1 's_GE NDA_NN1_NP1 provides_VVZ "_Y '_GE substantial_JJ evidence_NN1 that_CST the_AT drug_NN1 will_VM have_VHI the_AT effect_NN1 it_PPH1 purports_VVZ or_CC is_VBZ represented_VVN to_TO have_VHI under_II the_AT conditions_NN2 of_IO use_NN1 prescribed_VVN_JJ_VVD@ ,_Y recommended_VVD_VVN ,_Y or_CC suggested_VVN_VVD in_II the_AT proposed_JJ labeling_NN1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  323 ' " Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  323 '_"@_GE "_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  324 at 579 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  324 at_II 579_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  325 Section 505(e) requires the FDA to " withdraw approval of any drug after notice and opportunity for hearing if he finds that ' on the basis of new information before him ' substantial evidence of efficacy is lacking .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  325 Section_NN1 505(e)_FO requires_VVZ the_AT FDA_NN1_NP1 to_TO "_Y withdraw_VVI approval_NN1 of_IO any_DD drug_NN1 after_II_CS notice_NN1 and_CC opportunity_NN1 for_IF hearing_VVG_NN1 if_CSW@_CS he_PPHS1 finds_VVZ that_DD1 '_VBZ on_II the_AT basis_NN1 of_IO new_JJ information_NN1 before_II him_PPHO1 '_GE substantial_JJ evidence_NN1 of_IO efficacy_NN1 is_VBZ lacking_VVG ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  326 " Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  326 "_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  327 <p> -- ( n41 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  327 <p>_Y --_NN1_JJ (_Y n41_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  328 ) an NDA must summarize the general understanding of the application , the drug type , and the rationale for approval , as well as a description of the drug 's chemistry , its manufacturing practices , and its quality controls .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  328 )_Y an_AT1 NDA_NN1 must_VM summarize_VVI the_AT general_JJ_NN1 understanding_NN1 of_IO the_AT application_NN1 ,_Y the_AT drug_NN1 type_NN1 ,_Y and_CC the_AT rationale_NN1 for_IF approval_NN1 ,_Y as_II31 well_II32 as_II33 a_AT1 description_NN1 of_IO the_AT drug_NN1 's_GE chemistry_NN1 ,_Y its_Z' manufacturing_NN1 practices_NN2 ,_Y and_CC its_Z' quality_NN1 controls_NN2_VVZ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  329 See 21 C.F.R. 314.50(c)-(d) ( 2000 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  329 See_VV0 21_MC C.F.R._NP1 314.50(c)-(d)_ZZ1 (_Y 2000_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  330 It must contain pre-clinical data ( that is , the results of animal and in vitro studies ) regarding the product 's pharmacology and toxicology , and that data must be accompanied by a statement of compliance with good laboratory practices .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  330 It_PPH1 must_VM contain_VVI pre-clinical_JJ data_NN (_Y that_REX21 is_REX22 ,_Y the_AT results_NN2 of_IO animal_NN1 and_CC in_JJ21_RR21 vitro_JJ22_RR22 studies_NN2 )_Y regarding_II_VVG the_AT product_NN1 's_GE pharmacology_NN1 and_CC toxicology_NN1 ,_Y and_CC that_DD1_CST data_NN must_VM be_VBI accompanied_VVN by_II a_AT1 statement_NN1 of_IO compliance_NN1 with_IW good_JJ laboratory_NN1 practices_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  331 See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  331 See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  332 The NDA must describe the drug 's pharmacokinetics and bioavailability ( that is , how the drug is expected to react in the human system ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  332 The_AT NDA_NN1_NP1 must_VM describe_VVI the_AT drug_NN1 's_GE pharmacokinetics_NN1_NN2 and_CC bioavailability_NN1 (_Y that_REX21 is_REX22 ,_Y how_RRQ the_AT drug_NN1 is_VBZ expected_VVN_JJ to_TO react_VVI in_II the_AT human_JJ_NN1 system_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  333 See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  333 See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  334 It must contain a wealth of clinical data from Phase I , II , and IN clinical trials on humans .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  334 It_PPH1 must_VM contain_VVI a_AT1 wealth_NN1 of_IO clinical_JJ data_NN from_II Phase_NN1 I_ZZ1%_PPIS1_MC1% ,_Y II_MC ,_Y and_CC IN_II clinical_JJ trials_NN2 on_II humans_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  335 That data must also be accompanied by an integrated summary of the product 's effectiveness and safety profile , along with hill disclosure of the study results .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  335 That_DD1 data_NN must_VM also_RR be_VBI accompanied_VVN by_II an_AT1 integrated_JJ summary_NN1 of_IO the_AT product_NN1 's_GE effectiveness_NN1 and_CC safety_NN1 profile_NN1 ,_Y along_II21 with_II22 hill_NN1 disclosure_NN1 of_IO the_AT study_NN1 results_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  336 Finally , the NDA must include both a sample of the product and the product 's labeling .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  336 Finally_RR ,_Y the_AT NDA_NN1_NP1 must_VM include_VVI both_RR a_AT1 sample_NN1 of_IO the_AT product_NN1 and_CC the_AT product_NN1 's_VBZ_GE labeling_VVG_NN1@_JJ@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  337 ( n42 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  337 (_Y n42_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  338 ) See HUTT ET AL. , supra note 18 , at 688 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  338 )_Y See_VV0 HUTT_NP1 ET_RA21 AL._RA22 ,_Y supra_NN1 note_NN1_VV0 18_MC ,_Y at_II 688_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  339 The process from the discovery of a molecule 's treatment potential to its submission in an NDA is laborious , long , and expensive .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  339 The_AT process_NN1 from_II the_AT discovery_NN1 of_IO a_AT1 molecule_NN1 's_GE treatment_NN1 potential_NN1 to_II its_Z' submission_NN1 in_II an_AT1 NDA_NN1 is_VBZ laborious_JJ ,_Y long_RR_JJ ,_Y and_CC expensive_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  340 On average , for 10,000 drugs identified as having treatment potential and therefore submitted to laboratory and animal testing , only one might make it through Phase I , II , and III clinical testing on humans and become the subject of an NDA .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  340 On_II average_NN1_JJ ,_Y for_IF 10,000_MC drugs_NN2 identified_VVN as_CSA having_VHG treatment_NN1 potential_NN1_JJ and_CC therefore_RR submitted_VVN_VVD to_II laboratory_NN1 and_CC animal_NN1 testing_NN1_VVG ,_Y only_RR one_PN1_MC1 might_VM make_VVI it_PPH1 through_II Phase_NN1 I_ZZ1%_PPIS1_MC1% ,_Y II_MC ,_Y and_CC III_MC clinical_JJ testing_NN1 on_II humans_NN2 and_CC become_VV0 the_AT subject_NN1 of_IO an_AT1 NDA_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  341 See PhRMA , Innovation ( 2008 ) , http : **26;1432;TOOLONG .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  341 See_VV0 PhRMA_NP1 ,_Y Innovation_NN1 (_Y 2008_MC )_Y ,_Y http_NNU :_Y **26;1432;TOOLONG_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  342 The Tufts Center for the Study of Drug Development , for example , calculated that the average cost of bringing a new drug to market in 2001 was $802,000,000 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  342 The_AT Tufts_NN2 Center_NN1 for_IF the_AT Study_NN1 of_IO Drug_NN1 Development_NN1 ,_Y for_REX21 example_REX22 ,_Y calculated_VVD_VVN that_CST the_AT average_JJ_NN1 cost_NN1 of_IO bringing_VVG a_AT1 new_JJ drug_NN1 to_TO market_VVI in_II 2001_MC was_VBDZ $802,000,000_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  343 See Joseph A. DiMasi et al. , The Price of Innovation : New Estimates of Drug Development Costs , 22 J. HEALTH ECON. 151 , 166 ( 2003 ) ( presenting study by Tufts Center for the Study of Drug Development ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  343 See_VV0 Joseph_NP1 A._ZZ DiMasi_NP1 et_RA21 al._RA22 ,_Y The_AT Price_NN1 of_IO Innovation_NN1 :_Y New_JJ Estimates_NN2 of_IO Drug_NN1 Development_NN1 Costs_NN2_VVZ ,_Y 22_MC J._NP1 HEALTH_NN1 ECON._NP1 151_MC ,_Y 166_MC (_Y 2003_MC )_Y (_Y presenting_VVG study_NN1 by_II Tufts_NN2 Center_NN1 for_IF the_AT Study_NN1 of_IO Drug_NN1 Development_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  344 In a 2006 study , the Center for the Study of Drug Development pegged the average cost of developing a THE STUDY OF DRUG DEVELOPMENT , OUTLOOK 2008 , at 2 ( 2008 ) , available at http : **48;1460;TOOLONG .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  344 In_II a_AT1 2006_MC study_NN1 ,_Y the_AT Center_NN1 for_IF the_AT Study_NN1 of_IO Drug_NN1 Development_NN1 pegged_VVN_VVD@ the_AT average_JJ_NN1 cost_NN1 of_IO developing_VVG a_AT1 THE_AT STUDY_NN1 OF_IO DRUG_NN1 DEVELOPMENT_NN1 ,_Y OUTLOOK_NN1 2008_MC ,_Y at_II 2_MC (_Y 2008_MC )_Y ,_Y available_JJ at_II http_NNU :_Y **48;1460;TOOLONG_FU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  345 <p> -- ( n43. ) 21 U.S.C. 355(b) ( 2000 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  345 <p>_Y --_NN1_JJ (_Y n43._FO )_Y 21_MC U.S.C._NP1 355(b)_FO (_Y 2000_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  346 CDER examines six components of the NDA : medical , biopharmaceutical , pharmacological , statistical , chemical , and microbiological .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  346 CDER_NP1_NN1 examines_VVZ six_MC components_NN2 of_IO the_AT NDA_NP1_NN1 :_Y medical_JJ ,_Y biopharmaceutical_JJ ,_Y pharmacological_JJ ,_Y statistical_JJ ,_Y chemical_NN1_JJ ,_Y and_CC microbiological_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  347 Medical reviewers are responsible for evaluating the clinical sections of submissions and therefore take the lead role in NDA review .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  347 Medical_JJ reviewers_NN2 are_VBR responsible_JJ for_IF evaluating_VVG the_AT clinical_JJ sections_NN2 of_IO submissions_NN2 and_CC therefore_RR take_VV0 the_AT lead_NN1 role_NN1 in_II NDA_NP1_NN1 review_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  348 See CTR .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  348 See_VV0 CTR_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  349 FOR DRUG EVALUATION RESEARCH , FOOD DRUG ADMIN. , CDER HANDBOOK 15-19 ( n1998 ) , available at http : **37;1510;TOOLONG hereinafter CDER HANDBOOK .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  349 FOR_IF DRUG_NN1 EVALUATION_NN1 RESEARCH_NN1 ,_Y FOOD_NN1 DRUG_NN1 ADMIN._NP1 ,_Y CDER_JJR_NP1_VV0 HANDBOOK_NN1 15-19_MCMC (_Y n1998_FO )_Y ,_Y available_JJ at_II http_NNU :_Y **37;1510;TOOLONG_FU hereinafter_RR CDER_JJR HANDBOOK_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  350 CDER may also host Advisory Committee meetings at this stage to obtain outside advice and opinions from experts .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  350 CDER_NP1_NN1_VV0 may_VM also_RR host_VVI Advisory_JJ Committee_NN1 meetings_NN2 at_II this_DD1 stage_NN1 to_TO obtain_VVI outside_JJ_II advice_NN1 and_CC opinions_NN2 from_II experts_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  351 See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  351 See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  352 at 11 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  352 at_II 11_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  353 <p> -- ( n44 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  353 <p>_Y --_NN1_JJ (_Y n44_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  354 ) See 21 U.S.C. 352 ( 2000 ) ; 21 C.F.R. 201.56 ( 2008 ) ( general requirements for prescription drug labeling ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  354 )_Y See_VV0 21_MC U.S.C._NP1 352_MC (_Y 2000_MC )_Y ;_Y 21_MC C.F.R._NP1 201.56_MC (_Y 2008_MC )_Y (_Y general_JJ_NN1 requirements_NN2 for_IF prescription_NN1 drug_NN1 labeling_VVG_NN1@ )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  355 <p> -- ( n45 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  355 <p>_Y --_NN1_JJ (_Y n45_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  356 ) See 21 C.F.R. 201.56 ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  356 )_Y See_VV0 21_MC C.F.R._NP1 201.56_MC (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  357 <p> -- ( n46 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  357 <p>_Y --_NN1_JJ (_Y n46_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  358 ) See 21 C.F.R. 201.57(a) ( 6 ) -(8) , ( c ) n47 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  358 )_Y See_VV0 21_MC C.F.R._NP1 201.57(a)_FO (_Y 6_MC )_Y -(8)_NN1_JJ ,_Y (_Y c_ZZ1 )_Y n47_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  359 ) See 21 C.F.R. 201.57(a) ( 9 ) , ( c ) ( 5 ) ( 2008 ) ( requiring a description of situations in which the drug should not be used because the risk of use clearly outweighs any possible benefit ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  359 )_Y See_VV0 21_MC C.F.R._NP1 201.57(a)_FO (_Y 9_MC )_Y ,_Y (_Y c_ZZ1 )_Y (_Y 5_MC )_Y (_Y 2008_MC )_Y (_Y requiring_VVG a_AT1 description_NN1 of_IO situations_NN2 in_II which_DDQ the_AT drug_NN1 should_VM not_XX be_VBI used_VVN because_CS the_AT risk_NN1 of_IO use_NN1 clearly_RR outweighs_VVZ any_DD possible_JJ benefit_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  360 <p> -- ( n48 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  360 <p>_Y --_NN1_JJ (_Y n48_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  361 ) See 21 C.F.R. 201.57(a) ( n10 ) , ( c ) ( 6 ) ( 2008 ) ( requiring a description of any serious adverse reactions and potential safety hazards , subsequent limitation in use , and steps that should be taken if they occur ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  361 )_Y See_VV0 21_MC C.F.R._NP1 201.57(a)_FO (_Y n10_FO )_Y ,_Y (_Y c_ZZ1 )_Y (_Y 6_MC )_Y (_Y 2008_MC )_Y (_Y requiring_VVG a_AT1 description_NN1 of_IO any_DD serious_JJ adverse_JJ reactions_NN2 and_CC potential_JJ safety_NN1 hazards_NN2 ,_Y subsequent_JJ limitation_NN1 in_II use_NN1 ,_Y and_CC steps_NN2_VVZ@ that_CST_DD1 should_VM be_VBI taken_VVN if_CS_CSW@ they_PPHS2 occur_VV0 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  362 <p> -- ( n49 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  362 <p>_Y --_NN1_JJ (_Y n49_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  363 ) See 21 C.F.R. 201.57(a) ( n10 ) , ( c ) ( 6 ) , ( c ) ( 8 ) ( 2008 ) ( requiring a description of any special care to be exercised for the safe and effective use of the drug , including general precautions and information for patients on drug interactions ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  363 )_Y See_VV0 21_MC C.F.R._NP1 201.57(a)_FO (_Y n10_FO )_Y ,_Y (_Y c_ZZ1 )_Y (_Y 6_MC )_Y ,_Y (_Y c_ZZ1 )_Y (_Y 8_MC )_Y (_Y 2008_MC )_Y (_Y requiring_VVG a_AT1 description_NN1 of_IO any_DD special_JJ care_NN1 to_TO be_VBI exercised_VVN for_IF the_AT safe_JJ_NN1@ and_CC effective_JJ use_NN1 of_IO the_AT drug_NN1 ,_Y including_II_VVG@ general_JJ_NN1 precautions_NN2 and_CC information_NN1 for_IF patients_NN2 on_II drug_NN1 interactions_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  364 <p> -- ( n50 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  364 <p>_Y --_NN1_JJ (_Y n50_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  365 ) See 21 C.F.R. 201.57(a) ( n11 ) , ( c ) ( 7 ) ( 2008 ) ( requiring a description of any drug ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  365 )_Y See_VV0 21_MC C.F.R._NP1 201.57(a)_FO (_Y n11_FO )_Y ,_Y (_Y c_ZZ1 )_Y (_Y 7_MC )_Y (_Y 2008_MC )_Y (_Y requiring_VVG a_AT1 description_NN1 of_IO any_DD drug_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  366 <p> -- ( n51 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  366 <p>_Y --_NN1_JJ (_Y n51_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  367 ) See Palumbo Mullins , supra note 10 , at 429 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  367 )_Y See_VV0 Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 429_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  368 <p> -- ( n52. ) 21 C.F.R. 202.1(e) ( 2 ) ( i ) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  368 <p>_Y --_NN1_JJ (_Y n52._FO )_Y 21_MC C.F.R._NP1 202.1(e)_FO (_Y 2_MC )_Y (_Y i_ZZ1 )_Y (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  369 PhRMA 's Guiding Principles urge its members not to engage in this practice .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  369 PhRMA_NP1@_NN1 's_GE Guiding_JJ Principles_NN2 urge_VV0 its_Z' members_NN2 not_XX to_TO engage_VVI in_II_RP@ this_DD1 practice_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  370 See PHRMA , PHRMA GUIDING PRINCIPLES : DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES 4 ( 2005 ) , http : **46;1549;TOOLONG ( Principle 10 : " DTC television advertising that identifies a product by name should clearly state the health conditions for which the medicine is approved and the major risks associated with the medicine being advertised .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  370 See_VV0 PHRMA_NP1_NN1 ,_Y PHRMA_NP1_NN1 GUIDING_VVG_JJ@ PRINCIPLES_NN2 :_Y DIRECT_JJ_VV0@_RR@ TO_II CONSUMER_NN1 ADVERTISEMENTS_NN2 ABOUT_II PRESCRIPTION_NN1 MEDICINES_NN2 4_MC (_Y 2005_MC )_Y ,_Y http_NNU :_Y **46;1549;TOOLONG_FU (_Y Principle_NN1 10_MC :_Y "_Y DTC_NP1 television_NN1 advertising_NN1_VVG@ that_CST_DD1 identifies_VVZ a_AT1 product_NN1 by_II name_NN1 should_VM clearly_RR state_VVI the_AT health_NN1 conditions_NN2 for_IF which_DDQ the_AT medicine_NN1 is_VBZ approved_VVN_JJ and_CC the_AT major_JJ risks_NN2 associated_VVN with_IW the_AT medicine_NN1 being_VBG advertised_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  371 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  371 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  372 <p> -- ( n53 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  372 <p>_Y --_NN1_JJ (_Y n53_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  373 ) See 21 C.F.R. 202.1(e) ( 2 ) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  373 )_Y See_VV0 21_MC C.F.R._NP1 202.1(e)_FO (_Y 2_MC )_Y (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  374 <p> -- ( n54 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  374 <p>_Y --_NN1_JJ (_Y n54_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  375 ) Direct-to-Consumer Promotion ; Public Hearing , 60 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  375 )_Y Direct-to-Consumer_JJ_NN1 Promotion_NN1 ;_Y Public_JJ_NN1 Hearing_NN1 ,_Y 60_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  376 Reg. 42,581 , 42,582 ( Aug. 16 , 1995 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  376 Reg._NN1 42,581_MC ,_Y 42,582_MC (_Y Aug._NPM1 16_MC ,_Y 1995_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  377 <p> -- ( n55 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  377 <p>_Y --_NN1_JJ (_Y n55_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  378 ) See 21 C.F.R. 202.1(e) ( n1 ) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  378 )_Y See_VV0 21_MC C.F.R._NP1 202.1(e)_FO (_Y n1_FO )_Y (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  379 <p> -- ( n56 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  379 <p>_Y --_NN1_JJ (_Y n56_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  380 ) See 21 C.F.R. 202.1(e) ( 5 ) -(6) ( 2008 satisfy fair balance requirements ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  380 )_Y See_VV0 21_MC C.F.R._NP1 202.1(e)_FO (_Y 5_MC )_Y -(6)_NN1_JJ (_Y 2008_MC satisfy_VVI fair_JJ balance_NN1 requirements_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  381 <p> -- ( n57 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  381 <p>_Y --_NN1_JJ (_Y n57_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  382 ) See KIM SHEEHAN , CONTROVERSIES IN CONTEMPORARY ADVERTISING 209 ( 2004 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  382 )_Y See_VV0 KIM_NP1 SHEEHAN_NP1 ,_Y CONTROVERSIES_NN2 IN_II CONTEMPORARY_JJ ADVERTISING_NN1 209_MC (_Y 2004_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  383 <p> -- ( n58 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  383 <p>_Y --_NN1_JJ (_Y n58_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  384 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  384 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  385 at 210 ; Palumbo Mullins , supra note 10 , at 424 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  385 at_II 210_MC ;_Y Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 424_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  386 <p> -- ( n59 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  386 <p>_Y --_NN1_JJ (_Y n59_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  387 ) See SHEEHAN , supra note 57 , at 210 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  387 )_Y See_VV0 SHEEHAN_NP1 ,_Y supra_NN1 note_NN1_VV0 57_MC ,_Y at_II 210_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  388 <p> -- ( n60 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  388 <p>_Y --_NN1_JJ (_Y n60_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  389 ) Direct-to-Consumer Advertising of Prescription Drugs ; Withdrawal of Moratorium , 50 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  389 )_Y Direct-to-Consumer_JJ_NN1 Advertising_NN1 of_IO Prescription_NN1 Drugs_NN2 ;_Y Withdrawal_NN1 of_IO Moratorium_NN1 ,_Y 50_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  390 Reg. 36,677 ( Sept. 9 , 1985 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  390 Reg._NN1 36,677_MC (_Y Sept._NPM1 9_MC ,_Y 1985_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  391 <p> -- ( n61 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  391 <p>_Y --_NN1_JJ (_Y n61_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  392 ) See SHEEHAN , supra note 57 , at 210-11 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  392 )_Y See_VV0 SHEEHAN_NP1 ,_Y supra_NN1 note_NN1_VV0 57_MC ,_Y at_II 210-11_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  393 <p> -- ( n62 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  393 <p>_Y --_NN1_JJ (_Y n62_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  394 ) FOOD DRUG ADMIN. , GUIDANCE FOR INDUSTRY : CONSUMER-DIRECTED BROADCAST ADVERTISEMENTS ( August 1999 ) hereinafter GUIDANCE , available at http : **37;1597;TOOLONG .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  394 )_Y FOOD_NN1 DRUG_NN1 ADMIN._NP1 ,_Y GUIDANCE_NN1 FOR_IF INDUSTRY_NN1 :_Y CONSUMER-DIRECTED_JJ_NN1 BROADCAST_NN1_JJ@ ADVERTISEMENTS_NN2 (_Y August_NPM1 1999_MC )_Y hereinafter_RR GUIDANCE_NN1 ,_Y available_JJ at_II http_NNU :_Y **37;1597;TOOLONG_FU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  395 <p> -- ( n63 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  395 <p>_Y --_NN1_JJ (_Y n63_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  396 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  396 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  397 at 1 ; SHEEHAN , supra note 57 , at 211 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  397 at_II 1_MC1 ;_Y SHEEHAN_NP1 ,_Y supra_NN1 note_NN1_VV0 57_MC ,_Y at_II 211_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  398 <p> -- ( n64 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  398 <p>_Y --_NN1_JJ (_Y n64_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  399 ) See 21 C.F.R. 202.1(e) ( n1 ) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  399 )_Y See_VV0 21_MC C.F.R._NP1 202.1(e)_FO (_Y n1_FO )_Y (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  400 On September 27 , 2007 , the President signed the Food and Drug Administration Amendment statement be presented in a " clear , conspicuous and neutral manner .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  400 On_II September_NPM1 27_MC ,_Y 2007_MC ,_Y the_AT President_NN1 signed_VVD_VVN the_AT Food_NN1 and_CC Drug_NN1 Administration_NN1 Amendment_NN1 statement_NN1 be_VBI presented_VVN in_II a_AT1 "_Y clear_JJ ,_Y conspicuous_JJ and_CC neutral_JJ manner_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  401 " FDA Amendment Act of 2007 , Pub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  401 "_Y FDA_NP1_NN1 Amendment_NN1 Act_NN1 of_IO 2007_MC ,_Y Pub_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  402 L. No. 110-85 , 503(B) , 121 Star .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  402 L._NP1 No._XX 110-85_MCMC ,_Y 503(B)_FO ,_Y 121_MC Star_NN1_JJ@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  403 823 , 940 ( to be codified at 21 U.S.C. 353(b) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  403 823_MC ,_Y 940_MC (_Y to_TO be_VBI codified_VVN@ at_II 21_MC U.S.C._NP1 353(b)_FO )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  404 <p> -- ( n65 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  404 <p>_Y --_NN1_JJ (_Y n65_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  405 ) GUIDANCE supra note 62 , at 2-3 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  405 )_Y GUIDANCE_NN1 supra_NN1 note_NN1_VV0 62_MC ,_Y at_II 2-3_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  406 <p> -- ( n66 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  406 <p>_Y --_NN1_JJ (_Y n66_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  407 ) See Palumbo Mullins , supra note 10 , at 430 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  407 )_Y See_VV0 Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 430_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  408 <p> -- ( n67 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  408 <p>_Y --_NN1_JJ (_Y n67_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  409 ) On May 8 , 2008 , Ruth S. Day , Ph.D , testified before the House Committee on Energy and Commerce , Subcommittee on Oversight and Investigations , on the field of " cognitive accessibility , " which is the study of what people understand and remember after viewing DTC advertising .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  409 )_Y On_II May_NPM1 8_MC ,_Y 2008_MC ,_Y Ruth_NP1 S._NP1 Day_NP1 ,_Y Ph.D_NNA ,_Y testified_VVD_VVN@ before_II_CS the_AT House_NN1 Committee_NN1 on_II Energy_NN1 and_CC Commerce_NN1 ,_Y Subcommittee_NN1 on_II Oversight_NP1_NN1 and_CC Investigations_NN2 ,_Y on_II the_AT field_NN1 of_IO "_Y cognitive_JJ accessibility_NN1 ,_Y "_Y which_DDQ is_VBZ the_AT study_NN1 of_IO what_DDQ people_NN understand_VV0 and_CC remember_VV0 after_II viewing_VVG DTC_NP1 advertising_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  410 Dr. Day recommended that the FDA adopt a formal " evidence-based approach " for analyzing the cognitive accessibility of broadcast DTC advertising .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  410 Dr._NNB Day_NP1 recommended_VVD that_CST the_AT FDA_NN1_NP1 adopt_VV0 a_AT1 formal_JJ "_Y evidence-based_JJ_NN1 approach_NN1 "_Y for_IF analyzing_VVG the_AT cognitive_JJ accessibility_NN1 of_IO broadcast_NN1_JJ@ DTC_NP1 advertising_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  411 See Direct-to-Consumer Drug Ads : What do People Understand and Remember : Hearing Before Subcomm. on Oversight Investigations of the H. Comm. on Energy Commerce , 110th Cong .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  411 See_VV0 Direct-to-Consumer_NP1 Drug_NN1 Ads_NN2 :_Y What_DDQ do_VD0 People_NN Understand_VV0 and_CC Remember_VV0 :_Y Hearing_VVG_NN1 Before_II_CS Subcomm._NP1 on_II Oversight_NP1_NN1 Investigations_NN2 of_IO the_AT H._NP1 Comm._NP1 on_II Energy_NN1 Commerce_NN1 ,_Y 110th_MD Cong_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  412 ( 2008 ) http : **95;1636;TOOLONG .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  412 (_Y 2008_MC )_Y http_NNU :_Y **95;1636;TOOLONG_FU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  413 Day-testimony.pdf .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  413 Day-testimony.pdf_JJ_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  414 <p> -- ( n68 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  414 <p>_Y --_NN1_JJ (_Y n68_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  415 ) See 21 C.F.R. 312.84(c) ( 2008 ) ( FDA not approvable for marketing letter ) ; see also Palumbo Mullins , supra note 10 , at 429 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  415 )_Y See_VV0 21_MC C.F.R._NP1 312.84(c)_FO (_Y 2008_MC )_Y (_Y FDA_NP1_NN1 not_XX approvable_JJ for_IF marketing_NN1_VVG@ letter_NN1 )_Y ;_Y see_VV0 also_RR Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 429_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  416 <p> -- ( n69 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  416 <p>_Y --_NN1_JJ (_Y n69_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  417 ) See Palumbo Mullins , supra note 10 , at 429 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  417 )_Y See_VV0 Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 429_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  418 <p> -- ( n70 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  418 <p>_Y --_NN1_JJ (_Y n70_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  419 ) See 21 C.F.R. 314.120(a) ( FDA " not approvable letter " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  419 )_Y See_VV0 21_MC C.F.R._NP1 314.120(a)_FO (_Y FDA_NP1_NN1 "_Y not_XX approvable_JJ letter_NN1 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  420 <p> -- ( n71 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  420 <p>_Y --_NN1_JJ (_Y n71_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  421 ) See Palumbo Mullins , supra note 10 , at 429 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  421 )_Y See_VV0 Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 429_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  422 A study by the General Accounting Office ( GAO ) found that , in a five-year period between August 1997 and August 2002 , the FDA issued eighty-eight NOV and warning letters for violative DTC advertising .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  422 A_AT1 study_NN1 by_II the_AT General_JJ_NN1 Accounting_NN1_VVG_JJ@ Office_NN1 (_Y GAO_NP1 )_Y found_VVD that_CST_DD1 ,_Y in_II a_AT1 five-year_JJ period_NN1 between_II August_NPM1 1997_MC and_CC August_NPM1 2002_MC ,_Y the_AT FDA_NP1_NN1 issued_VVD eighty-eight_MC NOV_NPM1 and_CC warning_NN1_VVG@ letters_NN2 for_IF violative_JJ DTC_NP1 advertising_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  423 See U.S. GEN .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  423 See_VV0 U.S._NP1 GEN_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  424 ACCOUNTING OFFICE , GAO-03-177 , PRESCRIPTION DRUGS : FDA OVERSIGHT OF DIRECT-TO-CONSUMER ADVERTISING HAS LIMITATIONS 18 ( 2002 ) hereinafter 2002 GAO REPORT .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  424 ACCOUNTING_VVG_NN1_JJ@ OFFICE_NN1 ,_Y GAO-03-177_NP1 ,_Y PRESCRIPTION_NN1 DRUGS_NN2 :_Y FDA_NP1_NN1 OVERSIGHT_NN1_NP1 OF_IO DIRECT-TO-CONSUMER_JJ_NN1 ADVERTISING_NN1 HAS_VHZ LIMITATIONS_NN2 18_MC (_Y 2002_MC )_Y hereinafter_RR 2002_MC GAO_NP1 REPORT_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  425 <p> -- ( n72 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  425 <p>_Y --_NN1_JJ (_Y n72_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  426 ) See 2002 GAO REPORT , supra note 71 , at 21 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  426 )_Y See_VV0 2002_MC GAO_NP1 REPORT_NN1 ,_Y supra_NN1 note_NN1_VV0 71_MC ,_Y at_II 21_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  427 <p> -- ( n73 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  427 <p>_Y --_NN1_JJ (_Y n73_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  428 ) FDA Amendments Act of 2007 , 823 , 939-42 ( to be codified at 21 U.S.C. 353b ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  428 )_Y FDA_NP1_NN1 Amendments_NN2 Act_NN1 of_IO 2007_MC ,_Y 823_MC ,_Y 939-42_MCMC (_Y to_TO be_VBI codified_VVN@ at_II 21_MC U.S.C._NP1 353b_FO )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  429 <p> -- ( n74 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  429 <p>_Y --_NN1_JJ (_Y n74_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  430 ) The FDAAA provides the FDA with authority to mandate submission of television advertisements not later than forty-five days prior to broadcast .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  430 )_Y The_AT FDAAA_NN1_NP1 provides_VVZ the_AT FDA_NN1 with_IW authority_NN1 to_II mandate_NN1 submission_NN1 of_IO television_NN1 advertisements_NN2 not_XX later_RRR_JJR than_CSN forty-five_MC days_NNT2 prior_II21 to_II22 broadcast_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  431 Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  431 Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  432 at 939-43 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  432 at_II 939-43_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  433 <p> -- ( n75 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  433 <p>_Y --_NN1_JJ (_Y n75_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  434 ) See 21 C.F.R. 202.1(j) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  434 )_Y See_VV0 21_MC C.F.R._NP1 202.1(j)_FO (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  435 <p> -- ( n76 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  435 <p>_Y --_NN1_JJ (_Y n76_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  436 ) See 21 C.F.R. 202.1(j) ( 4 ) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  436 )_Y See_VV0 21_MC C.F.R._NP1 202.1(j)_FO (_Y 4_MC )_Y (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  437 <p> -- ( n77 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  437 <p>_Y --_NN1_JJ (_Y n77_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  438 ) User Fee Program for Advisory Review of Direct-to-Consumer Television Advertisements for Prescription Drug and Biological Products ; Request for Notification of Participation and Number of Advertisements for Review , 72 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  438 )_Y User_NN1 Fee_NN1 Program_NN1 for_IF Advisory_JJ Review_NN1 of_IO Direct-to-Consumer_NP1 Television_NN1 Advertisements_NN2 for_IF Prescription_NN1 Drug_NN1 and_CC Biological_JJ Products_NN2 ;_Y Request_VV0_NN1 for_IF Notification_NN1 of_IO Participation_NN1 and_CC Number_NN1 of_IO Advertisements_NN2 for_IF Review_NN1_NP1@ ,_Y 72_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  439 Reg. 60,677 , 60,678 ( Oct. 25 , 2007 ) hereinafter User Fee Notice .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  439 Reg._NN1 60,677_MC ,_Y 60,678_MC (_Y Oct._NPM1 25_MC ,_Y 2007_MC )_Y hereinafter_RR User_NN1 Fee_NN1 Notice_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  440 <p> -- ( n78 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  440 <p>_Y --_NN1_JJ (_Y n78_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  441 ) PHRMA , PHRMA GUIDING PRINCIPLES : DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES 5 ( 2005 ) , available at http : **46;1733;TOOLONG ( Principle 8 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  441 )_Y PHRMA_NP1_NN1 ,_Y PHRMA_NP1_NN1 GUIDING_VVG_JJ@ PRINCIPLES_NN2 :_Y DIRECT_JJ_VV0@_RR@ TO_II CONSUMER_NN1 ADVERTISEMENTS_NN2 ABOUT_II PRESCRIPTION_NN1 MEDICINES_NN2 5_MC (_Y 2005_MC )_Y ,_Y available_JJ at_II http_NNU :_Y **46;1733;TOOLONG_FU (_Y Principle_NN1 8_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  442 <p> -- ( n79 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  442 <p>_Y --_NN1_JJ (_Y n79_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  443 ) See , e.g. , ELI LILLY CO. , PROVIDING VALUE TO PATIENTS AND SOCIETY : LILLY CORPORATE CITIZENSHIP REPORT 2006-07 GLAXOSMITHKLINE , ANSWERING THE QUESTIONS THAT MATTER : CORPORATE RESPONSIBILITY REPORT 2007 , at 64 , available at http : **72;1834;TOOLONG ; MERCK , MERCK 'S ALIGNMENT WITH THE " PHRMA GUIDING PRINCIPLES--DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINE " 3 , available at http : **83;1908;TOOLONG ingprinciplesfinal.pdf .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  443 )_Y See_VV0 ,_Y e.g._REX ,_Y ELI_NP1 LILLY_NP1 CO._NP1_FO ,_Y PROVIDING_VVG VALUE_NN1 TO_II PATIENTS_NN2 AND_CC SOCIETY_NN1 :_Y LILLY_NP1 CORPORATE_JJ CITIZENSHIP_NN1 REPORT_NN1 2006-07_MCMC GLAXOSMITHKLINE_NP1_VV0 ,_Y ANSWERING_VVG THE_AT QUESTIONS_NN2 THAT_CST_DD1 MATTER_VV0_NN1 :_Y CORPORATE_JJ RESPONSIBILITY_NN1 REPORT_NN1 2007_MC ,_Y at_II 64_MC ,_Y available_JJ at_II http_NNU :_Y **72;1834;TOOLONG_FU ;_Y MERCK_NP1_VV0 ,_Y MERCK_NP1 'S_GE ALIGNMENT_NN1 WITH_IW THE_AT "_Y PHRMA_NN1_NP1 GUIDING_VVG_JJ@ PRINCIPLES--DIRECT_NN2 TO_II CONSUMER_NN1 ADVERTISEMENTS_NN2 ABOUT_II PRESCRIPTION_NN1 MEDICINE_NN1 "_Y 3_MC ,_Y available_JJ at_II http_NNU :_Y **83;1908;TOOLONG_FU ingprinciplesfinal.pdf_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  444 <p> -- ( n80 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  444 <p>_Y --_NN1_JJ (_Y n80_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  445 ) See 2002 GAO REPORT , supra note 71 , at 21-23 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  445 )_Y See_VV0 2002_MC GAO_NP1 REPORT_NN1 ,_Y supra_NN1 note_NN1_VV0 71_MC ,_Y at_II 21-23_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  446 <p> -- ( n81 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  446 <p>_Y --_NN1_JJ (_Y n81_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  447 ) See 2006 GAO REPORT , supra note 4 , at 21-27 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  447 )_Y See_VV0 2006_MC GAO_NP1 REPORT_NN1 ,_Y supra_NN1 note_NN1_VV0 4_MC ,_Y at_II 21-27_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  448 <p> -- ( n82 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  448 <p>_Y --_NN1_JJ (_Y n82_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  449 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  449 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  450 at 17-19 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  450 at_II 17-19_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  451 <p> -- ( n83 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  451 <p>_Y --_NN1_JJ (_Y n83_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  452 ) User Fee Notice , supra note 77 , at 60,678 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  452 )_Y User_NN1 Fee_NN1 Notice_NN1_VV0 ,_Y supra_NN1 note_NN1_VV0 77_MC ,_Y at_II 60,678_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  453 <p> -- ( n84 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  453 <p>_Y --_NN1_JJ (_Y n84_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  454 ) See FDA Amendments Act of 2007 , Pub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  454 )_Y See_VV0 FDA_NN1_NP1 Amendments_NN2 Act_NN1 of_IO 2007_MC ,_Y Pub_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  455 L. No. 110-85 , Subsection 101-109 , 121 Star .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  455 L._NP1 No._XX 110-85_MCMC ,_Y Subsection_NN1_NP1@ 101-109_MCMC ,_Y 121_MC Star_NN1_JJ@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  456 823 , 825-42 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  456 823_MC ,_Y 825-42_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  457 <p> -- ( n85 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  457 <p>_Y --_NN1_JJ (_Y n85_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  458 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  458 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  459 <p> -- ( n86 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  459 <p>_Y --_NN1_JJ (_Y n86_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  460 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  460 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  461 104 , 121 Stat. at 837-38 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  461 104_MC ,_Y 121_MC Stat._NP1 at_II 837-38_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  462 <p> -- ( n87 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  462 <p>_Y --_NN1_JJ (_Y n87_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  463 ) User Fee Program for Advisory Review of Direct-to-Consumer Television Advertisements for Prescription Drugs and Biological Products ; 2924 ( Jan. 16 , 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  463 )_Y User_NN1 Fee_NN1 Program_NN1 for_IF Advisory_JJ Review_NN1 of_IO Direct-to-Consumer_NP1 Television_NN1 Advertisements_NN2 for_IF Prescription_NN1 Drugs_NN2 and_CC Biological_JJ Products_NN2 ;_Y 2924_MC (_Y Jan._NPM1 16_MC ,_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  464 <p> -- ( n88 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  464 <p>_Y --_NN1_JJ (_Y n88_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  465 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  465 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  466 The FDA responded in May 2008 to a GAO recommendation and developed criteria to prioritize its review of promotional material for those products that have the greatest potential to negatively affect the public health .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  466 The_AT FDA_NN1_NP1 responded_VVN_VVD in_II May_NPM1 2008_MC to_II a_AT1 GAO_NP1 recommendation_NN1 and_CC developed_JJ_VVD criteria_NN2 to_TO prioritize_VVI its_Z' review_NN1 of_IO promotional_JJ material_NN1 for_IF those_DD2 products_NN2 that_CST have_VH0 the_AT greatest_JJT potential_NN1_JJ to_TO negatively_RR affect_VVI the_AT public_JJ_NN1 health_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  467 But a GAO representative testified before a congressional subcommittee that the FDA still needed to document its application of that criteria and systematically track its review of voluntarily submitted materials in order to improve oversight .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  467 But_CCB a_AT1 GAO_NP1 representative_NN1 testified_VVD_VVN@ before_II a_AT1 congressional_JJ subcommittee_NN1 that_CST the_AT FDA_NN1_NP1 still_RR needed_VVN_VVD to_TO document_VVI its_Z' application_NN1 of_IO that_DD1 criteria_NN2 and_CC systematically_RR track_VV0@ its_Z' review_NN1 of_IO voluntarily_RR submitted_VVN_VVD materials_NN2 in_BCL21 order_BCL22 to_TO improve_VVI oversight_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  468 U.S. GEN .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  468 U.S._NP1 GEN_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  469 ACCOUNTING OFFICE , GAO-08-758T , PRESCRIPTION DRUGS : TRENDS IN FDA 'S OVERSIGHT OF DIRECT-TO-CONSUMER ADVERTISING 3 ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  469 ACCOUNTING_VVG_NN1_JJ@ OFFICE_NN1 ,_Y GAO-08-758T_NP1 ,_Y PRESCRIPTION_NN1 DRUGS_NN2 :_Y TRENDS_NN2 IN_II FDA_NP1 'S_GE OVERSIGHT_NN1 OF_IO DIRECT-TO-CONSUMER_JJ_NN1 ADVERTISING_NN1 3_MC (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  470 <p> -- ( n89 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  470 <p>_Y --_NN1_JJ (_Y n89_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  471 ) See supra Part I.A. <p> -- ( n90 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  471 )_Y See_VV0 supra_NN1 Part_NN1 I.A._NP1 <p>_Y --_NN1_JJ (_Y n90_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  472 ) See supra Part I.A. <p> -- ( n91 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  472 )_Y See_VV0 supra_NN1 Part_NN1 I.A._NP1 <p>_Y --_NN1_JJ (_Y n91_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  473 ) Palumbo Mullins , supra note 10 , at 425 n.18 ( quoting S. 1944 , 73d Cong .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  473 )_Y Palumbo_NP1@ Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 425_MC n.18_FO (_Y quoting_VVG S._NP1_NN1@ 1944_MC ,_Y 73d_NNU Cong_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  474 9(c) ( n1933 ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  474 9(c)_FO (_Y n1933_FO )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  475 <p> -- ( n92 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  475 <p>_Y --_NN1_JJ (_Y n92_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  476 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  476 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  477 at 425-26 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  477 at_II 425-26_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  478 <p> -- ( n93 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  478 <p>_Y --_NN1_JJ (_Y n93_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  479 ) See Palumbo Mullins , supra note 10 , at 429 supra note 57 , at 210 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  479 )_Y See_VV0 Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 429_MC supra_NN1 note_NN1_VV0 57_MC ,_Y at_II 210_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  480 <p> -- ( n95 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  480 <p>_Y --_NN1_JJ (_Y n95_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  481 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  481 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  482 at 216 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  482 at_II 216_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  483 <p> -- ( n96 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  483 <p>_Y --_NN1_JJ (_Y n96_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  484 ) A 2007 study in the Journal of Health Communication took issue with the FDA 's effectiveness in policing the " fair balance " requirement , finding that the average sixty-second commercial contained less than eight seconds of side-effect information .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  484 )_Y A_ZZ1_AT1 2007_MC study_NN1_VV0@ in_II the_AT Journal_NN1 of_IO Health_NN1 Communication_NN1 took_VVD issue_NN1 with_IW the_AT FDA_NP1_NN1 's_GE effectiveness_NN1 in_II policing_VVG the_AT "_Y fair_JJ balance_NN1 "_Y requirement_NN1 ,_Y finding_VVG that_CST the_AT average_NN1_JJ sixty-second_MD_NNU commercial_NN1@_JJ contained_VVD_VVN less_DAR than_CSN eight_MC seconds_NNT2 of_IO side-effect_JJ_NN1 information_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  485 See Wendy Macias et al. , A Wonderful Life or Diarrhea and Dry Mouth ?
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  485 See_VV0 Wendy_NP1 Macias_NP1 et_RA21 al._RA22 ,_Y A_ZZ1_AT1@ Wonderful_JJ Life_NN1 or_CC Diarrhea_NP1 and_CC Dry_JJ Mouth_NN1 ?_Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  486 Policy Issues of Direct-to-Consumer Drug Advertising on Television , 22 HEALTH COMM. 241 , 247 ( 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  486 Policy_NN1 Issues_NN2 of_IO Direct-to-Consumer_NP1 Drug_NN1 Advertising_NN1_VVG@ on_II Television_NN1 ,_Y 22_MC HEALTH_NN1 COMM._NP1 241_MC ,_Y 247_MC (_Y 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  487 <p> -- ( n97 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  487 <p>_Y --_NN1_JJ (_Y n97_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  488 ) See Public Views of Direct-to-Consumer Prescription Drug Advertising : Hearing Before the H. Subcomm. on Oversight Investigations , Comm. on Energy Commerce , 110th Cong .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  488 )_Y See_VV0 Public_JJ_NN1 Views_NN2 of_IO Direct-to-Consumer_NP1 Prescription_NN1 Drug_NN1 Advertising_NN1 :_Y Hearing_VVG_NN1 Before_II_CS the_AT H._NP1 Subcomm._NP1 on_II Oversight_NP1_NN1 Investigations_NN2 ,_Y Comm._NP1 on_II Energy_NN1 Commerce_NN1 ,_Y 110th_MD Cong_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  489 1-7 ( 2008 ) ( statement of Mollyann Brodie , Vice President and Director , Public Opinion and Media Research , Henry J. Kaiser Family Foundation ) , available at http : **66;1993;TOOLONG .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  489 1-7_MCMC (_Y 2008_MC )_Y (_Y statement_NN1 of_IO Mollyann_NP1 Brodie_NP1 ,_Y Vice_JJ_II President_NN1 and_CC Director_NN1 ,_Y Public_NN1 Opinion_NN1 and_CC Media_NN Research_NN1_VV0@ ,_Y Henry_NP1 J._NP1 Kaiser_NNB Family_NP1 Foundation_NN1 )_Y ,_Y available_JJ at_II http_NNU :_Y **66;1993;TOOLONG_FU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  490 <p> -- ( n98 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  490 <p>_Y --_NN1_JJ (_Y n98_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  491 ) See Donohue , supra note 1 , at 676 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  491 )_Y See_VV0 Donohue_NP1 ,_Y supra_NN1 note_NN1_VV0 1_MC1 ,_Y at_II 676_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  492 <p> -- ( n99 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  492 <p>_Y --_NN1_JJ (_Y n99_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  493 ) See , that violation letters sent by the FDA to manufacturers had fallen from 142 in 1997 to only 21 in 2006 , and attributing the decrease to policies and understaffing at the FDA that have weakened the FDA 's capacity to enforce these regulations ) ; 2006 GAO REPORT , supra note 4 , at 21-27 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  493 )_Y See_VV0 ,_Y that_DD1_CST violation_NN1 letters_NN2 sent_VVN by_II the_AT FDA_NN1_NP1 to_II manufacturers_NN2 had_VHD fallen_VVN from_II 142_MC in_II 1997_MC to_II_TO only_RR 21_MC in_II 2006_MC ,_Y and_CC attributing_VVG the_AT decrease_NN1 to_II policies_NN2 and_CC understaffing_VVG at_II the_AT FDA_NN1 that_CST have_VH0 weakened_VVN the_AT FDA_NP1_NN1 's_GE capacity_NN1 to_TO enforce_VVI these_DD2 regulations_NN2 )_Y ;_Y 2006_MC GAO_NP1 REPORT_NN1 ,_Y supra_NN1 note_NN1_VV0 4_MC ,_Y at_II 21-27_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  494 Reconciling the debate is beyond the scope of this Article , but it deserves mention that such a theory presupposes that transgressions of advertising regulations remain constant in proportion to spending ( that is , violations are occurring at the same rate , but are going undetected ) , which rejects the notion of applied learning from previous experience or the use of DDMAC 's voluntary pre-market advertising review .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  494 Reconciling_VVG the_AT debate_NN1 is_VBZ beyond_II the_AT scope_NN1 of_IO this_DD1 Article_NN1 ,_Y but_CCB it_PPH1 deserves_VVZ mention_NN1_VV0 that_CST_DD1 such_DA a_AT1 theory_NN1 presupposes_VVZ that_CST transgressions_NN2 of_IO advertising_NN1_VVG@ regulations_NN2 remain_VV0 constant_JJ_NN1@ in_II31 proportion_II32 to_II33 spending_NN1_VVG (_Y that_REX21 is_REX22 ,_Y violations_NN2 are_VBR occurring_VVG at_II the_AT same_DA rate_NN1 ,_Y but_CCB are_VBR going_VVG undetected_JJ )_Y ,_Y which_DDQ rejects_VVZ the_AT notion_NN1 of_IO applied_JJ learning_NN1 from_II previous_JJ experience_NN1 or_CC the_AT use_NN1 of_IO DDMAC_NP1_NN1 's_GE_VBZ voluntary_JJ pre-market_JJ_NN1 advertising_NN1 review_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  495 It should be noted that , after an initial uptick in 1999 in companies seeking FDA input through launch-campaign advisory letters pursuant to the FDA 's pre-market voluntary submission process , FDA advisory letters have remained relatively stable from 2000 to 2005 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  495 It_PPH1 should_VM be_VBI noted_VVN that_CST_DD1 ,_Y after_CS_II an_AT1 initial_JJ_NN1 uptick_NN1 in_II 1999_MC in_II companies_NN2 seeking_VVG FDA_NN1_NP1 input_NN1_VVN@ through_II launch-campaign_JJ advisory_JJ letters_NN2 pursuant_II21 to_II22 the_AT FDA_NP1_NN1 's_GE_VBZ pre-market_JJ_NN1 voluntary_JJ submission_NN1 process_NN1_VV0 ,_Y FDA_NP1_NN1 advisory_JJ letters_NN2 have_VH0 remained_VVN relatively_RR stable_JJ from_II 2000_MC to_II 2005_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  496 This fact suggests that the industry continues to seek out the FDA 's insight and approval before releasing campaigns to the public , CDER 2005 REPORT TO THE NATION : IMPROVING PUBLIC HEALTH THROUGH HUMAN DRUGS 45 ( 2005 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  496 This_DD1 fact_NN1 suggests_VVZ that_CST the_AT industry_NN1 continues_VVZ to_TO seek_VVI out_RP the_AT FDA_NP1_NN1 's_GE insight_NN1 and_CC approval_NN1 before_II releasing_VVG campaigns_NN2 to_II the_AT public_NN1_JJ ,_Y CDER_NP1_VV0_NN1_JJR 2005_MC REPORT_NN1_VV0@ TO_II THE_AT NATION_NN1 :_Y IMPROVING_JJ_VVG PUBLIC_JJ_NN1 HEALTH_NN1 THROUGH_II HUMAN_JJ_NN1 DRUGS_NN2 45_MC (_Y 2005_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  497 <p> -- ( n100 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  497 <p>_Y --_NN1_JJ (_Y n100_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  498 ) See SHEEHAN , supra note 57 , at 210 ; see also Louis A. Morris et al. , The Attitudes of Consumers toward Direct Advertising of Prescription Drugs , 101 PUB .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  498 )_Y See_VV0 SHEEHAN_NP1 ,_Y supra_NN1 note_NN1_VV0 57_MC ,_Y at_II 210_MC ;_Y see_VV0 also_RR Louis_NP1 A._ZZ Morris_NP1 et_RA21 al._RA22 ,_Y The_AT Attitudes_NN2 of_IO Consumers_NN2 toward_II Direct_JJ Advertising_NN1 of_IO Prescription_NN1 Drugs_NN2 ,_Y 101_MC PUB_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  499 HEALTH REP. 82 , 87 ( n1986 ) , cited in Palumbo Mullins , supra note 10 , at 424 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  499 HEALTH_NN1 REP._NN1 82_MC ,_Y 87_MC (_Y n1986_FO )_Y ,_Y cited_VVN_VVD in_II Palumbo_NP1 Mullins_NP1 ,_Y supra_NN1 note_NN1_VV0 10_MC ,_Y at_II 424_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  500 <p> -- ( n101 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  500 <p>_Y --_NN1_JJ (_Y n101_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  501 ) See SHEEHAN , supra note 57 , at 215 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  501 )_Y See_VV0 SHEEHAN_NP1 ,_Y supra_NN1 note_NN1_VV0 57_MC ,_Y at_II 215_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  502 <p> -- ( n102 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  502 <p>_Y --_NN1_JJ (_Y n102_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  503 ) Public Views of Direct-to-Consumer Advertising of Prescription Drugs , supra note 97 , at 5 , 12 fig.7 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  503 )_Y Public_JJ_NN1 Views_NN2 of_IO Direct-to-Consumer_NP1 Advertising_NN1 of_IO Prescription_NN1 Drugs_NN2 ,_Y supra_NN1 note_NN1_VV0 97_MC ,_Y at_II 5_MC ,_Y 12_MC fig.7_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  504 <p> -- ( n103 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  504 <p>_Y --_NN1_JJ (_Y n103_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  505 ) See SHEEHAN , supra note 57 , at 210 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  505 )_Y See_VV0 SHEEHAN_NP1 ,_Y supra_NN1 note_NN1_VV0 57_MC ,_Y at_II 210_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  506 <p> -- ( n104 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  506 <p>_Y --_NN1_JJ (_Y n104_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  507 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  507 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  508 Although it continues to support a case-by-case approach , the AMA remains generally skeptical of DTC advertising .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  508 Although_CS it_PPH1 continues_VVZ to_TO support_VVI a_AT1 case-by-case_JJ_NN1 approach_NN1 ,_Y the_AT AMA_NN1_NP1 remains_VVZ generally_RR skeptical_JJ of_IO DTC_NP1 advertising_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  509 In testimony before Congress in May 2008 , it recommended additional research into the effect , if any , of DTC advertising on the doctor-patient relationship .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  509 In_II testimony_NN1 before_II_CS Congress_NN1 in_II May_NPM1 2008_MC ,_Y it_PPH1 recommended_VVD additional_JJ research_NN1 into_II the_AT effect_NN1 ,_Y if_CS any_DD ,_Y of_IO DTC_NP1 advertising_NN1 on_II the_AT doctor-patient_JJ_NN1 relationship_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  510 Direct-to-Consumer Before the H. Subcomm. on Oversight Investigation of the H. Comm. on Energy Commerce , 110th Cong .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  510 Direct-to-Consumer_JJ_NN1 Before_II_CS the_AT H._NP1 Subcomm._NP1 on_II Oversight_NP1_NN1 Investigation_NN1 of_IO the_AT H._NP1 Comm._NP1 on_II Energy_NN1 Commerce_NN1 ,_Y 110th_MD Cong_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  511 12 ( 2008 ) ( statement of Nancy H. Nielson , President Elect , American Medical Association ) , available at http : **82;2061;TOOLONG AMA additionally recommended a set of guidelines for DTC advertising , including a moratorium on DTC advertising of all newly approved drugs until physicians " have been appropriately educated about the drug .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  511 12_MC (_Y 2008_MC )_Y (_Y statement_NN1 of_IO Nancy_NP1 H._NP1 Nielson_NP1 ,_Y President_NNB Elect_NP1 ,_Y American_JJ Medical_JJ Association_NN1 )_Y ,_Y available_JJ at_II http_NNU :_Y **82;2061;TOOLONG_FU AMA_NN1_NP1 additionally_RR recommended_VVN_VVD a_AT1 set_NN1 of_IO guidelines_NN2 for_IF DTC_NP1 advertising_NN1 ,_Y including_II_VVG@ a_AT1 moratorium_NN1 on_II DTC_NP1 advertising_NN1 of_IO all_DB newly_RR approved_JJ_VVN drugs_NN2 until_CS_II@ physicians_NN2 "_Y have_VH0 been_VBN appropriately_RR educated_VVN about_II the_AT drug_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  512 " Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  512 "_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  513 at 6-7 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  513 at_II 6-7_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  514 The AMA recommends that the length of the moratorium be determined by the FDA in consultation with the manufacturer and be dependent upon numerous factors , including the innovative nature of the drug , the severity of the disease the drug is intended to treat , the availability of alternative therapies , and the intensity and the timeliness of education about the drug for physicians who are likely to prescribe it .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  514 The_AT AMA_NN1_NP1 recommends_VVZ that_CST the_AT length_NN1 of_IO the_AT moratorium_NN1 be_VBI determined_VVN by_II the_AT FDA_NN1_NP1 in_II31 consultation_II32 with_II33 the_AT manufacturer_NN1 and_CC be_VBI dependent_JJ upon_II numerous_JJ factors_NN2 ,_Y including_II_VVG@ the_AT innovative_JJ nature_NN1 of_IO the_AT drug_NN1 ,_Y the_AT severity_NN1 of_IO the_AT disease_NN1 the_AT drug_NN1 is_VBZ intended_VVN to_TO treat_VVI ,_Y the_AT availability_NN1 of_IO alternative_JJ_NN1 therapies_NN2 ,_Y and_CC the_AT intensity_NN1 and_CC the_AT timeliness_NN1 of_IO education_NN1 about_II the_AT drug_NN1 for_IF physicians_NN2 who_PNQS are_VBR likely_JJ to_TO prescribe_VVI it_PPH1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  515 See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  515 See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  516 <p> -- ( n105 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  516 <p>_Y --_NN1_JJ (_Y n105_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  517 ) SHEEHAN , supra note 57 , at 216 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  517 )_Y SHEEHAN_NP1 ,_Y supra_NN1 note_NN1_VV0 57_MC ,_Y at_II 216_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  518 <p> -- ( n106 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  518 <p>_Y --_NN1_JJ (_Y n106_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  519 ) KATHRYN J. AIKIN , DIRECT-TO-CONSUMER ADVERTISING OF PRESCRIPTION DRUGS : PHYSICIAN SURVEY <p> -- ( n107 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  519 )_Y KATHRYN_NP1 J._NP1 AIKIN_NP1 ,_Y DIRECT-TO-CONSUMER_JJ_NN1 ADVERTISING_NN1 OF_IO PRESCRIPTION_NN1 DRUGS_NN2 :_Y PHYSICIAN_NN1 SURVEY_NN1_VV0@ <p>_Y --_NN1_JJ (_Y n107_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  520 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  520 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  521 at 3 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  521 at_II 3_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  522 <p> -- ( n108 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  522 <p>_Y --_NN1_JJ (_Y n108_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  523 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  523 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  524 at 32 , 38 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  524 at_II 32_MC ,_Y 38_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  525 <p> -- ( n109 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  525 <p>_Y --_NN1_JJ (_Y n109_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  526 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  526 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  527 at 34 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  527 at_II 34_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  528 <p> -- ( n110 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  528 <p>_Y --_NN1_JJ (_Y n110_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  529 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  529 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  530 at 12 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  530 at_II 12_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  531 <p> -- ( n111 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  531 <p>_Y --_NN1_JJ (_Y n111_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  532 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  532 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  533 at 12-13 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  533 at_II 12-13_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  534 <p> -- ( n112 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  534 <p>_Y --_NN1_JJ (_Y n112_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  535 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  535 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  536 at 21 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  536 at_II 21_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  537 <p> -- ( n113 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  537 <p>_Y --_NN1_JJ (_Y n113_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  538 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  538 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  539 at 22 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  539 at_II 22_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  540 <p> -- ( n114 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  540 <p>_Y --_NN1_JJ (_Y n114_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  541 ) See RESTATEMENT ( THIRD ) OF TORTS : PRODUCTS LIABILITY 6 ( n1998 ) hereinafter RESTATEMENT ( THIRD ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  541 )_Y See_VV0 RESTATEMENT_NN1 (_Y THIRD_MD )_Y OF_IO TORTS_NN2 :_Y PRODUCTS_NN2 LIABILITY_NN1 6_MC (_Y n1998_FO )_Y hereinafter_RR RESTATEMENT_NN1 (_Y THIRD_MD )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  542 <p> -- ( n115 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  542 <p>_Y --_NN1_JJ (_Y n115_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  543 ) See Reyes v. Wyeth Labs. , 498 F.2d 1264 , 1276 ( 5th Cir. 1974 ) ( " Prescription drugs are likely to be complex medicines , esoteric in formula and varied in effect .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  543 )_Y See_VV0 Reyes_NN2_NP1 v._II Wyeth_NP1 Labs._ZZ ,_Y 498_MC F.2d_FO 1264_MC ,_Y 1276_MC (_Y 5th_MD Cir._NP1 1974_MC )_Y (_Y "_Y Prescription_NN1 drugs_NN2 are_VBR likely_JJ to_TO be_VBI complex_JJ medicines_NN2 ,_Y esoteric_JJ in_II formula_NN1 and_CC varied_VVN_VVD in_II effect_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  544 As a medical expert , the prescribing physician can take into account the propensities of the drug , as well as the susceptibilities of his patient .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  544 As_II_CSA a_AT1 medical_JJ expert_NN1 ,_Y the_AT prescribing_NN1@ physician_NN1 can_VM take_VVI into_II account_NN1_VV0 the_AT propensities_NN2 of_IO the_AT drug_NN1 ,_Y as_II31 well_II32 as_II33 the_AT susceptibilities_NN2 of_IO his_APPGE patient_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  545 His is the task of weighing the benefits of any medication against its potential dangers an individualized medical judgment bottomed on a knowledge of both patient and palliative. " ) ; see also In re Zyprexa Prods .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  545 His_PPGE@ is_VBZ the_AT task_NN1 of_IO weighing_VVG the_AT benefits_NN2 of_IO any_DD medication_NN1 against_II its_Z' potential_JJ_NN1 dangers_NN2 an_AT1 individualized_JJ@ medical_JJ judgment_NN1 bottomed_VVN_VVD on_II_RP@ a_AT1 knowledge_NN1 of_IO both_RR patient_JJ and_CC palliative._NNU "_Y )_Y ;_Y see_VV0 also_RR In_RP@_II re_II Zyprexa_NP1 Prods_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  546 Liab .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  546 Liab_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  547 Litig. , 489 F. Supp. 2d 230 , 266 ( E.D.N.Y. 2007 ) ( stating that " ' whether the physician in fact reads the drug manufacturer 's warning or passes its contents along to the recipient of the drug is irrelevant ' " for purposes of the learned intermediary doctrine ( quoting E.R. Squibb Sons , Inc. v. Fames , 697 So .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  547 Litig._NP1 ,_Y 489_MC F._NP1_RA@ Supp._NP1 2d_NNU 230_MC ,_Y 266_MC (_Y E.D.N.Y._NP1 2007_MC )_Y (_Y stating_VVG that_DD1_CST "_Y '_GE_"@ whether_CSW the_AT physician_NN1 in_II fact_NN1 reads_VVZ the_AT drug_NN1 manufacturer_NN1 's_GE warning_NN1 or_CC passes_VVZ its_Z' contents_NN2 along_RP to_II the_AT recipient_NN1 of_IO the_AT drug_NN1 is_VBZ irrelevant_JJ '_GE "_Y for_IF purposes_NN2 of_IO the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 (_Y quoting_VVG E.R._NP1 Squibb_NP1 Sons_NN2 ,_Y Inc._JJ v._II_NNU Fames_NN2 ,_Y 697_MC So_RR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  548 2d 825 , 827 ( Fla. 1997 ) ) ) ; West v. Searle Co. , 806 S.W.2d 608 , 613-14 ( Ark. 1991 ) ( stating that physicians must make independent judgments as to whether drugs are beneficial for their patients ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  548 2d_NNU 825_MC ,_Y 827_MC (_Y Fla._NP1 1997_MC )_Y )_Y )_Y ;_Y West_ND1 v._II Searle_NP1 Co._NP1 ,_Y 806_MC S.W.2d_FO 608_MC ,_Y 613-14_MCMC (_Y Ark._NP1 1991_MC )_Y (_Y stating_VVG that_CST physicians_NN2 must_VM make_VVI independent_JJ judgments_NN2 as_II21 to_II22 whether_CSW drugs_NN2 are_VBR beneficial_JJ for_IF their_APPGE patients_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  549 <p> -- ( n116 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  549 <p>_Y --_NN1_JJ (_Y n116_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  550 ) See Diane Schmauder Kane , Annotation , Construction and Application of the Learned-Intermediary Doctrine , 57 A.L.R.5th 1 ( n1998 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  550 )_Y See_VV0 Diane_NP1 Schmauder_NP1 Kane_NP1 ,_Y Annotation_NN1 ,_Y Construction_NN1 and_CC Application_NN1 of_IO the_AT Learned-Intermediary_NP1 Doctrine_NN1 ,_Y 57_MC A.L.R.5th_FO 1_MC1 (_Y n1998_FO )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  551 <p> -- ( n117 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  551 <p>_Y --_NN1_JJ (_Y n117_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  552 ) See RESTATEMENT ( THIRD ) , supra note 114 , 6 cmt. b ( " Only-health care professionals are in a position assess the relative advantages and disadvantages of a given form of prescription-based therapy .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  552 )_Y See_VV0 RESTATEMENT_NN1 (_Y THIRD_MD )_Y ,_Y supra_NN1 note_NN1_VV0 114_MC ,_Y 6_MC cmt._NNU b_ZZ1 (_Y "_Y Only-health_JJ_NN1 care_NN1 professionals_NN2 are_VBR in_II a_AT1 position_NN1 assess_VVI the_AT relative_JJ_NN1 advantages_NN2 and_CC disadvantages_NN2 of_IO a_AT1 given_JJ@ form_NN1 of_IO prescription-based_JJ_NN1 therapy_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  553 " ) ; see also Barbara Pope Flannagan , Products Liability : The Continued Viability of the Learned Intermediary Rule as it Applies to Product Warnings for Prescription Drugs , 20 U. RICH .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  553 "_Y )_Y ;_Y see_VV0 also_RR Barbara_NP1 Pope_NNB Flannagan_NP1 ,_Y Products_NN2 Liability_NN1 :_Y The_AT Continued_JJ Viability_NN1 of_IO the_AT Learned_JJ@ Intermediary_NN1 Rule_NN1 as_CSA it_PPH1 Applies_VVZ to_II Product_NN1 Warnings_NN2 for_IF Prescription_NN1 Drugs_NN2 ,_Y 20_MC U._NP1 RICH_NP1@_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  554 L. REV. 405 , 412 ( n1986 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  554 L._NP1_NNU@ REV._NNU 405_MC ,_Y 412_MC (_Y n1986_FO )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  555 <p> -- ( n118 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  555 <p>_Y --_NN1_JJ (_Y n118_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  556 ) See Vitanza v. Upjohn Co. , 778 A.2d 829 , 846 ( Conn. 2001 ) ( acknowledging that a physician " is in the best position to convey adequate warnings based upon the highly personal doctor-patient relationship " ) ; see also West , 806 S.W.2d at 613 ( listing common rationales supporting the doctrine ) ; Terhune v. A.H .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  556 )_Y See_VV0 Vitanza_NP1_NN1@ v._II Upjohn_NP1 Co._NP1 ,_Y 778_MC A.2d_FO 829_MC ,_Y 846_MC (_Y Conn._NP1 2001_MC )_Y (_Y acknowledging_VVG that_CST a_AT1 physician_NN1 "_Y is_VBZ in_II the_AT best_JJT position_NN1_VV0@ to_TO convey_VVI adequate_JJ warnings_NN2 based_VVN upon_II the_AT highly_RR personal_JJ doctor-patient_JJ_NN1 relationship_NN1 "_Y )_Y ;_Y see_VV0 also_RR West_ND1 ,_Y 806_MC S.W.2d_FO at_II 613_MC (_Y listing_VVG common_JJ rationales_NN2 supporting_VVG the_AT doctrine_NN1 )_Y ;_Y Terhune_NP1 v._II A.H_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  557 Robins Co. , 577 P.2d 975 , 978 ( Wash .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  557 Robins_NP Co._NP1_NN1 ,_Y 577_MC P.2d_FO 975_MC ,_Y 978_MC (_Y Wash_NN1_VV0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  558 1978 ) ( " The reasons for this rule should be obvious .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  558 1978_MC )_Y (_Y "_Y The_AT reasons_NN2 for_IF this_DD1 rule_NN1 should_VM be_VBI obvious_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  559 " ) ; David P. Graham Jeremy C. Vest , Doctors , Drugs , and Duties to Warn , 72 DEF .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  559 "_Y )_Y ;_Y David_NP1 P._NP1 Graham_NP1 Jeremy_NP1 C._NP1 Vest_NN1 ,_Y Doctors_NN2 ,_Y Drugs_NN2 ,_Y and_CC Duties_NN2 to_TO_II Warn_VV0 ,_Y 72_MC DEF_NP1_NN1_VV0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  560 COUNS .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  560 COUNS_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  561 J. 380 , 381 ( 2005 ) ( " The assumptions that underlie the doctrine are that patients , in light of their experience and expertise , are in a better position than their patients to evaluate and communicate the manufacturers ' warnings directly to the patients .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  561 J._NP1 380_MC ,_Y 381_MC (_Y 2005_MC )_Y (_Y "_Y The_AT assumptions_NN2 that_CST underlie_VV0 the_AT doctrine_NN1 are_VBR that_CST patients_NN2 ,_Y in_II31 light_II32 of_II33 their_APPGE experience_NN1 and_CC expertise_NN1 ,_Y are_VBR in_II a_AT1 better_JJR position_NN1 than_CSN their_APPGE patients_NN2 to_TO evaluate_VVI and_CC communicate_VVI the_AT manufacturers_NN2 '_GE warnings_NN2 directly_RR to_II the_AT patients_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  562 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  562 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  563 <p> -- ( n119 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  563 <p>_Y --_NN1_JJ (_Y n119_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  564 ) See Monica Renee Matter , Emerging DTC Advertising of Prescription Drugs and the Learned Intermediary Doctrine , 69 DEF .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  564 )_Y See_VV0 Monica_NP1 Renee_NP1_NN1 Matter_NN1_VV0 ,_Y Emerging_VVG_JJ DTC_NP1 Advertising_NN1 of_IO Prescription_NN1 Drugs_NN2 and_CC the_AT Learned_JJ@ Intermediary_NN1 Doctrine_NN1 ,_Y 69_MC DEF_NP1_NN1_VV0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  565 COUNS .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  565 COUNS_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  566 J. 79 , 81 ( 2002 ) ( discussing common rationales favoring the rule ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  566 J._NP1 79_MC ,_Y 81_MC (_Y 2002_MC )_Y (_Y discussing_VVG common_JJ rationales_NN2 favoring_VVG the_AT rule_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  567 <p> -- ( n120 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  567 <p>_Y --_NN1_JJ (_Y n120_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  568 ) See , e.g. , Gravis v. Parke-Davis Co. , 502 S.W.2d 863 , 870 ( Tex .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  568 )_Y See_VV0 ,_Y e.g._REX ,_Y Gravis_NP1 v._II Parke-Davis_NP1 Co._NP1 ,_Y 502_MC S.W.2d_FO 863_MC ,_Y 870_MC (_Y Tex_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  569 Civ .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  569 Civ_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  570 App. 1973 ) ( " The entire system of drug distribution in America is set up so as to place the responsibility of distribution and use upon professional people .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  570 App._NP1 1973_MC )_Y (_Y "_Y The_AT entire_JJ system_NN1 of_IO drug_NN1 distribution_NN1 in_II America_NP1 is_VBZ set_VVN up_RP so_BCL21 as_BCL22 to_TO place_VVI the_AT responsibility_NN1 of_IO distribution_NN1 and_CC use_VVI upon_II professional_JJ people_NN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  571 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  571 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  572 <p> -- ( n121 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  572 <p>_Y --_NN1_JJ (_Y n121_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  573 ) See In re Norplant Contraceptive Prods .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  573 )_Y See_VV0 In_RP@ re_II Norplant_NP1_NN1 Contraceptive_JJ_NN1 Prods_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  574 Liab .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  574 Liab_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  575 Litig. , 215 F. Supp. 2d 795 , 806-09 ( E.D. Tex .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  575 Litig._NP1 ,_Y 215_MC F._NP1_RA@ Supp._NP1 2d_NNU 795_MC ,_Y 806-09_MCMC (_Y E.D._NN1 Tex_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  576 2002 ) ( concluding that forty-eight states , the District of Columbia , and Puerto Rico have either applied or recognized the learned intermediary doctrine , and A.2d at 838 n.11 ( finding that forty-four other jurisdictions have adopted the learned intermediary doctrine , including lower state courts and federal courts applying state law ) ; Larkin v. Pfizer , Inc. , 153 S.W.3d 758 , 767 n.3 ( Ky. 2004 ) ( observing that thirty-four states have specifically adopted the learned intermediary doctrine ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  576 2002_MC )_Y (_Y concluding_VVG_JJ that_CST_DD1_RG% forty-eight_MC states_NN2 ,_Y the_AT District_NN1 of_IO Columbia_NP1 ,_Y and_CC Puerto_NP1 Rico_NP1 have_VH0 either_RR applied_VVN or_CC recognized_VVD the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 ,_Y and_CC A.2d_FO at_II 838_MC n.11_FO (_Y finding_VVG_NN1 that_CST_DD1_RG% forty-four_MC other_JJ jurisdictions_NN2 have_VH0 adopted_VVN the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 ,_Y including_II_VVG@ lower_JJR state_NN1 courts_NN2 and_CC federal_JJ courts_NN2 applying_VVG state_NN1 law_NN1 )_Y ;_Y Larkin_NP1 v._II Pfizer_NP1_NN1 ,_Y Inc._JJ ,_Y 153_MC S.W.3d_FO 758_MC ,_Y 767_MC n.3_FO (_Y Ky._NP1 2004_MC )_Y (_Y observing_VVG that_CST_DD1_RG% thirty-four_MC states_NN2 have_VH0 specifically_RR adopted_VVN the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  577 West Virginia appears to be the only state expressly declining to adopt the learned intermediary doctrine .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  577 West_NP1 Virginia_NP1 appears_VVZ to_TO be_VBI the_AT only_JJ state_NN1 expressly_RR declining_VVG_JJ to_TO adopt_VVI the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  578 See State ex rel .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  578 See_VV0 State_NN1 ex_II rel_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  579 Johnson Johnson Corp .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  579 Johnson_NP1 Johnson_NP1 Corp_NPX ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  580 v. Karl , 647 S.E.2d 899 , 914 ( W. Va .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  580 v._II Karl_NP1 ,_Y 647_MC S.E.2d_FO 899_MC ,_Y 914_MC (_Y W._NP1 Va_FW ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  581 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  581 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  582 New Jersey does not apply the learned intermediary doctrine where the prescription drug manufacturer attempts to advertise directly to consumers and the consumer relies on that advertisement .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  582 New_NP1 Jersey_NP1 does_VDZ not_XX apply_VVI the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 where_CS_RRQ the_AT prescription_NN1 drug_NN1 manufacturer_NN1 attempts_NN2_VVZ@ to_TO advertise_VVI directly_RR to_II consumers_NN2 and_CC the_AT consumer_NN1 relies_VVZ on_II that_DD1 advertisement_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  583 See Perez v. Wyeth Labs. , 734 A.2d 1245 , 1257-58 ( N.J. 1999 ) ; see also MacDonald v. Ortho Pharm .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  583 See_VV0 Perez_NP1 v._II Wyeth_NP1 Labs._ZZ ,_Y 734_MC A.2d_FO 1245_MC ,_Y 1257-58_MCMC (_Y N.J._NP1 1999_MC )_Y ;_Y see_VV0 also_RR MacDonald_NP1 v._II Ortho_NP1 Pharm_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  584 Corp. , 475 N.E.2d 65 , 69 ( Mass. 1985 ) ( recognizing an exception to the general application of the learned intermediary doctrine for oral contraceptives ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  584 Corp._NP1 ,_Y 475_MC N.E.2d_FO 65_MC ,_Y 69_MC (_Y Mass._NP1 1985_MC )_Y (_Y recognizing_VVG an_AT1 exception_NN1 to_II the_AT general_JJ_NN1 application_NN1 of_IO the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 for_IF oral_JJ_NN1 contraceptives_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  585 <p> -- ( n122 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  585 <p>_Y --_NN1_JJ (_Y n122_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  586 ) Sterling Drug , 8th Cir. 1966 ) ; see also Hruska v. Parke , Davis Co. , 6 F.2d 536 , 538 ( 8th Cir. 1925 ) ( acknowledging public is " not on an equal footing " with prescription drug manufacturers in terms of knowledge ) ; Marcus v. Specific Pharms. , 77 N.Y.S.2d 508 , 508-10 ( Sup .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  586 )_Y Sterling_NN1_JJ@ Drug_NN1 ,_Y 8th_MD Cir._NP1 1966_MC )_Y ;_Y see_VV0 also_RR Hruska_NP1_NN1@ v._II Parke_NP1 ,_Y Davis_NP1 Co._NP1 ,_Y 6_MC F.2d_FO 536_MC ,_Y 538_MC (_Y 8th_MD Cir._NP1 1925_MC )_Y (_Y acknowledging_VVG public_NN1 is_VBZ "_Y not_XX on_II an_AT1 equal_JJ footing_NN1 "_Y with_IW prescription_NN1 drug_NN1 manufacturers_NN2 in_II31 terms_II32 of_II33 knowledge_NN1 )_Y ;_Y Marcus_NP1 v._II Specific_JJ Pharms._NP1 ,_Y 77_MC N.Y.S.2d_FO 508_MC ,_Y 508-10_MCMC (_Y Sup_VV0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  587 Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  587 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  588 1948 ) ( first holding that a manufacturer 's duty to warn was fulfilled by Informing the physician ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  588 1948_MC )_Y (_Y first_MD holding_NN1@_VVG that_CST a_AT1 manufacturer_NN1 's_GE duty_NN1 to_TO warn_VVI was_VBDZ fulfilled_VVN by_II Informing_VVG the_AT physician_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  589 <p> -- ( n123 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  589 <p>_Y --_NN1_JJ (_Y n123_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  590 ) See Kane , supra note 116 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  590 )_Y See_VV0 Kane_NP1 ,_Y supra_NN1 note_NN1_VV0 116_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  591 <p> -- ( n124 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  591 <p>_Y --_NN1_JJ (_Y n124_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  592 ) See , e.g. , Beyette v. Ortho Pharm .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  592 )_Y See_VV0 ,_Y e.g._REX ,_Y Beyette_NP1_NN1 v._II Ortho_NP1 Pharm_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  593 Corp. , 823 F.2d 990 , 992 ( 6th Cir. 1987 ) ; Tetuan v. A.H .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  593 Corp._NP1 ,_Y 823_MC F.2d_FO 990_MC ,_Y 992_MC (_Y 6th_MD Cir._NP1 1987_MC )_Y ;_Y Tetuan_NP1_NN1_JJ v._II A.H_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  594 Robins Co. , 738 P.2d 1210 , 1227-28 ( Karl .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  594 Robins_NP Co._NP1_NN1 ,_Y 738_MC P.2d_FO 1210_MC ,_Y 1227-28_MCMC (_Y Karl_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  595 1987 ) ; Terhune v. A. H. Robins Co. , 577 P.2d 975 , 978 ( Wash .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  595 1987_MC )_Y ;_Y Terhune_NP1 v._II A._ZZ H._NP1 Robins_NP Co._NP1_NN1 ,_Y 577_MC P.2d_FO 975_MC ,_Y 978_MC (_Y Wash_NN1_VV0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  596 1978 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  596 1978_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  597 <p> -- ( n125 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  597 <p>_Y --_NN1_JJ (_Y n125_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  598 ) See RESTATEMENT ( SECOND ) OF TORTS 388 cmt. n ( n1965 ) ( " Modern life would be intolerable unless one were permitted to rely to do , particularly if it is their duty to do so .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  598 )_Y See_VV0 RESTATEMENT_NN1 (_Y SECOND_MD_NNT1 )_Y OF_IO TORTS_NN2 388_MC cmt._NNU n_ZZ1 (_Y n1965_FO )_Y (_Y "_Y Modern_JJ life_NN1 would_VM be_VBI intolerable_JJ unless_CS one_PN1 were_VBDR permitted_VVN to_TO rely_VVI to_II do_VD0 ,_Y particularly_RR if_CS it_PPH1 is_VBZ their_APPGE duty_NN1 to_TO do_VDI so_RR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  599 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  599 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  600 <p> -- ( n126 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  600 <p>_Y --_NN1_JJ (_Y n126_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  601 ) See RESTATEMENT ( THIRD ) , supra note 114 , 6 ( n1998 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  601 )_Y See_VV0 RESTATEMENT_NN1 (_Y THIRD_MD )_Y ,_Y supra_NN1 note_NN1_VV0 114_MC ,_Y 6_MC (_Y n1998_FO )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  602 <p> -- ( n127 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  602 <p>_Y --_NN1_JJ (_Y n127_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  603 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  603 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  604 6 cmt. e .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  604 6_MC cmt._NNU e_ZZ1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  605 <p> -- ( n128 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  605 <p>_Y --_NN1_JJ (_Y n128_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  606 ) See , e.g. , MISS .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  606 )_Y See_VV0 ,_Y e.g._REX ,_Y MISS_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  607 CODE 11-1-63(c) ( 2008 ) ; N.C. GEN .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  607 CODE_NN1_VV0@ 11-1-63(c)_NN1_JJ (_Y 2008_MC )_Y ;_Y N.C._NP1 GEN_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  608 STAT. 99B-5(c) ( 2007 ) ; N.J. STAT. 2A:58C-4 ( 2008 ) ; OHIO REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  608 STAT._NP1 99B-5(c)_NN1_JJ (_Y 2007_MC )_Y ;_Y N.J._NP1 STAT._NP1 2A:58C-4_FO (_Y 2008_MC )_Y ;_Y OHIO_NP1 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  609 CODE 2307.76 ( 2008 ) ( codifying the learned intermediary doctrine ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  609 CODE_NN1_VV0@ 2307.76_MC (_Y 2008_MC )_Y (_Y codifying_VVG the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  610 <p> -- ( n129 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  610 <p>_Y --_NN1_JJ (_Y n129_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  611 ) See RESTATEMENT ( THIRD ) , supra note 114 , 6 cmt. e .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  611 )_Y See_VV0 RESTATEMENT_NN1 (_Y THIRD_MD )_Y ,_Y supra_NN1 note_NN1_VV0 114_MC ,_Y 6_MC cmt._NNU e_ZZ1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  612 <p> -- ( n130 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  612 <p>_Y --_NN1_JJ (_Y n130_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  613 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  613 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  614 <p> -- ( n131 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  614 <p>_Y --_NN1_JJ (_Y n131_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  615 ) See , e.g. , Mazur v. Merck Co. , 964 F.2d 1348 , 1355 ( 3d Cir. 1992 ) ( applying the " mass immunization exception " to the learned intermediary doctrine in an action brought against the manufacturer of a measles , mumps , and rubella vaccine ( MMR II ) by the parents of a child ; Brazzell v. United States , 788 F.2d 1352 , 1357-58 ( 8th Cir. 1986 ) ( swine flu vaccine ) ; Petty v. United States , 740 F.2d 1428 , 1438-39 ( 8th Cir. 1984 ) ( same ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  615 )_Y See_VV0 ,_Y e.g._REX ,_Y Mazur_VV0_NP1_NN1 v._II Merck_NP1 Co._NP1_NN1 ,_Y 964_MC F.2d_FO 1348_MC ,_Y 1355_MC (_Y 3d_NNU Cir._NP1 1992_MC )_Y (_Y applying_VVG the_AT "_Y mass_JJ_NN1 immunization_NN1 exception_NN1 "_Y to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 in_II an_AT1 action_NN1 brought_VVN_VVD against_II the_AT manufacturer_NN1 of_IO a_AT1 measles_NN ,_Y mumps_NN2_VVZ ,_Y and_CC rubella_NN1 vaccine_NN1 (_Y MMR_NP1 II_MC )_Y by_II the_AT parents_NN2 of_IO a_AT1 child_NN1 ;_Y Brazzell_NP1_VV0@ v._II United_NP1 States_NP1 ,_Y 788_MC F.2d_FO 1352_MC ,_Y 1357-58_MCMC (_Y 8th_MD Cir._NP1 1986_MC )_Y (_Y swine_NN flu_NN1 vaccine_NN1 )_Y ;_Y Petty_JJ v._II United_NP1 States_NP1 ,_Y 740_MC F.2d_FO 1428_MC ,_Y 1438-39_MCMC (_Y 8th_MD Cir._NP1 1984_MC )_Y (_Y same_DA )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  616 The most common example of the mass immunization exception has occurred with polio vaccines .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  616 The_AT most_RGT common_JJ example_NN1 of_IO the_AT mass_JJ_NN1 immunization_NN1 exception_NN1 has_VHZ occurred_VVN with_IW polio_NN1 vaccines_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  617 See , e.g. , Plummer v. Lederle Labs. , 819 F.2d 349 , 356 ( 2d Cir. 1987 ) ; Givens v. Merle , 556 F.2d 1341 , 1345 ( 5th Cir. 1977 ) ; Reyes v. Wyeth Labs. , 498 F.2d 1264 , 1276 ( 5th Cir. 1974 ) ; Davis v. Wyeth Labs. , 399 F.2d 121 , 131 ( 9th Cir. 1968 ) ; see also Cunningham v. Charles Pfizer Co. , 532 P.2d 1377 , 1380 ( Okla. 1974 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  617 See_VV0 ,_Y e.g._REX ,_Y Plummer_NP1_NN1 v._II Lederle_NP1 Labs._ZZ ,_Y 819_MC F.2d_FO 349_MC ,_Y 356_MC (_Y 2d_NNU Cir._NP1 1987_MC )_Y ;_Y Givens_NP1 v._II Merle_NP1 ,_Y 556_MC F.2d_FO 1341_MC ,_Y 1345_MC (_Y 5th_MD Cir._NP1 1977_MC )_Y ;_Y Reyes_NP1_NN2_VVZ v._II Wyeth_NP1 Labs._ZZ ,_Y 498_MC F.2d_FO 1264_MC ,_Y 1276_MC (_Y 5th_MD Cir._NP1 1974_MC )_Y ;_Y Davis_NP1 v._II Wyeth_NP1 Labs._ZZ ,_Y 399_MC F.2d_FO 121_MC ,_Y 131_MC (_Y 9th_MD Cir._NP1 1968_MC )_Y ;_Y see_VV0 also_RR Cunningham_NP1 v._II Charles_NP1 Pfizer_NP1 Co._NP1 ,_Y 532_MC P.2d_FO 1377_MC ,_Y 1380_MC (_Y Okla._NP1 1974_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  618 <p> -- ( n132 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  618 <p>_Y --_NN1_JJ (_Y n132_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  619 ) See Brooks v. Medtronic , 750 F.2d 1227 , 1232 ( 4th Cir. 1984 ) ( " ' The exception established for the vaccine cases is quite narrow and highly fact specific .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  619 )_Y See_VV0 Brooks_NP1_NN2@ v._II Medtronic_JJ ,_Y 750_MC F.2d_FO 1227_MC ,_Y 1232_MC (_Y 4th_MD Cir._NP1 1984_MC )_Y (_Y "_Y '_GE_"@ The_AT exception_NN1 established_VVN_VVD for_IF the_AT vaccine_NN1 cases_NN2 is_VBZ quite_RG narrow_JJ and_CC highly_RR fact_NN1 specific_JJ_NN1% ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  620 ' " ( quoting Stanback v. Parke , Davis 1981 ) ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  620 '_"@_GE "_Y (_Y quoting_VVG Stanback_NN1_NP1 v._II Parke_NP1 ,_Y Davis_NP1 1981_MC )_Y )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  621 <p> -- ( n133 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  621 <p>_Y --_NN1_JJ (_Y n133_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  622 ) See , e.g. , Mazur , 964 F.2d at 1363 ( stating that it is not the size of the immunization program that matters but whether the vaccine is administered " without an individualized medical balancing of the risks and benefits of inoculation " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  622 )_Y See_VV0 ,_Y e.g._REX ,_Y Mazur_NP1_VV0_NN1 ,_Y 964_MC F.2d_FO at_II 1363_MC (_Y stating_VVG that_CST it_PPH1 is_VBZ not_XX the_AT size_NN1 of_IO the_AT immunization_NN1 program_NN1_VV0@ that_CST matters_NN2 but_CCB whether_CSW the_AT vaccine_NN1 is_VBZ administered_VVN "_Y without_IW an_AT1 individualized_JJ@ medical_JJ balancing_NN1@ of_IO the_AT risks_NN2 and_CC benefits_NN2 of_IO inoculation_NN1 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  623 <p> -- ( n134 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  623 <p>_Y --_NN1_JJ (_Y n134_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  624 ) Walker v. Merck Co. , 648 F. Supp. 931 , 934-35 ( M.D. Ga .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  624 )_Y Walker_NP1_NN1 v._II Merck_NP1 Co._NP1_NN1 ,_Y 648_MC F._NP1_RA@ Supp._NP1 931_MC ,_Y 934-35_MCMC (_Y M.D._NP1 Ga_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  625 1986 ) , aff 'd , 831 F.2d 1069 ( 11th Cir. 1987 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  625 1986_MC )_Y ,_Y aff_NN1_VV0 'd_VM_VHD ,_Y 831_MC F.2d_FO 1069_MC (_Y 11th_MD Cir._NP1 1987_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  626 <p> -- ( n135 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  626 <p>_Y --_NN1_JJ (_Y n135_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  627 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  627 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  628 at 932 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  628 at_II 932_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  629 <p> -- ( n136 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  629 <p>_Y --_NN1_JJ (_Y n136_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  630 ) Percival v. Cyanamid Co. , 689 F. Supp. 1060 , 1061-63 ( W.D .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  630 )_Y Percival_NP1 v._II Cyanamid_NP1_JJ Co._NP1_NN1 ,_Y 689_MC F._NP1_RA@ Supp._NP1 1060_MC ,_Y 1061-63_MCMC (_Y W.D_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  631 Okla. 1987 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  631 Okla._NP1 1987_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  632 <p> -- ( n137 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  632 <p>_Y --_NN1_JJ (_Y n137_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  633 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  633 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  634 at 1062 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  634 at_II 1062_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  635 <p> -- ( n138 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  635 <p>_Y --_NN1_JJ (_Y n138_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  636 ) See , e.g. , Mazur , 964 F.2d at 1363 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  636 )_Y See_VV0 ,_Y e.g._REX ,_Y Mazur_NP1_VV0_NN1 ,_Y 964_MC F.2d_FO at_II 1363_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  637 <p> -- ( n139 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  637 <p>_Y --_NN1_JJ (_Y n139_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  638 ) See Victor E. Schwartz Liberty Mahshigian , National Childhood Vaccine Injury Act of 1986 : An Ad Hoc Remedy or a Window for the Future 394 ( n1987 ) ( discussing the availability of vaccines as one of the public policy reasons underlying Congress 's enactment of a no-fault system for compensation of childhood vaccine-related injuries ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  638 )_Y See_VV0 Victor_NP1 E._NP1 Schwartz_NP1 Liberty_NN1 Mahshigian_NN1@_JJ ,_Y National_JJ Childhood_NN1 Vaccine_NN1 Injury_NN1 Act_NN1 of_IO 1986_MC :_Y An_AT1 Ad_JJ21 Hoc_JJ22 Remedy_NN1 or_CC a_AT1 Window_NN1 for_IF the_AT Future_NN1_JJ 394_MC (_Y n1987_FO )_Y (_Y discussing_VVG the_AT availability_NN1 of_IO vaccines_NN2 as_CSA_II@ one_MC1 of_IO the_AT public_JJ_NN1 policy_NN1 reasons_NN2 underlying_VVG_JJ Congress_NN1 's_GE enactment_NN1 of_IO a_AT1 no-fault_JJ system_NN1 for_IF compensation_NN1 of_IO childhood_NN1 vaccine-related_NN1_JJ injuries_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  639 <p> -- ( n140 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  639 <p>_Y --_NN1_JJ (_Y n140_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  640 ) See , e.g. , Odgers v. Ortho Pharm .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  640 )_Y See_VV0 ,_Y e.g._REX ,_Y Odgers_VVZ_NP1_NN2 v._II Ortho_NP1_NN1 Pharm_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  641 Corp. , 609 F. Supp. 867 , 873-75 ( E.D. Mich. 1985 ) ; Stephens v. G.D .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  641 Corp._NP1 ,_Y 609_MC F._NP1_RA@ Supp._NP1 867_MC ,_Y 873-75_MCMC (_Y E.D._NN1 Mich._NP1 1985_MC )_Y ;_Y Stephens_NP1 v._II G.D_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  642 Searle Co. , 602 F. Supp. 379 , 380-81 ( E.D. Mich. 1985 ) ; Lukaszewicz v. Ortho Pharm .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  642 Searle_NP1 Co._NP1 ,_Y 602_MC F._NP1_RA@ Supp._NP1 379_MC ,_Y 380-81_MCMC (_Y E.D._NN1 Mich._NP1 1985_MC )_Y ;_Y Lukaszewicz_NP1_VV0@ v._II Ortho_NP1 Pharm_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  643 Corp. , 510 F. Supp. 961 , 964-65 ( E.D. Wis. 1981 ) , amended on other grounds , 532 F. Supp. 211 ( E.D. Wis. 1981 ) ; MacDonald v. Ortho Pharm .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  643 Corp._NP1 ,_Y 510_MC F._NP1_RA@ Supp._NP1 961_MC ,_Y 964-65_MCMC (_Y E.D._NN1 Wis._NP1 1981_MC )_Y ,_Y amended_VVN_VVD on_II other_JJ grounds_NN2 ,_Y 532_MC F._NP1_RA@ Supp._NP1 211_MC (_Y E.D._NN1 Wis._NP1 1981_MC )_Y ;_Y MacDonald_NP1 v._II Ortho_NP1 Pharm_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  644 Corp. , 475 N.E.2d 65 , 69-70 ( Mass. 1985 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  644 Corp._NP1 ,_Y 475_MC N.E.2d_FO 65_MC ,_Y 69-70_MCMC (_Y Mass._NP1 1985_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  645 But see Reaves v. Ortho Pharm .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  645 But_CCB see_VV0 Reaves_NN2_NP1 v._II Ortho_NP1 Pharm_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  646 Corp. , 765 F. Supp. 1287 , 1291 ( E.D. Mich. 1991 ) ( holding the learned intermediary doctrine applicable in cases involving oral contraceptives because oral contraceptives do not significantly differ from other prescription drugs ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  646 Corp._NP1 ,_Y 765_MC F._NP1_RA@ Supp._NP1 1287_MC ,_Y 1291_MC (_Y E.D._NN1 Mich._NP1 1991_MC )_Y (_Y holding_VVG the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 applicable_JJ in_II cases_NN2 involving_VVG oral_JJ_NN1 contraceptives_NN2 because_CS oral_JJ contraceptives_NN2 do_VD0 not_XX significantly_RR differ_VVI from_II other_JJ prescription_NN1 drugs_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  647 <p> -- ( n141 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  647 <p>_Y --_NN1_JJ (_Y n141_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  648 ) See , e.g. , MacDonald , 475 Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  648 )_Y See_VV0 ,_Y e.g._REX ,_Y MacDonald_NP1 ,_Y 475_MC Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  649 <p> -- ( n143 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  649 <p>_Y --_NN1_JJ (_Y n143_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  650 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  650 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  651 at 70 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  651 at_II 70_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  652 <p> -- ( n144 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  652 <p>_Y --_NN1_JJ (_Y n144_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  653 ) See Martin v. Ortho Pharm .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  653 )_Y See_VV0 Martin_NP1 v._II Ortho_NP1 Pharm_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  654 Corp. , 661 N.E.2d 352 , 357 ( Ill. 1996 ) ( concluding that the learned intermediary doctrine relieved manufacturer of duty to warn consumers that its contraceptives could cause physical deformities in children whose mothers ingested it during pregnancy ) ; McEwen v. Ortho Pharm .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  654 Corp._NP1 ,_Y 661_MC N.E.2d_FO 352_MC ,_Y 357_MC (_Y Ill._Z' 1996_MC )_Y (_Y concluding_VVG_JJ that_CST the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 relieved_JJ_VVD_VVN manufacturer_NN1 of_IO duty_NN1 to_TO warn_VVI consumers_NN2 that_CST its_Z' contraceptives_NN2 could_VM cause_VVI physical_JJ deformities_NN2 in_II children_NN2 whose_DDQGE mothers_NN2 ingested_VVD_VVN it_PPH1 during_II pregnancy_NN1 )_Y ;_Y McEwen_NP1 v._II Ortho_NP1 Pharm_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  655 Corp. , 528 P.2d 522 ( Or .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  655 Corp._NP1 ,_Y 528_MC P.2d_FO 522_MC (_Y Or_CC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  656 1974 ) ( finding the same for contraceptive warnings related to circulatory and visual damage ) ; see also In re Norplant Contraceptive Prods .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  656 1974_MC )_Y (_Y finding_VVG the_AT same_DA for_IF contraceptive_JJ_NN1 warnings_NN2 related_VVN_VVD to_II circulatory_JJ and_CC visual_JJ damage_NN1 )_Y ;_Y see_VV0 also_RR In_RP@_II re_II Norplant_NP1_NN1 Contraceptive_JJ_NN1 Prods_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  657 Liab .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  657 Liab_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  658 Litig. , 955 F. Supp. 700 , 709 ( E.D. Tex .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  658 Litig._NP1 ,_Y 955_MC F._NP1_RA@ Supp._NP1 700_MC ,_Y 709_MC (_Y E.D._NN1 Tex_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  659 1997 ) ( applying Texas law ) ; MacPherson v. Searle Co. , 775 F. Supp. 417 , 425-26 ( D.D.C .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  659 1997_MC )_Y (_Y applying_VVG Texas_NP1 law_NN1 )_Y ;_Y MacPherson_NP1 v._II Searle_NP1 Co._NP1 ,_Y 775_MC F._NP1_RA@ Supp._NP1 417_MC ,_Y 425-26_MCMC (_Y D.D.C_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  660 1991 ) ( applying District of Columbia law ) ; Zanzuri v. G.D .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  660 1991_MC )_Y (_Y applying_VVG District_NN1 of_IO Columbia_NP1 law_NN1 )_Y ;_Y Zanzuri_NP1_NN1_JJ v._II G.D_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  661 Searle Co. , 748 F. Supp. 1511 , 1514-15 ( S.D. Fla. 1990 ) ( applying Florida law ) ; Goodson v. Searle Labs. , 471 F. Supp. 546 , 549 ( D. Conn. G.D .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  661 Searle_NP1 Co._NP1 ,_Y 748_MC F._NP1_RA@ Supp._NP1 1511_MC ,_Y 1514-15_MCMC (_Y S.D._NP1 Fla._NP1 1990_MC )_Y (_Y applying_VVG Florida_NP1 law_NN1 )_Y ;_Y Goodson_NP1 v._II Searle_NP1 Labs._ZZ ,_Y 471_MC F._NP1_RA@ Supp._NP1 546_MC ,_Y 549_MC (_Y D._NP1 Conn._NP1 G.D_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  662 Searle , 441 F. Supp. 377 , 381 ( D. Md. 1975 ) , aff 'd , 567 F.2d 269 ( 4th Cir. 1977 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  662 Searle_NP1 ,_Y 441_MC F._NP1_RA@ Supp._NP1 377_MC ,_Y 381_MC (_Y D._NP1 Md._NNA 1975_MC )_Y ,_Y aff_NN1_VV0 'd_VM_VHD ,_Y 567_MC F.2d_FO 269_MC (_Y 4th_MD Cir._NP1 1977_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  663 <p> -- ( n145 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  663 <p>_Y --_NN1_JJ (_Y n145_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  664 ) See , e.g. , Hill v. Searle Labs. , Inc. , 884 F.2d 1064 , 1070 ( 8th Cir. 1989 ) ( " We believe that IUDs , like other forms of birth control , are atypical from most prescription drug products because the treating physician generally does not make an intervening , individualized medical judgment in the birth control decision .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  664 )_Y See_VV0 ,_Y e.g._REX ,_Y Hill_NP1_NN1 v._II Searle_NP1 Labs._ZZ ,_Y Inc._JJ ,_Y 884_MC F.2d_FO 1064_MC ,_Y 1070_MC (_Y 8th_MD Cir._NP1 1989_MC )_Y (_Y "_Y We_PPIS2 believe_VV0 that_CST IUDs_NN2 ,_Y like_II other_JJ forms_NN2 of_IO birth_NN1 control_NN1 ,_Y are_VBR atypical_JJ from_II most_DAT prescription_NN1 drug_NN1 products_NN2 because_CS the_AT treating_VVG physician_NN1 generally_RR does_VDZ not_XX make_VVI an_AT1 intervening_JJ ,_Y individualized_VVD medical_JJ judgment_NN1 in_II the_AT birth_NN1 control_NN1 decision_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  665 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  665 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  666 <p> -- ( n146 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  666 <p>_Y --_NN1_JJ (_Y n146_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  667 ) Lacy v. G.D .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  667 )_Y Lacy_JJ_NP1@ v._II G.D_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  668 Searle Co. , 567 A.2d 398 , 400 ( Del. 1989 ) ( applying the learned intermediary doctrine to IUD manufacturer where patient was required to undergo surgical removal of her ovaries and fallopian tubes after the IUD perforated her uterus ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  668 Searle_NP1 Co._NP1 ,_Y 567_MC A.2d_FO 398_MC ,_Y 400_MC (_Y Del._NP1 1989_MC )_Y (_Y applying_VVG the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 to_II IUD_NN1 manufacturer_NN1 where_CS_RRQ patient_NN1 was_VBDZ required_VVN to_TO undergo_VVI surgical_JJ removal_NN1 of_IO her_APPGE ovaries_NN2 and_CC fallopian_JJ_NN1 tubes_NN2 after_II_CS the_AT IUD_NN1 perforated_VVD@_VVN@ her_APPGE uterus_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  669 <p> -- ( n147 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  669 <p>_Y --_NN1_JJ (_Y n147_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  670 ) See Doe v. Solvay Pharm. , Inc. , 350 F. Supp. 2d 257 , 273 ( D. Me. 2004 ) ( rejecting application of learned intermediary exception for oral contraceptives to failure-to-warn for treatment of obsessive-compulsive disorder ( OCD ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  670 )_Y See_VV0 Doe_NP1_NN1@ v._II Solvay_NP1 Pharm._NP1 ,_Y Inc._JJ ,_Y 350_MC F._NP1_RA@ Supp._NP1 2d_NNU 257_MC ,_Y 273_MC (_Y D._NP1 Me._NN1 2004_MC )_Y (_Y rejecting_VVG application_NN1 of_IO learned_JJ@ intermediary_NN1 exception_NN1 for_IF oral_JJ_NN1 contraceptives_NN2 to_TO failure-to-warn_VVI for_IF treatment_NN1 of_IO obsessive-compulsive_JJ disorder_NN1 (_Y OCD_NP1 )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  671 <p> -- ( n148 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  671 <p>_Y --_NN1_JJ (_Y n148_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  672 ) See Mitchell v. VLI Corp. , 786 F. Supp. 966 , 970 ( M.D. Fla. 1992 ) ( concluding that the learned intermediary doctrine did not apply in products liability action brought by user of a nonprescription contraceptive sponge ) ; cf. Prager v. Allergan , Inc. , No. 89-C-6721 , 1990 WL 70875 , at *4 ( N.D. Ill .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  672 )_Y See_VV0 Mitchell_NP1 v._II VLI_NP1 Corp._NP1 ,_Y 786_MC F._NP1_RA@ Supp._NP1 966_MC ,_Y 970_MC (_Y M.D._NP1 Fla._NP1 1992_MC )_Y (_Y concluding_VVG_JJ that_CST the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 did_VDD not_XX apply_VVI in_II_RP@ products_NN2 liability_NN1 action_NN1 brought_VVN by_II user_NN1 of_IO a_AT1 nonprescription_NN1 contraceptive_NN1_JJ sponge_NN1 )_Y ;_Y cf._VV0 Prager_NN1_VV0_NP1 v._II Allergan_NP1 ,_Y Inc._JJ ,_Y No._XX 89-C-6721_MC ,_Y 1990_MC WL_NP1 70875_MC ,_Y at_II *4_FO (_Y N.D._NP1 Ill_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  673 May 2 , 1990 ) ( holding that doctrine did not apply to manufacturer of a nonprescription contact lens solution that allegedly caused plaintiff permanent eye damage ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  673 May_NPM1 2_MC ,_Y 1990_MC )_Y (_Y holding_VVG that_DD1_CST doctrine_NN1 did_VDD not_XX apply_VVI to_II manufacturer_NN1 of_IO a_AT1 nonprescription_NN1 contact_NN1 lens_NN1 solution_NN1 that_CST allegedly_RR caused_VVN_VVD plaintiff_NN1 permanent_JJ eye_NN1 damage_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  674 <p> -- ( n149 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  674 <p>_Y --_NN1_JJ (_Y n149_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  675 ) See supra notes 140-48 and accompanying text .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  675 )_Y See_VV0 supra_NN1 notes_NN2 140-48_MCMC and_CC accompanying_JJ_VVG text_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  676 <p> -- ( n150 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  676 <p>_Y --_NN1_JJ (_Y n150_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  677 ) Edwards v. Basel Pharms. , 933 P.2d 298 , 301 ( Okla. 1997 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  677 )_Y Edwards_NP1 v._II Basel_NP1 Pharms._NP1 ,_Y 933_MC P.2d_FO 298_MC ,_Y 301_MC (_Y Okla._NP1 1997_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  678 <p> -- ( n151 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  678 <p>_Y --_NN1_JJ (_Y n151_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  679 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  679 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  680 at 303 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  680 at_II 303_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  681 <p> -- ( n152 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  681 <p>_Y --_NN1_JJ (_Y n152_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  682 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  682 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  683 <p> -- ( n153. ) 734 A.2d 1245 ( N.J. 1999 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  683 <p>_Y --_NN1_JJ (_Y n153._FO )_Y 734_MC A.2d_FO 1245_MC (_Y N.J._NP1 1999_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  684 Until 2007 , the closest resemblance to the Perez ruling came in an Oklahoma Supreme Court ruling to the learned intermediary doctrine where the FDA mandated communication of a particular warning directly to the patient as well as to the physician .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  684 Until_CS_II@ 2007_MC ,_Y the_AT closest_JJT resemblance_NN1 to_II the_AT Perez_NP1 ruling_NN1 came_VVD in_II_RP@ an_AT1 Oklahoma_NP1 Supreme_JJ Court_NN1 ruling_NN1 to_II the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 where_CS_RRQ the_AT FDA_NN1_NP1 mandated_VVN_JJ@ communication_NN1 of_IO a_AT1 particular_JJ warning_NN1 directly_RR to_II the_AT patient_NN1_JJ as_II31_RG well_II32_RR as_II33_CSA to_II the_AT physician_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  685 See McKee v. Moore , 648 P.2d 21 , 25 ( Okla. 1982 ) ; see also Edwards , 933 P.2d at 303 ( FDA compliance does not necessarily satisfy state requirements which may or may not conform to the learned intermediary rule ) ; Tansy v. Dacomed Corp. , 890 P.2d 881 , 886 ( Okla. 1994 ) ( applying the exception to a medical device ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  685 See_VV0 McKee_NP1 v._II Moore_NP1 ,_Y 648_MC P.2d_FO 21_MC ,_Y 25_MC (_Y Okla._NP1 1982_MC )_Y ;_Y see_VV0 also_RR Edwards_NP1 ,_Y 933_MC P.2d_FO at_II 303_MC (_Y FDA_NP1_NN1 compliance_NN1 does_VDZ not_XX necessarily_RR satisfy_VVI state_NN1 requirements_NN2 which_DDQ may_VM or_CC may_VM not_XX conform_VVI to_II the_AT learned_JJ@ intermediary_NN1 rule_NN1 )_Y ;_Y Tansy_NN1 v._II Dacomed_JJ Corp._NP1 ,_Y 890_MC P.2d_FO 881_MC ,_Y 886_MC (_Y Okla._NP1 1994_MC )_Y (_Y applying_VVG the_AT exception_NN1 to_II a_AT1 medical_JJ device_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  686 This exception for FDA-required patient warnings is not based on an impression of an altered medical landscape , nor does it apply to all prescription drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  686 This_DD1 exception_NN1 for_IF FDA-required_JJ_NN1 patient_JJ_NN1 warnings_NN2 is_VBZ not_XX based_VVN on_II an_AT1 impression_NN1 of_IO an_AT1 altered_JJ medical_JJ landscape_NN1 ,_Y nor_CC does_VDZ it_PPH1 apply_VVI to_II all_DB prescription_NN1 drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  687 Rather , it is tied to compliance with existing laws applicable to a limited subset of prescription drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  687 Rather_RR@_RG ,_Y it_PPH1 is_VBZ tied_VVN to_II compliance_NN1 with_IW existing_JJ laws_NN2 applicable_JJ to_II a_AT1 limited_JJ subset_NN1 of_IO prescription_NN1 drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  688 See Edwards , 933 P.2d at 301 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  688 See_VV0 Edwards_NP1 ,_Y 933_MC P.2d_FO at_II 301_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  689 <p> -- ( n154 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  689 <p>_Y --_NN1_JJ (_Y n154_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  690 ) Perez , 734 A.2d at 1251 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  690 )_Y Perez_NP1 ,_Y 734_MC A.2d_FO at_II 1251_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  691 <p> -- ( n155 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  691 <p>_Y --_NN1_JJ (_Y n155_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  692 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  692 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  693 at 1248 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  693 at_II 1248_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  694 <p> -- ( n156 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  694 <p>_Y --_NN1_JJ (_Y n156_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  695 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  695 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  696 at 1247 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  696 at_II 1247_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  697 <p> -- ( n157 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  697 <p>_Y --_NN1_JJ (_Y n157_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  698 ) ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  698 )_Y )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  699 at 1247 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  699 at_II 1247_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  700 <p> -- ( n159 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  700 <p>_Y --_NN1_JJ (_Y n159_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  701 ) See In re Meridia Prods .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  701 )_Y See_VV0 In_RP@ re_II Meridia_NP1 Prods_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  702 Liab .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  702 Liab_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  703 Litig. , 328 F. Supp. 2d 791 , 812 n.19 ( N.D. Ohio 2004 ) ( " In the intervening period after Perez , no other state has followed New Jersey 's lead .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  703 Litig._NP1 ,_Y 328_MC F._NP1_RA@ Supp._NP1 2d_NNU 791_MC ,_Y 812_MC n.19_FO (_Y N.D._NP1 Ohio_NP1 2004_MC )_Y (_Y "_Y In_II the_AT intervening_JJ period_NN1 after_II_CS Perez_NP1 ,_Y no_AT other_JJ state_NN1 has_VHZ followed_VVN New_NP1 Jersey_NP1 's_GE lead_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  704 " ) ; see also Corey Schaecher , Comment , " Ask Your Doctor if This Product is Right for You " : Perez v. Wyeth Laboratories , Inc. , Direct-to-Consumer Advertising and the Future of the Learned Intermediary Doctrine in the Face of the Flood of Vioxx Claims , 26 ST .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  704 "_Y )_Y ;_Y see_VV0 also_RR Corey_NP1 Schaecher_NP1_NN1 ,_Y Comment_VV0_NN1 ,_Y "_Y Ask_VV0 Your_APPGE Doctor_NN1 if_CS This_DD1 Product_NN1 is_VBZ Right_JJ for_IF You_PPY "_Y :_Y Perez_NP1 v._II Wyeth_NP1 Laboratories_NN2 ,_Y Inc._JJ ,_Y Direct-to-Consumer_NP1 Advertising_NN1 and_CC the_AT Future_NN1 of_IO the_AT Learned_JJ@ Intermediary_NN1 Doctrine_NN1 in_II the_AT Face_NN1 of_IO the_AT Flood_NN1 of_IO Vioxx_NP1_NN1 Claims_VVZ_NN2 ,_Y 26_MC ST_NP1 ._NP1
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  705 LOUIS U. PUB .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  705 LOUIS_NP1 U._NP1 PUB_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  706 L. REV. 421 , 443 ( 2007 ) ( stating that post-Perez courts have been " reluctant , at best , ... to delineate an exception " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  706 L._NP1_NNU@ REV._NNU 421_MC ,_Y 443_MC (_Y 2007_MC )_Y (_Y stating_VVG that_DD1_CST post-Perez_JJ courts_NN2 have_VH0 been_VBN "_Y reluctant_JJ ,_Y at_RR21 best_RR22 ,_Y ..._... to_TO delineate_VVI an_AT1 exception_NN1 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  707 <p> -- ( n160 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  707 <p>_Y --_NN1_JJ (_Y n160_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  708 ) See , e.g. , In re Meridia , 328 F. Supp. 2d at 812 n.19 ( " The Court thus could not apply Perez 's logic even if it desired to do so .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  708 )_Y See_VV0 ,_Y e.g._REX ,_Y In_RP@_II re_II Meridia_NP1 ,_Y 328_MC F._NP1_RA@ Supp._NP1 2d_NNU at_II 812_MC n.19_FO (_Y "_Y The_AT Court_NN1 thus_RR could_VM not_XX apply_VVI Perez_NP1 's_GE logic_NN1 even_CS21 if_CS22 it_PPH1 desired_VVD to_TO do_VDI so_RR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  709 " ) ; In re Norplant Contraceptive Prods .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  709 "_Y )_Y ;_Y In_RP@_II re_II Norplant_NP1_NN1 Contraceptive_JJ_NN1 Prods_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  710 Liab 827 ( E.D. Tex .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  710 Liab_VV0_NN1_NP1@ 827_MC (_Y E.D._NN1 Tex_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  711 2002 ) ( " This argument ... lacks merit in all jurisdictions , except New Jersey .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  711 2002_MC )_Y (_Y "_Y This_DD1 argument_NN1 ..._... lacks_VVZ merit_NN1 in_II all_DB jurisdictions_NN2 ,_Y except_CS_II New_NP1 Jersey_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  712 ... Apart from New Jersey , direct-to-consumer advertising does not negate the applicability of the learned intermediary doctrine .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  712 ..._... Apart_II21 from_II22 New_NP1 Jersey_NP1 ,_Y direct-to-consumer_JJ_NN1 advertising_NN1 does_VDZ not_XX negate_VVI the_AT applicability_NN1 of_IO the_AT learned_JJ@ intermediary_NN1 doctrine_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  713 " ) ; Vitanza v. Upjohn Co. , 778 A.2d 829 ( Conn. 2001 ) ; McCombs v. Synthes ( U.S.A. ) , 587 S.E.2d 594 ( Ga .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  713 "_Y )_Y ;_Y Vitanza_NN1_NP1@ v._II Upjohn_NP1 Co._NP1 ,_Y 778_MC A.2d_FO 829_MC (_Y Conn._NP1 2001_MC )_Y ;_Y McCombs_NP1 v._II Synthes_NP1_NN2 (_Y U.S.A._NP1 )_Y ,_Y 587_MC S.E.2d_FO 594_MC (_Y Ga_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  714 2003 ) ; Larkin v. Pfizer , Inc. , 153 S.W.3d 758 ( Ky. 2004 ) ; Freeman v. Hoffman-La Roche , Inc. , 618 N.W.2d 827 ( Neb. 2000 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  714 2003_MC )_Y ;_Y Larkin_NP1 v._II Pfizer_NP1_NN1 ,_Y Inc._JJ ,_Y 153_MC S.W.3d_FO 758_MC (_Y Ky._NP1 2004_MC )_Y ;_Y Freeman_NN1 v._II Hoffman-La_NP1 Roche_NP1 ,_Y Inc._JJ ,_Y 618_MC N.W.2d_FO 827_MC (_Y Neb._NP1 2000_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  715 <p> -- ( n161 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  715 <p>_Y --_NN1_JJ (_Y n161_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  716 ) State ex rel .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  716 )_Y State_VV0_NN1 ex_II rel_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  717 Johnson Johnson Corp .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  717 Johnson_NP1 Johnson_NP1 Corp_NPX ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  718 v. Karl , 647 S.E.2d 899 ( W. Va .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  718 v._II Karl_NP1 ,_Y 647_MC S.E.2d_FO 899_MC (_Y W._NP1 Va_FW ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  719 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  719 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  720 <p> -- ( 162 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  720 <p>_Y --_NN1_JJ (_Y 162_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  721 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  721 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  722 at 906 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  722 at_II 906_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  723 <p> -- ( n163 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  723 <p>_Y --_NN1_JJ (_Y n163_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  724 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  724 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  725 at 910 ( quoting Lars Noah , Advertising Prescription Drugs to Consumers : Assessing the Regulatory and Liability Issues , 32 GA .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  725 at_II 910_MC (_Y quoting_VVG Lars_NP1 Noah_NP1 ,_Y Advertising_NN1_VVG@ Prescription_NN1 Drugs_NN2 to_II Consumers_NN2 :_Y Assessing_VVG the_AT Regulatory_JJ and_CC Liability_NN1 Issues_NN2 ,_Y 32_MC GA_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  726 L. REV. 141 , 160-61 n.78 ( 1997 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  726 L._NP1_NNU@ REV._NNU 141_MC ,_Y 160-61_MCMC n.78_FO (_Y 1997_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  727 <p> -- ( n164 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  727 <p>_Y --_NN1_JJ (_Y n164_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  728 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  728 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  729 at .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  729 at_II ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  730 at 908-09 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  730 at_II 908-09_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  731 <p> -- ( n166 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  731 <p>_Y --_NN1_JJ (_Y n166_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  732 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  732 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  733 at 913 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  733 at_II 913_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  734 <p> -- ( n167 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  734 <p>_Y --_NN1_JJ (_Y n167_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  735 ) See supra notes 153--58 and accompanying text .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  735 )_Y See_VV0 supra_NN1 notes_NN2 153--58_MCMC and_CC accompanying_JJ_VVG text_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  736 <p> -- ( n168 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  736 <p>_Y --_NN1_JJ (_Y n168_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  737 ) Karl , 647 S.E.2d at 917 ( Albright , J. , dissenting ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  737 )_Y Karl_NP1 ,_Y 647_MC S.E.2d_FO at_II 917_MC (_Y Albright_NP1_NN1 ,_Y J._NP1 ,_Y dissenting_VVG )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  738 <p> -- ( n169 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  738 <p>_Y --_NN1_JJ (_Y n169_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  739 ) See Am .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  739 )_Y See_VV0 Am_RA@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  740 Med .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  740 Med_NP1@_VVD ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  741 Ass'n , Council on Ethical Judicial Affairs , Code of Medical Ethics , Direct-to-Consumer Advertising of Prescription Drugs , Op. 5-015 , at 126 ( 2006-2007 ) ( " Physicians must maintain professional standards of informed consent when prescribing .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  741 Ass'n_VV0_NN1_NP1@ ,_Y Council_NN1 on_II Ethical_JJ Judicial_JJ Affairs_NN2 ,_Y Code_NN1 of_IO Medical_JJ Ethics_NN ,_Y Direct-to-Consumer_NP1 Advertising_NN1 of_IO Prescription_NN1 Drugs_NN2 ,_Y Op._NN1 5-015_MCMC ,_Y at_II 126_MC (_Y 2006-2007_MCMC )_Y (_Y "_Y Physicians_NN2 must_VM maintain_VVI professional_JJ standards_NN2 of_IO informed_JJ@ consent_NN1 when_CS prescribing_VVG ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  742 When a patient comes to a physician with a request for a drug he or she has seen advertised , the physician and the patient should engage in a dialogue that would assess and enhance the patient 's understanding of the treatment .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  742 When_CS a_AT1 patient_NN1 comes_VVZ to_II a_AT1 physician_NN1 with_IW a_AT1 request_NN1 for_IF a_AT1 drug_NN1 he_PPHS1 or_CC she_PPHS1 has_VHZ seen_VVN advertised_VVN_VVD_JJ@ ,_Y the_AT physician_NN1 and_CC the_AT patient_NN1 should_VM engage_VVI in_II_RP@ a_AT1 dialogue_NN1 that_CST_DD1 would_VM assess_VVI and_CC enhance_VVI the_AT patient_NN1 's_GE understanding_NN1 of_IO the_AT treatment_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  743 Although physicians should not be biased against drugs that are advertised , physicians should resist commercially induced pressure to prescribe drugs that may not be indicated .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  743 Although_CS physicians_NN2 should_VM not_XX be_VBI biased_VVN@ against_II drugs_NN2 that_CST are_VBR advertised_VVN ,_Y physicians_NN2 should_VM resist_VVI commercially_RR induced_VVN_JJ@_VVD pressure_NN1 to_TO prescribe_VVI drugs_NN2 that_CST_DD1 may_VM not_XX be_VBI indicated_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  744 Physicians should deny requests for inappropriate prescriptions and educate patients as to why certain advertised drugs may not be suitable the cost effectiveness of different options .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  744 Physicians_NN2 should_VM deny_VVI requests_NN2 for_IF inappropriate_JJ prescriptions_NN2 and_CC educate_VVI patients_NN2 as_II21 to_II22 why_RRQ certain_JJ advertised_JJ@ drugs_NN2 may_VM not_XX be_VBI suitable_JJ the_AT cost_NN1 effectiveness_NN1 of_IO different_JJ options_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  745 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  745 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  746 <p> -- ( n170 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  746 <p>_Y --_NN1_JJ (_Y n170_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  747 ) See RESTATEMENT ( THIRD ) OF TORTS : PRODUCTS LIABILITY 103 ( Council Draft No. 1 , 1993 ) ; see also Noah , supra note 163 , at 162-63 ( detailing the Restatement Reporters ' changes regarding DTC advertising ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  747 )_Y See_VV0 RESTATEMENT_NN1 (_Y THIRD_MD )_Y OF_IO TORTS_NN2 :_Y PRODUCTS_NN2 LIABILITY_NN1 103_MC (_Y Council_NN1 Draft_NN1_VV0 No._XX 1_MC1 ,_Y 1993_MC )_Y ;_Y see_VV0 also_RR Noah_NP1 ,_Y supra_NN1 note_NN1_VV0 163_MC ,_Y at_II 162-63_MCMC (_Y detailing_VVG the_AT Restatement_NN1 Reporters_NN2 '_GE changes_NN2 regarding_II DTC_NP1 advertising_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  748 <p> -- ( n171 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  748 <p>_Y --_NN1_JJ (_Y n171_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  749 ) See RESTATEMENT ( THIRD ) OF TORTS : PRODUCTS LIABILITY 4(b) ( 3 ) ( Council Draft No. 1A , 1994 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  749 )_Y See_VV0 RESTATEMENT_NN1 (_Y THIRD_MD )_Y OF_IO TORTS_NN2 :_Y PRODUCTS_NN2 LIABILITY_NN1 4(b)_FO (_Y 3_MC )_Y (_Y Council_NN1 Draft_NN1_VV0 No._XX 1A_FO ,_Y 1994_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  750 <p> -- ( n172 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  750 <p>_Y --_NN1_JJ (_Y n172_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  751 ) Id. , Memorandum at 2 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  751 )_Y Id._Z' ,_Y Memorandum_NN1 at_II 2_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  752 <p> -- ( n173 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  752 <p>_Y --_NN1_JJ (_Y n173_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  753 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  753 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  754 ( " We have removed from the black letter a special exception to the learned intermediary rule for direct advertising to patients .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  754 (_Y "_Y We_PPIS2 have_VH0 removed_VVN from_II the_AT black_JJ letter_NN1 a_AT1 special_JJ exception_NN1 to_II the_AT learned_JJ@ intermediary_NN1 rule_NN1 for_IF direct_JJ advertising_NN1 to_II patients_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  755 Instead we have amended comment e to indicate that , where government agencies mandate that advertisements carry warnings to patients , the learned intermediary rule does not apply .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  755 Instead_RR we_PPIS2 have_VH0 amended_VVN comment_NN1_VV0 e_ZZ1 to_TO indicate_VVI that_DD1_CST ,_Y where_CS_RRQ government_NN1 agencies_NN2 mandate_NN1 that_CST advertisements_NN2 carry_VV0 warnings_NN2 to_II patients_NN2 ,_Y the_AT learned_JJ@ intermediary_NN1 rule_NN1 does_VDZ not_XX apply_VVI ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  756 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  756 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  757 <p> -- ( n174 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  757 <p>_Y --_NN1_JJ (_Y n174_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  758 ) The learned intermediary exception relevant to advertisements was amended such that liability could exist if " reasonable instructions or warnings regarding foreseeable were not provided directly to the patient when the manufacturer knew or had reason to know that no medical provider would be in the position " to reduce the risks of harm through appropriate warnings or instructions .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  758 )_Y The_AT learned_JJ@ intermediary_NN1 exception_NN1 relevant_JJ to_II advertisements_NN2 was_VBDZ amended_VVN such_CS21 that_CS22 liability_NN1 could_VM exist_VVI if_CSW@_CS "_Y reasonable_JJ instructions_NN2 or_CC warnings_NN2 regarding_II_VVG foreseeable_JJ were_VBDR not_XX provided_VVN directly_RR to_II the_AT patient_NN1_JJ when_CS_RRQ the_AT manufacturer_NN1 knew_VVD or_CC had_VHD_VHN@ reason_NN1 to_TO know_VVI that_CST no_AT medical_JJ provider_NN1 would_VM be_VBI in_II the_AT position_NN1 "_Y to_TO reduce_VVI the_AT risks_NN2 of_IO harm_NN1 through_II appropriate_JJ warnings_NN2 or_CC instructions_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  759 " RESTATEMENT ( THIRD ) OF TORTS : PRODUCTS LIABILITY 4(b) ( 3 ) ( Tentative Draft No. 1 , 1994 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  759 "_Y RESTATEMENT_NN1 (_Y THIRD_MD )_Y OF_IO TORTS_NN2 :_Y PRODUCTS_NN2 LIABILITY_NN1 4(b)_FO (_Y 3_MC )_Y (_Y Tentative_JJ Draft_NN1 No._XX 1_MC1 ,_Y 1994_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  760 <p> -- ( n175 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  760 <p>_Y --_NN1_JJ (_Y n175_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  761 ) See Noah , supra note 163 , at 166 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  761 )_Y See_VV0 Noah_NP1 ,_Y supra_NN1 note_NN1_VV0 163_MC ,_Y at_II 166_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  762 <p> -- ( n176 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  762 <p>_Y --_NN1_JJ (_Y n176_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  763 ) RESTATEMENT ( THIRD ) , supra note 114 , at 6 cmt. e .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  763 )_Y RESTATEMENT_NN1 (_Y THIRD_MD )_Y ,_Y supra_NN1 note_NN1_VV0 114_MC ,_Y at_II 6_MC cmt._NNU e_ZZ1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  764 <p> -- ( n177 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  764 <p>_Y --_NN1_JJ (_Y n177_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  765 ) See Vitanza v. Upjohn Co. , 778 A.2d 829 ( Conn. 2001 ) ; McCombs v. Synthes ( U.S.A. ) , 587 S.E.2d 594 ( Ga .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  765 )_Y See_VV0 Vitanza_NP1_NN1@ v._II Upjohn_NP1 Co._NP1 ,_Y 778_MC A.2d_FO 829_MC (_Y Conn._NP1 2001_MC )_Y ;_Y McCombs_NP1 v._II Synthes_NP1_NN2 (_Y U.S.A._NP1 )_Y ,_Y 587_MC S.E.2d_FO 594_MC (_Y Ga_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  766 2003 ) ; Larkin v. Pfizer , Inc. , 153 S.W.3d 758 ( Ky. 2004 ) ; Freeman v. Hoffman-La Roche , Inc. , 618 N.W.2d 827 ( Neb. 2000 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  766 2003_MC )_Y ;_Y Larkin_NP1 v._II Pfizer_NP1_NN1 ,_Y Inc._JJ ,_Y 153_MC S.W.3d_FO 758_MC (_Y Ky._NP1 2004_MC )_Y ;_Y Freeman_NN1 v._II Hoffman-La_NP1 Roche_NP1 ,_Y Inc._JJ ,_Y 618_MC N.W.2d_FO 827_MC (_Y Neb._NP1 2000_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  767 <p> -- ( n178 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  767 <p>_Y --_NN1_JJ (_Y n178_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  768 ) See Rohrbough by Rohrbough v. Wyeth Labs. , 719 F. Supp. 470 , 478 ( N.D. W. Va .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  768 )_Y See_VV0 Rohrbough_NN1_VV0_NP1 by_II Rohrbough_NP1_NN1 v._II Wyeth_NP1 Labs._ZZ ,_Y 719_MC F._NP1_RA@ Supp._NP1 470_MC ,_Y 478_MC (_Y N.D._NP1 W._NP1 Va_FW ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  769 1989 ) ( finding Toxoids and Pertussis Vaccine ( DTP ) in a public health clinic qualified as a learned intermediary ) , aff 'd on other grounds 916 F.2d 970 ( 4th Cir. 1990 ) ; Walker v. Merck Co. , 648 F. Supp. 931 , 934 ( M.D. Ga .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  769 1989_MC )_Y (_Y finding_VVG_NN1 Toxoids_NN2_NP1 and_CC Pertussis_NP1_NN1 Vaccine_NN1 (_Y DTP_NN1 )_Y in_II a_AT1 public_JJ_NN1 health_NN1 clinic_NN1 qualified_VVN as_II a_AT1 learned_JJ@ intermediary_NN1 )_Y ,_Y aff_NN1_VV0 'd_VHD_VM on_II other_JJ grounds_NN2 916_MC F.2d_FO 970_MC (_Y 4th_MD Cir._NP1 1990_MC )_Y ;_Y Walker_NP1 v._II Merck_NP1 Co._NP1_NN1 ,_Y 648_MC F._NP1_RA@ Supp._NP1 931_MC ,_Y 934_MC (_Y M.D._NP1 Ga_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  770 1986 ) ; Singleton v. Airco , Inc. , 314 S.E.2d 680 , 682 ( Ga .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  770 1986_MC )_Y ;_Y Singleton_NP1 v._II Airco_NP1 ,_Y Inc._JJ ,_Y 314_MC S.E.2d_FO 680_MC ,_Y 682_MC (_Y Ga_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  771 Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  771 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  772 App. 1984 ) ( implying a nurse anesthetist qualified as a learned intermediary ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  772 App._NP1 1984_MC )_Y (_Y implying_VVG a_AT1 nurse_NN1 anesthetist_NN1 qualified_VVN as_II a_AT1 learned_JJ@ intermediary_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  773 <p> -- ( n179 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  773 <p>_Y --_NN1_JJ (_Y n179_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  774 ) See Haste v. Am .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  774 )_Y See_VV0 Haste_VV0_NN1 v._NNU_II Am_RA@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  775 Home Prods .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  775 Home_NN1_RL Prods_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  776 Corp. , 577 F.2d 1122 , 1124 ( 10th Cir. 1978 ) , cert .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  776 Corp._NP1 ,_Y 577_MC F.2d_FO 1122_MC ,_Y 1124_MC (_Y 10th_MD Cir._NP1 1978_MC )_Y ,_Y cert_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  777 denied 439 U.S. 955 ( 1978 ) ( suggesting a veterinarian could be a learned intermediary in product liability action brought against the manufacturer of an animal vaccine ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  777 denied_VVN_VVD 439_MC U.S._NP1 955_MC (_Y 1978_MC )_Y (_Y suggesting_VVG a_AT1 veterinarian_NN1 could_VM be_VBI a_AT1 learned_JJ@ intermediary_NN1 in_II product_NN1 liability_NN1 action_NN1 brought_VVN_VVD against_II the_AT manufacturer_NN1 of_IO an_AT1 animal_NN1 vaccine_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  778 <p> -- ( n180 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  778 <p>_Y --_NN1_JJ (_Y n180_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  779 ) See , e.g. , Smith v. Walter C. Best , Inc. , 927 F.2d 736 , 739 ( 3d Cir. 1990 ) ( using the term " knowledgeable purchaser " ) ; Higgins v. E.I. DuPont de Nemours Co. , 671 F. referring to a " knowledgeable industrial purchaser " ) ; Phillips v. A.P .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  779 )_Y See_VV0 ,_Y e.g._REX ,_Y Smith_NP1 v._II Walter_NP1 C._NP1 Best_RRT ,_Y Inc._JJ ,_Y 927_MC F.2d_FO 736_MC ,_Y 739_MC (_Y 3d_NNU Cir._NP1 1990_MC )_Y (_Y using_VVG the_AT term_NN1 "_Y knowledgeable_JJ purchaser_NN1 "_Y )_Y ;_Y Higgins_NP1 v._II E.I._NP1 DuPont_NP1 de_NP1 Nemours_NP1_VVZ Co._NP1_NN1 ,_Y 671_MC F._NP1_RA@ referring_VVG to_II a_AT1 "_Y knowledgeable_JJ industrial_JJ purchaser_NN1 "_Y )_Y ;_Y Phillips_NP1 v._II A.P_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  780 Green Refractories Co. , 630 A.2d 874 , 883 ( Pa .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  780 Green_NP1@_JJ Refractories_NP1 Co._NP1 ,_Y 630_MC A.2d_FO 874_MC ,_Y 883_MC (_Y Pa_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  781 Super .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  781 Super_JJ_NN1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  782 Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  782 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  783 1993 ) ( using the term " knowledgeable employer " ) ; see also Keith Laughery , Warnings in the Workplace : Expanding the Learned Intermediary Rule to Include Employers in the Context of Product **29;2188;TOOLONG Relationship , 46 S. TEX .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  783 1993_MC )_Y (_Y using_VVG the_AT term_NN1 "_Y knowledgeable_JJ employer_NN1 "_Y )_Y ;_Y see_VV0 also_RR Keith_NP1 Laughery_NP1 ,_Y Warnings_NN2 in_II the_AT Workplace_NN1 :_Y Expanding_VVG the_AT Learned_JJ@ Intermediary_NN1 Rule_NN1 to_TO_II Include_VV0 Employers_NN2 in_II the_AT Context_NN1 of_IO Product_NN1 **29;2188;TOOLONG_NN1 Relationship_NN1 ,_Y 46_MC S._NP1 TEX_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  784 L. REV. 627 ( 2005 ) ( advocating expansion of the doctrine in certain manufacturing relationships ) ; Victor E. Schwartz Christopher E. Appel , Effective Communication of Warnings in the Workplace : Avoiding Injuries in Working with Industrial Materials , 73 MO .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  784 L._NP1_NNU@ REV._NNU 627_MC (_Y 2005_MC )_Y (_Y advocating_VVG expansion_NN1 of_IO the_AT doctrine_NN1 in_II certain_JJ manufacturing_NN1 relationships_NN2 )_Y ;_Y Victor_NP1 E._NP1 Schwartz_NP1 Christopher_NP1 E._NP1 Appel_NP1 ,_Y Effective_JJ Communication_NN1 of_IO Warnings_NN2 in_II the_AT Workplace_NN1 :_Y Avoiding_VVG Injuries_NN2 in_II Working_VVG with_IW Industrial_JJ Materials_NN2 ,_Y 73_MC MO_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  785 L. REV. 1 ( 2008 ) ( discussing the parallels and doctrinal interplay of the learned intermediary rule with the sophisticated user doctrine in the case of industrial materials ) ; Carole A. Cheney , Comment , Not Just For Doctors : Applying the Learned Intermediary Doctrine to the Relationship Between Chemical Manufacturers , Industrial Employers , and Employees , 85 NW .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  785 L._NP1 REV._NNU_NNB 1_MC1 (_Y 2008_MC )_Y (_Y discussing_VVG the_AT parallels_NN2 and_CC doctrinal_JJ interplay_NN1 of_IO the_AT learned_JJ@ intermediary_NN1 rule_NN1 with_IW the_AT sophisticated_JJ user_NN1 doctrine_NN1 in_II the_AT case_NN1 of_IO industrial_JJ materials_NN2 )_Y ;_Y Carole_NP1 A._ZZ Cheney_NP1 ,_Y Comment_VV0_NN1 ,_Y Not_XX Just_RR For_IF Doctors_NN2 :_Y Applying_VVG the_AT Learned_JJ@ Intermediary_NN1 Doctrine_NN1 to_II the_AT Relationship_NN1 Between_II Chemical_NN1_JJ@ Manufacturers_NN2 ,_Y Industrial_JJ Employers_NN2 ,_Y and_CC Employees_NN2 ,_Y 85_MC NW_ND1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  786 U. L. REV. 562 , 575 ( 1991 ) ( discussing the prescription drug context ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  786 U._NP1 L._NP1 REV._NNU 562_MC ,_Y 575_MC (_Y 1991_MC )_Y (_Y discussing_VVG the_AT prescription_NN1 drug_NN1 context_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  787 <p> -- ( n181 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  787 <p>_Y --_NN1_JJ (_Y n181_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  788 ) See supra notes 117-120 and accompanying text .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  788 )_Y See_VV0 supra_NN1 notes_NN2 117-120_MCMC and_CC accompanying_JJ_VVG text_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  789 <p> -- ( n182 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  789 <p>_Y --_NN1_JJ (_Y n182_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  790 ) See State ex rel .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  790 )_Y See_VV0 State_NN1 ex_II rel_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  791 Johnson Johnson Co. v. Karl , 647 S.E.2d 899 , 917 ( W. Va .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  791 Johnson_NP1 Johnson_NP1 Co._NP1_NN1 v._II Karl_NP1 ,_Y 647_MC S.E.2d_FO 899_MC ,_Y 917_MC (_Y W._NP1 Va_FW ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  792 2007 ) ( Albright , J. , dissenting ) ( " But to presume , as the majority appears to , that the mere presence of pharmaceutical advertising in our society relegates the role of the physician to a mere dispensary of prescriptions is simply not true .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  792 2007_MC )_Y (_Y Albright_NP1_NN1 ,_Y J._NP1 ,_Y dissenting_VVG )_Y (_Y "_Y But_CCB to_TO presume_VVI ,_Y as_CSA_II the_AT majority_NN1 appears_VVZ to_TO ,_Y that_CST the_AT mere_JJ presence_NN1 of_IO pharmaceutical_JJ advertising_NN1 in_II our_APPGE society_NN1 relegates_VVZ the_AT role_NN1 of_IO the_AT physician_NN1 to_II a_AT1 mere_JJ dispensary_NN1 of_IO prescriptions_NN2 is_VBZ simply_RR not_XX true_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  793 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  793 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  794 <p> -- ( n183 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  794 <p>_Y --_NN1_JJ (_Y n183_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  795 ) The Massachusetts Supreme Judicial Court , for example , recently held that a physician could be liable to third parties injured as a result of the failure to warn a patient .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  795 )_Y The_AT Massachusetts_NP1 Supreme_JJ Judicial_JJ Court_NN1 ,_Y for_REX21 example_REX22 ,_Y recently_RR held_VVN_VVD that_CST a_AT1 physician_NN1 could_VM be_VBI liable_JJ to_II third_MD parties_NN2 injured_VVN_VVD as_II a_AT1 result_NN1 of_IO the_AT failure_NN1 to_TO warn_VVI a_AT1 patient_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  796 See Coombes v. Florio , 877 N.E.2d 567 , 571-72 ( Mass. 2007 ) ( holding that a doctor may be liable when his patient , who alleged he was not adequately warned that the medication he was on could cause drowsiness or fainting , injured the plaintiff in an automobile accident ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  796 See_VV0 Coombes_NP2 v._II Florio_NP1 ,_Y 877_MC N.E.2d_FO 567_MC ,_Y 571-72_MCMC (_Y Mass._NP1 2007_MC )_Y (_Y holding_VVG that_CST a_AT1 doctor_NN1 may_VM be_VBI liable_JJ when_CS his_APPGE patient_NN1_JJ ,_Y who_PNQS alleged_VVD he_PPHS1 was_VBDZ not_XX adequately_RR warned_VVN_VVD that_CST the_AT medication_NN1 he_PPHS1 was_VBDZ on_RP@_II could_VM cause_VVI drowsiness_NN1 or_CC fainting_VVG ,_Y injured_VVD_VVN the_AT plaintiff_NN1 in_II an_AT1 automobile_NN1 accident_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  797 <p> , 751 P.2d 470 , 478-79 ( Cal .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  797 <p>_Y ,_Y 751_MC P.2d_FO 470_MC ,_Y 478-79_MCMC (_Y Cal_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  798 1988 ) ( expressing concern that increased liability would drive prices of drugs too high and make them less available ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  798 1988_MC )_Y (_Y expressing_VVG concern_NN1 that_CST_DD1 increased_JJ_VVD liability_NN1 would_VM drive_VVI prices_NN2 of_IO drugs_NN2 too_RG high_JJ and_CC make_VV0 them_PPHO2 less_RGR available_JJ )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  799 <p> -- ( n185 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  799 <p>_Y --_NN1_JJ (_Y n185_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  800 ) See Richard C. Ausness , The Case for a " Strong " Regulatory Compliance Defense , 55 MD .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  800 )_Y See_VV0 Richard_NP1 C._NP1 Ausness_NP1 ,_Y The_AT Case_NN1 for_IF a_AT1 "_Y Strong_JJ "_Y Regulatory_JJ Compliance_NN1 Defense_NN1 ,_Y 55_MC MD_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  801 L. REV. 1210 , 1241 ( 1996 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  801 L._NP1_NNU@ REV._NNU 1210_MC ,_Y 1241_MC (_Y 1996_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  802 <p> -- ( n186 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  802 <p>_Y --_NN1_JJ (_Y n186_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  803 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  803 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  804 at 1241-47 ( 1996 ) ( providing examples of cases in which courts gave little weight to federal safety regulations spanning a variety of areas , such as flammability standards for clothing , pesticide warnings , automobile design , prescription drug warnings , aircraft design , and workplace safety standards ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  804 at_II 1241-47_MCMC (_Y 1996_MC )_Y (_Y providing_VVG examples_NN2 of_IO cases_NN2 in_II which_DDQ courts_NN2 gave_VVD little_DA1_JJ weight_NN1 to_II federal_JJ safety_NN1 regulations_NN2 spanning_VVG a_AT1 variety_NN1 of_IO areas_NN2 ,_Y such_II21 as_II22 flammability_NN1 standards_NN2 for_IF clothing_NN1 ,_Y pesticide_NN1 warnings_NN2 ,_Y automobile_NN1 design_NN1 ,_Y prescription_NN1 drug_NN1 warnings_NN2 ,_Y aircraft_NN design_NN1_VV0@ ,_Y and_CC workplace_NN1 safety_NN1 standards_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  805 <p> -- ( n187 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  805 <p>_Y --_NN1_JJ (_Y n187_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  806 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  806 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  807 <p> -- ( n188 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  807 <p>_Y --_NN1_JJ (_Y n188_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  808 ) See 2 AM .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  808 )_Y See_VV0 2_MC AM_RA@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  809 LAW INST. , REPORTER 'S STUDY , ENTERPRISE RESPONSIBILITY FOR PERSONAL INJURY 95-97 ( 1991 ) ; see also Richard B. Stewart , Regulatory Compliance Preclusion of Tort Liability : Limiting the Dual-Track System , 88 GEO .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  809 LAW_NN1 INST._NP1 ,_Y REPORTER_NN1 'S_GE STUDY_NN1 ,_Y ENTERPRISE_NN1 RESPONSIBILITY_NN1 FOR_IF PERSONAL_JJ INJURY_NN1 95-97_MCMC (_Y 1991_MC )_Y ;_Y see_VV0 also_RR Richard_NP1 B._NP1 Stewart_NP1 ,_Y Regulatory_JJ Compliance_NN1 Preclusion_NN1 of_IO Tort_NP1_NN1 Liability_NN1 :_Y Limiting_VVG the_AT Dual-Track_NP1 System_NN1 ,_Y 88_MC GEO_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  810 L.J .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  810 L.J_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  811 2167 , 2168-70 ( 2000 ) ) , supra note 114 , at 4 cmt. e .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  811 2167_MC ,_Y 2168-70_MCMC (_Y 2000_MC )_Y )_Y ,_Y supra_NN1 note_NN1_VV0 114_MC ,_Y at_II 4_MC cmt._NNU e_ZZ1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  812 <p> -- ( n190 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  812 <p>_Y --_NN1_JJ (_Y n190_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  813 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  813 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  814 <p> -- ( n191 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  814 <p>_Y --_NN1_JJ (_Y n191_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  815 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  815 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  816 4 Reporters ' Note cmt. d ( citing as an example Hawkins v. Evans Cooperage Co. , 766 F.2d 904 , 909 ( 5th Cir. 1985 ) ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  816 4_MC Reporters_NN2 '_GE Note_NN1_VV0 cmt._NNU d_ZZ1 (_Y citing_VVG as_II an_AT1 example_NN1 Hawkins_NP1 v._II Evans_NP1 Cooperage_NP1 Co._NP1 ,_Y 766_MC F.2d_FO 904_MC ,_Y 909_MC (_Y 5th_MD Cir._NP1 1985_MC )_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  817 <p> -- ( n192 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  817 <p>_Y --_NN1_JJ (_Y n192_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  818 ) See , e.g. , Sims v. Washex Mach .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  818 )_Y See_VV0 ,_Y e.g._REX ,_Y Sims_NP1 v._II Washex_NP1_NN1 Mach_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  819 Corp. , 932 S.W.2d 559 , 565 ( Tex .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  819 Corp._NP1 ,_Y 932_MC S.W.2d_FO 559_MC ,_Y 565_MC (_Y Tex_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  820 App. 1995 ) ( " Compliance with government regulations is strong evidence , although not conclusive , that a machine was not defectively designed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  820 App._NP1 1995_MC )_Y (_Y "_Y Compliance_NN1 with_IW government_NN1 regulations_NN2 is_VBZ strong_JJ evidence_NN1 ,_Y although_CS not_XX conclusive_JJ ,_Y that_CST a_AT1 machine_NN1 was_VBDZ not_XX defectively_RR designed_VVN_VVD ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  821 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  821 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  822 <p> -- ( n193 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  822 <p>_Y --_NN1_JJ (_Y n193_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  823 ) See , e.g. , Lorenz v. Celotex Corp. , 896 F.2d 148 , 152 ( 5th Cir. 1990 ) ( compliance with safety regulation is strong and substantial evidence of lack of defect ) ; Dentson v. Eddins Lee Bus Sales , Inc. , 491 So .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  823 )_Y See_VV0 ,_Y e.g._REX ,_Y Lorenz_NP1 v._II Celotex_NP1 Corp._NP1 ,_Y 896_MC F.2d_FO 148_MC ,_Y 152_MC (_Y 5th_MD Cir._NP1 1990_MC )_Y (_Y compliance_NN1 with_IW safety_NN1 regulation_NN1 is_VBZ strong_JJ and_CC substantial_JJ evidence_NN1 of_IO lack_NN1 of_IO defect_NN1 )_Y ;_Y Dentson_NP1 v._II Eddins_NP1 Lee_NP1 Bus_NN1 Sales_NPX ,_Y Inc._JJ ,_Y 491_MC So_RR ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  824 2d 942 , 944 ( Ala. 1986 ) ( ruling that a school bus that is not equipped with seatbelts is not defective when the legislature has , 863 P.2d 167 , 176 ( Cal .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  824 2d_NNU 942_MC ,_Y 944_MC (_Y Ala._NP1 1986_MC )_Y (_Y ruling_NN1_JJ that_CST a_AT1 school_NN1 bus_NN1_VV0@ that_CST_DD1 is_VBZ not_XX equipped_VVN with_IW seatbelts_NN2 is_VBZ not_XX defective_JJ when_CS the_AT legislature_NN1 has_VHZ ,_Y 863_MC P.2d_FO 167_MC ,_Y 176_MC (_Y Cal_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  825 1993 ) ( concluding that " the prudent course is to adopt for tort purposes the existing legislative and administrative standard of care " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  825 1993_MC )_Y (_Y concluding_VVG_JJ that_CST "_Y the_AT prudent_JJ course_NN1 is_VBZ to_TO adopt_VVI for_IF tort_NN1 purposes_NN2_VVZ% the_AT existing_JJ legislative_JJ and_CC administrative_JJ standard_NN1 of_IO care_NN1 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  826 <p> -- ( n194 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  826 <p>_Y --_NN1_JJ (_Y n194_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  827 ) Beatty v. Trailmaster Prods. , Inc. , 625 A.2d 1005 , 1014 ( Md. 1993 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  827 )_Y Beatty_NP1 v._II Trailmaster_NP1 Prods._NP1 ,_Y Inc._JJ ,_Y 625_MC A.2d_FO 1005_MC ,_Y 1014_MC (_Y Md._NP1 1993_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  828 <p> -- ( n195 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  828 <p>_Y --_NN1_JJ (_Y n195_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  829 ) See infra note 203 and accompanying text .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  829 )_Y See_VV0 infra_RR note_VV0 203_MC and_CC accompanying_JJ_VVG text_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  830 <p> -- ( n196 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  830 <p>_Y --_NN1_JJ (_Y n196_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  831 ) See States v. R.D. Werner Co. , 799 P.2d 427 , 430 ( Colo .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  831 )_Y See_VV0 States_NP1_NN2@ v._II R.D._NN1 Werner_NP1 Co._NP1 ,_Y 799_MC P.2d_FO 427_MC ,_Y 430_MC (_Y Colo_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  832 Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  832 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  833 App. 1990 ) ( ruling that the trial court did not err by admitting expert testimony on a ladder 's compliance with federal regulations ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  833 App._NP1 1990_MC )_Y (_Y ruling_NN1_JJ that_CST the_AT trial_NN1 court_NN1 did_VDD not_XX err_VVI by_II admitting_JJ_VVG expert_NN1_JJ@ testimony_NN1 on_II a_AT1 ladder_NN1 's_GE compliance_NN1 with_IW federal_JJ regulations_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  834 <p> -- ( n197 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  834 <p>_Y --_NN1_JJ (_Y n197_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  835 ) See Slisze v. Stanley-Bostitch , 979 P.2d 317 , 321 ( Utah 1999 ) ( ruling that federal OSHA standards regulating the design of a pneumatic nailer were admissible as government standards and established a rebuttable presumption of nondefectiveness as they provided " a legitimate source for determining the standard of reasonable care " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  835 )_Y See_VV0 Slisze_NN1_VV0_NP1 v._II Stanley-Bostitch_NP1 ,_Y 979_MC P.2d_FO 317_MC ,_Y 321_MC (_Y Utah_NP1 1999_MC )_Y (_Y ruling_NN1_JJ that_CST_DD1 federal_JJ OSHA_NN1 standards_NN2 regulating_VVG the_AT design_NN1 of_IO a_AT1 pneumatic_JJ nailer_NN1 were_VBDR admissible_JJ as_CSA_II@ government_NN1 standards_NN2 and_CC established_VVD_VVN a_AT1 rebuttable_JJ presumption_NN1 of_IO nondefectiveness_NN1 as_CSA they_PPHS2 provided_VVD "_Y a_AT1 legitimate_JJ source_NN1 for_IF determining_VVG the_AT standard_NN1 of_IO reasonable_JJ care_NN1 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  836 <p> -- ( n198 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  836 <p>_Y --_NN1_JJ (_Y n198_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  837 ) See Uptain 222 ( Colo .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  837 )_Y See_VV0 Uptain_NN1_JJ 222_MC (_Y Colo_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  838 Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  838 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  839 App. 1984 ) ( finding that manufacturer of a cleaning compound was entitled to presumption of nondefectiveness where an expert testified that the product label 's warnings complied with federal and local laws and was approved by the Environmental Protection Agency ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  839 App._NP1 1984_MC )_Y (_Y finding_VVG that_DD1_CST manufacturer_NN1 of_IO a_AT1 cleaning_NN1 compound_NN1 was_VBDZ entitled_VVN to_II presumption_NN1 of_IO nondefectiveness_NN1 where_CS_RRQ an_AT1 expert_NN1 testified_VVD that_CST the_AT product_NN1 label_NN1 's_GE warnings_NN2 complied_VVN_VVD with_IW federal_JJ and_CC local_JJ laws_NN2 and_CC was_VBDZ approved_VVN by_II the_AT Environmental_JJ Protection_NN1 Agency_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  840 <p> -- ( n199 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  840 <p>_Y --_NN1_JJ (_Y n199_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  841 ) See Alvarado v. J.C .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  841 )_Y See_VV0 Alvarado_NP1_NN1@ v._II J.C_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  842 Penney Co. , 735 F. Supp. 371 , 372-74 ( D. Kan. 1990 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  842 Penney_NP1@_NN1_JJ@ Co._NP1_NN1 ,_Y 735_MC F._NP1_RA@ Supp._NP1 371_MC ,_Y 372-74_MCMC (_Y D._NP1 Kan._NP1 1990_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  843 In a case involving a nightgown and robe that were ignited by an open-flame gas heater , the court held that that the regulatory compliance provision of the Kansas Products Liability Act did not create a conclusive presumption and thus a constitutional challenge by plaintiffs was moot .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  843 In_II a_AT1 case_NN1 involving_VVG a_AT1 nightgown_NN1 and_CC robe_NN1 that_CST were_VBDR ignited_VVN by_II an_AT1 open-flame_JJ_NN1 gas_NN1 heater_NN1 ,_Y the_AT court_NN1 held_VVD_VVN that_CST that_DD1 the_AT regulatory_JJ compliance_NN1 provision_NN1 of_IO the_AT Kansas_NP1 Products_NN2 Liability_NN1 Act_NN1 did_VDD not_XX create_VVI a_AT1 conclusive_JJ presumption_NN1 and_CC thus_RR a_AT1 constitutional_JJ challenge_NN1 by_II plaintiffs_NN2 was_VBDZ moot_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  844 See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  844 See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  845 <p> -- ( n200 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  845 <p>_Y --_NN1_JJ (_Y n200_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  846 ) See Champlain Enters. , Inc. v. United States , 957 F. Supp. 26 , 28 ( N.D.N.Y. 1997 ) ( ruling that the regulatory compliance provision of the Kansas Products Liability Act would provide an airplane manufacturer with a defense against liability if it established that the aircraft complied with government safety standards , unless the plaintiff can show have taken additional precautions " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  846 )_Y See_VV0 Champlain_JJ_NN1 Enters._NP1 ,_Y Inc._JJ v._II United_NP1 States_NP1 ,_Y 957_MC F._NP1_RA@ Supp._NP1 26_MC ,_Y 28_MC (_Y N.D.N.Y._NP1 1997_MC )_Y (_Y ruling_NN1_JJ that_CST the_AT regulatory_JJ compliance_NN1 provision_NN1 of_IO the_AT Kansas_NP1 Products_NN2 Liability_NN1 Act_NN1 would_VM provide_VVI an_AT1 airplane_NN1 manufacturer_NN1 with_IW a_AT1 defense_NN1 against_II liability_NN1 if_CS it_PPH1 established_VVD that_CST the_AT aircraft_NN complied_VVN_VVD with_IW government_NN1 safety_NN1 standards_NN2 ,_Y unless_CS the_AT plaintiff_NN1 can_VM show_VVI have_VHI taken_VVN additional_JJ precautions_NN2 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  847 <p> -- ( n201 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  847 <p>_Y --_NN1_JJ (_Y n201_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  848 ) See Brand v. Mazda Motor Corp. , 978 F. Supp. 1382 , 1387-88 , 1391-93 ( D. Kan. 1997 ) ( ruling that automobile manufacturer 's compliance with federal regulatory standards was not dispositive of liability or punitive damages absent clear and convincing evidence that the manufacturer acted with reckless indifference to consumer safety ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  848 )_Y See_VV0 Brand_NN1_NP1 v._II Mazda_NP1 Motor_NN1_VV0@ Corp._NP1 ,_Y 978_MC F._NP1_RA@ Supp._NP1 1382_MC ,_Y 1387-88_MCMC ,_Y 1391-93_MCMC (_Y D._NP1 Kan._NP1 1997_MC )_Y (_Y ruling_NN1_JJ that_CST_DD1 automobile_NN1 manufacturer_NN1 's_GE compliance_NN1 with_IW federal_JJ regulatory_JJ standards_NN2 was_VBDZ not_XX dispositive_JJ of_IO liability_NN1 or_CC punitive_JJ damages_NN2 absent_VV0@_JJ clear_JJ and_CC convincing_JJ evidence_NN1 that_CST the_AT manufacturer_NN1 acted_VVN_VVD with_IW reckless_JJ indifference_NN1 to_II consumer_NN1 safety_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  849 <p> -- ( n202 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  849 <p>_Y --_NN1_JJ (_Y n202_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  850 ) COLO .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  850 )_Y COLO_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  851 REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  851 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  852 STAT. 13-21-403(1) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  852 STAT._NP1 13-21-403(1)_NN1_JJ (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  853 <p> -- ( n203 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  853 <p>_Y --_NN1_JJ (_Y n203_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  854 ) See KAN .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  854 )_Y See_VV0 KAN_NN1_JJ_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  855 STAT. 60-3304(a) ( 2007 ) ; KY .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  855 STAT._NP1 60-3304(a)_NN1_JJ (_Y 2007_MC )_Y ;_Y KY_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  856 REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  856 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  857 STAT. 411.310(2) ( 2008 ) ; MICH .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  857 STAT._NP1 411.310(2)_FO (_Y 2008_MC )_Y ;_Y MICH_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  858 COMP .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  858 COMP_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  859 LAWS 600.2946(4) ( 2000 ) ; TENN .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  859 LAWS_NN2 600.2946(4)_FO (_Y 2000_MC )_Y ;_Y TENN_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  860 CODE 29-28-104 ( 2008 ) ; TEX .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  860 CODE_NN1_VV0@ 29-28-104_MCMC (_Y 2008_MC )_Y ;_Y TEX_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  861 CIV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  861 CIV_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  862 PRAC .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  862 PRAC_NP1_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  863 REM .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  863 REM_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  864 CODE 82.008 ( 2008 ) ; UTAH CODE 78B-6-703 ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  864 CODE_NN1_VV0@ 82.008_MC (_Y 2008_MC )_Y ;_Y UTAH_NP1 CODE_NN1 78B-6-703_MC (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  865 <p> -- ( n204 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  865 <p>_Y --_NN1_JJ (_Y n204_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  866 ) See , e.g. , Kernke v. The Menninger Clinic , Inc. , 173 F. Supp. 2d 1117 , 1121-22 ( D. Kan. 2001 ) ( finding insufficient evidence to overcome Kansas 's presumption of nondefectiveness clinical trial of an experimental treatment for schizophrenia ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  866 )_Y See_VV0 ,_Y e.g._REX ,_Y Kernke_NP1_VV0@ v._II The_AT Menninger_JJR@_NP1_NN1@ Clinic_NN1 ,_Y Inc._JJ ,_Y 173_MC F._NP1_RA@ Supp._NP1 2d_NNU 1117_MC ,_Y 1121-22_MCMC (_Y D._NP1 Kan._NP1 2001_MC )_Y (_Y finding_VVG insufficient_JJ evidence_NN1 to_TO overcome_VVI Kansas_NP1 's_GE presumption_NN1 of_IO nondefectiveness_NN1 clinical_JJ trial_NN1 of_IO an_AT1 experimental_JJ treatment_NN1 for_IF schizophrenia_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  867 At least two additional states , Arkansas and Washington , specifically provide by statute that parties may introduce evidence of regulatory compliance to show that a product is not defective or that its warnings are not inadequate .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  867 At_RR21 least_RR22 two_MC additional_JJ states_NN2 ,_Y Arkansas_NP1 and_CC Washington_NP1 ,_Y specifically_RR provide_VV0 by_II statute_NN1 that_CST parties_NN2 may_VM introduce_VVI evidence_NN1 of_IO regulatory_JJ compliance_NN1 to_TO show_VVI that_CST a_AT1 product_NN1 is_VBZ not_XX defective_JJ or_CC that_CST its_Z' warnings_NN2 are_VBR not_XX inadequate_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  868 See ARK .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  868 See_VV0 ARK_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  869 CODE 16-116-105(a) ( 2007 ) ; WASH .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  869 CODE_NN1_VV0@ 16-116-105(a)_NN1_JJ (_Y 2007_MC )_Y ;_Y WASH_VV0_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  870 REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  870 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  871 CODE 7.72.050(1) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  871 CODE_NN1_VV0@ 7.72.050(1)_FO (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  872 These statutes do not assign any particular evidentiary weight to compliance with safety standards .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  872 These_DD2 statutes_NN2 do_VD0 not_XX assign_VVI any_DD particular_JJ evidentiary_JJ_NN1 weight_NN1 to_II compliance_NN1 with_IW safety_NN1 standards_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  873 <p> -- ( n205 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  873 <p>_Y --_NN1_JJ (_Y n205_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  874 ) See Henry I. Miller , Failed FDA Reform , 21 REGULATION 24 , 24 ( 1998 ) ( attributing an increase in cost for new drug development and approval from $359 million to $500 million--in pretax 1990 dollars--between 1990 and 1993 , and an increase in the time for approval from 8.1 years to 15.2 years since the 1960s , to the " FDA 's regulatory zeal " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  874 )_Y See_VV0 Henry_NP1 I._NP1 Miller_NP1 ,_Y Failed_VVD_JJ@_VVN FDA_NP1_NN1 Reform_NN1 ,_Y 21_MC REGULATION_NN1 24_MC ,_Y 24_MC (_Y 1998_MC )_Y (_Y attributing_VVG an_AT1 increase_NN1 in_II cost_NN1 for_IF new_JJ drug_NN1 development_NN1 and_CC approval_NN1 from_II $359_NNU million_M to_II $500_NNU million--in_M1 pretax_NN1 1990_MC dollars--between_NNU2 1990_MC and_CC 1993_MC ,_Y and_CC an_AT1 increase_NN1 in_II the_AT time_NNT1 for_IF approval_NN1 from_II 8.1_MC years_NNT2 to_II 15.2_MC years_NNT2 since_CS_II@ the_AT 1960s_MC2 ,_Y to_II the_AT "_Y FDA_NP1_NN1 's_GE regulatory_JJ zeal_NN1 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  875 <p> -- ( n206 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  875 <p>_Y --_NN1_JJ (_Y n206_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  876 ) See N.J. STAT. 2A:58C-5c ( 2008 ) ; OHIO REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  876 )_Y See_VV0 N.J._NP1 STAT._NP1 2A:58C-5c_FO (_Y 2008_MC )_Y ;_Y OHIO_NP1 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  877 CODE 2307.80(C) ( 2008 ) ; OR .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  877 CODE_NN1_VV0@ 2307.80(C)_FO (_Y 2008_MC )_Y ;_Y OR_CC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  878 REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  878 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  879 STAT. 30.927 ( 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  879 STAT._NP1 30.927_MC (_Y 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  880 statute to include medical devices and over-the-counter drugs in addition to prescription drugs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  880 statute_NN1 to_TO include_VVI medical_JJ devices_NN2 and_CC over-the-counter_JJ_VV0_NN1 drugs_NN2 in_II31 addition_II32 to_II33 prescription_NN1 drugs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  881 OHIO LAWS FILE 144 ( Am .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  881 OHIO_NP1 LAWS_NN2 FILE_VV0@_NN1 144_MC (_Y Am_RA@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  882 Sub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  882 Sub_NN1_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  883 S.B. 80 ) ( amending OHIO REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  883 S.B._NP1 80_MC )_Y (_Y amending_VVG OHIO_NP1 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  884 CODE 2307.80 ) ( effective Apr. 7 , 2005 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  884 CODE_NN1_VV0@ 2307.80_MC )_Y (_Y effective_JJ Apr._NN1 7_MC ,_Y 2005_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  885 <p> -- ( n207 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  885 <p>_Y --_NN1_JJ (_Y n207_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  886 ) See ARIZ .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  886 )_Y See_VV0 ARIZ_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  887 REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  887 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  888 STAT. 12-701(A) ( 2009 ) ; UTAH CODE 78B-8-203(1) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  888 STAT._NP1 12-701(A)_NN1_JJ (_Y 2009_MC )_Y ;_Y UTAH_NP1 CODE_NN1 78B-8-203(1)_NN1 (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  889 <p> -- ( n208 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  889 <p>_Y --_NN1_JJ (_Y n208_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  890 ) See MICH .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  890 )_Y See_VV0 MICH_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  891 COMP .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  891 COMP_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  892 LAWS 600.2946(5) ( 2000 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  892 LAWS_NN2 600.2946(5)_FO (_Y 2000_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  893 The Supreme Court of the United States recently found that an exception in the Michigan law which preserves liability if the drug company withheld or misrepresented information that would have altered the FDA 's decision to approve the drug product ( i.e. , " fraud-on-the-FDA " ) was valid and not preempted .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  893 The_AT Supreme_JJ Court_NN1 of_IO the_AT United_NP1 States_NP1 recently_RR found_VVN_VVD that_CST an_AT1 exception_NN1 in_II the_AT Michigan_NP1 law_NN1 which_DDQ preserves_VVZ liability_NN1 if_CS the_AT drug_NN1 company_NN1 withheld_VVN_VVD or_CC misrepresented_JJ@_VVD information_NN1 that_CST_DD1 would_VM have_VHI altered_VVN the_AT FDA_NP1_NN1 's_GE decision_NN1 to_TO approve_VVI the_AT drug_NN1 product_NN1 (_Y i.e._REX ,_Y "_Y fraud-on-the-FDA_NP1 "_Y )_Y was_VBDZ valid_JJ and_CC not_XX preempted_VVN@_JJ@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  894 Warner-Lambert Co. v. Kent , 128 S. Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  894 Warner-Lambert_NP1 Co._NP1_NN1 v._II Kent_NP1 ,_Y 128_MC S._NP1 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  895 1168 ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  895 1168_MC (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  896 <p> -- ( n209 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  896 <p>_Y --_NN1_JJ (_Y n209_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  897 ) See OHIO REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  897 )_Y See_VV0 OHIO_NP1 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  898 CODE 2307.80(B)-(C) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  898 CODE_VV0@_NN1 2307.80(B)-(C)_ZZ1 (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  899 <p> -- ( n210 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  899 <p>_Y --_NN1_JJ (_Y n210_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  900 ) Compare OR .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  900 )_Y Compare_VV0 OR_CC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  901 REV .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  901 REV_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  902 STAT. 30.927 ( 2007 ) ( requiring " clear and convincing " evidence of ( 2008 ) ( providing a preponderance of the evidence standard ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  902 STAT._NP1 30.927_MC (_Y 2007_MC )_Y (_Y requiring_VVG "_Y clear_JJ and_CC convincing_JJ "_Y evidence_NN1 of_IO (_Y 2008_MC )_Y (_Y providing_VVG a_AT1 preponderance_NN1 of_IO the_AT evidence_NN1 standard_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  903 <p> -- ( n211 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  903 <p>_Y --_NN1_JJ (_Y n211_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  904 ) See 21 C.F.R. 314.80(b)-(c) ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  904 )_Y See_VV0 21_MC C.F.R._NP1 314.80(b)-(c)_ZZ1 (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  905 <p> -- ( n212 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  905 <p>_Y --_NN1_JJ (_Y n212_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  906 ) See generally James P. Muehlberger Cary Silverman , Lawsuits Without Injury : The Rise of Consumer Protection Claims , LITIG .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  906 )_Y See_VV0 generally_RR James_NP1 P._NP1 Muehlberger_NP1 Cary_NP1 Silverman_NP1 ,_Y Lawsuits_NN2 Without_IW Injury_NN1 :_Y The_AT Rise_NN1 of_IO Consumer_NN1 Protection_NN1 Claims_NN2_VVZ ,_Y LITIG_NP1_VV0_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  907 WATCH , Oct. 2006 , at 4 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  907 WATCH_VV0_NN1 ,_Y Oct._NPM1 2006_MC ,_Y at_II 4_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  908 <p> -- ( n213 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  908 <p>_Y --_NN1_JJ (_Y n213_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  909 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  909 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  910 <p> -- ( n214 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  910 <p>_Y --_NN1_JJ (_Y n214_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  911 ) See N.J. Citizen Action v. Schering-Plough Corp. , 842 A.2d 174 , 177 ( N.J. Super .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  911 )_Y See_VV0 N.J._NP1 Citizen_NN1 Action_NN1 v._II Schering-Plough_NP1 Corp._NP1 ,_Y 842_MC A.2d_FO 174_MC ,_Y 177_MC (_Y N.J._NP1 Super_JJ_NN1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  912 Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  912 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  913 App .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  913 App_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  914 Div. 2003 ) ( holding plaintiffs who claimed allergy medication was not as effective as advertised failed to establish a causal nexus between representations and any loss suffered under the New Jersey Consumer Fraud Act ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  914 Div._MC 2003_MC )_Y (_Y holding_VVG_JJ@ plaintiffs_NN2 who_PNQS claimed_VVD allergy_NN1 medication_NN1 was_VBDZ not_XX as_RG effective_JJ as_CSA advertised_VVN failed_VVN_VVD_JJ@ to_TO establish_VVI a_AT1 causal_JJ nexus_NN1 between_II representations_NN2 and_CC any_DD loss_NN1 suffered_VVN_VVD under_II the_AT New_NP1 Jersey_NP1 Consumer_NN1 Fraud_NN1 Act_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  915 <p> -- ( n215 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  915 <p>_Y --_NN1_JJ (_Y n215_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  916 ) See Williams v. Purdue Pharma Co. , 297 F. Supp. 2d 171 , 177-78 ( dismissing District of Columbia 's Consumer Protection Procedures Act claim that the manufacturer over-promoted the drug as providing " smooth and sustained " pain relief for twelve hours with little chance of addiction , .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  916 )_Y See_VV0 Williams_NP1 v._II Purdue_NP1 Pharma_NP1 Co._NP1 ,_Y 297_MC F._NP1_RA@ Supp._NP1 2d_NNU 171_MC ,_Y 177-78_MCMC (_Y dismissing_VVG_JJ@ District_NN1 of_IO Columbia_NP1 's_GE Consumer_NN1 Protection_NN1 Procedures_NN2 Act_VV0@_NN1 claim_VV0_NN1 that_CST the_AT manufacturer_NN1 over-promoted_VVN_VVD@ the_AT drug_NN1 as_CSA_II@ providing_VVG "_Y smooth_JJ and_CC sustained_JJ "_Y pain_NN1 relief_NN1 for_IF twelve_MC hours_NNT2 with_IW little_DA1_JJ chance_NN1 of_IO addiction_NN1 ,_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  917 <p> -- ( n216 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  917 <p>_Y --_NN1_JJ (_Y n216_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  918 ) See In re Prempro Prods .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  918 )_Y See_VV0 In_RP@ re_II Prempro_NP1_NN1 Prods_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  919 Liab .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  919 Liab_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  920 Litig. , 230 F.R.D. 555 , 566-68 ( E.D. Ark. 2005 ) ( denying certification of a consumer-protection class due to material variations in the consumer laws of the twenty-nine states at issue and the need to show individual plaintiffs relied on the allegedly deceptive advertisement and were injured as a result ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  920 Litig._NP1 ,_Y 230_MC F.R.D._NP1 555_MC ,_Y 566-68_MCMC (_Y E.D._NN1 Ark._NP1 2005_MC )_Y (_Y denying_VVG certification_NN1 of_IO a_AT1 consumer-protection_JJ_NN1 class_NN1 due_II21 to_II22 material_NN1_JJ@ variations_NN2 in_II the_AT consumer_NN1 laws_NN2 of_IO the_AT twenty-nine_MC states_NN2_VVZ at_II issue_NN1 and_CC the_AT need_NN1 to_TO show_VVI individual_JJ plaintiffs_NN2 relied_VVN_VVD on_II the_AT allegedly_RR deceptive_JJ advertisement_NN1 and_CC were_VBDR injured_VVN as_II a_AT1 result_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  921 <p> -- ( n217 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  921 <p>_Y --_NN1_JJ (_Y n217_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  922 ) See In re W. Va .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  922 )_Y See_VV0 In_RP@ re_II W._NP1 Va_FW ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  923 Rezulin Litig. , 585 S.E.2d 52 , 62-65 ( W. Va .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  923 Rezulin_NP1@ Litig._NP1 ,_Y 585_MC S.E.2d_FO 52_MC ,_Y 62-65_MCMC (_Y W._NP1 Va_FW ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  924 2003 ) ( ruling that the statutory requirement that a plaintiff show an " ascertainable loss " under West Virginia Consumer Credit and Protection Act did not require a showing of actual damages and finding that plaintiffs needed only to allege that they received a product that was different or inferior to that which they believed they purchased ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  924 2003_MC )_Y (_Y ruling_NN1_JJ that_CST the_AT statutory_JJ requirement_NN1 that_CST a_AT1 plaintiff_NN1 show_VV0_NN1 an_AT1 "_Y ascertainable_JJ loss_NN1 "_Y under_II West_NP1 Virginia_NP1 Consumer_NN1 Credit_NN1 and_CC Protection_NN1 Act_NN1 did_VDD not_XX require_VVI a_AT1 showing_NN1@ of_IO actual_JJ damages_NN2 and_CC finding_VVG_NN1 that_CST plaintiffs_NN2 needed_VVD_VVN only_RR to_TO_II allege_VVI that_CST they_PPHS2 received_VVD a_AT1 product_NN1 that_CST_DD1 was_VBDZ different_JJ or_CC inferior_JJ to_II that_DD1 which_DDQ they_PPHS2 believed_VVD they_PPHS2 purchased_VVD )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  925 <p> -- ( n218 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  925 <p>_Y --_NN1_JJ (_Y n218_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  926 ) See Int'l Union of Operating Eng'rs Local No. 68 Welfare Fund v. Merck Co. , 929 A.2d 1076 , 1088 ( N.J. 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  926 )_Y See_VV0 Int'l_NN1_NP1_VV0 Union_NN1_NP1 of_IO Operating_NN1_VVG Eng'rs_VVZ_NP1_NN2 Local_JJ@_NN1 No._XX 68_MC Welfare_NN1 Fund_NN1 v._II Merck_NP1 Co._NP1_NN1 ,_Y 929_MC A.2d_FO 1076_MC ,_Y 1088_MC (_Y N.J._NP1 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  927 <p> -- ( n219 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  927 <p>_Y --_NN1_JJ (_Y n219_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  928 ) of Consumer Protection Acts , 54 KAN .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  928 )_Y of_IO Consumer_NN1 Protection_NN1 Acts_NN2_VVZ ,_Y 54_MC KAN_JJ_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  929 L. REV. 1 , 32-33 ( 2005 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  929 L._NP1 REV._NNU_NNB 1_MC1 ,_Y 32-33_MCMC (_Y 2005_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  930 <p> -- ( n220 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  930 <p>_Y --_NN1_JJ (_Y n220_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  931 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  931 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  932 at 22-27 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  932 at_II 22-27_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  933 <p> -- ( n221 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  933 <p>_Y --_NN1_JJ (_Y n221_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  934 ) See , e.g. , Victor E. Schwartz , Cary Silverman Christopher E. Appel , " That 's Unfair !
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  934 )_Y See_VV0 ,_Y e.g._REX ,_Y Victor_NP1 E._NP1 Schwartz_NP1 ,_Y Cary_NP1 Silverman_NP1 Christopher_NP1 E._NP1 Appel_NP1 ,_Y "_Y That_DD1_CST 's_VBZ Unfair_JJ !_Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  935 " Says Who--The Government or Litigant ?
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  935 "_Y Says_VVZ Who--The_NP1 Government_NN1 or_CC Litigant_NP1_NN1_JJ ?_Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  936 Consumer Protection Claims Involving Regulated Conduct , 47 WASHBURN L.J .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  936 Consumer_NN1 Protection_NN1 Claims_NN2_VVZ Involving_VVG Regulated_JJ@ Conduct_NN1 ,_Y 47_MC WASHBURN_NP1 L.J_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  937 93 , 119 ( 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  937 93_MC ,_Y 119_MC (_Y 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  938 <p> -- ( n222 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  938 <p>_Y --_NN1_JJ (_Y n222_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  939 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  939 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  940 at 102 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  940 at_II 102_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  941 Regulatory-compliance exemptions to state consumer laws vary from state to state but generally fit within three categories : ( 1 ) rules of construction suggesting or requiring that courts interpret the state consumer law consistently with the interpretations and policy of the FTC ; ( 2 ) exemptions for authorized or permitted conduct ; ( 3 ) exemptions applicable to specific regulated industries or conduct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  941 Regulatory-compliance_JJ_NN1 exemptions_NN2 to_TO state_VVI consumer_NN1 laws_NN2 vary_VV0 from_II state_NN1 to_II state_NN1 but_CCB generally_RR fit_VV0_JJ within_II three_MC categories_NN2 :_Y (_Y 1_MC1 )_Y rules_NN2 of_IO construction_NN1 suggesting_VVG or_CC requiring_VVG that_CST courts_NN2 interpret_VV0 the_AT state_NN1 consumer_NN1 law_NN1 consistently_RR with_IW the_AT interpretations_NN2 and_CC policy_NN1 of_IO the_AT FTC_NP1 ;_Y (_Y 2_MC )_Y exemptions_NN2 for_IF authorized_JJ or_CC permitted_JJ@_VVD_VVN conduct_NN1 ;_Y (_Y 3_MC )_Y exemptions_NN2 applicable_JJ to_II specific_JJ regulated_JJ@ industries_NN2 or_CC conduct_NN1_VV0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  942 See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  942 See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  943 at 102-17 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  943 at_II 102-17_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  944 <p> -- ( n223 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  944 <p>_Y --_NN1_JJ (_Y n223_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  945 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  945 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  946 at 106 ( quoting Taylor v. Bear Stearns Co. , 572 F. Supp. 667 ( N.D. Ga .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  946 at_II 106_MC (_Y quoting_VVG Taylor_NP1 v._II Bear_NN1 Stearns_VVZ_NP1 Co._NP1_NN1 ,_Y 572_MC F._NP1_RA@ Supp._NP1 667_MC (_Y N.D._NP1 Ga_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  947 See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  947 See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  948 at 119-22 ; see also Muehlberger Silverman , supra note 212 , at 5-6 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  948 at_II 119-22_MCMC ;_Y see_VV0 also_RR Muehlberger_NP1 Silverman_NP1_NN1 ,_Y supra_NN1 note_NN1_VV0 212_MC ,_Y at_II 5-6_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  949 <p> -- ( n225 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  949 <p>_Y --_NN1_JJ (_Y n225_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  950 ) U.S. CONST. art .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  950 )_Y U.S._NP1 CONST._NP1 art_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  951 VI , cl. 2 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  951 VI_MC_NP1@ ,_Y cl._MC 2_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  952 <p> -- ( n226 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  952 <p>_Y --_NN1_JJ (_Y n226_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  953 ) See La .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  953 )_Y See_VV0 La_FU_NP1_FW ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  954 Pub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  954 Pub_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  955 Serv .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  955 Serv_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  956 Comm'n v. FCC , 476 U.S. 355 , 369 ( 1986 ) ( " Pre-emption may result not only from action taken by Congress itself ; a federal agency action within the scope of its congressionally delegated authority may pre-empt state regulation .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  956 Comm'n_VV0_NN1 v._II FCC_NP1 ,_Y 476_MC U.S._NP1 355_MC ,_Y 369_MC (_Y 1986_MC )_Y (_Y "_Y Pre-emption_NN1 may_VM result_VVI not_XX only_RR from_II action_NN1 taken_VVN by_II Congress_NN1 itself_PPX1 ;_Y a_AT1 federal_JJ agency_NN1 action_NN1 within_II the_AT scope_NN1 of_IO its_Z' congressionally_RR delegated_JJ_VVN authority_NN1 may_VM pre-empt_VVI state_NN1 regulation_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  957 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  957 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  958 <p> -- ( n227 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  958 <p>_Y --_NN1_JJ (_Y n227_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  959 ) See 21 U.S.C. 393(b) ( 2006 ) ( charging the FDA with ensuring that drugs are safe and effective ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  959 )_Y See_VV0 21_MC U.S.C._NP1 393(b)_FO (_Y 2006_MC )_Y (_Y charging_VVG the_AT FDA_NN1 with_IW ensuring_VVG that_CST drugs_NN2 are_VBR safe_JJ and_CC effective_JJ )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  960 <p> -- ( n228 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  960 <p>_Y --_NN1_JJ (_Y n228_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  961 ) See 21 U.S.C. 360k(a) ( 2006 ) ( providing that a state shall not " establish or continue in effect with respect to a device intended for human use any requirement--(1) which is different from , or in addition to , any requirement applicable under federal law to the device , and ( 2 ) which relates to the safety or effectiveness of the device to the device under " relevant federal law ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  961 )_Y See_VV0 21_MC U.S.C._NP1 360k(a)_FO (_Y 2006_MC )_Y (_Y providing_CS21 that_CS22 a_AT1 state_NN1 shall_VM not_XX "_Y establish_VV0 or_CC continue_VV0 in_II_RP@ effect_NN1 with_II31 respect_II32 to_II33 a_AT1 device_NN1 intended_VVN_VVD for_IF human_NN1_JJ use_VV0_NN1 any_DD requirement--(1)_MC1 which_DDQ is_VBZ different_JJ from_II ,_Y or_CC in_II31 addition_II32 to_II33 ,_Y any_DD requirement_NN1 applicable_JJ under_II federal_JJ law_NN1 to_II the_AT device_NN1 ,_Y and_CC (_Y 2_MC )_Y which_DDQ relates_VVZ to_II the_AT safety_NN1 or_CC effectiveness_NN1 of_IO the_AT device_NN1 to_II the_AT device_NN1 under_II_RG@ "_Y relevant_JJ federal_JJ law_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  962 <p> -- ( n229 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  962 <p>_Y --_NN1_JJ (_Y n229_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  963 ) See , e.g. , Riegel v. Medtronic , Inc. , 128 S. Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  963 )_Y See_VV0 ,_Y e.g._REX ,_Y Riegel_NP1_VV0@ v._II Medtronic_JJ ,_Y Inc._JJ ,_Y 128_MC S._NP1 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  964 999 , 1006-08 ( 2008 ) ( discussing the scope of the MDA 's express preemption provision regarding medical device compliance with FDA pre-market approval process ) ; Sprietsma v. Mercury Marine , 537 U.S. 51 , 67-68 ( 2002 ) ( analyzing the confines of an express preemption provision in the Federal Boat Safety Act ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  964 999_MC ,_Y 1006-08_MCMC (_Y 2008_MC )_Y (_Y discussing_VVG the_AT scope_NN1 of_IO the_AT MDA_NP1_NN1 's_GE express_JJ@ preemption_NN1 provision_NN1 regarding_II_VVG medical_JJ device_NN1 compliance_NN1 with_IW FDA_NP1_NN1 pre-market_JJ_NN1 approval_NN1 process_NN1 )_Y ;_Y Sprietsma_NP1 v._II Mercury_NP1 Marine_JJ_NN1@ ,_Y 537_MC U.S._NP1 51_MC ,_Y 67-68_MCMC (_Y 2002_MC )_Y (_Y analyzing_VVG the_AT confines_NN2 of_IO an_AT1 express_JJ@ preemption_NN1 provision_NN1 in_II the_AT Federal_JJ Boat_NN1 Safety_NN1 Act_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  965 <p> -- ( n230 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  965 <p>_Y --_NN1_JJ (_Y n230_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  966 ) See Crosby v. Nat'l Foreign Trade Council , 530 U.S. 363 , 372 ( 2000 ) ( " Even without an express provision for preemption , we have found that state law must yield to a congressional Act .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  966 )_Y See_VV0 Crosby_NP1 v._II Nat'l_NP1_NN1 Foreign_JJ Trade_NN1 Council_NN1 ,_Y 530_MC U.S._NP1 363_MC ,_Y 372_MC (_Y 2000_MC )_Y (_Y "_Y Even_RR without_IW an_AT1 express_JJ@ provision_NN1 for_IF preemption_NN1 ,_Y we_PPIS2 have_VH0 found_VVN that_CST_DD1 state_VV0_NN1 law_NN1 must_VM yield_VVI to_II a_AT1 congressional_JJ Act_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  967 ... " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  967 ..._... "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  968 <p> -- ( n231 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  968 <p>_Y --_NN1_JJ (_Y n231_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  969 ) See Rice v. Santa Fe Elevator Corp. , 331 U.S. 218 , 230-31 ( 1947 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  969 )_Y See_VV0 Rice_NN1 v._II Santa_NP1 Fe_NP1 Elevator_NN1 Corp._NP1 ,_Y 331_MC U.S._NP1 218_MC ,_Y 230-31_MCMC (_Y 1947_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  970 <p> -- ( n232 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  970 <p>_Y --_NN1_JJ (_Y n232_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  971 ) Fla .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  971 )_Y Fla_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  972 Lime Avocado Growers , Inc. v. Paul 373 U.S. 132 , 142-43 ( 1963 ) ; see also Hillsborough County v. Automated 713 ( 1985 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  972 Lime_NN1 Avocado_NN1 Growers_NN2 ,_Y Inc._JJ v._II Paul_NP1 373_MC U.S._NP1 132_MC ,_Y 142-43_MCMC (_Y 1963_MC )_Y ;_Y see_VV0 also_RR Hillsborough_NP1 County_NN1 v._II Automated_JJ 713_MC (_Y 1985_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  973 <p> -- ( n233 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  973 <p>_Y --_NN1_JJ (_Y n233_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  974 ) Geier v. Am .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  974 )_Y Geier_NN1_JJR@_NP1@ v._NNU_II Am_RA@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  975 Honda Motor Co. , 529 U.S. 861 , 869-74 ( 2000 ) ; see also Gade v. Nat'l Solid Wastes Mgmt .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  975 Honda_NP1 Motor_NN1 Co._NN1_NP1 ,_Y 529_MC U.S._NP1 861_MC ,_Y 869-74_MCMC (_Y 2000_MC )_Y ;_Y see_VV0 also_RR Gade_VV0@_NP1 v._II_NNU Nat'l_NP1_NN1 Solid_JJ_NN1@ Wastes_NN2_VVZ Mgmt_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  976 Ass'n , 505 U.S. 88 , 98 ( 1992 ) ; Hines v. Davidowitz , 312 U.S. 52 , 67 ( 1941 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  976 Ass'n_VV0_NN1_NP1@ ,_Y 505_MC U.S._NP1 88_MC ,_Y 98_MC (_Y 1992_MC )_Y ;_Y Hines_NP1 v._II Davidowitz_NP1 ,_Y 312_MC U.S._NP1 52_MC ,_Y 67_MC (_Y 1941_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  977 <p> -- ( n234 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  977 <p>_Y --_NN1_JJ (_Y n234_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  978 ) See James O'Reilly , A State of Extinction : Does Food and Drug Administration Approval of a Prescription Drug Label Extinguish State Claims for Inadequate Warning ?
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  978 )_Y See_VV0 James_NP1 O'Reilly_NP1 ,_Y A_ZZ1_AT1@ State_NN1 of_IO Extinction_NN1 :_Y Does_VDZ Food_NN1 and_CC Drug_NN1 Administration_NN1 Approval_NN1 of_IO a_AT1 Prescription_NN1 Drug_NN1 Label_NN1_VV0 Extinguish_VV0 State_NN1_VV0 Claims_VVZ_NN2 for_IF Inadequate_JJ Warning_NN1 ?_Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  979 , 58 FOOD DRUG L.J .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  979 ,_Y 58_MC FOOD_NN1 DRUG_NN1 L.J_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  980 287 , 291 ( arguing that it is unlikely that an implied field preemption claim could prevail in the prescription drug field ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  980 287_MC ,_Y 291_MC (_Y arguing_VVG that_CST it_PPH1 is_VBZ unlikely_JJ that_CST an_AT1 implied_JJ@ field_NN1 preemption_NN1 claim_NN1 could_VM prevail_VVI in_II the_AT prescription_NN1 drug_NN1 field_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  981 <p> -- ( n235 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  981 <p>_Y --_NN1_JJ (_Y n235_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  982 ) See , e.g. , Crosby , 530 U.S. at 372 ; see also Christine H. Kim , The Case for Preemption of Prescription Drug Failure-to-Warn Claims , 62 FOOD DRUG L.J .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  982 )_Y See_VV0 ,_Y e.g._REX ,_Y Crosby_NP1 ,_Y 530_MC U.S._NP1 at_II 372_MC ;_Y see_VV0 also_RR Christine_NP1 H._NP1 Kim_NP1 ,_Y The_AT Case_NN1 for_IF Preemption_NN1 of_IO Prescription_NN1 Drug_NN1 Failure-to-Warn_VV0 Claims_NN2 ,_Y 62_MC FOOD_NN1 DRUG_NN1 L.J_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  983 399 , 402 ( 2007 ) ( separating the three distinct forms of implied preemption ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  983 399_MC ,_Y 402_MC (_Y 2007_MC )_Y (_Y separating_VVG the_AT three_MC distinct_JJ forms_NN2 of_IO implied_JJ@ preemption_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  984 <p> -- ( n236 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  984 <p>_Y --_NN1_JJ (_Y n236_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  985 ) See Kim , supra increased amicus curiae filings in federal preemption cases ) ; Mark C. Levy Gregory J. Wartman , Amicus Curiae Efforts to Reform Product Liability at the Food and Drug Administration : FDA 's Influence on Federal Preemption of Class III Medical Devices and Pharmaceuticals , 60 FOOD DRUG L.J .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  985 )_Y See_VV0 Kim_NP1 ,_Y supra_NN1 increased_JJ amicus_NN1 curiae_NN2 filings_NN2 in_II federal_JJ preemption_NN1 cases_NN2 )_Y ;_Y Mark_NP1 C._NP1 Levy_NP1 Gregory_NP1 J._NP1 Wartman_NP1 ,_Y Amicus_NP1 Curiae_NP1 Efforts_NN2 to_II Reform_NN1 Product_NN1 Liability_NN1 at_II the_AT Food_NN1 and_CC Drug_NN1 Administration_NN1 :_Y FDA_NP1 's_GE Influence_NN1 on_II Federal_JJ Preemption_NN1 of_IO Class_NN1 III_MC Medical_JJ Devices_NN2 and_CC Pharmaceuticals_NN2 ,_Y 60_MC FOOD_NN1 DRUG_NN1 L.J_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  986 495 , 497-99 ( 2005 ) ; Catherine M. Sharkey , Federalism in Action : FDA Regulatory Preemption in Pharmaceutical Cases in State Versus Federal Courts , 15 J.L. POL'Y 1013 , 1032-34 ( 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  986 495_MC ,_Y 497-99_MCMC (_Y 2005_MC )_Y ;_Y Catherine_NP1 M._NN1 Sharkey_NP1_NN1@ ,_Y Federalism_NN1 in_II Action_NN1 :_Y FDA_NP1_NN1 Regulatory_JJ Preemption_NN1 in_II Pharmaceutical_JJ Cases_NN2 in_II State_NN1_NP1@ Versus_II Federal_JJ Courts_NN2 ,_Y 15_MC J.L._NP1 POL'Y_NP1_NN1 1013_MC ,_Y 1032-34_MCMC (_Y 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  987 <p> -- ( n237 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  987 <p>_Y --_NN1_JJ (_Y n237_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  988 ) See , e.g. , Corrected Amicus Brief for the United States , Kallas v. Pfizer , Inc. , No. 04-00998 ( D. Utah Sept. 29 , 2005 ) ; see also Sharkey , supra note 236 , at 1038 ( estimating that the FDA is directly involved in one quarter of federal court drug preemption cases since 2000 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  988 )_Y See_VV0 ,_Y e.g._REX ,_Y Corrected_VVD_VVN_JJ@ Amicus_NP1_NN1 Brief_NN1_JJ for_IF the_AT United_NP1 States_NP1 ,_Y Kallas_NP2_NN2@ v._II Pfizer_NP1_NN1 ,_Y Inc._JJ ,_Y No._XX 04-00998_MCMC (_Y D._NP1 Utah_NP1 Sept._NPM1 29_MC ,_Y 2005_MC )_Y ;_Y see_VV0 also_RR Sharkey_NP1 ,_Y supra_NN1 note_NN1_VV0 236_MC ,_Y at_II 1038_MC (_Y estimating_VVG that_CST the_AT FDA_NN1_NP1 is_VBZ directly_RR involved_JJ in_II one_MC1 quarter_NN1 of_IO federal_JJ court_NN1 drug_NN1 preemption_NN1 cases_NN2 since_II 2000_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  989 <p> -- ( n238 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  989 <p>_Y --_NN1_JJ (_Y n238_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  990 ) See Colacicco v. Apotex , Inc. , 432 F. Supp. 2d 514 , 528 ( E.D. Pa. 2006 ) ( citing 21 C.F.R. 314.150 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  990 )_Y See_VV0 Colacicco_NP1_NN1@ v._II Apotex_NP1_NN1 ,_Y Inc._JJ ,_Y 432_MC F._NP1_RA@ Supp._NP1 2d_NNU 514_MC ,_Y 528_MC (_Y E.D._NN1 Pa._NP1_NN1@ 2006_MC )_Y (_Y citing_VVG 21_MC C.F.R._NP1 314.150_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  991 <p> -- ( , 529 U.S. 861 , 863 ( 2000 ) ( internal quotation marks omitted ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  991 <p>_Y --_NN1_JJ (_Y ,_Y 529_MC U.S._NP1 861_MC ,_Y 863_MC (_Y 2000_MC )_Y (_Y internal_JJ quotation_NN1 marks_NN2 omitted_VVN )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  992 <p> -- ( n240 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  992 <p>_Y --_NN1_JJ (_Y n240_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  993 ) See Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products , 71 Fed .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  993 )_Y See_VV0 Requirements_NN2 on_II Content_NN1_JJ and_CC Format_NN1 of_IO Labeling_VVG_NP1 for_IF Human_JJ_NN1 Prescription_NN1 Drug_NN1 and_CC Biological_JJ Products_NN2 ,_Y 71_MC Fed_VVD_VVN ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  994 Reg. 3922 , 3933-34 ( Jan. 24 , 2006 ) ( effective date June 30 , 2006 ) hereinafter " FDA Preamble " .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  994 Reg._NN1 3922_MC ,_Y 3933-34_MCMC (_Y Jan._NPM1 24_MC ,_Y 2006_MC )_Y (_Y effective_JJ date_NN1 June_NPM1 30_MC ,_Y 2006_MC )_Y hereinafter_RR "_Y FDA_NP1_NN1 Preamble_NN1 "_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  995 <p> -- ( n241 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  995 <p>_Y --_NN1_JJ (_Y n241_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  996 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  996 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  997 <p> -- ( n242 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  997 <p>_Y --_NN1_JJ (_Y n242_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  998 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  998 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0  999 at 3935 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0  999 at_II 3935_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1000 <p> -- ( n243 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1000 <p>_Y --_NN1_JJ (_Y n243_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1001 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1001 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1002 <p> -- ( n244 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1002 <p>_Y --_NN1_JJ (_Y n244_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1003 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1003 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1004 at 3935-36 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1004 at_II 3935-36_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1005 <p> -- ( n245 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1005 <p>_Y --_NN1_JJ (_Y n245_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1006 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1006 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1007 at 3935 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1007 at_II 3935_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1008 <p> -- ( n246 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1008 <p>_Y --_NN1_JJ (_Y n246_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1009 ) See , e.g. , W. Wylie Blair , Implied Preemption of State Tort Law Claims Against Prescription Drug Manufacturers Based on FDA Approval , 27 J. LEGAL MED. 289 , 301 ( 2006 ) ( proposing amendment of the Food , Drug , and Cosmetic Act , enactment of state statutes , or the use of judicial intervention to adopt the FDA 's interpretation of the scope of implied preemption ) the Challenged Role of Failure to Warn and Defective Design Pharmaceutical Cases in Revealing Scientific Fraud , Marketing Mischief , and Conflicts of Interest , 35 HOFSTRA L. REV. 1773 , 1778 ( 2007 ) ( juxtaposing the FDA 's preemption position with deficiencies in the agency 's post-market regulatory scheme and suggesting a possible retreat from the FDA 's strong stance on implied preemption ) ; Margaret Gilhooley , Addressing Potential Drug Risks : The Limits of Testing , Risk Signals , Preemption , and the Drug Reform Legislation , 59 S.C.L. REV. 347 , 388 ( 2008 ) ( recommending the FDA change its policy and require that drug sponsors petition the agency for a statement of preemptive effect on the need for a warning ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1009 )_Y See_VV0 ,_Y e.g._REX ,_Y W._NP1 Wylie_NP1 Blair_NP1 ,_Y Implied_VVD_JJ@_VVN Preemption_NN1 of_IO State_NN1_NP1@ Tort_NN1_NP1 Law_NN1 Claims_VVZ_NN2 Against_II Prescription_NN1 Drug_NN1 Manufacturers_NN2 Based_VVN on_II FDA_NP1_NN1 Approval_NN1 ,_Y 27_MC J._NP1 LEGAL_JJ MED._NP1 289_MC ,_Y 301_MC (_Y 2006_MC )_Y (_Y proposing_VVG_JJ@ amendment_NN1 of_IO the_AT Food_NN1 ,_Y Drug_NN1 ,_Y and_CC Cosmetic_JJ Act_NN1 ,_Y enactment_NN1 of_IO state_NN1 statutes_NN2 ,_Y or_CC the_AT use_NN1 of_IO judicial_JJ intervention_NN1 to_TO adopt_VVI the_AT FDA_NP1_NN1 's_GE interpretation_NN1 of_IO the_AT scope_NN1 of_IO implied_JJ@ preemption_NN1 )_Y the_AT Challenged_JJ@ Role_NN1 of_IO Failure_NN1 to_TO_II Warn_VV0 and_CC Defective_JJ Design_NN1 Pharmaceutical_JJ Cases_NN2 in_II Revealing_VVG_JJ Scientific_JJ Fraud_NN1 ,_Y Marketing_NN1_VVG@ Mischief_NN1 ,_Y and_CC Conflicts_NN2 of_IO Interest_NN1 ,_Y 35_MC HOFSTRA_NP1 L._NP1 REV._NNU 1773_MC ,_Y 1778_MC (_Y 2007_MC )_Y (_Y juxtaposing_VVG the_AT FDA_NP1_NN1 's_GE preemption_NN1 position_NN1 with_IW deficiencies_NN2 in_II the_AT agency_NN1 's_GE_VBZ post-market_JJ regulatory_JJ scheme_NN1 and_CC suggesting_VVG a_AT1 possible_JJ retreat_NN1 from_II the_AT FDA_NP1_NN1 's_GE strong_JJ stance_NN1 on_II implied_JJ@ preemption_NN1 )_Y ;_Y Margaret_NP1 Gilhooley_NP1 ,_Y Addressing_VVG Potential_JJ_NN1 Drug_NN1 Risks_NN2_VVZ@ :_Y The_AT Limits_NN2 of_IO Testing_NP1_NN1_VVG ,_Y Risk_VV0_NN1 Signals_NN2 ,_Y Preemption_NN1_NP1@ ,_Y and_CC the_AT Drug_NN1 Reform_NN1 Legislation_NN1 ,_Y 59_MC S.C.L._NP1 REV._NNU 347_MC ,_Y 388_MC (_Y 2008_MC )_Y (_Y recommending_VVG the_AT FDA_NN1_NP1 change_VV0 its_Z' policy_NN1 and_CC require_VV0 that_DD1_CST drug_NN1 sponsors_NN2 petition_VV0@ the_AT agency_NN1 for_IF a_AT1 statement_NN1 of_IO preemptive_JJ effect_NN1 on_II the_AT need_NN1 for_IF a_AT1 warning_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1010 <p> -- ( n247 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1010 <p>_Y --_NN1_JJ (_Y n247_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1011 ) Compare Howard L. Dorfman et al. , Presumption of Innocence : FDA 's Authority to Regulate the Specifics of Prescription Drug Labeling and the Preemption Debate , 61 FOOD DRUG L.J .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1011 )_Y Compare_VV0 Howard_NP1 L._NP1 Dorfman_NP1 et_RA21 al._RA22 ,_Y Presumption_NN1 of_IO Innocence_NN1 :_Y FDA_NP1 's_GE Authority_NN1 to_TO_II Regulate_VV0 the_AT Specifics_NN2 of_IO Prescription_NN1 Drug_NN1 Labeling_VVG_NP1_NN1@ and_CC the_AT Preemption_NN1 Debate_NN1 ,_Y 61_MC FOOD_NN1 DRUG_NN1 L.J_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1012 585 , 610-11 ( 2006 ) ( advocating substantial , or Chevron level , deference to the Preamble ) , with Leslie C. A Role for Implied Preemption , 62 FOOD DRUG L.J .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1012 585_MC ,_Y 610-11_MCMC (_Y 2006_MC )_Y (_Y advocating_VVG substantial_JJ ,_Y or_CC Chevron_NP1_NN1 level_NN1_JJ ,_Y deference_NN1 to_II the_AT Preamble_NN1 )_Y ,_Y with_IW Leslie_NP1 C._NP1 A_AT1@_ZZ1 Role_NN1 for_IF Implied_JJ@ Preemption_NN1 ,_Y 62_MC FOOD_NN1 DRUG_NN1 L.J_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1013 227 , 247 ( 2007 ) ( concluding that the Preamble warrants low level or Skidmore deference ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1013 227_MC ,_Y 247_MC (_Y 2007_MC )_Y (_Y concluding_VVG_JJ that_CST the_AT Preamble_NN1 warrants_VVZ low_JJ level_NN1_JJ or_CC Skidmore_NP1 deference_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1014 See also Catherine M. Sharkey , Preemption by Preamble : Federal Agencies and the Federalization of Tort Law , 56 DEPAUL L. REV. 227 , 243-45 ( 2007 ) ( examining increased use of preemption by federal agencies and corresponding judicial deference to agency determinations ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1014 See_VV0 also_RR Catherine_NP1 M._NN1 Sharkey_NP1_NN1@ ,_Y Preemption_NN1_NP1@ by_II Preamble_NN1 :_Y Federal_JJ Agencies_NN2 and_CC the_AT Federalization_NN1 of_IO Tort_NP1_NN1 Law_NN1 ,_Y 56_MC DEPAUL_NP1 L._NP1 REV._NNU 227_MC ,_Y 243-45_MCMC (_Y 2007_MC )_Y (_Y examining_VVG increased_JJ use_NN1 of_IO preemption_NN1 by_II federal_JJ agencies_NN2 and_CC corresponding_JJ_VVG judicial_JJ deference_NN1 to_II agency_NN1 determinations_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1015 <p> -- ( n248 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1015 <p>_Y --_NN1_JJ (_Y n248_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1016 ) Compare In re Bextra Celebrex Mktg .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1016 )_Y Compare_VV0 In_RP@ re_II Bextra_NP1 Celebrex_NP1 Mktg_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1017 Sales Practices Prod .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1017 Sales_NPX Practices_NN2 Prod_VV0_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1018 Liab .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1018 Liab_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1019 Litig. , No. 05-1699 , 2006 WL 2374742 ( N.D. Cal Aug. 16 , 2006 ) ( same Celebrex ) , Conte v. Wyeth , Inc. , No. 04-437382 , 2006 WL 2692469 ( Cal .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1019 Litig._NP1 ,_Y No._XX 05-1699_MCMC ,_Y 2006_MC WL_NP1 2374742_MC (_Y N.D._NP1 Cal_NNU Aug._NPM1 16_MC ,_Y 2006_MC )_Y (_Y same_DA Celebrex_NN1_NP1 )_Y ,_Y Conte_NP1_NN1 v._II Wyeth_NP1 ,_Y Inc._JJ ,_Y No._XX 04-437382_MCMC ,_Y 2006_MC WL_NP1 2692469_MC (_Y Cal_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1020 App .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1020 App_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1021 Dep't Super .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1021 Dep't_VV0 Super_JJ_NN1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1022 Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1022 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1023 Sept. 14 , 2006 ) ( same metroclopramide ) , and Abramowitz v. Cephalon , Inc. , No .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1023 Sept._NPM1 14_MC ,_Y 2006_MC )_Y (_Y same_DA metroclopramide_NN1 )_Y ,_Y and_CC Abramowitz_NP1_VV0@_NN1@ v._II Cephalon_NP1_NN1 ,_Y Inc._JJ ,_Y No_XX ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1024 BER-L-617-04 , 2006 WL 560639 ( N.J. Super .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1024 BER-L-617-04_NP1 ,_Y 2006_MC WL_NP1 560639_MC (_Y N.J._NP1 Super_JJ_NN1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1025 Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1025 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1026 Law Div .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1026 Law_NN1 Div_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1027 Mar. 3 , 2006 ) ( finding implied preemption for FDA 's approval of risks associated Co. , 467 F.3d 85 ( 2d Cir. 2006 ) , aff 'd sub .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1027 Mar._NPM1 3_MC ,_Y 2006_MC )_Y (_Y finding_VVG_NN1 implied_JJ@_VVD_VVN preemption_NN1 for_IF FDA_NP1_NN1 's_GE approval_NN1 of_IO risks_NN2 associated_VVN Co._NP1 ,_Y 467_MC F.3d_FO 85_MC (_Y 2d_NNU Cir._NP1 2006_MC )_Y ,_Y aff_NN1 'd_VHD_VM sub_JJ_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1028 nom , Warner-Lambert Co. v. Kent , 128 S. Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1028 nom_VV0_NN1 ,_Y Warner-Lambert_NP1 Co._NP1_NN1 v._II Kent_NP1 ,_Y 128_MC S._NP1 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1029 1168 ( 2008 ) , Weiss v. Fujisawa Pharm .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1029 1168_MC (_Y 2008_MC )_Y ,_Y Weiss_VV0_NP1_NN1 v._II Fujisawa_NP1 Pharm_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1030 Co. , 464 F. Supp. 2d 666 ( E.D. Ky. 2006 ) , Jackson v. Pfizer , Inc. , 432 F. Supp. 2d 964 ( D. Neb. 2006 ) , and Levine v. Wyeth , 944 A.2d 179 ( Vt. 2006 ) , cert .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1030 Co._NP1_NN1 ,_Y 464_MC F._NP1_RA@ Supp._NP1 2d_NNU 666_MC (_Y E.D._NN1 Ky._NP1 2006_MC )_Y ,_Y Jackson_NP1 v._II Pfizer_NP1_NN1 ,_Y Inc._JJ ,_Y 432_MC F._NP1_RA@ Supp._NP1 2d_NNU 964_MC (_Y D._NP1 Neb._NP1 2006_MC )_Y ,_Y and_CC Levine_NP1_VV0@_NN1@ v._II Wyeth_NP1 ,_Y 944_MC A.2d_FO 179_MC (_Y Vt._NP1 2006_MC )_Y ,_Y cert_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1031 granted , 128 S. Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1031 granted_VVN_VVD ,_Y 128_MC S._NP1 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1032 1118 ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1032 1118_MC (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1033 <p> -- ( n249 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1033 <p>_Y --_NN1_JJ (_Y n249_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1034 ) Medtronic , Inc. v. Lohr , 518 U.S. 470 , 505 ( 1996 ) ( Breyer , J. , concurring ) ; see also Chevron v. Nat'l Res .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1034 )_Y Medtronic_NP1@_JJ ,_Y Inc._JJ v._II Lohr_NP1_NN1 ,_Y 518_MC U.S._NP1 470_MC ,_Y 505_MC (_Y 1996_MC )_Y (_Y Breyer_NP1_NN1 ,_Y J._NP1 ,_Y concurring_VVG )_Y ;_Y see_VV0 also_RR Chevron_NN1_NP1 v._II Nat'l_NP1_NN1 Res_NN2_JJ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1035 Def .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1035 Def_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1036 Council 467 U.S. 837 , 863-64 ( 1984 ) ( " The fact that the agency has from time to time changed its interpretation .. , does not .. , lead us to conclude that no deference should be accorded the agency 's interpretation of the statute .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1036 Council_NN1 467_MC U.S._NP1 837_MC ,_Y 863-64_MCMC (_Y 1984_MC )_Y (_Y "_Y The_AT fact_NN1 that_CST the_AT agency_NN1 has_VHZ from_RR41 time_RR42 to_RR43 time_RR44 changed_VVN its_Z' interpretation_NN1 .._... ,_Y does_VDZ not_XX .._... ,_Y lead_VV0 us_PPIO2 to_TO conclude_VVI that_CST no_AT deference_NN1 should_VM be_VBI accorded_VVN the_AT agency_NN1 's_GE interpretation_NN1 of_IO the_AT statute_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1037 An initial agency interpretation is not instantly carved in stone .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1037 An_AT1 initial_JJ_NN1 agency_NN1 interpretation_NN1 is_VBZ not_XX instantly_RR carved_VVN_VVD in_II stone_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1038 " ) 471 U.S. 707 , 718 ( 1985 ) ; see also Dowhal v. SmithKline Beecham Consumer , 88 P.3d 1 , 5-6 , 9-10 ( Cal .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1038 "_Y )_Y 471_MC U.S._NP1 707_MC ,_Y 718_MC (_Y 1985_MC )_Y ;_Y see_VV0 also_RR Dowhal_JJ_NP1 v._II SmithKline_NP1 Beecham_NP1 Consumer_NN1 ,_Y 88_MC P.3d_FO 1_MC1 ,_Y 5-6_MCMC ,_Y 9-10_MCMC (_Y Cal_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1039 2004 ) ( according deference to FDA position expressed in letters issued in response to a manufacturer inquiry and citizen petition stating that California law was preempted to the extent it required warnings on nicotine replacement devices that conflicted with the FDA 's determination that a manufacturer could include only approved warnings ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1039 2004_MC )_Y (_Y according_VVG_II_CS_JJ@ deference_NN1 to_II FDA_NP1_NN1 position_NN1 expressed_VVN_VVD in_II letters_NN2 issued_VVN_VVD in_II31 response_II32 to_II33 a_AT1 manufacturer_NN1 inquiry_NN1 and_CC citizen_NN1 petition_NN1 stating_VVG that_CST California_NP1 law_NN1 was_VBDZ preempted_VVN@ to_II the_AT extent_NN1 it_PPH1 required_JJ_VVD@ warnings_NN2 on_II nicotine_NN1 replacement_NN1 devices_NN2 that_CST conflicted_VVD with_IW the_AT FDA_NP1_NN1 's_GE determination_NN1 that_CST a_AT1 manufacturer_NN1 could_VM include_VVI only_RR_JJ approved_JJ_VVN warnings_NN2 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1040 <p> -- ( 251 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1040 <p>_Y --_NN1_JJ (_Y 251_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1041 ) Levine v. Wyeth , 944 A.2d 179 ( Vt. 2006 ) , cert .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1041 )_Y Levine_VV0_NN1 v._II Wyeth_NP1 ,_Y 944_MC A.2d_FO 179_MC (_Y Vt._NP1 2006_MC )_Y ,_Y cert_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1042 granted , 128 S. Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1042 granted_VVN_VVD ,_Y 128_MC S._NP1 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1043 1118 ( 2008 ) ( No. 06-1249 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1043 1118_MC (_Y 2008_MC )_Y (_Y No._XX 06-1249_MCMC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1044 The Court also decided two other cases this term considering preemption in the FDA context .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1044 The_AT Court_NN1 also_RR decided_VVD_VVN two_MC other_JJ cases_NN2 this_DD1 term_NN1 considering_II_VVG_CS preemption_NN1 in_II the_AT FDA_NN1_NP1 context_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1045 See Riegel v. Medtronic , Inc. , 128 S. Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1045 See_VV0 Riegel_NP1_NN1@ v._II Medtronic_JJ ,_Y Inc._JJ ,_Y 128_MC S._NP1 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1046 999 ( 2008 ) ; Warner-Lambert Co. v. Kent , 128 S. Ct .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1046 999_MC (_Y 2008_MC )_Y ;_Y Warner-Lambert_NP1 Co._NP1_NN1 v._II Kent_NP1 ,_Y 128_MC S._NP1 Ct_NP1_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1047 1168 ( 2008 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1047 1168_MC (_Y 2008_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1048 <p> -- ( n252 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1048 <p>_Y --_NN1_JJ (_Y n252_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1049 ) See Levine , 944 A.2d at 182 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1049 )_Y See_VV0 Levine_NP1 ,_Y 944_MC A.2d_FO at_II 182_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1050 <p> -- ( n253 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1050 <p>_Y --_NN1_JJ (_Y n253_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1051 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1051 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1052 at 183 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1052 at_II 183_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1053 <p> -- ( -- ( n255 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1053 <p>_Y --_NN1_JJ (_Y --_NN1_JJ (_Y n255_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1054 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1054 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1055 at 188 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1055 at_II 188_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1056 <p> -- ( n256 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1056 <p>_Y --_NN1_JJ (_Y n256_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1057 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1057 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1058 <p> -- ( n257 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1058 <p>_Y --_NN1_JJ (_Y n257_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1059 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1059 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1060 at 194 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1060 at_II 194_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1061 <p> -- ( n258 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1061 <p>_Y --_NN1_JJ (_Y n258_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1062 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1062 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1063 at 192 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1063 at_II 192_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1064 <p> -- ( n259 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1064 <p>_Y --_NN1_JJ (_Y n259_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1065 ) See Brief for the United States as Amicus Curiae Supporting Petitioner , Wyeth v. Levine , No. 06-1249 ( U.S. filed Dec. 2007 ) , available at http : **63;2219;TOOLONG .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1065 )_Y See_VV0 Brief_NN1_JJ for_IF the_AT United_NP1 States_NP1 as_CSA_II@ Amicus_NP1 Curiae_NP1 Supporting_JJ_VVG Petitioner_NN1 ,_Y Wyeth_VVZ_NP1 v._II Levine_NP1 ,_Y No._XX 06-1249_MCMC (_Y U.S._NP1 filed_VVD Dec._NP 2007_MC )_Y ,_Y available_JJ at_II http_NNU :_Y **63;2219;TOOLONG_FU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1066 <p> -- ( n260 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1066 <p>_Y --_NN1_JJ (_Y n260_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1067 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1067 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1068 at 9-11 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1068 at_II 9-11_MCMC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1069 <p> -- ( n261 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1069 <p>_Y --_NN1_JJ (_Y n261_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1070 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1070 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1071 at 9 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1071 at_II 9_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1072 <p> -- ( n262 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1072 <p>_Y --_NN1_JJ (_Y n262_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1073 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1073 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1074 at 11 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1074 at_II 11_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1075 <p> -- ( n263 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1075 <p>_Y --_NN1_JJ (_Y n263_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1076 ) See Colacicco v. Apotex , Inc. , 432 F. Supp. 2d 514 ( E.D. Pa. 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1076 )_Y See_VV0 Colacicco_NP1_NN1@ v._II Apotex_NP1_NN1 ,_Y Inc._JJ ,_Y 432_MC F._NP1_RA@ Supp._NP1 2d_NNU 514_MC (_Y E.D._NN1 Pa._NP1_NN1@ 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1077 <p> -- ( n264 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1077 <p>_Y --_NN1_JJ (_Y n264_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1078 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1078 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1079 at 529 ; see also Sykes v. Glaxo-SmithKline , 484 F. Supp. 2d 289 , 308-10 ( E.D. Pa. 2007 ) ( preempting state tort actions against pediatric vaccine manufacturers under the National Childhood Vaccine Injury Compensation Act ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1079 at_II 529_MC ;_Y see_VV0 also_RR Sykes_NP1 v._II Glaxo-SmithKline_NP1 ,_Y 484_MC F._NP1_RA@ Supp._NP1 2d_NNU 289_MC ,_Y 308-10_MCMC (_Y E.D._NN1 Pa._NP1_NN1@ 2007_MC )_Y (_Y preempting_VVG_JJ@ state_NN1 tort_NN1_VV0 actions_NN2_VVZ@ against_II pediatric_JJ vaccine_NN1 manufacturers_NN2 under_II the_AT National_JJ Childhood_NN1 Vaccine_NN1 Injury_NN1 Compensation_NN1 Act_NN1 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1080 <p> -- ( n265 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1080 <p>_Y --_NN1_JJ (_Y n265_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1081 ) See Prod .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1081 )_Y See_VV0 Prod_VV0_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1082 Liab .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1082 Liab_VV0_NN1_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1083 Litig. , MDL No. 1699 , 2006 WL 2374742 , at *9 ( N.D. Cal .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1083 Litig._NP1 ,_Y MDL_MC No._XX 1699_MC ,_Y 2006_MC WL_NP1 2374742_MC ,_Y at_II *9_FO (_Y N.D._NP1 Cal_NNU ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1084 Aug. 16 , 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1084 Aug._NPM1 16_MC ,_Y 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1085 <p> -- ( n266. ) 499 F.3d 239 , 241 ( 3d Cir. 2007 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1085 <p>_Y --_NN1_JJ (_Y n266._FO )_Y 499_MC F.3d_FO 239_MC ,_Y 241_MC (_Y 3d_NNU Cir._NP1 2007_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1086 <p> -- ( n267 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1086 <p>_Y --_NN1_JJ (_Y n267_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1087 ) See DEL .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1087 )_Y See_VV0 DEL_FW_NP1@ ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1088 CODE tit. 6 2513(b) ( 2009 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1088 CODE_VV0@_NN1 tit._NNU 6_MC 2513(b)_FO (_Y 2009_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1089 <p> -- ( n268 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1089 <p>_Y --_NN1_JJ (_Y n268_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1090 ) See Pennsylvania Employees , 499 F.3d at 243 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1090 )_Y See_VV0 Pennsylvania_NP1 Employees_NN2 ,_Y 499_MC F.3d_FO at_II 243_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1091 <p> -- ( n269 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1091 <p>_Y --_NN1_JJ (_Y n269_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1092 ) Id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1092 )_Y Id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1093 at 251 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1093 at_II 251_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1094 <p> -- ( n270 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1094 <p>_Y --_NN1_JJ (_Y n270_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1095 ) See id .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1095 )_Y See_VV0 id_Z' ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1096 at 252 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1096 at_II 252_MC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1097 <p> -- ( n271 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1097 <p>_Y --_NN1_JJ (_Y n271_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1098 ) See Richard Epstein , Why the FDA Must Preempt Tort Litigation : A Critique of Chevron Deference and a Response to Richard Nagareda , 1 J. TORT L. 1 , 1 ( 2006 ) ( " Federal preemption of state tort actions for pharmaceuticals is long overdue , both under current law and as a matter of sound legal policy .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1098 )_Y See_VV0 Richard_NP1 Epstein_NP1 ,_Y Why_RRQ the_AT FDA_NN1_NP1 Must_VM Preempt_NP1_VV0 Tort_NP1_NN1 Litigation_NN1 :_Y A_AT1@_ZZ1 Critique_NN1 of_IO Chevron_NP1_NN1 Deference_NN1 and_CC a_AT1 Response_NN1 to_II Richard_NP1 Nagareda_NP1 ,_Y 1_MC1 J._NP1 TORT_NP1 L._NP1 1_MC1 ,_Y 1_MC1 (_Y 2006_MC )_Y (_Y "_Y Federal_JJ preemption_NN1 of_IO state_NN1 tort_NN1_VV0 actions_NN2 for_IF pharmaceuticals_NN2 is_VBZ long_RR overdue_JJ ,_Y both_RR_DB2 under_RG@_II current_JJ law_NN1 and_CC as_II a_AT1 matter_NN1 of_IO sound_JJ@_NN1 legal_JJ policy_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1099 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1099 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1100 <p> -- ( n272 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1100 <p>_Y --_NN1_JJ (_Y n272_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1101 ) See Buckman Co. v. Plaintiffs ' Legal Comm. , 531 U.S. 341 , 350 ( 2001 ) ( 's detailed regulatory regime in the shadow of 50 States ' tort regimes will dramatically increase the burdens facing potential applicants-burdens not contemplated by Congress in enacting the FDCA .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1101 )_Y See_VV0 Buckman_NP1_NN1 Co._NP1_NN1 v._II Plaintiffs_NN2 '_GE Legal_JJ Comm._NP1 ,_Y 531_MC U.S._NP1 341_MC ,_Y 350_MC (_Y 2001_MC )_Y (_Y 's_GE_VBZ detailed_JJ regulatory_JJ regime_NN1 in_II the_AT shadow_NN1 of_IO 50_MC States_NP1 '_GE tort_NN1 regimes_NN2 will_VM dramatically_RR increase_VVI the_AT burdens_NN2 facing_VVG potential_JJ_NN1 applicants-burdens_NN2 not_XX contemplated_VVN by_II Congress_NN1 in_II enacting_VVG the_AT FDCA_NN1_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1102 ... " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1102 ..._... "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1103 <p> -- ( n273 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1103 <p>_Y --_NN1_JJ (_Y n273_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1104 ) See FDA Preamble , supra note 240 , at 3934 ( " In order to more fully address the comments expressing concern about the product liability implications of revising the labeling for prescription drugs , we believe it would be useful to set forth in some detail the arguments made in those amicus briefs .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1104 )_Y See_VV0 FDA_NN1_NP1 Preamble_NN1 ,_Y supra_NN1 note_NN1_VV0 240_MC ,_Y at_II 3934_MC (_Y "_Y In_II order_NN1 to_II more_RGR fully_RR address_VV0@ the_AT comments_NN2 expressing_VVG concern_NN1 about_II the_AT product_NN1 liability_NN1 implications_NN2 of_IO revising_VVG the_AT labeling_NN1@_JJ@_VVG for_IF prescription_NN1 drugs_NN2 ,_Y we_PPIS2 believe_VV0 it_PPH1 would_VM be_VBI useful_JJ to_TO set_VVI forth_RR in_II some_DD detail_NN1_VV0@ the_AT arguments_NN2 made_VVN_VVD in_II those_DD2 amicus_NN1 briefs_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1105 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1105 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1106 <p> -- ( n274 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1106 <p>_Y --_NN1_JJ (_Y n274_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1107 ) See 21 U.S.C. 301 ( 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1107 )_Y See_VV0 21_MC U.S.C._NP1 301_MC (_Y 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1108 <p> -- ( n275 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1108 <p>_Y --_NN1_JJ (_Y n275_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1109 ) See 21 U.S.C. 360k(a) ( 2006 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1109 )_Y See_VV0 21_MC U.S.C._NP1 360k(a)_FO (_Y 2006_MC )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1110 <p> -- ( n276 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1110 <p>_Y --_NN1_JJ (_Y n276_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1111 ) See supra Part III.A .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1111 )_Y See_VV0 supra_NN1 Part_NN1 III.A_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1112 <p> -- ( n277 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1112 <p>_Y --_NN1_JJ (_Y n277_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1113 ) See supra Part III.B ; see also Dorfman et al. , supra note 247 , at 622 ( " The public policy balance weighs in favor of a uniform federal scheme to provide for the introduction of urgently needed medical therapies without compromising FDA 's role of ensuring scientifically sound precautionary language with regard to adverse events , and allow for clear understanding by the recipients .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1113 )_Y See_VV0 supra_NN1 Part_NN1 III.B_NP1 ;_Y see_VV0 also_RR Dorfman_NP1 et_RA21 al._RA22 ,_Y supra_NN1 note_NN1_VV0 247_MC ,_Y at_II 622_MC (_Y "_Y The_AT public_JJ_NN1 policy_NN1 balance_NN1 weighs_VVZ in_II31 favor_II32 of_II33 a_AT1 uniform_JJ federal_JJ scheme_NN1 to_TO provide_VVI for_IF the_AT introduction_NN1 of_IO urgently_RR needed_VVN_VVD medical_JJ therapies_NN2 without_IW compromising_VVG_JJ@ FDA_NP1_NN1 's_GE role_NN1 of_IO ensuring_VVG scientifically_RR sound_VV0@_JJ@ precautionary_JJ language_NN1 with_II31 regard_II32 to_II33 adverse_JJ events_NN2 ,_Y and_CC allow_VV0 for_IF clear_JJ understanding_NN1 by_II the_AT recipients_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1114 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1114 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1115 <p> -- ( n278 .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1115 <p>_Y --_NN1_JJ (_Y n278_FO ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1116 ) See , e.g. , Jennifer Girod , The Learned Intermediary Doctrine : An Efficient Protection for Patients , Past and Present , 40 IND .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1116 )_Y See_VV0 ,_Y e.g._REX ,_Y Jennifer_NP1 Girod_NP1 ,_Y The_AT Learned_JJ@ Intermediary_NN1 Doctrine_NN1 :_Y An_AT1 Efficient_JJ Protection_NN1 for_IF Patients_NN2 ,_Y Past_JJ_NN1_RL and_CC Present_NN1_JJ ,_Y 40_MC IND_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1117 L. REV. 397 , 398 , 416 ( 2007 ) ( discussing the potential benefits of DTC advertising ) ; Jack B. Harrison Mina J. Jerrerson , " Some Accurate Information is Better Than No Information at All " : Arguments Against An Exception to the Learned Intermediary Doctrine Based on Direct-to-Consumer Advertising , 78 OR .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1117 L._NP1_NNU@ REV._NNU 397_MC ,_Y 398_MC ,_Y 416_MC (_Y 2007_MC )_Y (_Y discussing_VVG the_AT potential_JJ_NN1 benefits_NN2 of_IO DTC_NP1 advertising_NN1 )_Y ;_Y Jack_NP1 B._NP1 Harrison_NP1 Mina_NP1 J._NP1 Jerrerson_NP1 ,_Y "_Y Some_DD Accurate_JJ Information_NN1 is_VBZ Better_JJR_RRR Than_CSN No_XX Information_NN1 at_RR21 All_RR22 "_Y :_Y Arguments_NN2 Against_II An_AT1 Exception_NN1 to_II the_AT Learned_JJ@ Intermediary_NN1 Doctrine_NN1 Based_VVN on_II Direct-to-Consumer_NP1 Advertising_NN1 ,_Y 78_MC OR_CC ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1118 L. REV. 605 , 606 ( 1999 ) ( " DTC advertising increases consumer awareness of illnesses and their symptoms , empowers consumers to take charge of their healthcare decisions , and enhances the quality of the dialogue between physicians and patients .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1118 L._NP1_NNU@ REV._NNU 605_MC ,_Y 606_MC (_Y 1999_MC )_Y (_Y "_Y DTC_NP1 advertising_NN1 increases_VVZ_NN2 consumer_NN1 awareness_NN1 of_IO illnesses_NN2 and_CC their_APPGE symptoms_NN2 ,_Y empowers_VVZ consumers_NN2 to_TO take_VVI charge_NN1 of_IO their_APPGE healthcare_NN1 decisions_NN2 ,_Y and_CC enhances_VVZ the_AT quality_NN1 of_IO the_AT dialogue_NN1 between_II physicians_NN2 and_CC patients_NN2 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1119 " ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1119 "_Y )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1120 <p> GRAPH : Figure 1 Ads Rank Low as a Source of Information for Rx Drugs <p> By Victor E. Schwartz ; Cary Silverman ; Michael J. Hulka and Christopher E. Appel <p> Victor , Hardy Bacon L.L.P. ( Washington , D.C. ) ; Co-Author , PROSSER , WADE AND SCHWARTZ 'S TORTS ( 11th ed. 2005 ) ; Member , Advisory Committees of the American Law Institute 's Restatement of the Law ( Third ) Torts : Products Liability , Apportionment of Liability , General Principles , Liability for Physical and Emotional Harm projects ; J.D. , Columbia University ( magna cum laude ) ; B.A. , Boston University ( summa cum laude ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1120 <p>_Y GRAPH_NN1 :_Y Figure_NN1_VV0% 1_MC1 Ads_NN2 Rank_NP1_VV0@ Low_NP1_JJ_RR@ as_II_CSA a_AT1 Source_NN1 of_IO Information_NN1 for_IF Rx_NP1 Drugs_NN2 <p>_Y By_II Victor_NP1 E._NP1 Schwartz_NP1 ;_Y Cary_NP1 Silverman_NP1_NN1 ;_Y Michael_NP1 J._NP1 Hulka_NP1 and_CC Christopher_NP1 E._NP1 Appel_NP1 <p>_Y Victor_NP1 ,_Y Hardy_NP1 Bacon_NP1 L.L.P._NP1 (_Y Washington_NP1 ,_Y D.C._NP1 )_Y ;_Y Co-Author_NN1 ,_Y PROSSER_NP1 ,_Y WADE_NP1_VV0 AND_CC SCHWARTZ_NP1_NN1 'S_GE TORTS_NN2 (_Y 11th_MD ed._NN1 2005_MC )_Y ;_Y Member_NN1 ,_Y Advisory_JJ Committees_NN2 of_IO the_AT American_JJ Law_NN1 Institute_NN1 's_GE Restatement_NN1 of_IO the_AT Law_NN1 (_Y Third_MD_NP1% )_Y Torts_VVZ_NP1 :_Y Products_NN2 Liability_NN1 ,_Y Apportionment_NN1 of_IO Liability_NN1 ,_Y General_JJ_NN1 Principles_NN2 ,_Y Liability_NN1 for_IF Physical_JJ and_CC Emotional_JJ Harm_NN1 projects_NN2 ;_Y J.D._NP1 ,_Y Columbia_NP1 University_NN1 (_Y magna_RR31 cum_RR32 laude_RR33 )_Y ;_Y B.A._NP1 ,_Y Boston_NP1 University_NN1 (_Y summa_RR31 cum_RR32 laude_RR33 )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1121 <p> Cary Silverman , Of Counsel , Shook , Hardy Bacon L.L.P. ( Washington , D.C. ) ; J.D. , M.P.A. , The George Washington University Law School ( 2000 ) ( with honors ) ; B.S. , Management Science , State University of New York College at Geneseo ( n1997 ) .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1121 <p>_Y Cary_NP1 Silverman_NP1 ,_Y Of_IO Counsel_NP1 ,_Y Shook_VVD_VVN ,_Y Hardy_NP1 Bacon_NP1 L.L.P._NP1 (_Y Washington_NP1 ,_Y D.C._NP1 )_Y ;_Y J.D._NP1 ,_Y M.P.A._NP1 ,_Y The_AT George_NP1 Washington_NP1 University_NN1 Law_NN1 School_NN1 (_Y 2000_MC )_Y (_Y with_IW honors_NN2 )_Y ;_Y B.S._NP1 ,_Y Management_NN1 Science_NN1 ,_Y State_VV0_NN1_NP1@ University_NN1 of_IO New_NP1 York_NP1 College_NN1 at_II Geneseo_NP1 (_Y n1997_FO )_Y ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1122 <p> Michael J. Hulka , Counsel , Eli Lilly and Company ; Law Clerk , Judge Michael S. Kanne , U.S. Court of Appeals for the Seventh Circuit ; J.D. , Indiana University Bloomington School of Law ( magna cum laude ) ; Editor-in-Chief , Indiana Law Journal .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1122 <p>_Y Michael_NP1 J._NP1 Hulka_NP1 ,_Y Counsel_NP1 ,_Y Eli_NP1 Lilly_NP1 and_CC Company_NN1 ;_Y Law_NN1 Clerk_NN1 ,_Y Judge_NP1@_VV0 Michael_NP1 S._NP1 Kanne_NP1 ,_Y U.S._NP1 Court_NN1 of_IO Appeals_NN2 for_IF the_AT Seventh_MD Circuit_NN1 ;_Y J.D._NP1 ,_Y Indiana_NP1 University_NN1 Bloomington_NP1_NN1@ School_NN1 of_IO Law_NN1 (_Y magna_RR31 cum_RR32 laude_RR33 )_Y ;_Y Editor-in-Chief_NN1_JJ ,_Y Indiana_NP1 Law_NN1 Journal_NN1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1123 The views expressed herein do .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1123 The_AT views_NN2 expressed_VVN_VVD herein_RR do_VD0 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1124 <p> Christopher E. Appel , Attorney , Public Policy Group , Shook , Hardy Bacon L.L.P. ( Washington , D.C. ) ; J.D. , Wake Forest University School of Law ; B.S. , University of Virginia .
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1124 <p>_Y Christopher_NP1 E._NP1 Appel_NP1 ,_Y Attorney_NN1 ,_Y Public_JJ_NN1 Policy_NN1 Group_NN1 ,_Y Shook_VVD_VVN ,_Y Hardy_NP1 Bacon_NP1 L.L.P._NP1 (_Y Washington_NP1 ,_Y D.C._NP1 )_Y ;_Y J.D._NP1 ,_Y Wake_VV0_NN1 Forest_NN1 University_NN1 School_NN1 of_IO Law_NN1 ;_Y B.S._NP1 ,_Y University_NN1 of_IO Virginia_NP1 ._Y
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  A    0 1125 <p>
SENTPOS COCA_acad_wlp_2009_04_FILE##4071377 COCA  B    0 1125 <p>_Y
